# Patent

## Title
Gene expression markers for colorectal cancer prognosis

## Abstract

A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This is divisional application of U.S. application Ser. No. 13/009,733, filed Jan. 19, 2011 now U.S. Pat. No. 8,198,024, which is a divisional application of U.S. application Ser. No. 12/696,934, filed Jan. 29, 2010 now U.S. Pat. No. 8,153,378, which is a divisional application of U.S. application Ser. No. 11/653,102, filed Jan. 11, 2007, now U.S. Pat. No. 7,695,913, which claims the benefit of U.S Provisional Application No. 60/758,392, filed Jan. 11, 2006, U.S. Provisional Application No. 60/800,277, filed May 12, 2006, and U.S. Provisional Application No. 60/810,077, filed May 31, 2006, all of which are incorporated herein by reference in their entirety.


SEQUENCE LISTING
This application contains a Sequence Listing, which was submitted as an ASCII text file titled “GHDX026DIV8Sequence Listing” (590,772 bytes, created Feb. 16, 2012), and which is incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention provides genes and gene sets, the expression levels of which are useful for predicting outcome of colorectal cancer.
2. Description of Related Art
Colorectal cancer is the number two cause of cancer-related death in the United States and the European Union, accounting for 10% of all cancer-related deaths. Although colon cancer and rectal cancer may represent identical or similar disease at the molecular level, surgery for rectal cancer is complicated by anatomical issues. Possibly for this reason, the rate of local recurrence for rectal cancer is significantly higher than for colon cancer, and so the treatment approach is significantly different. Approximately 100,000 colon cancers are newly diagnosed each year in the United States, with about 65% of these being diagnosed as stage II/III colorectal cancer as discussed below.
Refining a diagnosis of colorectal cancer involves evaluating the progression status of the cancer using standard classification criteria. Two classification systems have been widely used in colorectal cancer, the modified Duke's or Astler-Coller staging system (Stages A-D) (Astler V B, Coller F A., Ann Surg 1954; 139:846-52), and more recently TNM staging (Stages I-IV) as developed by the American Joint Committee on Cancer (AJCC Cancer Staging Manual, 6th Edition, Springer-Verlag, New York, 2002). Both systems apply measures of the spread of the primary tumor through layers of colon or rectal wall to the adjacent organs, lymph nodes and distant sites to evaluate tumor progression. Estimates of recurrence risk and treatment decisions in colon cancer are currently based primarily on tumor stage.
There are approximately 33,000 newly diagnosed Stage II colorectal cancers each year in the United States. Nearly all of these patients are treated by surgical resection of the tumor and, in addition, about 40% are currently treated with chemotherapy based on 5-fluorouracil (5-FU). The decision whether to administer adjuvant chemotherapy is not straightforward. The five-year survival rate for Stage II colon cancer patients treated with surgery alone is approximately 80%. Standard adjuvant treatment with 5-FU+leucovorin (folinic acid) demonstrates an absolute benefit of only 2-4% in this population and shows significant toxicity, including a rate of toxic death from chemotherapy as high as 1%. Thus, a large number of patients receive toxic therapy from which only a few benefit.
A test capable of prognosis after surgery in Stage II colorectal cancer patients would be of great benefit for guiding treatment decisions for these patients.
The benefit of chemotherapy in Stage III colon cancer is more evident than it is in Stage II. A large proportion of the 31,000 patients annually diagnosed with Stage III colon cancer receive 5-FU-based adjuvant chemotherapy, and the absolute benefit of 5-FU+leucovorin in this setting is around 18-24%, depending on the particular regimen employed. Current standard-of-care chemotherapy treatment for Stage III colon cancer patients (5-FU+leucovorin or 5-FU+leucovorin+oxaliplatin) is moderately effective, achieving an improvement in 5-yr survival rate from about 50% (surgery alone) to about 65% (5-FU+leucovorin) or 70% (5-FU+leucovorin+oxaliplatin). Treatment with 5-FU+leucovorin alone or in combination with oxaliplatin is accompanied by a range of adverse side-effects, including toxic death in approximately 1% of patients treated. Furthermore, the three-year survival rate for Stage III colon cancer patients treated with surgery alone is about 47% and it has not been established whether a subset of Stage III patients exists for which recurrence risk resembles that observed for Stage II patients.
A test that would quantify recurrence risk based on molecular markers rather than tumor stage alone would be useful for identifying a subset of Stage III patients that may not require adjuvant therapy to achieve acceptable outcomes.
Staging of rectal tumors is carried out based on similar criteria as for colon tumor staging, although there are some differences resulting for example from differences in the arrangement of the draining lymph nodes. As a result, Stage II/III rectal tumors bear a reasonable correlation to Stage II/III colon tumors as to their state of progression. As noted above, the rate of local recurrence and other aspects of prognosis differ between rectal cancer and colon cancer, and these differences may arise from difficulties in accomplishing total resection of rectal tumors. Nevertheless, there is no compelling evidence that there is a difference between colon cancer and rectal cancer as to the molecular characteristics of the respective tumors. Prognostic tests for rectal cancer would have utility similar in nature as described for colon cancer prognostic tests and the same prognostic markers might well apply to both cancer types.
In addition, there is a clear need for safer and more efficacious drugs for the treatment of colon cancer. Current chemotherapy for colon cancer is based on the relatively crude approach of administering drugs that generally interfere with the proliferation of dividing cells. Recent clinical studies have demonstrated the feasibility of developing improved drugs based on detailed molecular understanding of particular cancer types and subtypes. For example, the HER2 (ERBB2) gene is amplified and the HER2 protein is overexpressed in a subset of breast cancers; HERCEPTIN® (Genentech, Inc.) a drug developed to target HER2, is indicated only for those patients who have an higher than normal copy number of HER2 as demonstrated by fluorescent in situ hybridization (FISH) or a high level of HER2 expression as demonstrated by immunohistochemistry. Genes, whose expression is associated with clinical outcome in human cancer patients, are a valuable resource for selection of targets for drug compound screening and further drug development activities.
Molecularly targeted drugs, such as HERCEPTIN® (Genentech, Inc.) can be developed and commercialized in conjunction with a diagnostic test that can identify patients who are likely to benefit from the drug; one aspect of such a test is the identification of those patients likely to have a positive outcome without any treatment other than surgery. For example, 80% of Stage II colon cancer patients survive five years or more when treated with surgery alone. Gene markers that identify patients more likely to be among the 20% whose cancer will recur without additional treatment are useful in drug development, for example in screening patients for inclusion in a clinical trial.
SUMMARY OF THE INVENTION
In one aspect, the present invention concerns a method for predicting the clinical outcome in a subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 1A-B, 2A-B, 3A-B, 4A-B, 5A-B, 6 and/or 7, or their expression products, in a biological sample comprising cancer cells obtained from said subject wherein: (a) evidence of increased expression of one or more of the genes listed in Table 1A, 2A, 3A, 4A, and/or 5A, or the corresponding expression product, indicates a decreased likelihood of a positive clinical outcome; and (b) evidence of increased expression of one or more of the genes listed in Table 1B, 2B, 3B, 4B and/or 5B, or the corresponding expression product, indicates an increased likelihood of a positive clinical outcome. It is contemplated that if the likelihood of positive clinical outcome is predicted to be decreased said patient is subjected to further therapy following said surgical removal. It is further contemplated that the therapy is chemotherapy and/or radiation therapy.
The clinical outcome of the method of the invention may be expressed, for example, in terms of Recurrence-Free Interval (RFI), Overall Survival (OS), Disease-Free Survival (DFS), or Distant Recurrence-Free Interval (DRFI).
In one embodiment, the cancer is Dukes B (stage II) or Dukes C (stage III) colorectal cancer.
In another aspect, the invention concerns a method of predicting the duration of Recurrence-Free Interval (RFI) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 1A, 5A, 1B, and/or 5B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein: (a) evidence of increased expression of one or more of the genes listed in Table 1A or 5A, or the corresponding expression product, indicates that said RFI is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 1B, or 5B, or the corresponding expression product, indicates that said RFI is predicted to be longer.
In another aspect, the invention concerns a method of predicting Overall Survival (OS) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 2A and/or 2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein: (a) evidence of increased expression of one or more of the genes listed in Table 2A, or the corresponding expression product, indicates that said OS is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 2B, or the corresponding expression product, indicates that said OS is predicted to be longer.
In another aspect, the invention concerns a method of predicting Disease-Free Survival (DFS) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 3A, and/or 3B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein: (a) evidence of increased expression of one or more of the genes listed in Table 3A, or the corresponding expression product, indicates that said DFS is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 3B, or the corresponding expression product, indicates that said DFS is predicted to be longer.
In another aspect, the invention concerns a method of predicting the duration of Distant Recurrence-Free Interval (DRFI) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 4A and/or 4B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein: (a) evidence of increased expression of one or more of the genes listed in Table 4A, or the corresponding expression product, indicates that said DRFI is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 4B, or the corresponding expression product, indicates that said DRFI is predicted to be longer.
In another aspect, the invention concerns a method of predicting clinical outcome for a subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising determining evidence of the expression level of one or more predictive RNA transcripts listed in Tables 1.2A-B, 2.2A-B, 3.2A-B, 4.2A-B, 5.2A-B, 6.2 and/or 7.2, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1.2A, 2.2A, 3.2A, 4.2A and/or 5.2A, or the corresponding expression product, indicates a decreased likelihood of a positive clinical outcome; and (b) evidence of increased expression of one or more of the genes listed in Table 1.2B, 2.2B, 3.2B, 4.2B and/or 5.2B, or the corresponding expression product, indicates an increased likelihood of a positive clinical outcome.
In another aspect, the invention concerns a method of predicting the duration of Recurrence-Free Interval (RFI) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 1.2A, 1.2B, 5.2A and/or 5.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1.2A or 5.2A, or the corresponding expression product, indicates that said RFI is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 1.2B or 5.2B, or the corresponding expression product, indicates that said RFI is predicted to be longer.
In another aspect, the invention concerns a method of predicting Overall Survival (OS) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 2.2A and/or 2.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 2.2A, or the corresponding expression product, indicates that said OS is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 2.2B, or the corresponding expression product, indicates that said OS is predicted to be longer.
In another aspect, the invention concerns a method of predicting Disease-Free Survival (DFS) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 3.2A and/or 3.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 3.2A; or the corresponding expression product, indicates that said DFS is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 3.2B, or the corresponding expression product, indicates that said DFS is predicted to be longer.
In another aspect, the invention concerns a method of predicting the duration of Distant Recurrence-Free Interval (DRFI) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 4.2A and/or 4.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 4.2A, or the corresponding expression product, indicates that said DRFI is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 4.2B, or the corresponding expression product, indicates that said DRFI is predicted to be longer.
In another aspect, the invention concerns a method of predicting clinical outcome for a subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising determining evidence of the expression level of one or more predictive RNA transcripts listed in Tables 1A-B, 1.2A-B, 2A-B, 2.2A-B, 3A-B, 3.2A-B, 4A-B, 4.2A-B, 5A-B, 5.2A-B, 6, 6.2, 7 and/or 7.2, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1A, 1.2A, 2A, 2.2A, 3A, 3.2A, 4A, 4.2A, 5A and/or 5.2A, or the corresponding expression product, indicates a decreased likelihood of a positive clinical outcome; and (b) evidence of increased expression of one or more of the genes listed in Table 1B, 1.2B, 2B, 2.2B, 3B, 3.2B, 4B, 4.2B, 5B and/or 5.2B, or the corresponding expression product, indicates an increased likelihood of a positive clinical outcome.
In another aspect, the invention concerns a method of predicting the duration of Recurrence-Free Interval (RFI) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 1A, 1.2A, 1B, 1.2B, 5A, 5.2A, 5B and/or 5.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1A, 1.2A, 5A and/or 5.2A, or the corresponding expression product, indicates that said RFI is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 1B, 1.2B, 5B and/or 5.2B, or the corresponding expression product, indicates that said RFI is predicted to be longer.
In another aspect, the invention concerns a method of predicting Overall Survival (OS) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 2A, 2.2A, 2B and/or 2.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 2A and/or 2.2A, or the corresponding expression product, indicates that said OS is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 2B and/or 2.2B, or the corresponding expression product, indicates that said OS is predicted to be longer.
In another aspect, the invention concerns a method of predicting Disease-Free Survival (DFS) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 3A, 3.2A, 3B and/or 3.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 3A and/or 3.2A, or the corresponding expression product, indicates that said DFS is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 3B and/or 3.2B, or the corresponding expression product, indicates that said DFS is predicted to be longer.
In another aspect, the invention concerns a method of predicting the duration of Distant Recurrence-Free Interval (DRFI) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 4A, 4.2A, 4B and/or 4.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 4A and/or 4.2A, or the corresponding expression product, indicates that said DRFI is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 4B and/or 4.2B, or the corresponding expression product, indicates that said DRFI is predicted to be longer.
In another aspect, the invention concerns a method of predicting clinical outcome in a subject diagnosed with Dukes B (stage II) colorectal cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts selected from the group consisting of ALCAM, CD24, CDH11, CENPE, CLTC, CYR61, EMR3, ICAM2, LOX, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SIR2, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, WIF, CAPG, CD28, CDC20, CKS1B, DKK1, HSD17B2, and MMP7, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein: (a) evidence of increased expression of one or more of the genes selected from the group consisting of ALCAM, CD24, CDH11, CENPE, CLTC, CYR61, EMR3, ICAM2, LOX, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SIR2, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or the corresponding expression product, indicates a decreased likelihood of positive clinical outcome; and (b) evidence of increased expression of one or more of the genes selected from the group consisting of CAPG, CD28, CDC20, CKS1B, DKK1, HSD17B2, and MMP7, or the corresponding expression product, indicates an increased likelihood of positive clinical outcome.
In another aspect, the invention concerns a method of predicting clinical outcome in a subject diagnosed with Dukes C (stage III) colorectal cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts selected from the group consisting of CAPG, CD28, CKS1B, CYR61, DKK1, HSD17B2, LOX, MMP7, SIR2, ALCAM, CD24, CDC20, CDH11, CENPE, CLTC, EMR3, ICAM2, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein: (a) evidence of increased expression of one or more of the genes selected from the group consisting of CAPG, CD28, CKS1B, CYR61, DKK1, HSD17B2, LOX, MMP7, and SIR2, or the corresponding expression product, indicates a decreased likelihood of positive clinical outcome; and (b) evidence of increased expression of one or more of the genes selected from the group consisting of ALCAM, CD24, CDC20, CDH11, CENPE, CLTC, EMR3, ICAM2, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or the corresponding expression product, indicates an increased likelihood of positive clinical outcome.
For all aspects of the method of the invention, determining the expression level of one or more genes may be obtained, for example, by a method of gene expression profiling. The method of gene expression profiling may be, for example, a PCR-based method.
For all aspects of the invention, the expression levels of the genes may be normalized relative to the expression levels of one or more reference genes, or their expression products.
For all aspects of the invention, the subject preferably is a human patient.
For all aspects of the invention, the method may further comprise determining evidence of the expression levels of at least two of said genes, or their expression products. It is further contemplated that the method of the invention may further comprise determining evidence of the expression levels of at least three of said genes, or their expression products. It is also contemplated that the method of the invention may further comprise determining evidence of the expression levels of at least four of said genes, or their expression products. It is also contemplated that the method of the invention may further comprise determining evidence of the expression levels of at least five of said genes, or their expression products.
For all, aspects of the invention, the method may further comprise the step of creating a report summarizing said prediction.
For all aspects of the invention, it is contemplated that for every increment of an increase in the level of one or more predictive RNA transcripts or their expression products, the patient is identified to show an incremental increase in clinical outcome.
For all aspects of the invention, the determination of expression levels may occur more than one time. For all aspects of the invention, the determination of expression levels may occur before the patient is subjected to any therapy following surgical resection.
In a different aspect the invention is directed to a report comprising the predicted clinical outcome in a subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising a prediction of clinical outcome based on information comprising the expression level of one or more predictive RNA transcripts listed in Tables 1A-B, 2A-B, 3A-B, 4A-B, 5A-B, 6 and/or 7, or their expression products, in a biological sample comprising cancer cells obtained from said subject wherein: (a) evidence of increased expression of one or more of the genes listed in Table 1A, 2A, 3A, 4A, and/or 5A, or the corresponding expression product, indicates a decreased likelihood of a positive clinical outcome; and (b) evidence of increased expression of one or more of the genes listed in Table 1B, 2B, 3B, 4B and/or 5B, or the corresponding expression product, indicates an increased likelihood of a positive clinical outcome. The clinical outcome of the report of the invention may be expressed, for example, in terms of Recurrence-Free Interval (RFI), Overall Survival (OS), Disease-Free Survival (DFS), or Distant Recurrence-Free Interval (DRFI). In one embodiment that cancer is Dukes B (stage II) or Dukes C (stage III) colorectal cancer. The prediction of clinical outcome may comprise an estimate of the likelihood of a particular clinical outcome for a subject or may comprise the classification of a subject into a risk group based on said estimate.
In another aspect the invention is directed to a report predicting clinical outcome for a subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising a prediction of clinical outcome based on information comprising the expression level of one or more predictive RNA transcripts listed in Tables 1.2A-B, 2.2A-B, 3.2A-B, 4.2A-B, 5.2A-B, 6.2 and/or 7.2, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1.2A, 2.2A, 3.2A, 4.2A and/or 5.2A, or the corresponding expression product, indicates a decreased likelihood of a positive clinical outcome; and (b) evidence of increased expression of one or more of the genes listed in Table 1.2B, 2.2B, 3.2B, 4.2B and/or 5.2B, or the corresponding expression product, indicates an increased likelihood of a positive clinical outcome. The clinical outcome of the report of the invention may be expressed, for example, in terms of Recurrence-Free Interval (RFI), Overall Survival (OS), Disease-Free Survival (DFS), or Distant Recurrence-Free Interval (DRFI). In one embodiment that cancer is Dukes B (stage II) or Dukes C (stage III) colorectal cancer. The prediction of clinical outcome may comprise an estimate of the likelihood of a particular clinical outcome for a subject or may comprise the classification of a subject into a risk group based on said estimate.
In another aspect, the invention concerns a report predicting clinical outcome for a subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising a prediction of clinical outcome based on information comprising the expression level of one or more predictive RNA transcripts listed in Tables 1A-B, 1.2A-B, 2A-B, 2.2A-B, 3A-B, 3.2A-B, 4A-B, 4.2A-B, 5A-B, 5.2A-B, 6, 6.2, 7 and/or 7.2, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1A, 1.2A, 2A, 2.2A, 3A, 3.2A, 4A, 4.2A, 5A and/or 5.2A, or the corresponding expression product, indicates a decreased likelihood of a positive clinical outcome; and (b) evidence of increased expression of one or more of the genes listed in Table 1B, 1.2B, 2B, 2.2B, 3B, 3.2B, 4B, 4.2B, 5B and/or 5.2B, or the corresponding expression product, indicates an increased likelihood of a positive clinical outcome. The prediction of clinical outcome may comprise an estimate of the likelihood of a particular clinical outcome for a subject or may comprise the classification of a subject into a risk group based on said estimate.
In another aspect the invention is directed to a report predicting clinical outcome in a subject diagnosed with Dukes B (stage II) colorectal cancer following surgical resection of said cancer, comprising a prediction of clinical outcome based on information comprising the expression level of one or more predictive RNA transcripts selected from the group consisting of ALCAM, CD24, CDH11, CENPE, CLTC, CYR61, EMR3, ICAM2, LOX, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SIR2, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, WIF, CAPG, CD28, CDC20, CKS1B, DKK1, HSD17B2, and MMP7, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein: (a) evidence of increased expression of one or more of the genes selected from the group consisting of ALCAM, CD24, CDH11, CENPE, CLTC, CYR61, EMR3, ICAM2, LOX, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SIR2, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or the corresponding expression product, indicates a decreased likelihood of positive clinical outcome; and (b) evidence of increased expression of one or more of the genes selected from the group consisting of CAPG, CD28, CDC20, CKS1B, DKK1, HSD17B2, and MMP7, or the corresponding expression product, indicates an increased likelihood of positive clinical outcome. The prediction of clinical outcome may comprise an estimate of the likelihood of a particular clinical outcome for a subject or may comprise the classification of a subject into a risk group based on said estimate.
In another aspect the invention is directed to a report predicting clinical outcome in a subject diagnosed with Dukes C (stage III) colorectal cancer following surgical resection of said cancer, comprising a prediction of clinical outcome based on information comprising the expression level of one or more predictive RNA transcripts selected from the group consisting of CAPG, CD28, CKS1B, CYR61, DKK1, HSD17B2, LOX, MMP7, SIR2, ALCAM, CD24, CDC20, CDH11, CENPE, CLTC, EMR3, ICAM2, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein: (a) evidence of increased expression of one or more of the genes selected from the group consisting of CAPG, CD28, CKS1B, CYR61, DKK1, HSD17B2, LOX, MMP7, and SIR2, or the corresponding expression product, indicates a decreased likelihood of positive clinical outcome; and (b) evidence of increased expression of one or more of the genes selected from the group consisting of ALCAM, CD24, CDC20, CDH11, CENPE, CLTC, EMR3, ICAM2, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or the corresponding expression product, indicates an increased likelihood of positive clinical outcome. The prediction of clinical outcome may comprise an estimate of the likelihood of a particular clinical outcome for a subject or may comprise the classification of a subject into a risk group based on said estimate.
In a different aspect the invention concerns a kit comprising one or more of (1) extraction buffer/reagents and protocol; (2) reverse transcription buffer/reagents and protocol; and (3) qPCR buffer/reagents and protocol suitable for performing the methods of this invention. The kit may comprise data retrieval and analysis software.



BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 shows a dendrogram representing the expression clustering of 142 genes that were statistically significantly related to recurrence-free interval (Tables 1.2A and 1.2B) in the univariate Cox proportional hazards analysis. The cluster analysis used the unweighted pair-group average amalgamation method and 1-Pearson r as the distance measure. The identities of particular genes in clusters of interest are indicated along the x-axis.



DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
A. Definitions
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, N.Y. 1994), and March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 4th ed., John Wiley & Sons (New York, N.Y. 1992), provide one skilled in the art with a general guide to many of the terms used in the present application.
One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defined below.
The term “tumor,” as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
The terms “cancer” and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, breast cancer, ovarian cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.
The “pathology” of cancer includes all phenomena that compromise the well-being of the patient. This includes, without limitation, abnormal or uncontrollable cell growth, metastasis, interference with the normal functioning of neighboring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, neoplasia, premalignancy, malignancy, invasion of surrounding or distant tissues or organs, such as lymph nodes, etc.
The term “colorectal cancer” is used in the broadest sense and refers to (1) all stages and all forms of cancer arising from epithelial cells of the large intestine and/or rectum and/or (2) all stages and all forms of cancer affecting the lining of the large intestine and/or rectum. In the staging systems used for classification of colorectal cancer, the colon and rectum are treated as one organ.
According to the tumor, node, metastatis (TNM) staging system of the American Joint Committee on Cancer (AJCC) (Greene et al. (eds.), AJCC Cancer Staging Manual. 6th Ed. New York, N.Y.: Springer; 2002), the various stages of colorectal cancer are defined as follows:
Tumor: T1: tumor invades submucosa; T2: tumor invades muscularis propria; T3: tumor invades through the muscularis propria into the subserose, or into the pericolic or perirectal tissues; T4: tumor directly invades other organs or structures, and/or perforates.
Node: N0: no regional lymph node metastasis; N1: metastasis in 1 to 3 regional lymph nodes; N2: metastasis in 4 or more regional lymph nodes.
Metastasis: M0: mp distant metastasis; M1: distant metastasis present.
Stage groupings: Stage I: T1 N0 M0; T2 N0 M0; Stage II: T3 N0 M0; T4 N0 M0; Stage III: any T, N1-2; M0; Stage 1V: any T, any N, M1.
According to the Modified Duke Staging System, the various stages of colorectal cancer are defined as follows:
Stage A: the tumor penetrates into the mucosa of the bowel wall but not further. Stage B: tumor penetrates into and through the muscularis propria of the bowel wall; Stage C: tumor penetrates into but not through muscularis propria of the bowel wall, there is pathologic evidence of colorectal cancer in the lymph nodes; or tumor penetrates into and through the muscularis propria of the bowel wall, there is pathologic evidence of cancer in the lymph nodes; Stage D: tumor has spread beyond the confines of the lymph nodes, into other organs, such as the liver, lung or bone.
Prognostic factors are those variables related to the natural history of colorectal cancer, which influence the recurrence rates and outcome of patients once they have developed colorectal cancer. Clinical parameters that have been associated with a worse prognosis include, for example, lymph node involvement, and high grade tumors. Prognostic factors are frequently used to categorize patients into subgroups with different baseline relapse risks.
The term “prognosis” is used herein to refer to the prediction of the likelihood of cancer-attributable death or progression, including recurrence, metastatic spread, and drug resistance, of a neoplastic disease, such as colon cancer.
The term “prediction” is used herein to refer to the likelihood that a patient will have a particular clinical outcome, whether positive or negative, following surgical removal of the primary tumor. The predictive methods of the present invention can be used clinically to make treatment decisions by choosing the most appropriate treatment modalities for any particular patient. The predictive methods of the present invention are valuable tools in predicting if a patient is likely to respond favorably to a treatment regimen, such as surgical intervention. The prediction may include prognostic factors.
The term “positive clinical outcome” means an improvement in any measure of patient status, including those measures ordinarily used in the art, such as an increase in the duration of Recurrence-Free interval (RFI), an increase in the time of Overall Survival (OS), an increase in the time of Disease-Free Survival (DFS), an increase in the duration of Distant Recurrence-Free Interval (DRFI), and the like. An increase in the likelihood of positive clinical outcome corresponds to a decrease in the likelihood of cancer recurrence.
The term “risk classification” means the level of risk or the prediction that a subject will experience a particular clinical outcome. A subject may be classified into a risk group or classified at a level of risk based on the predictive methods of the present invention. A “risk group” is a group of subjects or individuals with a similar level of risk for a particular clinical outcome.
The term “long-term” survival is used herein to refer to survival for at least 3 years, more preferably for at least 5 years.
The term “Recurrence-Free Interval (RFI)” is used herein to refer to time in years to first colon cancer recurrence censoring for second primary cancer as a first event or death without evidence of recurrence.
The term “Overall Survival (OS)” is used herein to refer to time in years from surgery to death from any cause.
The term “Disease-Free Survival (DFS)” is used herein to refer to time in years to colon cancer recurrence or death from any cause.
The term “Distant Recurrence-Free Interval (DRFI)” is used herein to refer to the time (in years) from surgery to the first anatomically distant cancer recurrence.
The calculation of the measures listed above in practice may vary from study to study depending on the definition of events to be either censored or not considered.
The term “microarray” refers to an ordered arrangement of hybridizable array elements, preferably polynucleotide probes, on a substrate.
The term “polynucleotide,” when used in singular or plural, generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as defined herein include, without limitation, single- and double-stranded DNA, DNA including single- and double-stranded regions, single- and double-stranded RNA, and RNA including single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or include single- and double-stranded regions. In addition, the term “polynucleotide” as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. The term “polynucleotide” specifically includes cDNAs. The term includes DNAs (including cDNAs) and RNAs that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are “polynucleotides” as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritiated bases, are included within the term “polynucleotides” as defined herein. In general, the term “polynucleotide” embraces all chemically, enzymatically and/or metabolically modified forms of unmodified polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells.
The term “oligonucleotide” refers to a relatively short polynucleotide, including, without limitation, single-stranded deoxyribonucleotides, single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are often synthesized by chemical methods, for example using automated oligonucleotide synthesizers that are commercially available. However, oligonucleotides can be made by a variety of other methods, including in vitro recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms.
The terms “differentially expressed gene,” “differential gene expression” and their synonyms, which are used interchangeably, refer to a gene whose expression is activated to a higher or lower level in a subject suffering from a disease, specifically cancer, such as colon cancer, relative to its expression in a normal or control subject. The terms also include genes whose expression is activated to a higher or lower level at different stages of the same disease. It is also understood that a differentially expressed gene may be either activated or inhibited at the nucleic acid level or protein level, or may be subject to alternative splicing to result in a different polypeptide product. Such differences may be evidenced by a change in mRNA levels, surface expression, secretion or other partitioning of a polypeptide, for example. Differential gene expression may include a comparison of expression between two or more genes or their gene products, or a comparison of the ratios of the expression between two or more genes or their gene products, or even a comparison of two differently processed products of the same gene, which differ between normal subjects and subjects suffering from a disease, specifically cancer, or between various stages of the same disease. Differential expression includes both quantitative, as well as qualitative, differences in the temporal or cellular expression pattern in a gene or its expression products among, for example, normal and diseased cells, or among cells which have undergone different disease events or disease stages. For the purpose of this invention, “differential gene expression” is considered to be present when there is at least an about two-fold, preferably at least about four-fold, more preferably at least about six-fold, most preferably at least about ten-fold difference between the expression of a given gene in normal and diseased subjects, or in various stages of disease development in a diseased subject.
The term “over-expression” with regard to an RNA transcript is used to refer to the level of the transcript determined by normalization to the level of reference mRNAs, which might be all measured transcripts in the specimen or a particular reference set of mRNAs.
The phrase “gene amplification” refers to a process by which multiple copies of a gene or gene fragment are formed in a particular cell or cell line. The duplicated region (a stretch of amplified DNA) is often referred to as “amplicon.” Usually, the amount of the messenger RNA (mRNA) produced, i.e., the level of gene expression, also increases in the proportion of the number of copies made of the particular gene expressed.
“Stringency” of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).
“Stringent conditions” or “high stringency conditions”, as defined herein, typically: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50% formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5×Denhardt's solution, sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC (sodium chloride/sodium citrate) and 50% formamide, followed by a high-stringency wash consisting of 0.1×SSC containing EDTA at 55° C.
“Moderately stringent conditions” may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and % SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37° C. in a solution comprising: 20% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1×SSC at about 37-50° C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.
In the context of the present invention, reference to “at least one,” “at least two,” “at least five,” etc. of the genes listed in any particular gene set means any one or any and all combinations of the genes listed.
The term “node negative” cancer, such as “node negative” colon cancer, is used herein to refer to cancer that has not spread to the lymph nodes.
The terms “splicing” and “RNA splicing” are used interchangeably and refer to RNA processing that removes introns and joins exons to produce mature mRNA with continuous coding sequence that moves into the cytoplasm of an eukaryotic cell.
In theory, the term “exon” refers to any segment of an interrupted gene that is represented in the mature RNA product (B. Lewin. Genes IV Cell Press, Cambridge Mass. 1990). In theory the term “intron” refers to any segment of DNA that is transcribed but removed from within the transcript by splicing together the exons on either side of it. Operationally, exon sequences occur in the mRNA sequence of a gene as defined by Ref. SEQ ID numbers. Operationally, intron sequences are the intervening sequences within the genomic DNA of a gene, bracketed by exon sequences and having GT and AG splice consensus sequences at their 5′ and 3′ boundaries.
The term “expression cluster” is used herein to refer to a group of genes which demonstrate similar expression patterns when studied within samples from a defined set of patients. As used herein, the genes within an expression cluster show similar expression patterns when studied within samples from patients with Stage II and/or Stage III cancers of the colon and/or rectum.
B.1 General Description of the Invention
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, 2nd edition (Sambrook et al., 1989); “Oligonucleotide Synthesis” (M. J. Gait, ed., 1984); “Animal Cell Culture” (R. I. Freshney, ed., 1987); “Methods in Enzymology” (Academic Press, Inc.); “Handbook of Experimental Immunology”, 4th edition (D. M. Weir & C. C. Blackwell, eds., Blackwell Science Inc., 1987); “Gene Transfer Vectors for Mammalian Cells” (J. M. Miller & M. P. Calos, eds., 1987); “Current Protocols in Molecular Biology” (F. M. Ausubel et al., eds., 1987); and “PCR: The Polymerase Chain Reaction”, (Mullis et al., eds., 1994).
Based on evidence of differential expression of RNA transcripts in normal and cancer cells, the present invention provides prognostic gene markers for colorectal cancer. Thus, in a particular aspect, the invention provides prognostic gene markers of Stage II and/or Stage III colorectal cancer, including markers that are specifically prognostic to the outcome of either Stage II or Stage III disease and those that have prognostic value at both stages, reflecting underlying differences in tumor cells in the two stages and/or in the extent of tumor progression. The prognostic markers and associated information provided by the present invention allow physicians to make more intelligent treatment decisions, and to customize the treatment of colorectal cancer to the needs of individual patients, thereby maximizing the benefit of treatment and minimizing the exposure of patients to unnecessary treatments, which do not provide any significant benefits and often carry serious risks due to toxic side-effects.
Disruptions in the normal functioning of various physiological processes, including proliferation, apoptosis, angiogenesis and invasion, have been implicated in the pathology in cancer. The relative contribution of dysfunctions in particular physiological processes to the pathology of particular cancer types is not well characterized. Any physiological process integrates the contributions of numerous gene products expressed by the various cells involved in the process. For example, tumor cell invasion of adjacent normal tissue and intravasation of the tumor cell into the circulatory system are effected by an array of proteins that mediate various cellular characteristics, including cohesion among tumor cells, adhesion of tumor cells to normal cells and connective tissue, ability of the tumor cell first to alter its morphology and then to migrate through surrounding tissues, and ability of the tumor cell to degrade surrounding connective tissue structures.
Multi-analyte gene expression tests can measure the expression level of one or more genes involved in each of several relevant physiologic processes or component cellular characteristics. In some instances the predictive power of the test, and therefore its utility, can be improved by using the expression values obtained for individual genes to calculate a score which is more highly correlated with outcome than is the expression value of the individual genes. For example, the calculation of a quantitative score (recurrence score) that predicts the likelihood of recurrence in estrogen receptor-positive, node-negative breast cancer is describe in a co-pending U.S. Patent application (Publication Number 20050048542). The equation used to calculate such a recurrence score may group genes in order to maximize the predictive value of the recurrence score. The grouping of genes may be performed at least in part based on knowledge of their contribution to physiologic functions or component cellular characteristics such as discussed above. The formation of groups, in addition, can facilitate the mathematical weighting of the contribution of various expression values to the recurrence score. The weighting of a gene group representing a physiological process or component cellular characteristic can reflect the contribution of that process or characteristic to the pathology of the cancer and clinical outcome. Accordingly, in an important aspect, the present invention also provides specific groups of the prognostic genes identified herein, that together are more reliable and powerful predictors of outcome than the individual genes or random combinations of the genes identified.
In addition, based on the determination of a recurrence score, one can choose to partition patients into subgroups at any particular value(s) of the recurrence score, where all patients with values in a given range can be classified as belonging to a particular risk group. Thus, the values chosen will define subgroups of patients with respectively greater or lesser risk.
The utility of a gene marker in predicting colon cancer outcome may not be unique to that marker. An alternative marker having a expression pattern that is closely similar to a particular test marker may be substituted for or used in addition to a test marker and have little impact on the overall predictive utility of the test. The closely similar expression patterns of two genes may result from involvement of both genes in a particular process and/or being under common regulatory control in colon tumor cells. The present invention specifically includes and contemplates the use of such substitute genes or gene sets in the methods of the present invention.
The prognostic markers and associated information provided by the present invention predicting the clinical outcome in Stage II and/or Stage III cancers of the colon and/or rectum has utility in the development of drugs to treat Stage II and/or Stage III cancers of the colon and/or rectum.
The prognostic markers and associated information provided by the present invention predicting the clinical outcome in Stage II and/or Stage III cancers of the colon and/or rectum also have utility in screening patients for inclusion in clinical trials that test the efficacy of drug compounds for the treatment of patients with Stage II and/or Stage III cancers of the colon and/or rectum. In particular the prognostic markers may be used on samples collected from patients in a clinical trial and the results of the test used in conjunction with patient outcomes in order to determine whether subgroups of patients are more or less likely to show a response to the drug than the whole group or other subgroups.
The prognostic markers and associated information provided by the present invention predicting the clinical outcome in Stage II and/or Stage III cancers of the colon and/or rectum are useful as inclusion criterion for a clinical trial. For example, a patient is more likely to be included in a clinical trial if the results of the test indicate a higher likelihood that the patient will have a poor clinical outcome if treated with surgery alone and a patient is less likely to be included in a clinical trial if the results of the test indicate a lower likelihood that the patient will have a poor clinical outcome if treated with surgery alone.
In a particular embodiment, prognostic markers and associated information are used to design or produce a reagent that modulates the level or activity of the gene's transcript or its expression product. Said reagents may include but are not limited to an antisense RNA, a small inhibitory RNA, a ribozyme, a monoclonal or polyclonal antibody.
In a further embodiment, said gene or its transcript, or more particularly, an expression product of said transcript is used in an (screening) assay to identify a drug compound, wherein said drug compounds is used in the development of a drug to treat Stage II and/or Stage III cancers of the colon and/or rectum.
In various embodiments of the inventions, various technological approaches are available for determination of expression levels of the disclosed genes, including, without limitation, RT-PCR, microarrays, serial analysis of gene expression (SAGE) and Gene Expression Analysis by Massively Parallel Signature Sequencing (MPSS), which will be discussed in detail below. In particular embodiments, the expression level of each gene may be determined in relation to various features of the expression products of the gene including exons, introns, protein epitopes and protein activity. In other embodiments, the expression level of a gene may be inferred from analysis of the structure of the gene, for example from the analysis of the methylation pattern of gene's promoter(s).
B.2 Gene Expression Profiling
Methods of gene expression profiling include methods based on hybridization analysis of polynucleotides, methods based on sequencing of polynucleotides, and proteomics-based methods. The most commonly used methods known in the art for the quantification of mRNA expression in a sample include northern blotting and in situ hybridization (Parker & Barnes, Methods in Molecular Biology 106:247-283 (1999)); RNAse protection assays (Hod, Biotechniques 13:852-854 (1992)); and PCR-based methods, such as reverse transcription polymerase chain reaction (RT-PCR) (Weis et al., Trends in Genetics 8:263-264 (1992)). Alternatively, antibodies may be employed that can recognize sequence-specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. Representative methods for sequencing-based gene expression analysis include Serial Analysis of Gene Expression (SAGE), and gene expression analysis by massively parallel signature sequencing (MPSS).
a. Reverse Transcriptase PCR (RT-PCR)
Of the techniques listed above, the most sensitive and most flexible quantitative method is RT-PCR, which can be used to determine mRNA levels in various samples. The results can be used to compare gene expression patterns between sample sets, for example in normal and tumor tissues and in patients with or without drug treatment.
The first step is the isolation of mRNA from a target sample. The starting material is typically total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines, respectively. Thus RNA can be isolated from a variety of primary tumors, including breast, lung, colon, prostate, brain, liver, kidney, pancreas, spleen, thymus, testis, ovary, uterus, etc., tumor, or tumor cell lines, with pooled DNA from healthy donors. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples.
General methods for mRNA extraction are well known in the art and are disclosed in standard textbooks of molecular biology, including Ausubel et al., Current Protocols of Molecular Biology, John Wiley and Sons (1997). Methods for RNA extraction from paraffin embedded tissues are disclosed, for example, in Rupp and Locker, Lab Invest. 56:A67 (1987), and De Andrés et al., BioTechniques 18:42044 (1995). In particular, RNA isolation can be performed using purification kit, buffer set and protease from commercial manufacturers, such as Qiagen, according to the manufacturer's instructions. For example, total RNA from cells in culture can be isolated using Qiagen RNeasy mini-columns. Other commercially available RNA isolation kits include MasterPureTM Complete DNA and RNA Purification Kit (EPICENTRE®, Madison, Wis.), and Paraffin Block RNA Isolation Kit (Ambion, Inc.). Total RNA from tissue samples can be isolated using RNA Stat-60 (Tel-Test). RNA prepared from tumor can be isolated, for example, by cesium chloride density gradient centrifugation.
As RNA cannot serve as a template for PCR, the first step in gene expression profiling by RT-PCR is the reverse transcription of the RNA template into cDNA, followed by its exponential amplification in a PCR reaction. The two most commonly used reverse transcriptases are avilo myeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murine leukemia virus reverse transcriptase (MMLV-RT). The reverse transcription step is typically primed using specific primers, random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression profiling. For example, extracted RNA can be reverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer, Calif., USA), following the manufacturer's instructions. The derived cDNA can then be used as a template in the subsequent PCR reaction.
Although the PCR step can use a variety of thermostable DNA-dependent DNA polymerases, it typically employs the Taq DNA polymerase, which has a 5′-3′ nuclease activity but lacks a 3′-5′ proofreading endonuclease activity. Thus, TaqMan® PCR typically utilizes the 5′-nuclease activity of Taq or Tth polymerase to hydrolyze a hybridization probe bound to its target amplicon, but any enzyme with equivalent 5′ nuclease activity can be used. Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction. A third oligonucleotide, or probe, is designed to detect nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe. During the amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner. The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.
TaqMan® RT-PCR can be performed using commercially available equipment, such as, for example, ABI PRISM 7700TM Sequence Detection SystemTM (Perkin-Elmer-Applied Biosystems, Foster City, Calif., USA), or Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany). In a preferred embodiment, the 5′ nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7700TM Sequence Detection SystemTM. The system consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 96-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.
5′-Nuclease assay data are initially expressed as Ct, or the threshold cycle. As discussed above, fluorescence values are recorded during every cycle and represent the amount of product amplified to that point in the amplification reaction. The point when the fluorescent signal is first recorded as statistically significant is the threshold cycle (Ct).
To minimize errors and the effect of sample-to-sample variation, RT-PCR is usually performed using an internal standard. The ideal internal standard is expressed at a constant level among different tissues, and is unaffected by the experimental treatment. RNAs most frequently used to normalize patterns of gene expression are mRNAs for the housekeeping genes glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and β-actin.
A more recent variation of the RT-PCR technique is the real time quantitative PCR, which measures PCR product accumulation through a dual-labeled fluorigenic probe (i.e., TaqMan® probe). Real time PCR is compatible both with quantitative competitive PCR, where internal competitor for each target sequence is used for normalization, and with quantitative comparative PCR using a normalization gene contained within the sample, or a housekeeping gene for RT-PCR. For further details see, e.g. Held et al., Genome Research 6:986-994 (1996).
The steps of a representative protocol for profiling gene expression using fixed, paraffin-embedded tissues as the RNA source, including mRNA isolation, purification, primer extension and amplification are given in various published journal articles (for example: T. E. Godfrey et al. J. Molec. Diagnostics 2: 84-91 (2000); K. Specht et al., Am. J. Pathol. 158: 419-29 (2001)). Briefly, a representative process starts with cutting about 10 μm thick sections of paraffin-embedded tumor tissue samples. The RNA is then extracted, and protein and DNA are removed. After analysis of the RNA concentration, RNA repair and/or amplification steps may be included, if necessary, and RNA is reverse transcribed using gene specific promoters followed by RT-PCR.
b. MassARRAY System
In the MassARRAY-based gene expression profiling method, developed by Sequenom, Inc. (San Diego, Calif.) following the isolation of RNA and reverse transcription, the obtained cDNA is spiked with a synthetic DNA molecule (competitor), which matches the targeted cDNA region in all positions, except a single base, and serves as an internal standard. The cDNA/competitor mixture is PCR amplified and is subjected to a post-PCR shrimp alkaline phosphatase (SAP) enzyme treatment, which results in the dephosphorylation of the remaining nucleotides. After inactivation of the alkaline phosphatase, the PCR products from the competitor and cDNA are subjected to primer extension, which generates distinct mass signals for the competitor- and cDNA-derives PCR products. After purification, these products are dispensed on a chip array, which is pre-loaded with components needed for analysis with matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis. The cDNA present in the reaction is then quantified by analyzing the ratios of the peak areas in the mass spectrum generated. For further details see, e.g. Ding and Cantor, Proc. Natl. Acad. Sci. USA 100:3059-3064 (2003).
c. Other PCR-Based Methods
Further PCR-based techniques include, for example, differential display (Liang and Pardee, Science 257:967-971 (1992)); amplified fragment length polymorphism (iAFLP) (Kawamoto et al., Genome Res. 12:1305-1312 (1999)); BeadArrayTM technology (Illumina, San Diego, Calif.; Oliphant et al., Discovery of Markers for Disease (Supplement to Biotechniques), June 2002; Ferguson et al., Analytical Chemistry 72:5618 (2000)); BeadsArray for Detection of Gene Expression (BADGE), using the commercially available Luminex100 LabMAP system and multiple color-coded microspheres (Luminex Corp., Austin, Tex.) in a rapid assay for gene expression (Yang et al., Genome Res. 11:1888-1898 (2001)); and high coverage expression profiling (HiCEP) analysis (Fukumura et al., Nucl. Acids. Res. 31(16) e94 (2003)).
d. Microarrays
Differential gene expression can also be identified, or confirmed using the microarray technique. Thus, the expression profile of colon cancer-associated genes can be measured in either fresh or paraffin-embedded tumor tissue, using microarray technology. In this method, polynucleotide sequences of interest (including cDNAs and oligonucleotides) are plated, or arrayed, on a microchip substrate. The arrayed sequences are then hybridized with specific DNA probes from cells or tissues of interest. Just as in the RT-PCR method, the source of mRNA typically is total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines. Thus RNA can be isolated from a variety of primary tumors or tumor cell lines. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples, which are routinely prepared and preserved in everyday clinical practice.
In a specific embodiment of the microarray technique, PCR amplified inserts of cDNA clones are applied to a substrate in a dense array. Preferably at least 10,000 nucleotide sequences are applied to the substrate. The microarrayed genes, immobilized on the microchip at 10,000 elements each, are suitable for hybridization under stringent conditions. Fluorescently labeled cDNA probes may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest. Labeled cDNA probes applied to the chip hybridize with specificity to each spot of DNA on the array. After stringent washing to remove non-specifically bound probes, the chip is scanned by confocal laser microscopy or by another detection method, such as a CCD camera. Quantitation of hybridization of each arrayed element allows for assessment of corresponding mRNA abundance. With dual color fluorescence, separately labeled cDNA probes generated from two sources of RNA are hybridized pair wise to the array. The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously. The miniaturized scale of the hybridization affords a convenient and rapid evaluation of the expression pattern for large numbers of genes. Such methods have been shown to have the sensitivity required to detect rare transcripts, which are expressed at a few copies per cell, and to reproducibly detect at least approximately two-fold differences in the expression levels (Schena et al., Proc. Natl. Acad. Sci. USA 93(2):106-149 (1996)). Microarray analysis can be performed by commercially available equipment, following manufacturer's protocols, such as by using the Affymetrix GenChip technology, or Incyte's microarray technology.
The development of microarray methods for large-scale analysis of gene expression makes it possible to search systematically for molecular markers of cancer classification and outcome prediction in a variety of tumor types.
e. Serial Analysis of Gene Expression (SAGE)
Serial analysis of gene expression (SAGE) is a method that allows the simultaneous and quantitative analysis of a large number of gene transcripts, without the need of providing an individual hybridization probe for each transcript. First, a short sequence tag (about 10-14 bp) is generated that contains sufficient information to uniquely identify a transcript, provided that the tag is obtained from a unique position within each transcript. Then, many transcripts are linked together to form long serial molecules, that can be sequenced, revealing the identity of the multiple tags simultaneously. The expression pattern of any population of transcripts can be quantitatively evaluated by determining the abundance of individual tags, and identifying the gene corresponding to each tag. For more details see, e.g. Velculescu et al., Science 270:484-487 (1995); and Velculescu et al., Cell 88:243-51 (1997).
f. Gene Expression Analysis by Massively Parallel Signature Sequencing (MPSS)
This method, described by Brenner et al., Nature Biotechnology 18:630-634 (2000), is a sequencing approach that combines non-gel-based signature sequencing with in vitro cloning of millions of templates on separate 5 μm diameter microbeads. First, a microbead library of DNA templates is constructed by in vitro cloning. This is followed by the assembly of a planar array of the template-containing microbeads in a flow cell at a high density (typically greater than 3×106 microbeads/cm2). The free ends of the cloned templates on each microbead are analyzed simultaneously, using a fluorescence-based signature sequencing method that does not require DNA fragment separation. This method has been shown to simultaneously and accurately provide, in a single operation, hundreds of thousands of gene signature sequences from a yeast cDNA library.
g. Immunohistochemistry
Immunohistochemistry methods are also suitable for detecting the expression levels of the prognostic markers of the present invention. Thus, antibodies or antisera, preferably polyclonal antisera, and most preferably monoclonal antibodies specific for each marker are used to detect expression. The antibodies can be detected by direct labeling of the antibodies themselves, for example, with radioactive labels, fluorescent labels, hapten labels such as, biotin, or an enzyme such as horse radish peroxidase or alkaline phosphatase. Alternatively, unlabeled primary antibody is used in conjunction with a labeled secondary antibody, comprising antisera, polyclonal antisera or a monoclonal antibody specific for the primary antibody. Immunohistochemistry protocols and kits are well known in the art and are commercially available.
h. Proteomics
The term “proteome” is defined as the totality of the proteins present in a sample (e.g. tissue, organism, or cell culture) at a certain point of time. Proteomics includes, among other things, study of the global changes of protein expression in a sample (also referred to as “expression proteomics”). Proteomics typically includes the following steps: (1) separation of individual proteins in a sample by 2-D gel electrophoresis (2-D PAGE); (2) identification of the individual proteins recovered from the gel, e.g. my mass spectrometry or N-terminal sequencing, and (3) analysis of the data using bioinformatics. Proteomics methods are valuable supplements to other methods of gene expression profiling, and can be used, alone or in combination with other methods, to detect the products of the prognostic markers of the present invention.
i. Promoter Methylation Analysis
A number of methods for quantization of RNA transcripts (gene expression analysis) or their protein translation products are discussed herein. The expression level of genes may also be inferred from information regarding chromatin structure, such as for example the methylation status of gene promoters and other regulatory elements and the acetylation status of histones.
In particular, the methylation status of a promoter influences the level of expression of the gene regulated by that promoter. Aberrant methylation of particular gene promoters has been implicated in expression regulation, such as for example silencing of tumor suppressor genes. Thus, examination of the methylation status of a gene's promoter can be utilized as a surrogate for direct quantization of RNA levels.
Several approaches for measuring the methylation status of particular DNA elements have been devised, including methylation-specific PCR (Herman J. G. et al. (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA. 93, 9821-9826.) and bisulfite DNA sequencing (Frommer M. et al. (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA. 89, 1827-1831.). More recently, microarray-based technologies have been used to characterize promoter methylation status (Chen C. M. (2003) Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. Am. J. Pathol. 163, 37-45.).
j. Coexpression of Genes
A further aspect of the invention is the identification of gene expression clusters. Gene expression clusters can be identified by analysis of expression data using statistical analyses known in the art, including pairwise analysis of correlation based on Pearson correlation coefficients (Pearson K. and Lee A. (1902) Biometrika 2, 357).
In one embodiment, an expression cluster identified herein includes BGN, CALD1, COL1A1, COL1A2, SPARC, VIM and other genes which are known to be synthesized predominantly by stromal cells and to be involved in remodeling extracellular matrix. This expression cluster is referred to herein as the Extracellular Matrix Remodeling/Stromal cluster.
In another embodiment, an expression cluster identified herein includes ANXA2, KLK6, KLK10, LAMA3, LAMC2, MASPIN, SLPI, and other genes encoding epithelial cell secreted products, most of which are secreted predominantly by epithelial cells but which may be secreted by other cell types. This expression cluster is referred to herein as the Epithelial/Secreted cluster.
In still another embodiment, an expression cluster identified herein includes DUSP1, EGR1, EGR3, FOS, NR4A1, RHOB, and other genes whose transcription is upregulated early after exposure of cells to certain stimuli. A variety of stimuli trigger transcription of early response genes, e.g. exposure to growth factor s, which enables cells to quickly increase their motility and their ability to transport nutrients such as glucose. This expression cluster is referred to herein as the Early Response cluster.
In yet another embodiment, an expression cluster identified herein includes MCP1, CD68, CTSB, OPN, and other genes encoding proteins usually associated with cells of the immune system. This expression cluster is referred to herein as the Immune cluster.
In a further embodiment, an expression cluster identified herein includes CCNE2, CDC20, SKP2, CHK1, BRCA1, CSEL1 and other genes implicated in cell proliferation and regulation of the cell cycle. This expression cluster is referred to herein as the Proliferation/Cell Cycle cluster.
k. General Description of the mRNA Isolation, Purification and Amplification
The steps of a representative protocol for profiling gene expression using fixed, paraffin-embedded tissues as the RNA source, including mRNA isolation, purification, primer extension and amplification are provided in various published journal articles (for example: T. E. Godfrey et al., J. Molec. Diagnostics 2: 84-91 (2000); K. Specht et al., Am. J. Pathol. 158: 419-29 (2001)). Briefly, a representative process starts with cutting about 10 μm thick sections of paraffin-embedded tumor tissue samples. The RNA is then extracted, and protein and DNA are removed. After analysis of the RNA concentration, RNA repair and/or amplification steps may be included, if necessary, and RNA is reverse transcribed using gene specific promoters followed by RT-PCR. Finally, the data are analyzed to identify the best treatment option(s) available to the patient on the basis of the characteristic gene expression pattern identified in the tumor sample examined, dependent on the predicted likelihood of cancer recurrence.
l. Colon Cancer Gene Set, Assayed Gene Subsequences, and Clinical Application of Gene Expression Data
An important aspect of the present invention is to use the measured expression of certain genes by colon cancer tissue to provide prognostic information. For this purpose it is necessary to correct for (normalize away) both differences in the amount of RNA assayed and variability in the quality of the RNA used. Therefore, the assay typically measures and incorporates the expression of certain normalizing genes, including well known housekeeping genes, such as GAPDH and Cyp1. Alternatively, normalization can be based on the mean or median signal (Ct) of all of the assayed genes or a large subset thereof (global normalization approach). On a gene-by-gene basis, measured normalized amount of a patient tumor mRNA is compared to the amount found in a colon cancer tissue reference set. The number (N) of colon cancer tissues in this reference set should be sufficiently high to ensure that different reference sets (as a whole) behave essentially the same way. If this condition is met, the identity of the individual colon cancer tissues present in a particular set will have no significant impact on the relative amounts of the genes assayed. Usually, the colon cancer tissue reference set consists of at least about 30, preferably at least about 40 different FPE colon cancer tissue specimens. Unless noted otherwise, normalized expression levels for each mRNA/tested tumor/patient will be expressed as a percentage of the expression level measured in the reference set. More specifically, the reference set of a sufficiently high number (e.g. 40) of tumors yields a distribution of normalized levels of each mRNA species. The level measured in a particular tumor sample to be analyzed falls at some percentile within this range, which can be determined by methods well known in the art. Below, unless noted otherwise, reference to expression levels of a gene assume normalized expression relative to the reference set although this is not always explicitly stated.
m. Design of Intron-Based PCR Primers and Probes
According to one aspect of the present invention, PCR primers and probes are designed based upon intron sequences present in the gene to be amplified. Accordingly, the first step in the primer/probe design is the delineation of intron sequences within the genes. This can be done by publicly available software, such as the DNA BLAT software developed by Kent, W. J., Genome Res. 12(4):656-64 (2002), or by the BLAST software including its variations. Subsequent steps follow well established methods of PCR primer and probe design.
In order to avoid non-specific signals, it is important to mask repetitive sequences within the introns when designing the primers and probes. This can be easily accomplished by using the Repeat Masker program available on-line through the Baylor College of Medicine, which screens DNA sequences against a library of repetitive elements and returns a query sequence in which the repetitive elements are masked. The masked intron sequences can then be used to design primer and probe sequences using any commercially or otherwise publicly available primer/probe design packages, such as Primer Express (Applied Biosystems); MGB assay-by-design (Applied Biosystems); Primer3 (Steve Rozen and Helen J. Skaletsky (2000) Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S (eds) Bioinformatics Methods and Protocols: Methods in Molecular Biology. Humana Press, Totowa, N.J., pp 365-386).
The most important factors considered in PCR primer design include primer length, melting temperature (Tm), and G/C content, specificity, complementary primer sequences, and 3′-end sequence. In general, optimal PCR primers are generally 17-30 bases in length, and contain about 20-80%, such as, for example, about 50-60% G+C bases. Tm's between 50 and 80° C., e.g. about 50 to 70° C. are typically preferred.
For further guidelines for PCR primer and probe design see, e.g. Dieffenbach, C. W. et al., “General Concepts for PCR Primer Design” in: PCR Primer, A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, 1995, pp. 133-155; Innis and Gelfand, “Optimization of PCRs” in: PCR Protocols, A Guide to Methods and Applications, CRC Press, London, 1994, pp. 5-11; and Plasterer, T. N. Primerselect: Primer and probe design. Methods Mol. Biol. 70:520-527 (1997), the entire disclosures of which are hereby expressly incorporated by reference.
n. Kits of the Invention
The materials for use in the methods of the present invention are suited for preparation of kits produced in accordance with well known procedures. The invention thus provides kits comprising agents, which may include gene-specific or gene-selective probes and/or primers, for quantitating the expression of the disclosed genes for predicting prognostic outcome or response to treatment. Such kits may optionally contain reagents for the extraction of RNA from tumor samples, in particular fixed paraffin-embedded tissue samples and/or reagents for RNA amplification. In addition, the kits may optionally comprise the reagent(s) with an identifying description or label or instructions relating to their use in the methods of the present invention. The kits may comprise containers (including microtiter plates suitable for use in an automated implementation of the method), each with one or more of the various reagents (typically in concentrated form) utilized in the methods, including, for example, pre-fabricated microarrays, buffers, the appropriate nucleotide triphosphates (e.g., dATP, dCTP, dGTP and dTTP; or rATP, rCTP, rGTP and UTP), reverse transcriptase, DNA polymerase, RNA polymerase, and one or more probes and primers of the present invention (e.g., appropriate length poly(T) or random primers linked to a promoter reactive with the RNA polymerase). Mathematical algorithms used to estimate or quantify prognostic or predictive information are also properly potential components of kits.
o. Reports of the Invention
The methods of this invention, when practiced for commercial diagnostic purposes generally produce a report or summary of the normalized expression levels of one or more of the selected genes. The methods of this invention will produce a report comprising a prediction of the clinical outcome of a subject diagnosed with colorectal cancer following surgical resection of said cancer. The methods and reports of this invention can further include storing the report in a database. Alternatively, the method can further create a record in a database for the subject and populate the record with data. In one embodiment the report is a paper report, in another embodiment the report is an auditory report, in another embodiment the report is an electronic record. It is contemplated that the report is provided to a physician and/or the patient. The receiving of the report can further include establishing a network connection to a server computer that includes the data and report and requesting the data and report from the server computer.
The methods provided by the present invention may also be automated in whole or in part.
All aspects of the present invention may also be practiced such that a limited number of additional genes that are co-expressed with the disclosed genes, for example as evidenced by high Pearson correlation coefficients, are included in a prognostic or predictive test in addition to and/or in place of disclosed genes.
Having described the invention, the same will be more readily understood through reference to the following Example, which is provided by way of illustration, and is not intended to limit the invention in any way.
EXAMPLES
A Study to Explore Relationships Between Genomic Tumor Expression Profiles and the Likelihood of Recurrence in Dukes' B and Duke's C Patients Treated with Resection of the Colon
The primary objective of this study was to determine whether there is a significant relationship between the expression of each of 757 amplicons identified in Table B and clinical outcome in stage II and stage III colon cancer patients who receive colon resection (surgery) without chemotherapy.
Study Design
This was an exploratory study using tissue and outcome data from National Surgical Adjuvant Breast and Bowel Project (NSABP) Studies C-01 and C-02 in up to 400 Dukes B (stage II) and Dukes C (stage III) patients who received colon resection (surgery) only or surgery and postoperative Bacillus Calmette-Guerin (BCG).
Inclusion Criteria
Patients enrolled in either NSABP Study C-01: “A Clinical Trial To Evaluate Postoperative Immunotherapy And Postoperative Systemic Chemotherapy In The Management Of Resectable Colon Cancer” or NSABP Study C-02: “A Protocol To Evaluate The Postoperative Portal Vein Infusion Of 5-Flourouracil And Heparin In Adenocarcinoma Of The Colon” Details of C-01 and C-02 can be found on the NSABP Website at the following URL:

    
    
        http://www.nsabp.pittedu/NSABP_Protocols.htm#treatment %20closed
    
    


Tissue samples from the surgery only and surgery+postoperative BCG arms of NSABP C01 and from the surgery only arm of NSABP C02 surgery were combined into one sample set.
Exclusion Criteria
Patients enrolled in NSABP Study C-01 or NSABP Study C-02 were excluded from the present study if one or more of the following applied:
No tumor block available from initial diagnosis in the NSABP archive.

    
    
        Insufficient tumor in block as assessed by examination of hematoxylin and eosin (H&E) slide
        Insufficient RNA (<700 ng) recovered from tissue sections for RT-PCR analysis.
    
    


Of 1943 patients enrolled in NSABP Study C-01 or NSABP Study C-02, 270 patient samples were available after application of exclusion criteria and used in the gene expression study disclosed herein. The overall demographic and clinical characteristics of the 270 included samples were similar to the original NSABP combined cohorts.
Gene Panel
Seven hundred sixty-one genes, including seven reference genes, were chosen for expression analysis. These genes are listed in Table A together with the sequences of primers and probes used in qRT-PCR to determine expression level.
Experimental Materials and Methods
The expression of 750 cancer-related genes and 7 genes designated for use as reference genes was quantitatively assessed for each patient using TaqMan® RT-PCR, which was performed in singlet with RNA input at 1 nanogram per reaction.
Data Analysis Methods
Reference Normalization
For normalization of extraneous effects, cycle threshold (CT) measurements obtained by RT-PCR were normalized relative to the mean expression of a set of six reference genes. The resulting reference-normalized expression measurements typically range from 0 to 15, where a one unit increase generally reflects a 2-fold increase in RNA quantity.
Comparison of Study Cohort to Original NSABP Study Populations
We compared the distribution of clinical and demographic variables for the current study cohort of evaluable tissue blocks versus the original NSABP C-01 and C-02 study populations. There were no clinically meaningful differences in the distributions.
Univariate Analysis
For each of the 757 amplicons under study, we used the Cox proportional hazard model to examine the relationship between gene expression and recurrence free interval (RFI). The likelihood ratio was used as the test of statistical significance. The method of Benjamini and Hochberg (Benjamini, Y. and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B 57, 289-300.), as well as resampling and permutation based methods (Tusher V G, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA, 98:5116-5121; Storey J D, Tibshirani R (2001) Estimating false discovery rates under dependence, with applications to DNA microarrays. Stanford: Stanford University, Department of Statistics; Report No.: Technical Report 2001-28; Korn E L, Troendle J, McShane L, Simon R (2001) Controlling the number of false discoveries: Application to high-dimensional genomic data. Technical Report 003. 2001. National Cancer Institute.) were applied to the resulting set of p-values to estimate false discovery rates. All analyses were repeated for each of the alternative endpoints: distant recurrence free interval (DRFI), overall survival (OS), and disease free survival (DFS).
Multivariate Analysis
For each of the 757 amplicons under study, we used the Cox proportional hazard model to examine the relationship between gene expression and RFI, while controlling for the effects of other standard clinical covariates (including tumor location, surgery type, tumor grade, number of lymph nodes examined, and number of positive lymph nodes. The difference in the log likelihoods of the (reduced) model including only the standard clinical covariates and the (full) model including the standard clinical covariates plus gene expression was used as the test of statistical significance.
Non-Linear Analysis
For each of the 757 amplicons under study, we explored alternative functional relationships between gene expression and recurrence using several different methods. For each amplicon, we fit a Cox proportional hazards model of RFI as a function of gene expression using a 2 degree-of-freedom (DF) natural spline (Stone C, Koo C. (1985) In Proceedings of the Statistical Computing Section ASA. Washington, D.C., 45-48). Statistical significance was assessed by the 2 DF likelihood ratio test for the model. Functional relationships were also explored by examining the pattern of (smoothed) Martingale residuals derived from univariate Cox proportional hazards models of RFI as a strictly linear function of gene expression (Gray RJ (1992) Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. Journal of the American Statistical Association, 87:942-951; Gray RJ (1994) Spline-based tests in survival analysis. Biometrics, 50:640-652; Gray RJ (1990) Some diagnostic methods for Cox regression models through hazard smoothing. Biometrics, 46:93-102.). Additionally, cumulative sums of Martingale residuals from each the same Cox proportional hazards models were used to detect departures from linearity (Lin D, Wei L, Ying Z. (1993) Checking the Cox Model with Cumulative Sums of Martingale-Based Residuals. Vol. 80, No. 3, 557-572).
Interaction with Stage
We determined whether there is a significantly different relationship between gene expression and RFI in stage II and stage III patients. For each of the 757 amplicons, we tested the hypothesis that there is a significant difference between the (reduced) proportional hazards model for gene expression and tumor stage versus the (full) proportional hazards model based on gene expression, tumor stage, and their interaction. The difference in the log likelihoods of the reduced and full models was used as the test of statistical significance.
Table A shows qRT-PCR probe and primer sequences for all genes included in the study described in the Example.
Table B shows target amplicons for all genes included in the study described in the Example.
First Analysis Study Results
Reference Gene set for the first analysis was CLTC, FZD6, NEDD8, RPLPO, RPS13, UBB, UBC.
Table 1A shows associations for those genes whose increased expression is predictive of shorter Recurrence-Free Interval (RFI) based on univariate proportional hazards analysis.
Table 1B shows associations for those genes whose increased expression is predictive of longer Recurrence-Free Interval (RFI) based on univariate proportional hazards analysis.
Table 2A shows associations for those genes whose increased expression is predictive of decreased rate of Overall Survival (OS) based on univariate proportional hazards analysis.
Table 2B shows associations for those genes whose increased expression is predictive of increased rate of Overall Survival (OS) based on univariate proportional hazards analysis.
Table 3A shows associations for those genes whose increased expression is predictive of decreased rate of Disease Free Survival (DFS) based on univariate proportional hazards analysis.
Table 3B shows associations for those genes whose increased expression is predictive of increased rate of Disease Free Survival (DFS) based on univariate proportional hazards analysis.
Table 4A shows associations for those genes whose increased expression is predictive of shorter Distant Recurrence-Free Interval (DRFI) based on univariate proportional hazards analysis.
Table 4B shows associations for those genes whose increased expression is predictive of longer Distant Recurrence-Free Interval (DRFI) based on univariate proportional hazards analysis.
Table 5A shows associations between gene expression and RFI for those genes whose increased expression is predictive of shorter Recurrence-Free Interval (RFI), based on a multivariate analysis controlling for particular demographic and clinical characteristics of patients included in the analysis.
Table 5B shows associations between gene expression and RFI for those genes whose increased expression is predictive of longer Recurrence-Free Interval (RFI), based on a multivariate analysis controlling for particular demographic and clinical characteristics of patients included in the analysis.
Table 6 shows genes for which an association between gene expression and clinical outcome was identified based on a nonlinear proportional hazards analysis, using a 2 degree-of-freedom natural spline.
Table 7 shows all genes exhibiting an interaction (p-value<0.05) with tumor stage.
Table 1A shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio>1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using RFI as the metric for clinical outcome.











TABLE 1A






Hazard


Accession


Gene
Ratio
P Value
OfficialSymbol
Number



















RARB
2.13
0.0252
RARB
NM_016152


ITGB1
1.94
0.0002
ITGB1
NM_002211


ALDOA
1.92
0.0853
ALDOA
NM_000034


ANXA2
1.90
<.0001
ANXA2
NM_004039


CYP3A4
1.81
0.0038
CYP3A4
NM_017460


KRAS2
1.64
0.0043
KRAS
NM_004985


COX2
1.62
0.0521
PTGS2
NM_000963


RhoC
1.61
0.0034
RHOC
NM_175744


TJP1
1.60
0.0554
TJP1
NM_003257


RhoB
1.57
0.0001
RHOB
NM_004040


KIAA0125
1.56
0.0940
KIAA0125
NM_014792


TIMP1
1.52
<.0001
TIMP1
NM_003254


UBC
1.49
0.0031
UBC
NM_021009


ANXA5
1.49
0.0084
ANXA5
NM_001154


NTN1
1.49
0.0386
NTN1
NM_004822


AKT3
1.47
<.0001
AKT3
NM_005465


CALD1
1.46
0.0007
CALD1
NM_004342


IGFBP7
1.46
0.0019
IGFBP7
NM_001553


VEGFC
1.45
0.0092
VEGFC
NM_005429


BGN
1.44
0.0002
BGN
NM_001711


CYP1B1
1.44
0.0180
CYP1B1
NM_000104


DLC1
1.43
0.0012
DLC1
NM_006094


SI
1.43
0.0063
SI
NM_001041


CCNE2 variant 1
1.43
0.0506
CCNE2
NM_057749


LAMC2
1.42
0.0003
LAMC2
NM_005562


TIMP2
1.42
0.0018
TIMP2
NM_003255


CDC42BPA
1.42
0.0029
CDC42BPA
NM_003607


p21
1.41
0.0062
CDKN1A
NM_000389


HB-EGF
1.40
0.0105
HBEGF
NM_001945


TLN1
1.40
0.0260
TLN1
NM_006289


DUSP1
1.39
<.0001
DUSP1
NM_004417


ROCK1
1.39
0.0121
ROCK1
NM_005406


CTSB
1.39
0.0307
CTSB
NM_001908


ITGAV
1.38
0.0020
ITGAV
NM_002210


HSPG2
1.38
0.0215
HSPG2
NM_005529


GADD45B
1.37
0.0002
GADD45B
NM_015675


VCL
1.37
0.0201
VCL
NM_003373


SBA2
1.37
0.0250
WSB2
NM_018639


Maspin
1.36
<.0001
SERPINB5
NM_002639


CGB
1.36
0.0018
CGB
NM_000737


TIMP3
1.36
0.0024
TIMP3
NM_000362


VIM
1.36
0.0073
VIM
NM_003380


S100A1
1.36
0.0247
S100A1
NM_006271


INHBA
1.35
0.0008
INHBA
NM_002192


SIR2
1.35
0.0039
SIRT1
NM_012238


TMSB10
1.35
0.0469
TMSB10
NM_021103


CD68
1.34
0.0036
CD68
NM_001251


RBX1
1.34
0.0469
RBX1
NM_014248


INHBB
1.34
0.0514
INHBB
NM_002193


PKR2
1.34
0.0628
PKM2
NM_002654


FOS
1.33
0.0006
FOS
NM_005252


FYN
1.33
0.0036
FYN
NM_002037


LOXL2
1.33
0.0064
LOXL2
NM_002318


STC1
1.33
0.0101
STC1
NM_003155


DKK1
1.33
0.0208
DKK1
NM_012242


IGFBP5
1.32
0.0064
IGFBP5
NM_000599


EPAS1
1.32
0.0270
EPAS1
NM_001430


UNC5C
1.32
0.0641
UNC5C
NM_003728


FAP
1.31
0.0017
FAP
NM_004460


IGFBP3
1.31
0.0041
IGFBP3
NM_000598


SNAI2
1.31
0.0055
SNAI2
NM_003068


PRKCA
1.31
0.0065
PRKCA
NM_002737


FST
1.31
0.0399
FST
NM_006350


KCNH2 iso a/b
1.31
0.0950
KCNH2
NM_000238


CTHRC1
1.30
0.0017
CTHRC1
NM_138455


PDGFC
1.30
0.0034
PDGFC
NM_016205


EGR1
1.30
0.0048
EGR1
NM_001964


TAGLN
1.30
0.0058
TAGLN
NM_003186


SPARC
1.30
0.0104
SPARC
NM_003118


KLF6
1.30
0.0514
KLF6
NM_001300


GRIK1
1.30
0.0753
GRIK1
NM_000830


CYR61
1.29
0.0018
CYR61
NM_001554


SLPI
1.29
0.0026
SLPI
NM_003064


COL1A2
1.29
0.0076
COL1A2
NM_000089


MAPK14
1.29
0.0916
MAPK14
NM_139012


LAMA3
1.28
0.0020
LAMA3
NM_000227


THBS1
1.28
0.0053
THBS1
NM_003246


NRP2
1.28
0.0120
NRP2
NM_003872


LOX
1.27
0.0028
LOX
NM_002317


S100A4
1.27
0.0067
S100A4
NM_002961


CXCR4
1.27
0.0083
CXCR4
NM_003467


CEBPB
1.27
0.0943
CEBPB
NM_005194


AKAP12
1.26
0.0044
AKAP12
NM_005100


ADAMTS12
1.26
0.0100
ADAMTS12
NM_030955


CRYAB
1.25
0.0038
CRYAB
NM_001885


Grb10
1.25
0.0108
GRB10
NM_005311


MCP1
1.25
0.0118
CCL2
NM_002982


COL1A1
1.25
0.0167
COL1A1
NM_000088


EFNB2
1.25
0.0241
EFNB2
NM_004093


ANXA1
1.25
0.0292
ANXA1
NM_000700


ANGPT2
1.25
0.0485
ANGPT2
NM_001147


EphB6
1.25
0.0825
EPHB6
NM_004445


HSPA1A
1.24
0.0018
HSPA1A
NM_005345


TGFB3
1.24
0.0081
TGFB3
NM_003239


PTGER3
1.24
0.0306
PTGER3
NM_000957


FXYD5
1.24
0.0367
FXYD5
NM_014164


CAPG
1.24
0.0604
CAPG
NM_001747


PDGFB
1.23
0.0157
PDGFB
NM_002608


ANTXR1
1.23
0.0164
ANTXR1
NM_032208


TGFBI
1.23
0.0191
TGFBI
NM_000358


CTGF
1.23
0.0233
CTGF
NM_001901


PDGFA
1.23
0.0274

NM_002607


P14ARF
1.23
0.0362

S78535


KLK10
1.22
0.0005
KLK10
NM_002776


ITGA5
1.22
0.0178
ITGA5
NM_002205


GBP2
1.22
0.0201
GBP2
NM_004120


SIAT4A
1.22
0.0231
ST3GAL1
NM_003033


GJB2
1.22
0.0271
GJB2
NM_004004


LAT
1.22
0.0306
LAT
NM_014387


CTSL
1.22
0.0331
CTSL
NM_001912


DAPK1
1.22
0.0384
DAPK1
NM_004938


SKP1A
1.22
0.0542
SKP1A
NM_006930


NDRG1
1.22
0.0712
NDRG1
NM_006096


ITGB5
1.22
0.0991
ITGB5
NM_002213


KLK6
1.21
0.0034
KLK6
NM_002774


SFRP2
1.21
0.0037
SFRP2
NM_003013


TMEPAI
1.21
0.0173
TMEPAI
NM_020182


ID4
1.21
0.0530
ID4
NM_001546


SFRP4
1.20
0.0077
SFRP4
NM_003014


HOXB7
1.20
0.0274
HOXB7
NM_004502


GJA1
1.20
0.0311
GJA1
NM_000165


CDH11
1.20
0.0662
CDH11
NM_001797


PAI1
1.19
0.0060
SERPINE1
NM_000602


S100P
1.19
0.0119
S100P
NM_005980


EGR3
1.19
0.0164
EGR3
NM_004430


EMP1
1.19
0.0460
EMP1
NM_001423


ABCC5
1.19
0.0536
ABCC5
NM_005688


FZD1
1.19
0.0701
FZD1
NM_003505


MAD
1.19
0.0811
MXD1
NM_002357


EFNA1
1.19
0.0920
EFNA1
NM_004428


OPN_osteopontin
1.18
0.0028
SPP1
NM_000582


ALDH1A1
1.18
0.0246
ALDH1A1
NM_000689


NR4A1
1.18
0.0277
NR4A1
NM_002135


SIAT7B
1.18
0.0301
ST6GALNAC2
NM_006456


p16-INK4
1.18
0.0439

L27211


TUBB
1.18
0.0761
TUBB2
NM_001069


IL6
1.18
0.0939
IL6
NM_000600


RAB32
1.18
0.0948
RAB32
NM_006834


TULP3
1.18
0.0953
TULP3
NM_003324


F3
1.17
0.0561
F3
NM_001993


PLK3
1.16
0.0792
PLK3
NM_004073


EPHA2
1.16
0.0962
EPHA2
NM_004431


SLC2A1
1.15
0.0745
SLC2A1
NM_006516


CXCL12
1.14
0.0911
CXCL12
NM_000609


S100A2
1.13
0.0287
S100A2
NM_005978


FABP4
1.13
0.0340
FABP4
NM_001442


STMY3
1.13
0.0517
MMP11
NM_005940


BCAS1
1.13
0.0939
BCAS1
NM_003657


REG4
1.11
0.0026
REG4
NM_032044


pS2
1.09
0.0605
TFF1
NM_003225


MUC2
1.06
0.0626
MUC2
NM_002457









Table 1B shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio<1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using RFI as the metric for clinical outcome.











TABLE 1B









Accession


Gene
Hazard Ratio
P Value
OfficialSymbol
Number



















ORC1L
0.42
0.0728
ORC1L
NM_004153


HSPA8
0.62
0.0430
HSPA8
NM_006597


E2F1
0.64
0.0009
E2F1
NM_005225


RAD54L
0.65
0.0026
RAD54L
NM_003579


RPLPO
0.67
0.0150
RPLP0
NM_001002


BRCA1
0.68
0.0001
BRCA1
NM_007295


DHFR
0.69
0.0096
DHFR
NM_000791


SLC25A3
0.69
0.0110
SLC25A3
NM_213611


PPM1D
0.71
0.0033
PPM1D
NM_003620


SKP2
0.71
0.0098
SKP2
NM_005983


FASN
0.72
0.0071
FASN
NM_004104


HNRPD
0.72
0.0686
HNRPD
NM_031370


ENO1
0.73
0.0418
ENO1
NM_001428


RPS13
0.75
0.0786
RPS13
NM_001017


DDB1
0.75
0.0804
DDB1
NM_001923


C20 orf1
0.76
0.0122
TPX2
NM_012112


KIF22
0.76
0.0137
KIF22
NM_007317


Chk1
0.76
0.0174
CHEK1
NM_001274


TCF-1
0.77
0.0021
TCF1
NM_000545


ST14
0.77
0.0446
ST14
NM_021978


RRM1
0.77
0.0740
RRM1
NM_001033


BRCA2
0.77
0.0800
BRCA2
NM_000059


LMNB1
0.78
0.0513
LMNB1
NM_005573


CMYC
0.79
0.0086
MYC
NM_002467


CDC20
0.79
0.0290
CDC20
NM_001255


CSEL1
0.79
0.0344
CSE1L
NM_001316


Bax
0.79
0.0662
BAX
NM_004324


NME1
0.79
0.0742
NME1
NM_000269


c-myb (MYB
0.80
0.0077
MYB
NM_005375


official)


CDCA7 v2
0.80
0.0159
CDCA7
NM_145810


EFP
0.80
0.0405
TRIM25
NM_005082


UBE2M
0.80
0.0437
UBE2M
NM_003969


RRM2
0.81
0.0168
RRM2
NM_001034


ABCC6
0.81
0.0373
ABCC6
NM_001171


SURV
0.81
0.0584
BIRC5
NM_001168


CKS2
0.81
0.0753
CKS2
NM_001827


RAF1
0.81
0.0899
RAF1
NM_002880


EPHB2
0.82
0.0190
EPHB2
NM_004442


NOTCH1
0.82
0.0232
NOTCH1
NM_017617


UMPS
0.82
0.0456
UMPS
NM_000373


CCNE2
0.82
0.0544
CCNE2
NM_057749


PI3KC2A
0.82
0.0916
PIK3C2A
NM_002645


CD80
0.82
0.0954
CD80
NM_005191


AREG
0.83
0.0014
AREG
NM_001657


EREG
0.83
0.0062
EREG
NM_001432


MYBL2
0.83
0.0259
MYBL2
NM_002466


ABCB1
0.83
0.0322
ABCB1
NM_000927


HRAS
0.83
0.0760
HRAS
NM_005343


SLC7A5
0.84
0.0585
SLC7A5
NM_003486


MAD2L1
0.84
0.0590
MAD2L1
NM_002358


Ki-67
0.85
0.0620
MKI67
NM_002417


MCM2
0.85
0.0700
MCM2
NM_004526


ING5
0.85
0.0947
ING5
NM_032329


Cdx2
0.88
0.0476
CDX2
NM_001265


PTPRO
0.89
0.0642
PTPRO
NM_030667


cripto (TDGF1
0.90
0.0803
TDGF1
NM_003212


official)









Table 2A shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio>1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using OS as the metric for clinical outcome.











TABLE 2A






Hazard


Accession


Gene
Ratio
P Value
OfficialSymbol
Number



















RARB
1.75
0.0820
RARB
NM_016152


RhoC
1.70
0.0001
RHOC
NM_175744


ANXA2
1.64
0.0002
ANXA2
NM_004039


CYP3A4
1.58
0.0064
CYP3A4
NM_017460


p21
1.54
<.0001
CDKN1A
NM_000389


ITGB1
1.54
0.0058
ITGB1
NM_002211


UBC
1.50
0.0003
UBC
NM_021009


TNF
1.46
0.0859
TNF
NM_000594


VEGFC
1.44
0.0049
VEGFC
NM_005429


HMLH
1.44
0.0435
MLH1
NM_000249


RhoB
1.37
0.0015
RHOB
NM_004040


TGFBR1
1.37
0.0127
TGFBR1
NM_004612


SPINT2
1.37
0.0235
SPINT2
NM_021102


PFN1
1.37
0.0842
PFN1
NM_005022


HSPG2
1.36
0.0115
HSPG2
NM_005529


TIMP1
1.35
0.0008
TIMP1
NM_003254


INHBB
1.35
0.0190
INHBB
NM_002193


VCL
1.34
0.0099
VCL
NM_003373


KCNH2 iso a/b
1.33
0.0362
KCNH2
NM_000238


LAMC2
1.32
0.0005
LAMC2
NM_005562


FXYD5
1.31
0.0021
FXYD5
NM_014164


HLA-G
1.31
0.0458
HLA-G
NM_002127


GADD45B
1.30
0.0002
GADD45B
NM_015675


CDC42
1.30
0.0120
CDC42
NM_001791


LAMB3
1.30
0.0163
LAMB3
NM_000228


DKK1
1.30
0.0209
DKK1
NM_012242


UNC5C
1.30
0.0452
UNC5C
NM_003728


UBL1
1.29
0.0171
SUMO1
NM_003352


HB-EGF
1.29
0.0262
HBEGF
NM_001945


KRAS2
1.29
0.0726
KRAS
NM_004985


ID3
1.28
0.0023
ID3
NM_002167


LOXL2
1.28
0.0039
LOXL2
NM_002318


EphB6
1.28
0.0322
EPHB6
NM_004445


DUSP1
1.27
0.0003
DUSP1
NM_004417


BGN
1.27
0.0040
BGN
NM_001711


CALD1
1.27
0.0119
CALD1
NM_004342


CDC42BPA
1.27
0.0151
CDC42BPA
NM_003607


SBA2
1.27
0.0373
WSB2
NM_018639


INHBA
1.26
0.0018
INHBA
NM_002192


NRP1
1.26
0.0113
NRP1
NM_003873


TIMP2
1.26
0.0123
TIMP2
NM_003255


KLF6
1.26
0.0444
KLF6
NM_001300


KLK10
1.25
<.0001
KLK10
NM_002776


TIMP3
1.25
0.0083
TIMP3
NM_000362


CAPG
1.25
0.0170
CAPG
NM_001747


IGFBP7
1.25
0.0249
IGFBP7
NM_001553


S100A1
1.25
0.0529
S100A1
NM_006271


SHC1
1.25
0.0605
SHC1
NM_003029


CTSB
1.25
0.0766
CTSB
NM_001908


ANXA5
1.25
0.0787
ANXA5
NM_001154


PKR2
1.25
0.0800
PKM2
NM_002654


HSPA1A
1.24
0.0003
HSPA1A
NM_005345


CGB
1.24
0.0148
CGB
NM_000737


DLC1
1.24
0.0231
DLC1
NM_006094


TMSB10
1.24
0.0890
TMSB10
NM_021103


LAMA3
1.23
0.0017
LAMA3
NM_000227


FOS
1.23
0.0028
FOS
NM_005252


SNAI2
1.23
0.0123
SNAI2
NM_003068


SPARC
1.23
0.0134
SPARC
NM_003118


SIR2
1.23
0.0173
SIRT1
NM_012238


KRT19
1.23
0.0217
KRT19
NM_002276


CTSD
1.23
0.0395
CTSD
NM_001909


EPAS1
1.23
0.0409
EPAS1
NM_001430


GAGE4
1.23
0.0468
GAGE4
NM_001474


BMP4
1.22
0.0024
BMP4
NM_001202


PLK3
1.22
0.0056
PLK3
NM_004073


Grb10
1.22
0.0059
GRB10
NM_005311


FYN
1.22
0.0120
FYN
NM_002037


STC1
1.22
0.0409
STC1
NM_003155


G-Catenin
1.22
0.0661
JUP
NM_002230


HK1
1.22
0.0872
HK1
NM_000188


MADH4
1.22
0.0956
SMAD4
NM_005359


KLK6
1.21
0.0011
KLK6
NM_002774


CTHRC1
1.21
0.0065
CTHRC1
NM_138455


LAT
1.21
0.0146
LAT
NM_014387


IGFBP3
1.21
0.0149
IGFBP3
NM_000598


AKT3
1.21
0.0212
AKT3
NM_005465


HSPA1B
1.21
0.0262
HSPA1B
NM_005346


THY1
1.21
0.0278
THY1
NM_006288


ANXA1
1.21
0.0322
ANXA1
NM_000700


LOX
1.20
0.0067
LOX
NM_002317


CD68
1.20
0.0223
CD68
NM_001251


EFNB2
1.20
0.0268
EFNB2
NM_004093


DYRK1B
1.20
0.0473
DYRK1B
NM_004714


PTK2
1.20
0.0889
PTK2
NM_005607


THBS1
1.19
0.0203
THBS1
NM_003246


TAGLN
1.19
0.0263
TAGLN
NM_003186


TULP3
1.19
0.0334
TULP3
NM_003324


SR-A1
1.19
0.0387
SR-A1
NM_021228


APC
1.19
0.0433
APC
NM_000038


ERK1
1.19
0.0488

Z11696


VIM
1.19
0.0661
VIM
NM_003380


CREBBP
1.19
0.0802
CREBBP
NM_004380


ANGPT2
1.19
0.0860
ANGPT2
NM_001147


Maspin
1.18
0.0029
SERPINB5
NM_002639


PDGFB
1.18
0.0252
PDGFB
NM_002608


S100A4
1.18
0.0270
S100A4
NM_002961


EGR1
1.18
0.0334
EGR1
NM_001964


IGFBP5
1.18
0.0526
IGFBP5
NM_000599


NOTCH2
1.18
0.0527
NOTCH2
NM_024408


PAI1
1.17
0.0036
SERPINE1
NM_000602


NR4A1
1.17
0.0110
NR4A1
NM_002135


BCAS1
1.17
0.0137
BCAS1
NM_003657


BRK
1.17
0.0137
PTK6
NM_005975


AKAP12
1.17
0.0195
AKAP12
NM_005100


EMP1
1.17
0.0291
EMP1
NM_001423


SIAT4A
1.17
0.0304
ST3GAL1
NM_003033


MRP3
1.17
0.0334
ABCC3
NM_003786


COL1A1
1.17
0.0399
COL1A1
NM_000088


Upa
1.17
0.0588
PLAU
NM_002658


UNC5B
1.17
0.0986
UNC5B
NM_170744


PDGFC
1.16
0.0355
PDGFC
NM_016205


MCP1
1.16
0.0449
CCL2
NM_002982


CTGF
1.16
0.0576
CTGF
NM_001901


COL1A2
1.16
0.0612
COL1A2
NM_000089


RAB32
1.16
0.0645
RAB32
NM_006834


SIN3A
1.16
0.0787
SIN3A
NM_015477


SKP1A
1.16
0.0837
SKP1A
NM_006930


EFNA1
1.16
0.0957
EFNA1
NM_004428


S100A2
1.15
0.0040
S100A2
NM_005978


MMP7
1.15
0.0374
MMP7
NM_002423


HOXB7
1.15
0.0405
HOXB7
NM_004502


FAP
1.15
0.0455
FAP
NM_004460


ANTXR1
1.15
0.0482
ANTXR1
NM_032208


TGFBI
1.15
0.0553
TGFBI
NM_000358


TMEPAI
1.14
0.0435
TMEPAI
NM_020182


CYR61
1.14
0.0490
CYR61
NM_001554


SLPI
1.14
0.0724
SLPI
NM_003064


TP53I3
1.14
0.0831
TP53I3
NM_004881


PDGFA
1.14
0.0845

NM_002607


SFRP2
1.13
0.0255
SFRP2
NM_003013


S100A8
1.13
0.0693
S100A8
NM_002964


F3
1.13
0.0708
F3
NM_001993


Bcl2
1.13
0.0962
BCL2
NM_000633


OPN_osteopontin
1.12
0.0097
SPP1
NM_000582


FZD6
1.12
0.0692
FZD6
NM_003506


OSM
1.11
0.0744
OSM
NM_020530


EGLN3
1.11
0.0884
EGLN3
NM_022073


SIAT7B
1.11
0.0938
ST6GALNAC2
NM_006456


FABP4
1.10
0.0454
FABP4
NM_001442


EFNA3
1.10
0.0958
EFNA3
NM_004952


MMP2
1.10
0.0969
MMP2
NM_004530


GSTT1
1.09
0.0737
GSTT1
NM_000853


REG4
1.07
0.0286
REG4
NM_032044









Table 2B shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio<1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using OS as the metric for clinical outcome.











TABLE 2B






Hazard


Accession


Gene
Ratio
P Value
Official Symbol
Number



















HSPA8
0.62
0.0145
HSPA8
NM_006597


SKP2
0.70
0.0010
SKP2
NM_005983


DHFR
0.74
0.0085
DHFR
NM_000791


PRDX4
0.74
0.0197
PRDX4
NM_006406


RRM1
0.75
0.0162
RRM1
NM_001033


SLC25A3
0.75
0.0342
SLC25A3
NM_213611


RPLPO
0.75
0.0416
RPLP0
NM_001002


E2F1
0.78
0.0190
E2F1
NM_005225


SURV
0.79
0.0086
BIRC5
NM_001168


c-myb (MYB
0.80
0.0020
MYB
NM_005375


official)


BRCA1
0.80
0.0077
BRCA1
NM_007295


Chk1
0.80
0.0186
CHEK1
NM_001274


ST14
0.80
0.0407
ST14
NM_021978


TCF-1
0.81
0.0045
TCF1
NM_000545


CCNE2
0.81
0.0112
CCNE2
NM_057749


PPM1D
0.81
0.0194
PPM1D
NM_003620


CDC20
0.81
0.0213
CDC20
NM_001255


EI24
0.81
0.0585
EI24
NM_004879


C20 orf1
0.82
0.0348
TPX2
NM_012112


DUT
0.83
0.0396
DUT
NM_001948


CD44E
0.83
0.0439

X55150


KIF22
0.83
0.0506
KIF22
NM_007317


PPID
0.83
0.0615
PPID
NM_005038


UBE2M
0.83
0.0805
UBE2M
NM_003969


LMNB1
0.83
0.0868
LMNB1
NM_005573


MCM2
0.84
0.0207
MCM2
NM_004526


CDC6
0.84
0.0218
CDC6
NM_001254


MRPL40
0.84
0.0769
MRPL40
NM_003776


EPHB2
0.85
0.0253
EPHB2
NM_004442


CMYC
0.85
0.0371
MYC
NM_002467


AURKB
0.85
0.0375
AURKB
NM_004217


CDCA7 v2
0.85
0.0421
CDCA7
NM_145810


ABCB1
0.86
0.0390
ABCB1
NM_000927


SMARCA3
0.86
0.0601
SMARCA3
NM_003071


Cdx2
0.88
0.0166
CDX2
NM_001265


PPARG
0.88
0.0645
PPARG
NM_005037


MYBL2
0.88
0.0647
MYBL2
NM_002466


EREG
0.89
0.0411
EREG
NM_001432


AREG
0.90
0.0235
AREG
NM_001657









Table 3A shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio>1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using DFS as the metric for clinical outcome.











TABLE 3A






Hazard

Official
Accession


Gene
Ratio
P Value
Symbol
Number



















ANXA2
1.74
<.0001
ANXA2
NM_004039


CYP3A4
1.69
0.0020
CYP3A4
NM_017460


RhoC
1.53
0.0009
RHOC
NM_175744


TJP1
1.45
0.0787
TJP1
NM_003257


UBC
1.43
0.0007
UBC
NM_021009


p21
1.42
0.0004
CDKN1A
NM_000389


HB-EGF
1.39
0.0032
HBEGF
NM_001945


SPINT2
1.37
0.0154
SPINT2
NM_021102


HMLH
1.36
0.0711
MLH1
NM_000249


VEGFC
1.35
0.0157
VEGFC
NM_005429


PKR2
1.34
0.0187
PKM2
NM_002654


LAMC2
1.33
0.0002
LAMC2
NM_005562


ITGB1
1.33
0.0499
ITGB1
NM_002211


TIMP1
1.32
0.0007
TIMP1
NM_003254


VCL
1.31
0.0114
VCL
NM_003373


INHBB
1.31
0.0302
INHBB
NM_002193


GADD45B
1.30
<.0001
GADD45B
NM_015675


RhoB
1.30
0.0053
RHOB
NM_004040


DUSP1
1.28
<.0001
DUSP1
NM_004417


HK1
1.28
0.0297
HK1
NM_000188


GRIK1
1.28
0.0364
GRIK1
NM_000830


FOS
1.27
0.0002
FOS
NM_005252


CGB
1.27
0.0126
CGB
NM_000737


KLF6
1.27
0.0288
KLF6
NM_001300


ANXA5
1.27
0.0504
ANXA5
NM_001154


KRAS2
1.27
0.0724
KRAS
NM_004985


INHBA
1.26
0.0009
INHBA
NM_002192


DLC1
1.26
0.0096
DLC1
NM_006094


IGFBP7
1.26
0.0116
IGFBP7
NM_001553


BGN
1.25
0.0039
BGN
NM_001711


LOXL2
1.25
0.0076
LOXL2
NM_002318


STC1
1.25
0.0135
STC1
NM_003155


CTSD
1.25
0.0208
CTSD
NM_001909


HSPG2
1.25
0.0485
HSPG2
NM_005529


KCNH2 iso a/b
1.25
0.0832
KCNH2
NM_000238


TIMP3
1.24
0.0057
TIMP3
NM_000362


FXYD5
1.24
0.0070
FXYD5
NM_014164


A-Catenin
1.24
0.0447
CTNNA1
NM_001903


LOX
1.23
0.0013
LOX
NM_002317


EGR1
1.23
0.0037
EGR1
NM_001964


CAPG
1.23
0.0191
CAPG
NM_001747


LAMB3
1.23
0.0377
LAMB3
NM_000228


GAGE4
1.23
0.0402
GAGE4
NM_001474


SHC1
1.23
0.0640
SHC1
NM_003029


MVP
1.23
0.0726
MVP
NM_017458


VEGF
1.22
0.0250
VEGF
NM_003376


UNC5B
1.22
0.0256
UNC5B
NM_170744


CDC42BPA
1.22
0.0297
CDC42BPA
NM_003607


SBA2
1.22
0.0614
WSB2
NM_018639


DKK1
1.22
0.0689
DKK1
NM_012242


EphB6
1.22
0.0763
EPHB6
NM_004445


IGFBP3
1.21
0.0078
IGFBP3
NM_000598


HSPA1B
1.21
0.0167
HSPA1B
NM_005346


CALD1
1.21
0.0277
CALD1
NM_004342


TIMP2
1.21
0.0309
TIMP2
NM_003255


NR4A1
1.20
0.0023
NR4A1
NM_002135


LAMA3
1.20
0.0028
LAMA3
NM_000227


SIAT4A
1.20
0.0082
ST3GAL1
NM_003033


PDGFB
1.20
0.0084
PDGFB
NM_002608


EMP1
1.20
0.0107
EMP1
NM_001423


THBS1
1.20
0.0126
THBS1
NM_003246


CD68
1.20
0.0143
CD68
NM_001251


FYN
1.20
0.0151
FYN
NM_002037


TULP3
1.20
0.0213
TULP3
NM_003324


EFNA1
1.20
0.0254
EFNA1
NM_004428


SIR2
1.20
0.0255
SIRT1
NM_012238


G-Catenin
1.20
0.0689
JUP
NM_002230


S100A1
1.20
0.0998
S100A1
NM_006271


Maspin
1.19
0.0013
SERPINB5
NM_002639


HSPA1A
1.19
0.0013
HSPA1A
NM_005345


SPARC
1.19
0.0359
SPARC
NM_003118


PTHR1
1.19
0.0801
PTHR1
NM_000316


SNAI2
1.18
0.0353
SNAI2
NM_003068


KRT19
1.18
0.0419
KRT19
NM_002276


ERK1
1.18
0.0459

Z11696


KLK10
1.17
0.0007
KLK10
NM_002776


BMP4
1.17
0.0121
BMP4
NM_001202


CYR61
1.17
0.0127
CYR61
NM_001554


Grb10
1.17
0.0216
GRB10
NM_005311


PLK3
1.17
0.0242
PLK3
NM_004073


EFNB2
1.17
0.0403
EFNB2
NM_004093


P14ARF
1.17
0.0439

S78535


ID3
1.17
0.0446
ID3
NM_002167


IGFBP5
1.17
0.0503
IGFBP5
NM_000599


THY1
1.17
0.0574
THY1
NM_006288


VIM
1.17
0.0858
VIM
NM_003380


EPAS1
1.17
0.0897
EPAS1
NM_001430


PAI1
1.16
0.0039
SERPINE1
NM_000602


F3
1.16
0.0172
F3
NM_001993


CTHRC1
1.16
0.0181
CTHRC1
NM_138455


ANTXR1
1.16
0.0237
ANTXR1
NM_032208


FAP
1.16
0.0289
FAP
NM_004460


ADAMTS12
1.16
0.0350
ADAMTS12
NM_030955


CTGF
1.16
0.0424
CTGF
NM_001901


PTGER3
1.16
0.0569
PTGER3
NM_000957


ANXA1
1.16
0.0699
ANXA1
NM_000700


NRP1
1.16
0.0797
NRP1
NM_003873


NDRG1
1.16
0.0856
NDRG1
NM_006096


KLK6
1.15
0.0092
KLK6
NM_002774


EGR3
1.15
0.0153
EGR3
NM_004430


HOXB7
1.15
0.0345
HOXB7
NM_004502


PDGFC
1.15
0.0363
PDGFC
NM_016205


Herstatin
1.15
0.0403

AF177761


MCP1
1.15
0.0409
CCL2
NM_002982


TGFBI
1.15
0.0437
TGFBI
NM_000358


TP53I3
1.15
0.0438
TP53I3
NM_004881


SLPI
1.15
0.0457
SLPI
NM_003064


PLAUR
1.15
0.0471
PLAUR
NM_002659


GJB2
1.15
0.0610
GJB2
NM_004004


COL1A1
1.15
0.0647
COL1A1
NM_000088


IL6
1.15
0.0790
IL6
NM_000600


APC
1.15
0.0821
APC
NM_000038


S100A2
1.14
0.0048
S100A2
NM_005978


TMEPAI
1.14
0.0300
TMEPAI
NM_020182


PDGFA
1.14
0.0644

NM_002607


S100A4
1.14
0.0680
S100A4
NM_002961


TAGLN
1.14
0.0820
TAGLN
NM_003186


Upa
1.14
0.0823
PLAU
NM_002658


COL1A2
1.14
0.0856
COL1A2
NM_000089


OSM
1.13
0.0299
OSM
NM_020530


BRK
1.13
0.0479
PTK6
NM_005975


SEMA3B
1.13
0.0525
SEMA3B
NM_004636


OPN_osteopontin
1.12
0.0084
SPP1
NM_000582


S100P
1.12
0.0283
S100P
NM_005980


SFRP2
1.12
0.0291
SFRP2
NM_003013


EGLN3
1.12
0.0465
EGLN3
NM_022073


SIAT7B
1.12
0.0570
ST6GALNAC2
NM_006456


MMP7
1.12
0.0743
MMP7
NM_002423


FABP4
1.11
0.0195
FABP4
NM_001442


AKAP12
1.11
0.0899
AKAP12
NM_005100


EFNA3
1.10
0.0684
EFNA3
NM_004952


SFRP4
1.10
0.0684
SFRP4
NM_003014


CRYAB
1.10
0.0987
CRYAB
NM_001885


GSTT1
1.09
0.0457
GSTT1
NM_000853


REG4
1.08
0.0074
REG4
NM_032044


pS2
1.08
0.0302
TFF1
NM_003225


MUC5B
1.08
0.0401
MUC5B
XM_039877


IGFBP2
1.08
0.0873
IGFBP2
NM_000597









Table 3B shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio<1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using DFS as the metric for clinical outcome.











TABLE 3B






Hazard

Official
Accession


Gene
Ratio
P Value
Symbol
Number



















HSPA8
0.70
0.0487
HSPA8
NM_006597


SLC25A3
0.71
0.0084
SLC25A3
NM_213611


E2F1
0.73
0.0019
E2F1
NM_005225


SKP2
0.73
0.0038
SKP2
NM_005983


PPM1D
0.75
0.0008
PPM1D
NM_003620


RRM1
0.76
0.0161
RRM1
NM_001033


RPLPO
0.76
0.0388
RPLP0
NM_001002


NPM1
0.78
0.0223
NPM1
NM_002520


DDB1
0.78
0.0673
DDB1
NM_001923


PRDX4
0.79
0.0526
PRDX4
NM_006406


BRCA1
0.80
0.0051
BRCA1
NM_007295


Chk1
0.80
0.0114
CHEK1
NM_001274


SURV
0.81
0.0155
BIRC5
NM_001168


C20 orf1
0.81
0.0195
TPX2
NM_012112


EI24
0.81
0.0382
EI24
NM_004879


RAD54L
0.81
0.0501
RAD54L
NM_003579


DHFR
0.81
0.0530
DHFR
NM_000791


c-myb (MYB
0.82
0.0029
MYB
NM_005375


official)


CCNE2
0.82
0.0109
CCNE2
NM_057749


KIF22
0.82
0.0235
KIF22
NM_007317


HMGB1
0.82
0.0849
HMGB1
NM_002128


LMNB1
0.83
0.0665
LMNB1
NM_005573


CDCA7 v2
0.84
0.0224
CDCA7
NM_145810


CDC20
0.84
0.0461
CDC20
NM_001255


FASN
0.84
0.0797
FASN
NM_004104


ABCB1
0.85
0.0157
ABCB1
NM_000927


MCM2
0.85
0.0183
MCM2
NM_004526


DUT
0.85
0.0469
DUT
NM_001948


KIF2C
0.85
0.0786
KIF2C
NM_006845


MCM6
0.85
0.0791
MCM6
NM_005915


EIF4E
0.85
0.0863
EIF4E
NM_001968


EPHB2
0.86
0.0271
EPHB2
NM_004442


RCC1
0.86
0.0444
RCC1
NM_001269


EFP
0.86
0.0760
TRIM25
NM_005082


AREG
0.87
0.0029
AREG
NM_001657


CMYC
0.87
0.0483
MYC
NM_002467


GCLC
0.87
0.0824
GCLC
NM_001498


TCF-1
0.88
0.0520
TCF1
NM_000545


MYBL2
0.88
0.0527
MYBL2
NM_002466


EREG
0.89
0.0237
EREG
NM_001432


Cdx2
0.90
0.0353
CDX2
NM_001265


PTPRO
0.92
0.0896
PTPRO
NM_030667


cripto (TDGF1
0.92
0.0913
TDGF1
NM_003212


official)


HLA-DRB1
0.93
0.0536
HLA-DRB1
NM_002124









Table 4A shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio>1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using DRFI as the metric for clinical outcome.











TABLE 4A






Hazard

Official
Accession


Gene
Ratio
P Value
Symbol
Number



















ALDOA
3.37
0.0106
ALDOA
NM_000034


DCK
2.74
0.0130
DCK
NM_000788


ITGB1
2.50
<.0001
ITGB1
NM_002211


COX2
2.15
0.0128
PTGS2
NM_000963


TJP1
2.12
0.0072
TJP1
NM_003257


STAT3
1.98
0.0062
STAT3
NM_003150


HMLH
1.93
0.0087
MLH1
NM_000249


CYP3A4
1.90
0.0092
CYP3A4
NM_017460


RhoC
1.89
0.0033
RHOC
NM_175744


ANXA2
1.87
0.0025
ANXA2
NM_004039


TIMP1
1.83
<.0001
TIMP1
NM_003254


WWOX
1.81
0.0288
WWOX
NM_016373


ANXA5
1.80
0.0029
ANXA5
NM_001154


FUS
1.79
0.0179
FUS
NM_004960


PADI4
1.78
0.0168
PADI4
NM_012387


RBX1
1.71
0.0082
RBX1
NM_014248


CRIP2
1.71
0.0343
CRIP2
NM_001312


HB-EGF
1.69
0.0013
HBEGF
NM_001945


KCNH2 iso a/b
1.69
0.0070
KCNH2
NM_000238


SBA2
1.68
0.0066
WSB2
NM_018639


RhoB
1.67
0.0010
RHOB
NM_004040


VIM
1.66
0.0010
VIM
NM_003380


LILRB3
1.66
0.0227
LILRB3
NM_006864


UBC
1.64
0.0051
UBC
NM_021009


p21
1.63
0.0032
CDKN1A
NM_000389


CCNE2 variant 1
1.62
0.0363
CCNE2
NM_057749


RAB6C
1.61
0.0107
RAB6C
NM_032144


MSH3
1.61
0.0213
MSH3
NM_002439


AKT3
1.59
0.0003
AKT3
NM_005465


PI3K
1.58
0.0552
PIK3C2B
NM_002646


RAP1GDS1
1.57
0.0154
RAP1GDS1
NM_021159


CTSB
1.57
0.0250
CTSB
NM_001908


PRDX6
1.57
0.0770
PRDX6
NM_004905


NRP2
1.56
0.0005
NRP2
NM_003872


DLC1
1.56
0.0026
DLC1
NM_006094


BGN
1.55
0.0006
BGN
NM_001711


SIR2
1.55
0.0016
SIRT1
NM_012238


CALD1
1.53
0.0046
CALD1
NM_004342


YWHAH
1.53
0.0429
YWHAH
NM_003405


CDC42
1.52
0.0207
CDC42
NM_001791


ITGA5
1.51
0.0004
ITGA5
NM_002205


KLF6
1.51
0.0197
KLF6
NM_001300


TLN1
1.51
0.0414
TLN1
NM_006289


LAMC2
1.49
0.0017
LAMC2
NM_005562


STC1
1.49
0.0040
STC1
NM_003155


CDC42BPA
1.49
0.0109
CDC42BPA
NM_003607


RBM5
1.49
0.0184
RBM5
NM_005778


INHBB
1.49
0.0310
INHBB
NM_002193


TGFBR1
1.49
0.0502
TGFBR1
NM_004612


ADAM10
1.49
0.0819
ADAM10
NM_001110


CEBPB
1.48
0.0399
CEBPB
NM_005194


AKT1
1.48
0.0846
AKT1
NM_005163


FYN
1.47
0.0036
FYN
NM_002037


ARG
1.47
0.0067
ABL2
NM_005158


HIF1A
1.47
0.0221
HIF1A
NM_001530


S100A1
1.47
0.0293
S100A1
NM_006271


KRAS2
1.47
0.0958
KRAS
NM_004985


CTHRC1
1.46
0.0008
CTHRC1
NM_138455


IGFBP7
1.46
0.0173
IGFBP7
NM_001553


ROCK1
1.46
0.0326
ROCK1
NM_005406


VEGFC
1.46
0.0516
VEGFC
NM_005429


EPAS1
1.45
0.0316
EPAS1
NM_001430


DUSP1
1.44
0.0008
DUSP1
NM_004417


FST
1.44
0.0340
FST
NM_006350


GADD45B
1.43
0.0013
GADD45B
NM_015675


FLT4
1.43
0.0663
FLT4
NM_002020


PTEN
1.43
0.0760
PTEN
NM_000314


FAP
1.42
0.0017
FAP
NM_004460


PDGFC
1.42
0.0033
PDGFC
NM_016205


LOXL2
1.42
0.0115
LOXL2
NM_002318


Pak1
1.42
0.0846
PAK1
NM_002576


Grb10
1.41
0.0020
GRB10
NM_005311


INHBA
1.41
0.0036
INHBA
NM_002192


GJA1
1.41
0.0039
GJA1
NM_000165


CTGF
1.41
0.0053
CTGF
NM_001901


COL1A2
1.41
0.0057
COL1A2
NM_000089


PTK2
1.40
0.0496
PTK2
NM_005607


THBS1
1.39
0.0059
THBS1
NM_003246


RANBP9
1.39
0.0333
RANBP9
NM_005493


RANBP2
1.39
0.0988
RANBP2
NM_006267


ITGAV
1.38
0.0210
ITGAV
NM_002210


TIMP2
1.38
0.0285
TIMP2
NM_003255


PTHR1
1.38
0.0297
PTHR1
NM_000316


GADD45
1.38
0.0340
GADD45A
NM_001924


c-abl
1.38
0.0526
ABL1
NM_005157


EGR1
1.37
0.0097
EGR1
NM_001964


NCAM1
1.37
0.0657
NCAM1
NM_000615


VCL
1.37
0.0845
VCL
NM_003373


LOX
1.36
0.0026
LOX
NM_002317


SNAI2
1.36
0.0178
SNAI2
NM_003068


SPARC
1.36
0.0198
SPARC
NM_003118


CDH11
1.36
0.0233
CDH11
NM_001797


NFKBp50
1.36
0.0767
NFKB1
NM_003998


CYR61
1.35
0.0065
CYR61
NM_001554


S100A4
1.35
0.0104
S100A4
NM_002961


TAGLN
1.35
0.0168
TAGLN
NM_003186


PCAF
1.34
0.0327
PCAF
NM_003884


NOTCH2
1.34
0.0390
NOTCH2
NM_024408


LRP5
1.34
0.0722
LRP5
NM_002335


SI
1.34
0.0787
SI
NM_001041


GBP2
1.33
0.0139
GBP2
NM_004120


Bcl2
1.33
0.0143
BCL2
NM_000633


MCP1
1.33
0.0159
CCL2
NM_002982


EPHA2
1.33
0.0184
EPHA2
NM_004431


PRKCA
1.33
0.0329
PRKCA
NM_002737


TIMP3
1.33
0.0337
TIMP3
NM_000362


ANGPT2
1.33
0.0476
ANGPT2
NM_001147


CTSD
1.33
0.0766
CTSD
NM_001909


SEMA3F
1.33
0.0931
SEMA3F
NM_004186


BCAS1
1.32
0.0044
BCAS1
NM_003657


ANXA1
1.32
0.0458
ANXA1
NM_000700


KRT19
1.32
0.0535
KRT19
NM_002276


PTPRJ
1.32
0.0618
PTPRJ
NM_002843


CAPG
1.32
0.0641
CAPG
NM_001747


FOS
1.31
0.0129
FOS
NM_005252


COL1A1
1.31
0.0236
COL1A1
NM_000088


CXCR4
1.31
0.0251
CXCR4
NM_003467


TUBB
1.31
0.0354
TUBB2
NM_001069


PIM1
1.31
0.0373
PIM1
NM_002648


IGFBP5
1.31
0.0477
IGFBP5
NM_000599


AP-1 (JUN official)
1.31
0.0519
JUN
NM_002228


GCNT1
1.31
0.0534
GCNT1
NM_001490


MAX
1.31
0.0650
MAX
NM_002382


PAI1
1.30
0.0017
SERPINE1
NM_000602


SLPI
1.30
0.0176
SLPI
NM_003064


IGFBP3
1.30
0.0320
IGFBP3
NM_000598


DAPK1
1.30
0.0402
DAPK1
NM_004938


ID3
1.30
0.0442
ID3
NM_002167


EFNA1
1.30
0.0623
EFNA1
NM_004428


AKAP12
1.29
0.0162
AKAP12
NM_005100


PDGFB
1.29
0.0242
PDGFB
NM_002608


CD68
1.29
0.0524
CD68
NM_001251


FGFR1
1.29
0.0709
FGFR1
NM_023109


GSK3B
1.29
0.0765
GSK3B
NM_002093


CXCL12
1.28
0.0129
CXCL12
NM_000609


DPYD
1.28
0.0186
DPYD
NM_000110


LAMA3
1.28
0.0193
LAMA3
NM_000227


MRP3
1.28
0.0384
ABCC3
NM_003786


ABCC5
1.28
0.0402
ABCC5
NM_005688


PDGFA
1.28
0.0482

NM_002607


XPA
1.28
0.0740
XPA
NM_000380


NDRG1
1.28
0.0786
NDRG1
NM_006096


FES
1.27
0.0458
FES
NM_002005


CTSL
1.27
0.0485
CTSL
NM_001912


IL6
1.27
0.0606
IL6
NM_000600


SFRP2
1.26
0.0085
SFRP2
NM_003013


Maspin
1.26
0.0096
SERPINB5
NM_002639


TGFBI
1.26
0.0470
TGFBI
NM_000358


NOS3
1.26
0.0978
NOS3
NM_000603


HSPA1A
1.25
0.0161
HSPA1A
NM_005345


S100A8
1.25
0.0180
S100A8
NM_002964


HOXB7
1.25
0.0396
HOXB7
NM_004502


P14ARF
1.25
0.0697

S78535


WISP1
1.25
0.0712
WISP1
NM_003882


ID4
1.25
0.0883
ID4
NM_001546


SFRP4
1.24
0.0200
SFRP4
NM_003014


FZD6
1.24
0.0220
FZD6
NM_003506


EGR3
1.24
0.0237
EGR3
NM_004430


ALDH1A1
1.24
0.0258
ALDH1A1
NM_000689


CRYAB
1.23
0.0394
CRYAB
NM_001885


TGFB3
1.23
0.0541
TGFB3
NM_003239


ANTXR1
1.23
0.0661
ANTXR1
NM_032208


KLK6
1.22
0.0211
KLK6
NM_002774


ILT-2
1.22
0.0676
LILRB1
NM_006669


EMP1
1.22
0.0871
EMP1
NM_001423


PLAUR
1.22
0.0943
PLAUR
NM_002659


S100A2
1.20
0.0100
S100A2
NM_005978


MMP7
1.19
0.0810
MMP7
NM_002423


OPN_osteopontin
1.17
0.0231
SPP1
NM_000582


FABP4
1.17
0.0325
FABP4
NM_001442


KLK10
1.17
0.0452
KLK10
NM_002776


PS2
1.16
0.0140
TFF1
NM_003225


STMY3
1.15
0.0850
MMP11
NM_005940


REG4
1.14
0.0042
REG4
NM_032044


MUC2
1.09
0.0370
MUC2
NM_002457









Table 4B shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio<1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using DRFI as the metric for clinical outcome.















Hazard


Accession


Gene
Ratio
P Value
Official Symbol
Number



















HSPA8
0.51
0.0261
HSPA8
NM_006597


RPS13
0.58
0.0089
RPS13
NM_001017


RPLPO
0.63
0.0324
RPLP0
NM_001002


NDUFS3
0.66
0.0142
NDUFS3
NM_004551


LMNB1
0.67
0.0202
LMNB1
NM_005573


ST14
0.67
0.0206
ST14
NM_021978


BRCA1
0.68
0.0032
BRCA1
NM_007295


TMSB4X
0.68
0.0075
TMSB4X
NM_021109


DHFR
0.68
0.0356
DHFR
NM_000791


SKP2
0.69
0.0248
SKP2
NM_005983


TCF-1
0.70
0.0015
TCF1
NM_000545


CDC20
0.70
0.0067
CDC20
NM_001255


SLC25A3
0.70
0.0418
SLC25A3
NM_213611


NME1
0.72
0.0503
NME1
NM_000269


RRM1
0.72
0.0850
RRM1
NM_001033


MCM2
0.76
0.0168
MCM2
NM_004526


ABCC6
0.76
0.0445
ABCC6
NM_001171


CKS2
0.76
0.0869
CKS2
NM_001827


EPHB2
0.77
0.0174
EPHB2
NM_004442


C20 orf1
0.77
0.0716
TPX2
NM_012112


CSEL1
0.77
0.0725
CSE1L
NM_001316


NFKBp65
0.78
0.0957
RELA
NM_021975


AURKB
0.79
0.0742
AURKB
NM_004217


CMYC
0.82
0.0901
MYC
NM_002467


Cdx2
0.85
0.0510
CDX2
NM_001265


EREG
0.85
0.0730
EREG
NM_001432


AREG
0.86
0.0365
AREG
NM_001657









Table 5A shows associations between gene expression and RFI, controlling for particular demographic and clinical characteristics of patients included in the analysis. All genes are listed whose expression correlates with RFI (p<0.1) and which demonstrated a Hazard Ratio>1 in a multivariate analysis including the following variables: tumor location, surgery, tumor grade, nodes examined, and number of positive nodes.











TABLE 5A







LR




Gene
HR
Chi-Square
DF
P-Value



















RARB
2.06780
4.23265
1
0.03965


CYP3A4
1.85387
7.99462
1
0.00469


ANXA2
1.80012
10.84166
1
0.00099


COX2
1.79051
4.52307
1
0.03344


RhoC
1.73986
9.97133
1
0.00159


MAPK14
1.68382
8.04253
1
0.00457


UBC
1.67323
11.69444
1
0.00063


RhoB
1.66612
15.92497
1
0.00007


ITGB1
1.65796
8.18638
1
0.00422


KRAS2
1.63873
6.80447
1
0.00909


NTN1
1.61833
5.43469
1
0.01974


ATP5E
1.60990
4.93660
1
0.02629


G-Catenin
1.58482
9.24422
1
0.00236


STC1
1.58163
11.10757
1
0.00086


SPINT2
1.52653
6.17276
1
0.01297


Claudin 4
1.50290
12.29943
1
0.00045


IGFBP7
1.48789
9.62569
1
0.00192


NCAM1
1.48294
5.11428
1
0.02373


TIMP1
1.46045
9.98492
1
0.00158


CEBPB
1.46025
5.23659
1
0.02212


KCNH2 iso a/b
1.44616
3.97304
1
0.04623


TMSB10
1.43107
4.65463
1
0.03097


VEGFC
1.41860
4.66904
1
0.03071


HB-EGF
1.41757
7.00399
1
0.00813


FST
1.41061
5.59674
1
0.01799


LAMC2
1.40860
11.33997
1
0.00076


GADD45B
1.40671
12.26323
1
0.00046


AKT3
1.40161
10.13028
1
0.00146


EFNA1
1.40048
8.86645
1
0.00290


p21
1.39939
5.42981
1
0.01980


INHBA
1.38204
11.03909
1
0.00089


CALD1
1.38009
6.93406
1
0.00846


DUSP1
1.36464
13.04379
1
0.00030


HSPG2
1.36387
4.11749
1
0.04244


GJB2
1.36358
8.42204
1
0.00371


EPAS1
1.36323
4.74318
1
0.02941


BGN
1.35821
7.66947
1
0.00562


TIMP2
1.35571
5.78791
1
0.01614


A-Catenin
1.35566
4.35623
1
0.03687


LOXL2
1.35470
7.23663
1
0.00714


DKK1
1.35126
3.88504
1
0.04872


ITGAV
1.34899
8.03554
1
0.00459


CGB
1.34840
7.06221
1
0.00787


EGR1
1.33424
8.41855
1
0.00371


TIMP3
1.33197
6.28550
1
0.01217


VIM
1.33196
4.92198
1
0.02652


TGFBI
1.32511
8.30278
1
0.00396


FXYD5
1.32500
6.22751
1
0.01258


VEGF
1.32291
4.93825
1
0.02627


ADAMTS12
1.31794
7.46749
1
0.00628


SLPI
1.31565
8.38324
1
0.00379


DLC1
1.30862
5.51638
1
0.01884


HOXB7
1.30822
8.04076
1
0.00457


TMEPAI
1.30395
8.43736
1
0.00368


IGFBP5
1.30260
5.44022
1
0.01968


CDC42BPA
1.30167
4.20771
1
0.04024


PDGFA
1.29760
5.54964
1
0.01848


GSTp
1.29594
3.96268
1
0.04652


FOS
1.29427
8.42847
1
0.00369


PDGFC
1.28813
6.81737
1
0.00903


IGFBP3
1.28701
6.33625
1
0.01183


LOX
1.28433
8.15598
1
0.00429


SPARC
1.28260
4.75876
1
0.02915


EFNB2
1.27720
4.71247
1
0.02994


Maspin
1.27645
10.57657
1
0.00115


THBS1
1.27619
6.61087
1
0.01014


TAGLN
1.26904
5.15123
1
0.02323


VEGF_altsplice1
1.26734
5.29282
1
0.02141


S100P
1.26586
9.88713
1
0.00166


HSPA1A
1.26209
8.59704
1
0.00337


MAD
1.26112
3.96163
1
0.04655


ANGPT2
1.25701
3.91148
1
0.04796


PRKCA
1.24853
4.69452
1
0.03026


F3
1.24848
5.06788
1
0.02437


FAP
1.24657
5.19589
1
0.02264


BRK
1.24507
5.44048
1
0.01968


CD68
1.23943
4.02530
1
0.04482


NR4A1
1.23772
7.09548
1
0.00773


CTHRC1
1.23465
5.21100
1
0.02244


SLC2A1
1.22967
5.22364
1
0.02228


Grb10
1.22209
4.12811
1
0.04218


p16-INK4
1.21325
4.44296
1
0.03505


MDK
1.21116
5.25025
1
0.02194


CYR61
1.19995
4.14452
1
0.04177


LAMA3
1.19794
4.33073
1
0.03743


FOXO3A
1.19557
4.20079
1
0.04041


EFNA3
1.19439
5.51728
1
0.01883


CRYAB
1.17514
3.90435
1
0.04816


CEACAM6
1.16804
3.96486
1
0.04646


OPN_osteopontin
1.16112
5.50891
1
0.01892


KLK10
1.15851
5.65625
1
0.01739


SFRP2
1.15773
4.02893
1
0.04473


KLK6
1.15163
4.65953
1
0.03088


S100A2
1.14185
3.94284
1
0.04707


REG4
1.09037
4.16995
1
0.04115









Table 5B shows associations between gene expression and RFI, controlling for particular demographic and clinical characteristics of patients included in the analysis. All genes are listed whose expression correlates with RFI (p<0.1) and which demonstrated a Hazard Ratio<1 in a multivariate analysis including the following variables: tumor location, surgery, tumor grade, nodes examined, and number of positive nodes.













TABLE 5B







Gene
HR
LR Chi-Square
DF
P-Value






















BFGF
0.46674
6.95233
1
0.00837



Fasl
0.47324
4.08714
1
0.04321



KLRK1
0.63331
10.28820
1
0.00134



DHFR
0.64947
7.64434
1
0.00570



BRCA1
0.65247
15.21566
1
0.00010



SLC25A3
0.67480
5.72977
1
0.01668



RAD54L
0.68215
5.38684
1
0.02029



PPM1D
0.68777
10.02879
1
0.00154



CD80
0.69347
8.70087
1
0.00318



ATP5A1
0.70467
4.06718
1
0.04372



PRKCB1
0.73152
5.21950
1
0.02234



KIF22
0.73945
5.13202
1
0.02349



Chk1
0.75865
4.38139
1
0.03633



TRAIL
0.76430
4.12533
1
0.04225



CDC20
0.77071
5.04557
1
0.02469



DUT
0.78196
4.13381
1
0.04203



ABCB1
0.79434
5.33783
1
0.02087



UMPS
0.80011
4.65425
1
0.03098



ING5
0.80230
4.04085
1
0.04441



CMYC
0.80757
4.26709
1
0.03886



GBP1
0.83015
3.98302
1
0.04596



AREG
0.86091
4.94239
1
0.02621










Table 6 shows associations between gene expression and clinical outcome based on a nonlinear proportional hazards analysis, using a 2 degree-of-freedom natural spline. All genes are listed which demonstrated a departure from a strictly linear relationship (p<0.05) with RFI in combined Stage II (Duke's B) and Stage III (Duke's C) patients. The relationship between gene expression and RFI was not constant throughout the observed range of expression values in the study, e.g. increases in gene expression may have been related to increases in duration of RFI in one portion of the observed range and with decreases in duration of RFI in a different portion of the range.












TABLE 6









Official
Accession



Gene
P-Value
Symbol
Number





















PTHLH
0.001
PTHLH
NM_002820



CDCA7 v2
0.002
CDCA7
NM_145810



CREBBP
0.002
CREBBP
NM_004380



KLF5
0.002
KLF5
NM_001730



LAMB3
0.004
LAMB3
NM_000228



TGFBR1
0.005
TGFBR1
NM_004612



NR4A1
0.005
NR4A1
NM_002135



Upa
0.005
PLAU
NM_002658



Cad17
0.007
CDH17
NM_004063



S100A4
0.008
S100A4
NM_002961



A-Catenin
0.008
CTNNA1
NM_001903



EPHB2
0.009
EPHB2
NM_004442



Axin 2
0.011
AXIN2
NM_004655



PTPRJ
0.011
PTPRJ
NM_002843



CAPN1
0.012
CAPN1
NM_005186



CEGP1
0.013
SCUBE2
NM_020974



APOC1
0.013
APOC1
NM_001645



GBP1
0.015
GBP1
NM_002053



SKP2
0.016
SKP2
NM_005983



ATP5E
0.016
ATP5E
NM_006886



GRIK1
0.017
GRIK1
NM_000830



PRKR
0.018
EIF2AK2
NM_002759



FUT6
0.020
FUT6
NM_000150



PFN2
0.020
PFN2
NM_053024



ITGB4
0.021
ITGB4
NM_000213



MADH7
0.021
SMAD7
NM_005904



RALBP1
0.021
RALBP1
NM_006788



AKT1
0.022
AKT1
NM_005163



KLK6
0.022
KLK6
NM_002774



PLK
0.023
PLK1
NM_005030



CYP2C8
0.025
CYP2C8
NM_000770



BTF3
0.026
BTF3
NM_001207



CCNE2 variant 1
0.026
CCNE2
NM_057749



STMY3
0.030
MMP11
NM_005940



NRP1
0.030
NRP1
NM_003873



SIAT4A
0.031
ST3GAL1
NM_003033



SEMA3B
0.033
SEMA3B
NM_004636



TRAG3
0.033
CSAG2
NM_004909



HSPE1
0.035
HSPE1
NM_002157



SBA2
0.036
WSB2
NM_018639



TK1
0.036
TK1
NM_003258



CCNB2
0.037
CCNB2
NM_004701



TMEPAI
0.037
TMEPAI
NM_020182



SPRY2
0.037
SPRY2
NM_005842



AGXT
0.038
AGXT
NM_000030



ALCAM
0.038
ALCAM
NM_001627



HSPCA
0.038
HSPCA
NM_005348



TIMP3
0.038
TIMP3
NM_000362



DET1
0.039
DET1
NM_017996



tusc4
0.040
TUSC4
NM_006545



SNAI2
0.040
SNAI2
NM_003068



CD28
0.040
CD28
NM_006139



RNF11
0.041
RNF11
NM_014372



PAI1
0.042
SERPINE1
NM_000602



XRCC1
0.042
XRCC1
NM_006297



EGLN1
0.044
EGLN1
NM_022051



EGFR
0.044
EGFR
NM_005228



HES6
0.044
HES6
NM_018645



KCNK4
0.045
KCNK4
NM_016611



CXCR4
0.047
CXCR4
NM_003467



PTP4A3
0.048
PTP4A3
NM_007079



p27
0.048
CDKN1B
NM_004064



MADH4
0.049
SMAD4
NM_005359



ICAM1
0.049
ICAM1
NM_000201










Table 7 shows all genes exhibiting an interaction (p-value<0.05) with tumor stage. The data were modeled using a proportional hazards model of RFI with gene expression, tumor stage, and their interaction as predictors.












TABLE 7








HR
HR
P-value for



Gene
Stage II
Stage III
Interaction





















ICAM2
1.49
0.68
0.0019



CD24
1.26
0.84
0.0054



PRDX6
2.29
0.73
0.0058



HSD17B2
0.62
1.29
0.0072



ALCAM
1.61
0.94
0.0088



SIR2
2.02
1.09
0.0089



NUFIP1
1.32
0.79
0.0093



EMR3
2.14
0.57
0.0127



CDC20
0.56
0.98
0.0130



MT3
1.37
0.79
0.0134



CLTC
1.80
0.71
0.0144



CYR61
1.73
1.10
0.0145



WIF
1.34
0.78
0.0195



TFF3
1.23
0.90
0.0209



SOS1
1.46
0.79
0.0287



TMSB4X
1.34
0.74
0.0293



CENPE
3.05
0.85
0.0330



CDH11
1.49
0.96
0.0339



CAPG
0.90
1.50
0.0348



TP53BP1
1.54
0.93
0.0357



MGAT5
1.25
0.73
0.0362



MADH2
1.36
0.70
0.0393



LOX
1.58
1.11
0.0396



DKK1
0.87
1.55
0.0415



CKS1B
0.31
1.75
0.0467



MMP7
0.92
1.28
0.0471



STAT5B
1.28
0.86
0.0471



CD28
0.69
1.25
0.0472










Second Analysis Study Results

Reference Gene Set for the second analysis was ATP5E, CLTC, GPX1, NEDD8, PGK1, UBB.
Table 1.2A shows associations for those genes whose increased expression is predictive of shorter Recurrence-Free Interval (RFI) based on univariate proportional hazards analysis.
Table 1.2B shows associations for those genes whose increased expression is predictive of longer Recurrence-Free Interval (RFI) based on univariate proportional hazards analysis.
Table 2.2A shows associations for those genes whose increased expression is predictive of decreased rate of Overall Survival (OS) based on univariate proportional hazards analysis.
Table 2.2B shows associations for those genes whose increased expression is predictive of increased rate of Overall Survival (OS) based on univariate proportional hazards analysis.
Table 3.2A shows associations for those genes whose increased expression is predictive of decreased rate of Disease Free Survival (DFS) based on univariate proportional hazards analysis.
Table 3.2B shows associations for those genes whose increased expression is predictive of increased rate of Disease Free Survival (DFS) based on univariate proportional hazards analysis.
Table 4.2A shows associations for those genes whose increased expression is predictive of shorter Distant Recurrence-Free Interval (DRFI) based on univariate proportional hazards analysis.
Table 4.2B shows associations for those genes whose increased expression is predictive of longer Distant Recurrence-Free Interval (DRFI) based on univariate proportional hazards analysis.
Table 5.2A shows associations between gene expression and RFI for those genes whose increased expression is predictive of shorter Recurrence-Free Interval (RFI), based on a multivariate analysis controlling for particular demographic and clinical characteristics of patients included in the analysis.
Table 5.2B shows associations between gene expression and RFI for those genes whose increased expression is predictive of longer Recurrence-Free Interval (RFI), based on a multivariate analysis controlling for particular demographic and clinical characteristics of patients included in the analysis.
Table 6.2 shows genes for which an association between gene expression and clinical outcome was identified based on a nonlinear proportional hazards analysis, using a 2 degree-of-freedom natural spline.
Table 7.2 shows all genes exhibiting an interaction (p-value<0.05) with tumor stage.
Table 1.2A shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio>1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using RFI as the metric for clinical outcome.















Hazard

Official
Accession


Gene
Ratio
P Value
Symbol
Number



















RARB
2.22
0.0294
RARB
NM_016152


ITGB1
2.04
0.0002
ITGB1
NM_002211


ANXA2
1.78
0.0003
ANXA2
NM_004039


CYP3A4
1.68
0.0075
CYP3A4
NM_017460


COX2
1.64
0.0604
PTGS2
NM_000963


KRAS2
1.62
0.0064
KRAS
NM_004985


TJP1
1.58
0.0751
TJP1
NM_003257


KIAA0125
1.58
0.0889
KIAA0125
NM_014792


RhoB
1.57
0.0002
RHOB
NM_004040


RhoC
1.56
0.0059
RHOC
NM_175744


NTN1
1.54
0.0336
NTN1
NM_004822


ANXA5
1.52
0.0086
ANXA5
NM_001154


TIMP1
1.52
<.0001
TIMP1
NM_003254


AKT3
1.50
<.0001
AKT3
NM_005465


CALD1
1.48
0.0007
CALD1
NM_004342


IGFBP7
1.46
0.0023
IGFBP7
NM_001553


CYP1B1
1.45
0.0222
CYP1B1
NM_000104


BGN
1.44
0.0002
BGN
NM_001711


VEGFC
1.44
0.0151
VEGFC
NM_005429


DLC1
1.44
0.0014
DLC1
NM_006094


SI
1.42
0.0086
SI
NM_001041


TIMP2
1.42
0.0022
TIMP2
NM_003255


CDC42BPA
1.41
0.0038
CDC42BPA
NM_003607


LAMC2
1.40
0.0004
LAMC2
NM_005562


ITGAV
1.40
0.0019
ITGAV
NM_002210


CTSB
1.40
0.0357
CTSB
NM_001908


DUSP1
1.39
<.0001
DUSP1
NM_004417


TLN1
1.39
0.0335
TLN1
NM_006289


CCNE2
1.39
0.0708
CCNE2
NM_057749


variant 1


TIMP3
1.38
0.0023
TIMP3
NM_000362


GHI BRAF
1.38
0.0537

GHI_BRAF_mut4


mut4


HB-EGF
1.38
0.0109
HBEGF
NM_001945


HSPG2
1.38
0.0258
HSPG2
NM_005529


VIM
1.37
0.0077
VIM
NM_003380


ROCK1
1.37
0.0168
ROCK1
NM_005406


S100A1
1.36
0.0233
S100A1
NM_006271


p21
1.36
0.0113
CDKN1A
NM_000389


CGB
1.36
0.0023
CGB
NM_000737


UBC
1.36
0.0137
UBC
NM_021009


GADD45B
1.36
0.0003
GADD45B
NM_015675


INHBA
1.35
0.0010
INHBA
NM_002192


VCL
1.34
0.0286
VCL
NM_003373


SIR2
1.34
0.0049
SIRT1
NM_012238


CD68
1.34
0.0042
CD68
NM_001251


Maspin
1.34
<.0001
SERPINB5
NM_002639


FST
1.33
0.0326
FST
NM_006350


EPAS1
1.33
0.0306
EPAS1
NM_001430


LOXL2
1.33
0.0076
LOXL2
NM_002318


STC1
1.33
0.0119
STC1
NM_003155


UNC5C
1.32
0.0642
UNC5C
NM_003728


IGFBP5
1.32
0.0080
IGFBP5
NM_000599


INHBB
1.32
0.0643
INHBB
NM_002193


FAP
1.32
0.0017
FAP
NM_004460


DKK1
1.31
0.0298
DKK1
NM_012242


FYN
1.31
0.0053
FYN
NM_002037


CTHRC1
1.31
0.0017
CTHRC1
NM_138455


FOS
1.31
0.0010
FOS
NM_005252


RBX1
1.31
0.0633
RBX1
NM_014248


TAGLN
1.31
0.0058
TAGLN
NM_003186


SBA2
1.31
0.0439
WSB2
NM_018639


CYR61
1.30
0.0018
CYR61
NM_001554


SPARC
1.30
0.0117
SPARC
NM_003118


SNAI2
1.30
0.0076
SNAI2
NM_003068


TMSB10
1.30
0.0757
TMSB10
NM_021103


IGFBP3
1.30
0.0056
IGFBP3
NM_000598


PDGFC
1.29
0.0040
PDGFC
NM_016205


SLPI
1.29
0.0026
SLPI
NM_003064


COL1A2
1.29
0.0087
COL1A2
NM_000089


NRP2
1.29
0.0112
NRP2
NM_003872


PRKCA
1.29
0.0093
PRKCA
NM_002737


KLF6
1.29
0.0661
KLF6
NM_001300


THBS1
1.28
0.0062
THBS1
NM_003246


EGR1
1.28
0.0067
EGR1
NM_001964


S100A4
1.28
0.0070
S100A4
NM_002961


CXCR4
1.28
0.0089
CXCR4
NM_003467


LAMA3
1.27
0.0024
LAMA3
NM_000227


LOX
1.26
0.0036
LOX
NM_002317


AKAP12
1.26
0.0046
AKAP12
NM_005100


ADAMTS12
1.26
0.0109
ADAMTS12
NM_030955


MCP1
1.25
0.0122
CCL2
NM_002982


Grb10
1.25
0.0107
GRB10
NM_005311


PTGER3
1.25
0.0240
PTGER3
NM_000957


CRYAB
1.25
0.0035
CRYAB
NM_001885


ANGPT2
1.25
0.0566
ANGPT2
NM_001147


ANXA1
1.25
0.0353
ANXA1
NM_000700


EphB6
1.24
0.0960
EPHB6
NM_004445


PDGFB
1.24
0.0139
PDGFB
NM_002608


COL1A1
1.24
0.0198
COL1A1
NM_000088


TGFB3
1.23
0.0094
TGFB3
NM_003239


CTGF
1.23
0.0265
CTGF
NM_001901


PDGFA
1.23
0.0312

NM_002607


HSPA1A
1.23
0.0027
HSPA1A
NM_005345


EFNB2
1.23
0.0331
EFNB2
NM_004093


CAPG
1.23
0.0724
CAPG
NM_001747


TGFBI
1.22
0.0231
TGFBI
NM_000358


SIAT4A
1.22
0.0253
ST3GAL1
NM_003033


LAT
1.22
0.0307
LAT
NM_014387


ITGA5
1.22
0.0224
ITGA5
NM_002205


GBP2
1.22
0.0225
GBP2
NM_004120


ANTXR1
1.22
0.0204
ANTXR1
NM_032208


ID4
1.22
0.0512
ID4
NM_001546


SFRP2
1.22
0.0039
SFRP2
NM_003013


TMEPAI
1.21
0.0170
TMEPAI
NM_020182


CTSL
1.21
0.0388
CTSL
NM_001912


KLK10
1.21
0.0007
KLK10
NM_002776


FXYD5
1.21
0.0547
FXYD5
NM_014164


GJB2
1.21
0.0356
GJB2
NM_004004


P14ARF
1.21
0.0451

S78535


DAPK1
1.21
0.0525
DAPK1
NM_004938


SKP1A
1.21
0.0663
SKP1A
NM_006930


SFRP4
1.21
0.0078
SFRP4
NM_003014


KLK6
1.20
0.0048
KLK6
NM_002774


GJA1
1.20
0.0345
GJA1
NM_000165


HOXB7
1.20
0.0278
HOXB7
NM_004502


NDRG1
1.20
0.0948
NDRG1
NM_006096


PAI1
1.19
0.0061
SERPINE1
NM_000602


CDH11
1.19
0.0762
CDH11
NM_001797


EGR3
1.19
0.0149
EGR3
NM_004430


EMP1
1.19
0.0533
EMP1
NM_001423


FZD1
1.19
0.0671
FZD1
NM_003505


ABCC5
1.19
0.0631
ABCC5
NM_005688


S100P
1.18
0.0160
S100P
NM_005980


OPN,
1.18
0.0030
SPP1
NM_000582


osteopontin


p16-INK4
1.17
0.0503

L27211


NR4A1
1.17
0.0332
NR4A1
NM_002135


TUBB
1.17
0.0950
TUBB2
NM_001069


SIAT7B
1.17
0.0352
ST6GALNAC2
NM_006456


ALDH1A1
1.17
0.0299
ALDH1A1
NM_000689


F3
1.16
0.0654
F3
NM_001993


SLC2A1
1.15
0.0806
SLC2A1
NM_006516


CXCL12
1.13
0.0986
CXCL12
NM_000609


STMY3
1.13
0.0518
MMP11
NM_005940


S100A2
1.13
0.0303
S100A2
NM_005978


FABP4
1.13
0.0363
FABP4
NM_001442


REG4
1.11
0.0034
REG4
NM_032044


pS2
1.09
0.0690
TFF1
NM_003225


MUC2
1.06
0.0674
MUC2
NM_002457









Table 1.2B shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio<1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using RFI as the metric for clinical outcome.















Hazard

Official
Accession


Gene
Ratio
P Value
Symbol
Number







ORC1L
0.41
0.0623
ORC1L
NM_004153


E2F1
0.63
0.0006
E2F1
NM_005225


HSPA8
0.63
0.0346
HSPA8
NM_006597


RAD54L
0.65
0.0026
RAD54L
NM_003579


BRCA1
0.68
0.0001
BRCA1
NM_007295


SLC25A3
0.70
0.0100
SLC25A3
NM_213611


PPM1D
0.71
0.0025
PPM1D
NM_003620


DHFR
0.71
0.0106
DHFR
NM_000791


SKP2
0.72
0.0087
SKP2
NM_005983


FASN
0.73
0.0070
FASN
NM_004104


HNRPD
0.73
0.0611
HNRPD
NM_031370


ENO1
0.74
0.0432
ENO1
NM_001428


C20 orf1
0.74
0.0086
TPX2
NM_012112


BRCA2
0.75
0.0515
BRCA2
NM_000059


DDB1
0.75
0.0639
DDB1
NM_001923


KIF22
0.76
0.0127
KIF22
NM_007317


RPLPO
0.76
0.0330
RPLP0
NM_001002


Chk1
0.76
0.0164
CHEK1
NM_001274


ST14
0.77
0.0392
ST14
NM_021978


Bax
0.77
0.0502
BAX
NM_004324


TCF-1
0.78
0.0023
TCF1
NM_000545


LMNB1
0.78
0.0458
LMNB1
NM_005573


RRM1
0.78
0.0693
RRM1
NM_001033


CSEL1
0.79
0.0261
CSE1L
NM_001316


CDC20
0.79
0.0274
CDC20
NM_001255


PRDX2
0.79
0.0930
PRDX2
NM_005809


RPS13
0.79
0.0906
RPS13
NM_001017


RAF1
0.80
0.0717
RAF1
NM_002880


CMYC
0.80
0.0095
MYC
NM_002467


UBE2M
0.80
0.0390
UBE2M
NM_003969


CKS2
0.80
0.0596
CKS2
NM_001827


NME1
0.80
0.0694
NME1
NM_000269


c-myb (MYB official)
0.80
0.0082
MYB
NM_005375


CD80
0.80
0.0688
CD80
NM_005191


CDCA7 v2
0.81
0.0164
CDCA7
NM_145810


EFP
0.81
0.0387
TRIM25
NM_005082


CCNE2
0.81
0.0405
CCNE2
NM_057749


SURV
0.81
0.0573
BIRC5
NM_001168


RRM2
0.82
0.0181
RRM2
NM_001034


ABCC6
0.82
0.0464
ABCC6
NM_001171


UMPS
0.82
0.0371
UMPS
NM_000373


PI3KC2A
0.82
0.0855
PIK3C2A
NM_002645


NOTCH1
0.82
0.0222
NOTCH1
NM_017617


EIF4E
0.82
0.0928
EIF4E
NM_001968


EPHB2
0.82
0.0183
EPHB2
NM_004442


AREG
0.83
0.0012
AREG
NM_001657


EREG
0.83
0.0059
EREG
NM_001432


MYBL2
0.83
0.0234
MYBL2
NM_002466


ABCB1
0.83
0.0342
ABCB1
NM_000927


HRAS
0.83
0.0708
HRAS
NM_005343


SLC7A5
0.84
0.0547
SLC7A5
NM_003486


MAD2L1
0.84
0.0653
MAD2L1
NM_002358


ING5
0.85
0.0920
ING5
NM_032329


Ki-67
0.85
0.0562
MKI67
NM_002417


MCM2
0.85
0.0671
MCM2
NM_004526


Cdx2
0.88
0.0430
CDX2
NM_001265


HES6
0.89
0.0966
HES6
NM_018645


PTPRO
0.89
0.0664
PTPRO
NM_030667


cripto (TDGF1 official)
0.90
0.0781
TDGF1
NM_003212









Table 2.2A shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio>1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using OS as the metric for clinical outcome.















Hazard

Official
Accession


Gene
Ratio
P Value
Symbol
Number



















RhoC
1.66
0.0002
RHOC
NM_175744


ITGB1
1.59
0.0049
ITGB1
NM_002211


ANXA2
1.58
0.0004
ANXA2
NM_004039


CYP3A4
1.49
0.0114
CYP3A4
NM_017460


p21
1.49
<.0001
CDKN1A
NM_000389


HMLH
1.42
0.0555
MLH1
NM_000249


VEGFC
1.41
0.0095
VEGFC
NM_005429


TGFBR1
1.40
0.0113
TGFBR1
NM_004612


UBC
1.38
0.0013
UBC
NM_021009


RhoB
1.37
0.0016
RHOB
NM_004040


HSPG2
1.37
0.0111
HSPG2
NM_005529


PFN1
1.35
0.0987
PFN1
NM_005022


TIMP1
1.35
0.0008
TIMP1
NM_003254


VCL
1.33
0.0116
VCL
NM_003373


INHBB
1.32
0.0265
INHBB
NM_002193


SPINT2
1.32
0.0358
SPINT2
NM_021102


GHI BRAF mut4
1.31
0.0822

GHI_BRAF_mut4


LAMC2
1.31
0.0007
LAMC2
NM_005562


KCNH2 iso a/b
1.31
0.0474
KCNH2
NM_000238


UNC5C
1.30
0.0417
UNC5C
NM_003728


CDC42
1.30
0.0122
CDC42
NM_001791


UBL1
1.29
0.0169
SUMO1
NM_003352


GADD45B
1.29
0.0003
GADD45B
NM_015675


KRAS2
1.29
0.0774
KRAS
NM_004985


HB-EGF
1.29
0.0219
HBEGF
NM_001945


DKK1
1.28
0.0304
DKK1
NM_012242


FXYD5
1.28
0.0035
FXYD5
NM_014164


CALD1
1.28
0.0107
CALD1
NM_004342


ANXA5
1.27
0.0723
ANXA5
NM_001154


HLA-G
1.27
0.0732
HLA-G
NM_002127


DUSP1
1.27
0.0004
DUSP1
NM_004417


LOXL2
1.27
0.0050
LOXL2
NM_002318


CDC42BPA
1.27
0.0155
CDC42BPA
NM_003607


BGN
1.27
0.0039
BGN
NM_001711


LAMB3
1.27
0.0221
LAMB3
NM_000228


EphB6
1.27
0.0373
EPHB6
NM_004445


SHC1
1.27
0.0582
SHC1
NM_003029


TIMP2
1.26
0.0126
TIMP2
NM_003255


CTSB
1.26
0.0748
CTSB
NM_001908


TIMP3
1.26
0.0072
TIMP3
NM_000362


ID3
1.26
0.0033
ID3
NM_002167


CAPG
1.26
0.0162
CAPG
NM_001747


NRP1
1.26
0.0135
NRP1
NM_003873


INHBA
1.26
0.0021
INHBA
NM_002192


KLF6
1.25
0.0477
KLF6
NM_001300


IGFBP7
1.25
0.0251
IGFBP7
NM_001553


S100A1
1.25
0.0528
S100A1
NM_006271


EPAS1
1.24
0.0382
EPAS1
NM_001430


DLC1
1.24
0.0228
DLC1
NM_006094


KLK10
1.24
<.0001
KLK10
NM_002776


SBA2
1.24
0.0493
WSB2
NM_018639


SPARC
1.24
0.0133
SPARC
NM_003118


GAGE4
1.23
0.0475
GAGE4
NM_001474


HSPA1A
1.23
0.0004
HSPA1A
NM_005345


SIR2
1.23
0.0179
SIRT1
NM_012238


CGB
1.23
0.0202
CGB
NM_000737


Grb10
1.22
0.0059
GRB10
NM_005311


SNAI2
1.22
0.0145
SNAI2
NM_003068


LAMA3
1.22
0.0019
LAMA3
NM_000227


AKT3
1.22
0.0169
AKT3
NM_005465


FYN
1.22
0.0138
FYN
NM_002037


FOS
1.22
0.0035
FOS
NM_005252


CTHRC1
1.21
0.0056
CTHRC1
NM_138455


CTSD
1.21
0.0506
CTSD
NM_001909


THY1
1.21
0.0290
THY1
NM_006288


ANXA1
1.21
0.0339
ANXA1
NM_000700


CD68
1.21
0.0227
CD68
NM_001251


G-Catenin
1.20
0.0789
JUP
NM_002230


PLK3
1.20
0.0081
PLK3
NM_004073


STC1
1.20
0.0577
STC1
NM_003155


TAGLN
1.20
0.0238
TAGLN
NM_003186


VIM
1.20
0.0632
VIM
NM_003380


HSPA1B
1.20
0.0302
HSPA1B
NM_005346


LAT
1.20
0.0184
LAT
NM_014387


KRT19
1.20
0.0309
KRT19
NM_002276


IGFBP3
1.20
0.0167
IGFBP3
NM_000598


BMP4
1.20
0.0035
BMP4
NM_001202


KLK6
1.20
0.0014
KLK6
NM_002774


THBS1
1.20
0.0206
THBS1
NM_003246


TULP3
1.19
0.0344
TULP3
NM_003324


ERK1
1.19
0.0522

Z11696


CREBBP
1.19
0.0866
CREBBP
NM_004380


S100A4
1.19
0.0259
S100A4
NM_002961


PDGFB
1.19
0.0205
PDGFB
NM_002608


EFNB2
1.19
0.0299
EFNB2
NM_004093


LOX
1.19
0.0104
LOX
NM_002317


PTK2
1.18
0.0983
PTK2
NM_005607


IGFBP5
1.18
0.0544
IGFBP5
NM_000599


APC
1.18
0.0461
APC
NM_000038


DYRK1B
1.18
0.0681
DYRK1B
NM_004714


NOTCH2
1.18
0.0533
NOTCH2
NM_024408


Maspin
1.18
0.0033
SERPINB5
NM_002639


AKAP12
1.18
0.0195
AKAP12
NM_005100


COL1A1
1.17
0.0417
COL1A1
NM_000088


EMP1
1.17
0.0295
EMP1
NM_001423


SIAT4A
1.17
0.0311
ST3GAL1
NM_003033


PAI1
1.17
0.0036
SERPINE1
NM_000602


NR4A1
1.17
0.0117
NR4A1
NM_002135


EGR1
1.17
0.0379
EGR1
NM_001964


BRK
1.17
0.0156
PTK6
NM_005975


UNC5B
1.17
0.0956
UNC5B
NM_170744


SR-A1
1.17
0.0512
SR-A1
NM_021228


MRP3
1.16
0.0353
ABCC3
NM_003786


hCRA a
1.16
0.0878

U78556


Upa
1.16
0.0630
PLAU
NM_002658


BCAS1
1.16
0.0147
BCAS1
NM_003657


PDGFC
1.16
0.0375
PDGFC
NM_016205


COL1A2
1.16
0.0620
COL1A2
NM_000089


CTGF
1.16
0.0580
CTGF
NM_001901


MCP1
1.16
0.0463
CCL2
NM_002982


RAB32
1.16
0.0686
RAB32
NM_006834


SKP1A
1.16
0.0842
SKP1A
NM_006930


FAP
1.16
0.0443
FAP
NM_004460


EFNA1
1.16
0.0990
EFNA1
NM_004428


HOXB7
1.15
0.0378
HOXB7
NM_004502


CYR61
1.15
0.0452
CYR61
NM_001554


TGFBI
1.15
0.0591
TGFBI
NM_000358


TMEPAI
1.15
0.0419
TMEPAI
NM_020182


SIN3A
1.15
0.0853
SIN3A
NM_015477


S100A2
1.15
0.0038
S100A2
NM_005978


PDGFA
1.15
0.0840

NM_002607


MMP7
1.15
0.0469
MMP7
NM_002423


ANTXR1
1.15
0.0520
ANTXR1
NM_032208


SLPI
1.14
0.0755
SLPI
NM_003064


SFRP2
1.13
0.0253
SFRP2
NM_003013


S100A8
1.13
0.0795
S100A8
NM_002964


TP53I3
1.13
0.0973
TP53I3
NM_004881


F3
1.13
0.0735
F3
NM_001993


OPN, osteopontin
1.12
0.0100
SPP1
NM_000582


EGLN3
1.11
0.0883
EGLN3
NM_022073


FZD6
1.11
0.0791
FZD6
NM_003506


OSM
1.10
0.0913
OSM
NM_020530


FABP4
1.10
0.0521
FABP4
NM_001442


GSTT1
1.09
0.0837
GSTT1
NM_000853


REG4
1.07
0.0300
REG4
NM_032044









Table 2.2B shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio<1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using OS as the metric for clinical outcome.















Hazard

Official
Accession


Gene
Ratio
P Value
Symbol
Number







ORC1L
0.52
0.0895
ORC1L
NM_004153


HSPA8
0.64
0.0164
HSPA8
NM_006597


SKP2
0.71
0.0012
SKP2
NM_005983


PRDX4
0.74
0.0202
PRDX4
NM_006406


DHFR
0.76
0.0111
DHFR
NM_000791


FGF18
0.76
0.0915
FGF18
NM_003862


SLC25A3
0.76
0.0391
SLC25A3
NM_213611


RRM1
0.77
0.0218
RRM1
NM_001033


E2F1
0.78
0.0180
E2F1
NM_005225


SURV
0.79
0.0098
BIRC5
NM_001168


PPM1D
0.80
0.0154
PPM1D
NM_003620


CCNE2
0.80
0.0090
CCNE2
NM_057749


BRCA1
0.80
0.0093
BRCA1
NM_007295


ST14
0.80
0.0436
ST14
NM_021978


c-myb (MYB official)
0.81
0.0027
MYB
NM_005375


Chk1
0.81
0.0220
CHEK1
NM_001274


C20 orf1
0.81
0.0305
TPX2
NM_012112


EI24
0.81
0.0574
EI24
NM_004879


CDC20
0.82
0.0234
CDC20
NM_001255


TCF-1
0.82
0.0061
TCF1
NM_000545


PPID
0.83
0.0584
PPID
NM_005038


KIF22
0.83
0.0466
KIF22
NM_007317


UBE2M
0.83
0.0850
UBE2M
NM_003969


MRPL40
0.83
0.0716
MRPL40
NM_003776


RPLPO
0.84
0.0987
RPLP0
NM_001002


LMNB1
0.84
0.0910
LMNB1
NM_005573


DUT
0.84
0.0401
DUT
NM_001948


CD44E
0.84
0.0483

X55150


MCM2
0.85
0.0214
MCM2
NM_004526


CDC6
0.85
0.0235
CDC6
NM_001254


AURKB
0.85
0.0373
AURKB
NM_004217


SMARCA3
0.86
0.0562
SMARCA3
NM_003071


CDCA7 v2
0.86
0.0435
CDCA7
NM_145810


EPHB2
0.86
0.0281
EPHB2
NM_004442


CMYC
0.86
0.0441
MYC
NM_002467


ABCB1
0.86
0.0352
ABCB1
NM_000927


Cdx2
0.87
0.0156
CDX2
NM_001265


PPARG
0.88
0.0655
PPARG
NM_005037


MYBL2
0.88
0.0667
MYBL2
NM_002466


EREG
0.89
0.0352
EREG
NM_001432


AREG
0.90
0.0221
AREG
NM_001657









Table 3.2A shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio>1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using DFS as the metric for clinical outcome.















Hazard

Official
Accession


Gene
Ratio
P Value
Symbol
Number



















ANXA2
1.67
<.0001
ANXA2
NM_004039


CYP3A4
1.59
0.0035
CYP3A4
NM_017460


RhoC
1.52
0.0010
RHOC
NM_175744


TJP1
1.44
0.0951
TJP1
NM_003257


HB-EGF
1.39
0.0023
HBEGF
NM_001945


p21
1.39
0.0006
CDKN1A
NM_000389


HMLH
1.37
0.0678
MLH1
NM_000249


ITGB1
1.37
0.0419
ITGB1
NM_002211


UBC
1.34
0.0024
UBC
NM_021009


VEGFC
1.33
0.0246
VEGFC
NM_005429


TIMP1
1.33
0.0007
TIMP1
NM_003254


CCNE2 variant 1
1.32
0.0745
CCNE2
NM_057749


SPINT2
1.32
0.0224
SPINT2
NM_021102


LAMC2
1.32
0.0002
LAMC2
NM_005562


VCL
1.31
0.0119
VCL
NM_003373


RhoB
1.31
0.0049
RHOB
NM_004040


PKR2
1.30
0.0258
PKM2
NM_002654


ANXA5
1.30
0.0406
ANXA5
NM_001154


GADD45B
1.30
0.0001
GADD45B
NM_015675


INHBB
1.29
0.0368
INHBB
NM_002193


DUSP1
1.29
<.0001
DUSP1
NM_004417


KRAS2
1.28
0.0686
KRAS
NM_004985


KLF6
1.28
0.0284
KLF6
NM_001300


IGFBP7
1.27
0.0103
IGFBP7
NM_001553


GRIK1
1.27
0.0421
GRIK1
NM_000830


DLC1
1.27
0.0084
DLC1
NM_006094


FOS
1.26
0.0003
FOS
NM_005252


HSPG2
1.26
0.0443
HSPG2
NM_005529


INHBA
1.26
0.0009
INHBA
NM_002192


TIMP3
1.26
0.0045
TIMP3
NM_000362


BGN
1.26
0.0035
BGN
NM_001711


CGB
1.26
0.0172
CGB
NM_000737


HK1
1.26
0.0352
HK1
NM_000188


SHC1
1.25
0.0562
SHC1
NM_003029


STC1
1.25
0.0161
STC1
NM_003155


LOXL2
1.24
0.0078
LOXL2
NM_002318


CAPG
1.24
0.0161
CAPG
NM_001747


UNC5B
1.23
0.0204
UNC5B
NM_170744


MVP
1.23
0.0729
MVP
NM_017458


CTSD
1.23
0.0256
CTSD
NM_001909


EGR1
1.23
0.0041
EGR1
NM_001964


LOX
1.23
0.0017
LOX
NM_002317


CDC42BPA
1.23
0.0278
CDC42BPA
NM_003607


GAGE4
1.23
0.0425
GAGE4
NM_001474


CALD1
1.22
0.0239
CALD1
NM_004342


FXYD5
1.22
0.0096
FXYD5
NM_014164


EphB6
1.22
0.0825
EPHB6
NM_004445


LAMB3
1.22
0.0444
LAMB3
NM_000228


VEGF
1.21
0.0267
VEGF
NM_003376


PDGFB
1.21
0.0062
PDGFB
NM_002608


TIMP2
1.21
0.0292
TIMP2
NM_003255


A-Catenin
1.21
0.0598
CTNNA1
NM_001903


IGFBP3
1.21
0.0081
IGFBP3
NM_000598


CD68
1.21
0.0138
CD68
NM_001251


S100A1
1.21
0.0886
S100A1
NM_006271


SIAT4A
1.21
0.0076
ST3GAL1
NM_003033


HSPA1B
1.21
0.0182
HSPA1B
NM_005346


DKK1
1.20
0.0900
DKK1
NM_012242


SBA2
1.20
0.0733
WSB2
NM_018639


SIR2
1.20
0.0250
SIRT1
NM_012238


THBS1
1.20
0.0119
THBS1
NM_003246


FYN
1.20
0.0156
FYN
NM_002037


TULP3
1.20
0.0205
TULP3
NM_003324


LAMA3
1.20
0.0026
LAMA3
NM_000227


NR4A1
1.20
0.0022
NR4A1
NM_002135


EFNA1
1.20
0.0258
EFNA1
NM_004428


EMP1
1.20
0.0102
EMP1
NM_001423


SPARC
1.19
0.0333
SPARC
NM_003118


G-Catenin
1.19
0.0761
JUP
NM_002230


CYR61
1.19
0.0103
CYR61
NM_001554


Maspin
1.19
0.0015
SERPINB5
NM_002639


HSPA1A
1.18
0.0018
HSPA1A
NM_005345


PTHR1
1.18
0.0856
PTHR1
NM_000316


EPAS1
1.18
0.0789
EPAS1
NM_001430


Grb10
1.18
0.0173
GRB10
NM_005311


ERK1
1.18
0.0464

Z11696


VIM
1.18
0.0772
VIM
NM_003380


SNAI2
1.18
0.0379
SNAI2
NM_003068


IGFBP5
1.17
0.0492
IGFBP5
NM_000599


CTHRC1
1.17
0.0155
CTHRC1
NM_138455


THY1
1.17
0.0562
THY1
NM_006288


NRP1
1.17
0.0747
NRP1
NM_003873


PTGER3
1.17
0.0493
PTGER3
NM_000957


ID3
1.17
0.0437
ID3
NM_002167


F3
1.17
0.0157
F3
NM_001993


CTGF
1.17
0.0394
CTGF
NM_001901


KRT19
1.17
0.0517
KRT19
NM_002276


PAI1
1.17
0.0033
SERPINE1
NM_000602


FAP
1.17
0.0260
FAP
NM_004460


ANXA1
1.16
0.0688
ANXA1
NM_000700


KLK10
1.16
0.0009
KLK10
NM_002776


EFNB2
1.16
0.0447
EFNB2
NM_004093


P14ARF
1.16
0.0573

S78535


MCP1
1.16
0.0359
CCL2
NM_002982


PLK3
1.16
0.0296
PLK3
NM_004073


ANTXR1
1.16
0.0243
ANTXR1
NM_032208


ADAMTS12
1.16
0.0346
ADAMTS12
NM_030955


EGR3
1.16
0.0109
EGR3
NM_004430


APC
1.16
0.0733
APC
NM_000038


PDGFC
1.16
0.0326
PDGFC
NM_016205


BMP4
1.16
0.0151
BMP4
NM_001202


HOXB7
1.15
0.0281
HOXB7
NM_004502


NDRG1
1.15
0.0912
NDRG1
NM_006096


Herstatin
1.15
0.0380

AF177761


TMEPAI
1.15
0.0268
TMEPAI
NM_020182


IL6
1.15
0.0914
IL6
NM_000600


PDGFA
1.15
0.0599

NM_002607


TGFBI
1.15
0.0439
TGFBI
NM_000358


Upa
1.15
0.0740
PLAU
NM_002658


S100A4
1.15
0.0621
S100A4
NM_002961


SLPI
1.15
0.0447
SLPI
NM_003064


KLK6
1.15
0.0112
KLK6
NM_002774


COL1A1
1.15
0.0637
COL1A1
NM_000088


GJB2
1.15
0.0604
GJB2
NM_004004


PKD1
1.15
0.0939
PKD1
NM_000296


TP53I3
1.15
0.0450
TP53I3
NM_004881


PLAUR
1.14
0.0477
PLAUR
NM_002659


TAGLN
1.14
0.0739
TAGLN
NM_003186


COL1A2
1.14
0.0818
COL1A2
NM_000089


S100A2
1.14
0.0045
S100A2
NM_005978


AKT3
1.14
0.0949
AKT3
NM_005465


SEMA3B
1.13
0.0467
SEMA3B
NM_004636


BRK
1.13
0.0476
PTK6
NM_005975


OSM
1.13
0.0344
OSM
NM_020530


SFRP2
1.12
0.0279
SFRP2
NM_003013


MRP3
1.12
0.0946
ABCC3
NM_003786


EGLN3
1.12
0.0452
EGLN3
NM_022073


SIAT7B
1.12
0.0603
ST6GALNAC2
NM_006456


OPN, osteopontin
1.12
0.0082
SPP1
NM_000582


S100P
1.12
0.0313
S100P
NM_005980


AKAP12
1.12
0.0865
AKAP12
NM_005100


MMP7
1.11
0.0909
MMP7
NM_002423


FABP4
1.11
0.0214
FABP4
NM_001442


CRYAB
1.11
0.0960
CRYAB
NM_001885


SFRP4
1.10
0.0625
SFRP4
NM_003014


EFNA3
1.10
0.0707
EFNA3
NM_004952


GSTT1
1.09
0.0516
GSTT1
NM_000853


pS2
1.08
0.0313
TFF1
NM_003225


REG4
1.08
0.0080
REG4
NM_032044


IGFBP2
1.08
0.0846
IGFBP2
NM_000597


MUC5B
1.08
0.0387
MUC5B
XM_039877









Table 3.2B shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio<1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using DFS as the metric for clinical outcome.















Hazard

Official
Accession


Gene
Ratio
P Value
Symbol
Number







HSPA8
0.72
0.0604
HSPA8
NM_006597


SLC25A3
0.73
0.0126
SLC25A3
NM_213611


E2F1
0.73
0.0019
E2F1
NM_005225


IFIT1
0.74
0.0820
IFIT1
NM_001548


PPM1D
0.74
0.0007
PPM1D
NM_003620


SKP2
0.75
0.0049
SKP2
NM_005983


RRM1
0.78
0.0224
RRM1
NM_001033


DDB1
0.79
0.0720
DDB1
NM_001923


NPM1
0.79
0.0255
NPM1
NM_002520


PRDX4
0.80
0.0570
PRDX4
NM_006406


BRCA1
0.80
0.0064
BRCA1
NM_007295


C20 orf1
0.81
0.0180
TPX2
NM_012112


Chk1
0.81
0.0148
CHEK1
NM_001274


EI24
0.81
0.0417
EI24
NM_004879


CCNE2
0.81
0.0094
CCNE2
NM_057749


HMGB1
0.82
0.0852
HMGB1
NM_002128


SURV
0.82
0.0185
BIRC5
NM_001168


KIF22
0.82
0.0264
KIF22
NM_007317


RAD54L
0.82
0.0674
RAD54L
NM_003579


c-myb (MYB official)
0.82
0.0038
MYB
NM_005375


DHFR
0.82
0.0669
DHFR
NM_000791


TNFRSF5
0.83
0.0855
CD40
NM_001250


LMNB1
0.83
0.0741
LMNB1
NM_005573


CDC20
0.85
0.0538
CDC20
NM_001255


CDCA7 v2
0.85
0.0277
CDCA7
NM_145810


FASN
0.85
0.0919
FASN
NM_004104


MCM2
0.85
0.0194
MCM2
NM_004526


ABCB1
0.85
0.0169
ABCB1
NM_000927


EIF4E
0.85
0.0902
EIF4E
NM_001968


DUT
0.86
0.0535
DUT
NM_001948


C20ORF126
0.86
0.0932
PDRG1
NM_030815


MCM6
0.86
0.0970
MCM6
NM_005915


EFP
0.87
0.0850
TRIM25
NM_005082


EPHB2
0.87
0.0314
EPHB2
NM_004442


GCLC
0.87
0.0862
GCLC
NM_001498


RCC1
0.87
0.0540
RCC1
NM_001269


AREG
0.87
0.0028
AREG
NM_001657


CMYC
0.88
0.0584
MYC
NM_002467


MYBL2
0.88
0.0567
MYBL2
NM_002466


TCF-1
0.88
0.0644
TCF1
NM_000545


EREG
0.89
0.0232
EREG
NM_001432


Cdx2
0.90
0.0354
CDX2
NM_001265


PTPRO
0.92
0.0935
PTPRO
NM_030667


cripto (TDGF1 official)
0.92
0.0950
TDGF1
NM_003212


HLA-DRB1
0.93
0.0521
HLA-DRB1
NM_002124









Table 4.2A shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio>1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using DRFI as the metric for clinical outcome.















Hazard

Official
Accession


Gene
Ratio
P Value
Symbol
Number



















ALDOA
3.21
0.0189
ALDOA
NM_000034


DCK
2.60
0.0248
DCK
NM_000788


ITGB1
2.58
0.0002
ITGB1
NM_002211


COX2
2.16
0.0198
PTGS2
NM_000963


TJP1
2.10
0.0122
TJP1
NM_003257


STAT3
1.87
0.0148
STAT3
NM_003150


ANXA5
1.83
0.0043
ANXA5
NM_001154


GHI BRAF mut4
1.82
0.0024

GHI_BRAF_mut4


TIMP1
1.80
<.0001
TIMP1
NM_003254


hMLH
1.80
0.0242
MLH1
NM_000249


PADI4
1.74
0.0288
PADI4
NM_012387


rhoC
1.74
0.0093
RHOC
NM_175744


CYP3A4
1.73
0.0219
CYP3A4
NM_017460


WWOX
1.72
0.0467
WWOX
NM_016373


ANXA2
1.70
0.0081
ANXA2
NM_004039


LILRB3
1.70
0.0295
LILRB3
NM_006864


VIM
1.66
0.0015
VIM
NM_003380


FUS
1.65
0.0432
FUS
NM_004960


KCNH2 iso a/b
1.64
0.0111
KCNH2
NM_000238


RhoB
1.63
0.0019
RHOB
NM_004040


CRIP2
1.62
0.0455
CRIP2
NM_001312


AKT3
1.60
0.0004
AKT3
NM_005465


RBX1
1.60
0.0195
RBX1
NM_014248


HB-EGF
1.59
0.0032
HBEGF
NM_001945


NRP2
1.55
0.0007
NRP2
NM_003872


MSH3
1.55
0.0353
MSH3
NM_002439


PI3K
1.54
0.0651
PIK3C2B
NM_002646


BGN
1.54
0.0009
BGN
NM_001711


RAB6C
1.54
0.0210
RAB6C
NM_032144


CTSB
1.53
0.0415
CTSB
NM_001908


DLC1
1.53
0.0047
DLC1
NM_006094


p21
1.53
0.0085
CDKN1A
NM_000389


CCNE2 variant 1
1.52
0.0647
CCNE2
NM_057749


CALD1
1.51
0.0069
CALD1
NM_004342


SBA2
1.51
0.0202
WSB2
NM_018639


SIR2
1.51
0.0028
SIRT1
NM_012238


ITGA5
1.50
0.0006
ITGA5
NM_002205


RAP1GDS1
1.50
0.0317
RAP1GDS1
NM_021159


CTHRC1
1.46
0.0010
CTHRC1
NM_138455


STC1
1.46
0.0083
STC1
NM_003155


KLF6
1.46
0.0362
KLF6
NM_001300


CDC42BPA
1.45
0.0187
CDC42BPA
NM_003607


CEBPB
1.45
0.0605
CEBPB
NM_005194


LAMC2
1.45
0.0031
LAMC2
NM_005562


TGFBR1
1.45
0.0824
TGFBR1
NM_004612


TLN1
1.45
0.0730
TLN1
NM_006289


CDC42
1.44
0.0387
CDC42
NM_001791


FYN
1.43
0.0070
FYN
NM_002037


IGFBP7
1.43
0.0283
IGFBP7
NM_001553


ARG
1.43
0.0119
ABL2
NM_005158


HIF1A
1.42
0.0397
HIF1A
NM_001530


FST
1.42
0.0460
FST
NM_006350


S100A1
1.42
0.0473
S100A1
NM_006271


FAP
1.42
0.0023
FAP
NM_004460


DUSP1
1.42
0.0014
DUSP1
NM_004417


EPAS1
1.41
0.0494
EPAS1
NM_001430


Grb10
1.41
0.0027
GRB10
NM_005311


VEGFC
1.41
0.0894
VEGFC
NM_005429


INHBB
1.41
0.0710
INHBB
NM_002193


GADD45B
1.40
0.0023
GADD45B
NM_015675


UBC
1.40
0.0368
UBC
NM_021009


GJA1
1.40
0.0053
GJA1
NM_000165


COL1A2
1.40
0.0086
COL1A2
NM_000089


RBM5
1.40
0.0423
RBM5
NM_005778


ROCK1
1.39
0.0604
ROCK1
NM_005406


CTGF
1.39
0.0081
CTGF
NM_001901


FLT4
1.39
0.0978
FLT4
NM_002020


PDGFC
1.39
0.0052
PDGFC
NM_016205


INHBA
1.39
0.0058
INHBA
NM_002192


LOXL2
1.38
0.0209
LOXL2
NM_002318


THBS1
1.37
0.0090
THBS1
NM_003246


ITGAV
1.37
0.0298
ITGAV
NM_002210


NCAM1
1.36
0.0714
NCAM1
NM_000615


PTHR1
1.35
0.0410
PTHR1
NM_000316


TIMP2
1.35
0.0446
TIMP2
NM_003255


LOX
1.35
0.0041
LOX
NM_002317


SPARC
1.35
0.0292
SPARC
NM_003118


TAGLN
1.34
0.0222
TAGLN
NM_003186


CYR61
1.34
0.0086
CYR61
NM_001554


RANBP9
1.34
0.0553
RANBP9
NM_005493


GADD45
1.34
0.0604
GADD45A
NM_001924


S100A4
1.34
0.0141
S100A4
NM_002961


SNAI2
1.33
0.0263
SNAI2
NM_003068


EGR1
1.33
0.0174
EGR1
NM_001964


CDH11
1.33
0.0355
CDH11
NM_001797


SI
1.33
0.0967
SI
NM_001041


PTK2
1.33
0.0911
PTK2
NM_005607


MCP1
1.32
0.0215
CCL2
NM_002982


PCAF
1.32
0.0463
PCAF
NM_003884


c-abl
1.32
0.0868
ABL1
NM_005157


TIMP3
1.32
0.0455
TIMP3
NM_000362


ANGPT2
1.31
0.0711
ANGPT2
NM_001147


NOTCH2
1.30
0.0645
NOTCH2
NM_024408


GBP2
1.30
0.0218
GBP2
NM_004120


PAI1
1.30
0.0022
SERPINE1
NM_000602


CXCR4
1.30
0.0341
CXCR4
NM_003467


BCAS1
1.30
0.0060
BCAS1
NM_003657


COL1A1
1.29
0.0349
COL1A1
NM_000088


PIM1
1.29
0.0507
PIM1
NM_002648


PDGFB
1.29
0.0288
PDGFB
NM_002608


Bcl2
1.29
0.0270
BCL2
NM_000633


SLPI
1.29
0.0222
SLPI
NM_003064


IGFBP5
1.29
0.0676
IGFBP5
NM_000599


ANXA1
1.29
0.0690
ANXA1
NM_000700


FGFR1
1.28
0.0790
FGFR1
NM_023109


CAPG
1.28
0.0987
CAPG
NM_001747


PRKCA
1.28
0.0548
PRKCA
NM_002737


EPHA2
1.28
0.0339
EPHA2
NM_004431


AKAP12
1.28
0.0215
AKAP12
NM_005100


FOS
1.28
0.0219
FOS
NM_005252


CXCL12
1.27
0.0169
CXCL12
NM_000609


GCNT1
1.27
0.0875
GCNT1
NM_001490


IGFBP3
1.27
0.0499
IGFBP3
NM_000598


DPYD
1.27
0.0259
DPYD
NM_000110


CD68
1.27
0.0752
CD68
NM_001251


EFNA1
1.27
0.0890
EFNA1
NM_004428


ABCC5
1.26
0.0536
ABCC5
NM_005688


TUBB
1.26
0.0635
TUBB2
NM_001069


PDGFA
1.26
0.0676

NM_002607


DAPK1
1.26
0.0701
DAPK1
NM_004938


SFRP2
1.25
0.0109
SFRP2
NM_003013


ID3
1.25
0.0744
ID3
NM_002167


CTSL
1.25
0.0679
CTSL
NM_001912


LAMA3
1.25
0.0299
LAMA3
NM_000227


KRT19
1.25
0.0982
KRT19
NM_002276


S100A8
1.25
0.0228
S100A8
NM_002964


IL6
1.25
0.0933
IL6
NM_000600


MRP3
1.25
0.0538
ABCC3
NM_003786


FES
1.25
0.0694
FES
NM_002005


AP-1 (JUN
1.25
0.0974
JUN
NM_002228


official)


WISP1
1.24
0.0897
WISP1
NM_003882


SFRP4
1.24
0.0250
SFRP4
NM_003014


TGFBI
1.24
0.0692
TGFBI
NM_000358


Maspin
1.24
0.0152
SERPINB5
NM_002639


HOXB7
1.23
0.0541
HOXB7
NM_004502


P14ARF
1.23
0.0944

S78535


HSPA1A
1.23
0.0259
HSPA1A
NM_005345


EGR3
1.22
0.0312
EGR3
NM_004430


CRYAB
1.22
0.0483
CRYAB
NM_001885


ALDH1A1
1.22
0.0372
ALDH1A1
NM_000689


TGFB3
1.22
0.0673
TGFB3
NM_003239


KLK6
1.21
0.0288
KLK6
NM_002774


ANTXR1
1.21
0.0942
ANTXR1
NM_032208


FZD6
1.20
0.0479
FZD6
NM_003506


ILT-2
1.20
0.0930
LILRB1
NM_006669


S100A2
1.20
0.0116
S100A2
NM_005978


MMP7
1.18
0.0987
MMP7
NM_002423


FABP4
1.17
0.0371
FABP4
NM_001442


OPN, osteopontin
1.17
0.0301
SPP1
NM_000582


KLK10
1.16
0.0581
KLK10
NM_002776


pS2
1.15
0.0186
TFF1
NM_003225


REG4
1.14
0.0053
REG4
NM_032044


MUC2
1.09
0.0429
MUC2
NM_002457









Table 4.2B shows associations between clinical outcome and gene expression for those genes which demonstrated a Hazard Ratio<1.0 and for which p<0.1. Univariate Cox Proportional Hazards Regression analysis was applied in combined Stage II (Duke's B) and Stage III (Duke's C) patients using DRFI as the metric for clinical outcome.


















Hazard

Official
Accession



Gene
Ratio
P Value
Symbol
Number









HSPA8
0.48
0.0114
HSPA8
NM_006597



RPS13
0.64
0.0082
RPS13
NM_001017



NDUFS3
0.66
0.0096
NDUFS3
NM_004551



ST14
0.66
0.0132
ST14
NM_021978



LMNB1
0.66
0.0135
LMNB1
NM_005573



TMSB4X
0.67
0.0039
TMSB4X
NM_021109



DHFR
0.68
0.0260
DHFR
NM_000791



BRCA1
0.68
0.0029
BRCA1
NM_007295



SKP2
0.68
0.0151
SKP2
NM_005983



SLC25A3
0.69
0.0265
SLC25A3
NM_213611



CDC20
0.69
0.0048
CDC20
NM_001255



RPLPO
0.70
0.0320
RPLP0
NM_001002



TCF-1
0.70
0.0013
TCF1
NM_000545



RRM1
0.71
0.0598
RRM1
NM_001033



ATP5A1
0.71
0.0827
ATP5A1
NM_004046



NME1
0.73
0.0378
NME1
NM_000269



CKS2
0.74
0.0537
CKS2
NM_001827



EI24
0.74
0.0639
EI24
NM_004879



C20 orf1
0.74
0.0435
TPX2
NM_012112



SDC1
0.74
0.0930
SDC1
NM_002997



CSEL1
0.75
0.0443
CSE1L
NM_001316



ABCC6
0.76
0.0416
ABCC6
NM_001171



MCM2
0.76
0.0136
MCM2
NM_004526



NFKBp65
0.77
0.0672
RELA
NM_021975



EPHB2
0.77
0.0133
EPHB2
NM_004442



FASN
0.78
0.0980
FASN
NM_004104



AURKB
0.78
0.0528
AURKB
NM_004217



VDR
0.79
0.0832
VDR
NM_000376



UMPS
0.80
0.0721
UMPS
NM_000373



UBE2C
0.81
0.0860
UBE2C
NM_007019



CMYC
0.82
0.0742
MYC
NM_002467



MYBL2
0.83
0.0780
MYBL2
NM_002466



Cdx2
0.84
0.0392
CDX2
NM_001265



MX1
0.85
0.0786
MX1
NM_002462



EREG
0.85
0.0638
EREG
NM_001432



AREG
0.85
0.0295
AREG
NM_001657










Table 5.2A shows associations between gene expression and RFI, controlling for particular demographic and clinical characteristics of patients included in the analysis. All genes are listed whose expression correlates with RFI (p<0.1) and which demonstrated a Hazard Ratio>1 in a multivariate analysis including the following variables: tumor location, year of surgery, tumor grade, treatment protocol (C-01 or C-02), BCG treatment (yes or no), and classification of patients according to lymph node status as follows: 0 positive nodes and <12 nodes examined, 0 positive nodes and ≧12 nodes examined, 1-3 positive nodes, and ≧4 positive nodes.

















Hazard
LR


Official
Accession


Gene
Ratio
Chi-Square
DF
P Value
Symbol
Number





















RARB
2.02
3.42
1
0.0644
RARB
NM_016152


COX2
1.69
3.13
1
0.0768
PTGS2
NM_000963


RhoC
1.60
8.71
1
0.0032
RHOC
NM_175744


CYP3A4
1.57
5.15
1
0.0233
CYP3A4
NM_017460


RhoB
1.54
12.40
1
0.0004
RHOB
NM_004040


ANXA2
1.54
7.01
1
0.0081
ANXA2
NM_004039


ITGB1
1.54
5.54
1
0.0186
ITGB1
NM_002211


NTN1
1.53
3.63
1
0.0568
NTN1
NM_004822


KRAS2
1.51
4.83
1
0.0279
KRAS
NM_004985


IGFBP7
1.44
8.53
1
0.0035
IGFBP7
NM_001553


TIMP1
1.43
9.03
1
0.0027
TIMP1
NM_003254


WWOX
1.43
2.73
1
0.0988
WWOX
NM_016373


CYP1B1
1.39
3.69
1
0.0548
CYP1B1
NM_000104


KCNH2 iso a/b
1.38
3.23
1
0.0723
KCNH2
NM_000238


STC1
1.37
6.55
1
0.0105
STC1
NM_003155


ITGAV
1.37
9.37
1
0.0022
ITGAV
NM_002210


VEGFC
1.37
3.62
1
0.0571
VEGFC
NM_005429


G-Catenin
1.36
4.78
1
0.0287
JUP
NM_002230


S100A1
1.34
4.12
1
0.0423
S100A1
NM_006271


GADD45B
1.34
9.63
1
0.0019
GADD45B
NM_015675


NCAM1
1.33
3.00
1
0.0832
NCAM1
NM_000615


CALD1
1.33
6.05
1
0.0139
CALD1
NM_004342


FST
1.33
4.24
1
0.0396
FST
NM_006350


INHBA
1.33
9.68
1
0.0019
INHBA
NM_002192


BGN
1.33
7.27
1
0.0070
BGN
NM_001711


Claudin 4
1.33
7.13
1
0.0076
CLDN4
NM_001305


CEBPB
1.33
2.96
1
0.0851
CEBPB
NM_005194


LAMC2
1.32
8.62
1
0.0033
LAMC2
NM_005562


SPINT2
1.32
3.14
1
0.0762
SPINT2
NM_021102


AKT3
1.32
7.54
1
0.0060
AKT3
NM_005465


TIMP3
1.32
6.33
1
0.0119
TIMP3
NM_000362


MAPK14
1.31
2.75
1
0.0972
MAPK14
NM_139012


HB-EGF
1.31
4.74
1
0.0294
HBEGF
NM_001945


DUSP1
1.30
11.34
1
0.0008
DUSP1
NM_004417


EFNA1
1.30
5.87
1
0.0154
EFNA1
NM_004428


PTK2
1.29
3.60
1
0.0576
PTK2
NM_005607


DLC1
1.29
5.19
1
0.0227
DLC1
NM_006094


EPAS1
1.28
3.30
1
0.0693
EPAS1
NM_001430


THBS1
1.28
7.51
1
0.0061
THBS1
NM_003246


TIMP2
1.28
4.20
1
0.0404
TIMP2
NM_003255


TGFBI
1.27
6.68
1
0.0098
TGFBI
NM_000358


DKK1
1.27
3.05
1
0.0806
DKK1
NM_012242


SPARC
1.26
4.37
1
0.0366
SPARC
NM_003118


PDGFC
1.26
6.74
1
0.0094
PDGFC
NM_016205


RAB6C
1.26
3.27
1
0.0704
RAB6C
NM_032144


LOXL2
1.26
4.48
1
0.0343
LOXL2
NM_002318


CD68
1.25
4.68
1
0.0305
CD68
NM_001251


LOX
1.25
7.16
1
0.0075
LOX
NM_002317


CDC42BPA
1.25
3.35
1
0.0671
CDC42BPA
NM_003607


TAGLN
1.25
4.83
1
0.0279
TAGLN
NM_003186


CTHRC1
1.25
5.96
1
0.0146
CTHRC1
NM_138455


PDGFA
1.25
4.63
1
0.0314

NM_002607


TMEPAI
1.24
5.63
1
0.0176
TMEPAI
NM_020182


RAB32
1.24
4.48
1
0.0343
RAB32
NM_006834


HSPA1A
1.24
8.19
1
0.0042
HSPA1A
NM_005345


VIM
1.24
2.97
1
0.0848
VIM
NM_003380


IGFBP5
1.23
3.69
1
0.0549
IGFBP5
NM_000599


EGR1
1.23
5.12
1
0.0236
EGR1
NM_001964


ANGPT2
1.23
2.96
1
0.0852
ANGPT2
NM_001147


NDRG1
1.22
2.91
1
0.0879
NDRG1
NM_006096


VEGF_altsplice1
1.22
4.08
1
0.0433

AF486837


SLPI
1.22
4.94
1
0.0262
SLPI
NM_003064


FOS
1.22
5.67
1
0.0172
FOS
NM_005252


VEGF
1.22
2.80
1
0.0942
VEGF
NM_003376


ADAMTS12
1.22
4.40
1
0.0359
ADAMTS12
NM_030955


Maspin
1.22
7.60
1
0.0058
SERPINB5
NM_002639


CGB
1.22
3.25
1
0.0713
CGB
NM_000737


CYR61
1.21
5.22
1
0.0224
CYR61
NM_001554


GJB2
1.21
3.77
1
0.0522
GJB2
NM_004004


IGFBP3
1.21
4.24
1
0.0396
IGFBP3
NM_000598


PRKCA
1.21
3.81
1
0.0508
PRKCA
NM_002737


S100P
1.21
6.98
1
0.0082
S100P
NM_005980


NRP2
1.21
3.25
1
0.0714
NRP2
NM_003872


EFNB2
1.21
3.00
1
0.0834
EFNB2
NM_004093


COL1A2
1.21
3.59
1
0.0581
COL1A2
NM_000089


VEGFB
1.20
2.80
1
0.0942
VEGFB
NM_003377


HOXB7
1.20
4.37
1
0.0367
HOXB7
NM_004502


Grb10
1.20
3.91
1
0.0480
GRB10
NM_005311


FAP
1.20
4.12
1
0.0425
FAP
NM_004460


GJA1
1.20
4.80
1
0.0285
GJA1
NM_000165


CTGF
1.19
3.38
1
0.0660
CTGF
NM_001901


NR4A1
1.18
5.13
1
0.0235
NR4A1
NM_002135


COL1A1
1.18
2.77
1
0.0961
COL1A1
NM_000088


ABCC5
1.17
2.80
1
0.0945
ABCC5
NM_005688


EMP1
1.17
3.06
1
0.0804
EMP1
NM_001423


SFRP2
1.17
4.89
1
0.0270
SFRP2
NM_003013


SLC2A1
1.17
3.52
1
0.0606
SLC2A1
NM_006516


F3
1.17
3.10
1
0.0783
F3
NM_001993


S100A4
1.17
2.87
1
0.0900
S100A4
NM_002961


BRK
1.17
2.81
1
0.0935
PTK6
NM_005975


CRYAB
1.17
3.77
1
0.0523
CRYAB
NM_001885


MDK
1.16
3.84
1
0.0500
MDK
NM_002391


OPN, osteopontin
1.16
6.07
1
0.0138
SPP1
NM_000582


SFRP4
1.16
4.09
1
0.0432
SFRP4
NM_003014


SIAT4A
1.16
2.76
1
0.0969
ST3GAL1
NM_003033


LAMA3
1.16
3.23
1
0.0725
LAMA3
NM_000227


AKAP12
1.15
2.74
1
0.0976
AKAP12
NM_005100


KLK10
1.15
5.23
1
0.0221
KLK10
NM_002776


EGR3
1.14
3.16
1
0.0755
EGR3
NM_004430


PAI1
1.13
3.39
1
0.0655
SERPINE1
NM_000602


CEACAM6
1.13
2.98
1
0.0845
CEACAM6
NM_002483


KLK6
1.13
3.74
1
0.0532
KLK6
NM_002774


Nkd-1
1.11
3.34
1
0.0674
NKD1
NM_033119


IGFBP2
1.11
3.15
1
0.0758
IGFBP2
NM_000597


REG4
1.08
3.51
1
0.0610
REG4
NM_032044









Table 5.2B shows associations between gene expression and RFI, controlling for particular demographic and clinical characteristics of patients included in the analysis. All genes are listed whose expression correlates with RFI (p<0.1) and which demonstrated a Hazard Ratio<1 in a multivariate analysis including the following variables: tumor location, year of surgery, tumor grade, treatment protocol (C-01 or C-02), BCG treatment (yes or no), and classification of patients according to lymph node status as follows: 0 positive nodes and <12 nodes examined, 0 positive nodes and ≧12 nodes examined, 1-3 positive nodes, and ≧4 positive nodes.

















Hazard
LR


Official
Accession


Gene
Ratio
Chi-Square
DF
P Value
Symbol
Number





















Fasl
0.43
5.57
1
0.0183
FASLG
NM_000639


BFGF
0.57
4.68
1
0.0306
NUDT6
NM_007083


EstR1
0.57
3.22
1
0.0726
ESR1
NM_000125


IFIT1
0.60
4.30
1
0.0381
IFIT1
NM_001548


KLRK1
0.64
10.81
1
0.0010
KLRK1
NM_007360


E2F1
0.65
7.49
1
0.0062
E2F1
NM_005225


BRCA1
0.66
16.33
1
<.0001
BRCA1
NM_007295


RAD54L
0.67
6.36
1
0.0117
RAD54L
NM_003579


ATP5A1
0.67
5.50
1
0.0190
ATP5A1
NM_004046


MCM3
0.68
2.84
1
0.0922
MCM3
NM_002388


DHFR
0.68
7.44
1
0.0064
DHFR
NM_000791


HSPA8
0.68
2.96
1
0.0855
HSPA8
NM_006597


APG-1
0.71
5.86
1
0.0155
HSPA4L
NM_014278


BRCA2
0.71
4.69
1
0.0304
BRCA2
NM_000059


TRAIL
0.71
7.27
1
0.0070
TNFSF10
NM_003810


SLC25A3
0.71
5.56
1
0.0184
SLC25A3
NM_213611


PPM1D
0.72
8.02
1
0.0046
PPM1D
NM_003620


Chk1
0.73
6.61
1
0.0102
CHEK1
NM_001274


CD80
0.73
6.85
1
0.0089
CD80
NM_005191


MADH2
0.73
3.93
1
0.0476
SMAD2
NM_005901


KIF22
0.75
5.77
1
0.0163
KIF22
NM_007317


TNFRSF5
0.76
3.52
1
0.0607
CD40
NM_001250


C20 orf1
0.76
4.82
1
0.0281
TPX2
NM_012112


ENO1
0.76
2.88
1
0.0894
ENO1
NM_001428


PRKCB1
0.77
4.25
1
0.0393
PRKCB1
NM_002738


RAF1
0.77
4.17
1
0.0412
RAF1
NM_002880


RRM1
0.78
3.07
1
0.0799
RRM1
NM_001033


UBE2M
0.78
4.43
1
0.0352
UBE2M
NM_003969


SKP2
0.79
3.42
1
0.0644
SKP2
NM_005983


DUT
0.79
4.38
1
0.0364
DUT
NM_001948


EI24
0.80
2.85
1
0.0912
EI24
NM_004879


UMPS
0.80
4.96
1
0.0260
UMPS
NM_000373


EFP
0.81
3.83
1
0.0502
TRIM25
NM_005082


HRAS
0.81
3.80
1
0.0513
HRAS
NM_005343


CDC20
0.81
3.78
1
0.0519
CDC20
NM_001255


CSF1
0.82
2.86
1
0.0910
CSF1
NM_000757


CKS2
0.82
2.90
1
0.0886
CKS2
NM_001827


ABCB1
0.82
4.02
1
0.0450
ABCB1
NM_000927


CDC6
0.83
4.23
1
0.0397
CDC6
NM_001254


GBP1
0.83
4.34
1
0.0373
GBP1
NM_002053


SURV
0.83
2.91
1
0.0878
BIRC5
NM_001168


CCNE2
0.83
2.75
1
0.0975
CCNE2
NM_057749


RRM2
0.83
4.19
1
0.0407
RRM2
NM_001034


CMYC
0.84
3.34
1
0.0677
MYC
NM_002467


TCF-1
0.84
3.96
1
0.0466
TCF1
NM_000545


c-myb (MYB official)
0.84
3.72
1
0.0538
MYB
NM_005375


NOTCH1
0.85
3.39
1
0.0658
NOTCH1
NM_017617


MCM2
0.85
3.30
1
0.0693
MCM2
NM_004526


ING5
0.85
2.84
1
0.0922
ING5
NM_032329


AREG
0.88
3.72
1
0.0538
AREG
NM_001657


HLA-DRB1
0.90
3.84
1
0.0500
HLA-DRB1
NM_002124









Table 6.2 shows associations between gene expression and clinical outcome based on a nonlinear proportional hazards analysis, using a 2 degree-of-freedom natural spline. All genes are listed which demonstrated a departure from a strictly linear relationship (p<0.05) with RFI in combined Stage II (Duke's B) and Stage III (Duke's C) patients. The relationship between gene expression and RFI was not constant throughout the observed range of expression values in the study, e.g. increases in gene expression may have been related to increases in duration of RFI in one portion of the observed range and with decreases in duration of RFI in a different portion of the range.















Official
Accession


Gene
P Value
Symbol
Number







PTHLH
<.0001
PTHLH
NM_002820


TGFBR1
0.0011
TGFBR1
NM_004612


CDCA7 v2
0.0020
CDCA7
NM_145810


S100A4
0.0034
S100A4
NM_002961


CREBBP
0.0040
CREBBP
NM_004380


Upa
0.0040
PLAU
NM_002658


KLF5
0.0048
KLF5
NM_001730


CYP2C8
0.0070
CYP2C8
NM_000770


HES6
0.0090
HES6
NM_018645


Cad17
0.0093
CDH17
NM_004063


CEGP1
0.0100
SCUBE2
NM_020974


GHI k-ras mut3
0.0100

GHI_k-ras_mut3


AKT1
0.0104
AKT1
NM_005163


LAMB3
0.0111
LAMB3
NM_000228


CAPG
0.0120
CAPG
NM_001747


FUT6
0.0130
FUT6
NM_000150


A-Catenin
0.0141
CTNNA1
NM_001903


CAPN1
0.0167
CAPN1
NM_005186


HSPE1
0.0180
HSPE1
NM_002157


MADH4
0.0180
SMAD4
NM_005359


STMY3
0.0190
MMP11
NM_005940


TRAG3
0.0200
CSAG2
NM_004909


GBP1
0.0200
GBP1
NM_002053


EFNA1
0.0210
EFNA1
NM_004428


SEMA3B
0.0210
SEMA3B
NM_004636


CLTC
0.0216
CLTC
NM_004859


BRK
0.0240
PTK6
NM_005975


Fas
0.0240
FAS
NM_000043


CCNE2 variant 1
0.0243
CCNE2
NM_057749


TMEPAI
0.0246
TMEPAI
NM_020182


PTPRJ
0.0260
PTPRJ
NM_002843


SKP2
0.0261
SKP2
NM_005983


AGXT
0.0273
AGXT
NM_000030


MAP2
0.0320
MAP2
NM_031846


PFN2
0.0330
PFN2
NM_053024


ATP5E
0.0350
ATP5E
NM_006886


NRP1
0.0352
NRP1
NM_003873


MYH11
0.0360
MYH11
NM_002474


cIAP2
0.0369
BIRC3
NM_001165


INHBA
0.0370
INHBA
NM_002192


EGLN1
0.0371
EGLN1
NM_022051


GRIK1
0.0380
GRIK1
NM_000830


KDR
0.0380
KDR
NM_002253


KLK6
0.0388
KLK6
NM_002774


APOC1
0.0390
APOC1
NM_001645


EP300
0.0390
EP300
NM_001429


DET1
0.0390
DET1
NM_017996


ITGB4
0.0394
ITGB4
NM_000213


CD3z
0.0400
CD3Z
NM_000734


MAX
0.0400
MAX
NM_002382


PAI1
0.0407
SERPINE1
NM_000602


MADH7
0.0430
SMAD7
NM_005904


SIR2
0.0440
SIRT1
NM_012238


NEDD8
0.0440
NEDD8
NM_006156


EPHB2
0.0445
EPHB2
NM_004442


BTF3
0.0460
BTF3
NM_001207


CD34
0.0470
CD34
NM_001773


VEGF_altsplice2
0.0480

AF214570


Wnt-5b
0.0480
WNT5B
NM_032642


RXRA
0.0482
RXRA
NM_002957


tusc4
0.0486
TUSC4
NM_006545









Table 7.2 shows all genes exhibiting an interaction (p-value<0.1) with tumor stage. The data were modeled using a proportional hazards model of RFI with gene expression, tumor stage, and their interaction as predictors. Patients who had 0 positive nodes but <12 nodes examined were excluded from these analyses.


















P-Value





HR
HR
for





Stage
Stage
Inter-
Official
Accession


Gene
II
III
action
Symbol
Number







SOS1
3.35
0.81
0.0009
SOS1
NM_005633


ALCAM
2.36
0.94
0.0020
ALCAM
NM_001627


pS2
1.58
1.04
0.0040
TFF1
NM_003225


TGFB2
1.83
0.95
0.0064
TGFB2
NM_003238


TFF3
1.57
0.90
0.0066
TFF3
NM_003226


KLF6
0.35
1.34
0.0092
KLF6
NM_001300


SNRPF
0.50
1.16
0.0106
SNRPF
NM_003095


CENPA
2.41
0.94
0.0106
CENPA
NM_001809


HES6
1.69
0.86
0.0119
HES6
NM_018645


CLDN1
0.51
0.95
0.0124
CLDN1
NM_021101


FGF2
0.19
0.97
0.0125
FGF2
NM_002006


LEF
1.94
0.94
0.0141
LEF1
NM_016269


MADH2
2.70
0.74
0.0145
SMAD2
NM_005901


TP53BP1
2.31
0.91
0.0153
TP53BP1
NM_005657


CCR7
1.89
0.98
0.0182
CCR7
NM_001838


MRP3
2.26
1.08
0.0204
ABCC3
NM_003786


UPP1
0.16
1.02
0.0208
UPP1
NM_003364


PTEN
3.46
1.00
0.0216
PTEN
NM_000314


ST14
1.64
0.66
0.0223
ST14
NM_021978


FYN
2.28
1.10
0.0241
FYN
NM_002037


CD24
1.33
0.84
0.0260
CD24
NM_013230


LMYC
1.80
0.82
0.0275
RLF
NM_012421


CDC42BPA
2.82
1.12
0.0315
CDC42BPA
NM_003607


CAV1
2.11
0.95
0.0364
CAV1
NM_001753


CHFR
1.81
0.99
0.0382
CHFR
NM_018223


MGAT5
1.59
0.72
0.0383
MGAT5
NM_002410


FPGS
1.93
0.71
0.0402
FPGS
NM_004957


EMR3
2.63
0.57
0.0488
EMR3
NM_032571


SIR2
2.17
1.07
0.0538
SIRT1
NM_012238


PTK2B
1.44
0.93
0.0542
PTK2B
NM_004103


Axin 2
1.38
0.90
0.0549
AXIN2
NM_004655


TRAG3
0.46
1.12
0.0570
CSAG2
NM_004909


MMP7
0.78
1.28
0.0608
MMP7
NM_002423


PFN2
1.33
0.84
0.0610
PFN2
NM_053024


PTPRJ
2.05
1.00
0.0632
PTPRJ
NM_002843


CXCR4
1.96
1.08
0.0644
CXCR4
NM_003467


CCNA2
1.55
0.79
0.0661
CCNA2
NM_001237


MMP12
0.74
1.11
0.0685
MMP12
NM_002426


KRT8
0.64
1.27
0.0694
KRT8
NM_002273


ABCC5
2.06
1.14
0.0704
ABCC5
NM_005688


PRDX6
2.09
0.74
0.0711
PRDX6
NM_004905


WIF
1.54
0.77
0.0738
WIF1
NM_007191


cdc25A
2.48
0.94
0.0769
CDC25A
NM_001789


KLF5
1.87
1.03
0.0772
KLF5
NM_001730


LRP5
1.92
0.98
0.0783
LRP5
NM_002335


PTPD1
0.54
1.00
0.0789
PTPN21
NM_007039


RALBP1
2.20
0.91
0.0791
RALBP1
NM_006788


TP53BP2
1.82
1.05
0.0819
TP53BP2
NM_005426


STAT5B
1.57
0.86
0.0822
STAT5B
NM_012448


PPARG
1.32
0.79
0.0844
PPARG
NM_005037


HB-EGF
0.50
1.38
0.0845
HBEGF
NM_001945


RARA
1.77
0.96
0.0848
RARA
NM_000964


GCNT1
1.86
1.07
0.0883
GCNT1
NM_001490


Ki-67
1.53
0.86
0.0885
MKI67
NM_002417


EFNB2
1.76
1.05
0.0895
EFNB2
NM_004093


LGMN
0.59
1.37
0.0900
LGMN
NM_001008530


DKK1
0.68
1.51
0.0922
DKK1
NM_012242


MADH4
2.04
0.98
0.0964
SMAD4
NM_005359


BIK
1.53
0.94
0.0966
BIK
NM_001197


CD44v3
1.58
0.97
0.0996

AJ251595v3





















TABLE A









Sequence ID



Gene
Accession
Reagent
Sequence
Number







A-Catenin
NM_001903.1
Forward Primer
CGTTCCGATCCTCTATACTGCAT
SEQ ID NO: 1





Probe
ATGCCTACAGCACCCTGATGTCGCA
SEQ ID NO: 2




Reverse Primer
AGGTCCCTGTTGGCCTTATAGG
SEQ ID NO: 3


 


ABCB1
NM_000927.2
Forward Primer
AAACACCACTGGAGCATTGA
SEQ ID NO: 4




Probe
CTCGCCAATGATGCTGCTCAAGTT
SEQ ID NO: 5




Reverse Primer
CAAGCCTGGAACCTATAGCC
SEQ ID NO: 6


 


ABCC5
NM_005688.1
Forward Primer
TGCAGACTGTACCATGCTGA
SEQ ID NO: 7




Probe
CTGCACACGGTTCTAGGCTCCG
SEQ ID NO: 8




Reverse Primer
GGCCAGCACCATAATCCTAT
SEQ ID NO: 9


 


ABCC6
NM_001171.2
Forward Primer
GGATGAACCTCGACCTGC
SEQ ID NO: 10




Probe
CCAGATAGCCTCGTCCGAGTGCTC
SEQ ID NO: 11




Reverse Primer
GAGCTGCACCGTCTCCAG
SEQ ID NO: 12


 


ACP1
NM_004300.2
Forward Primer
GCTACCAAGTCCGTGCTGT
SEQ ID NO: 13




Probe
TGATCGACAAATGTTACCCAGACACACA
SEQ ID NO: 14




Reverse Primer
GAAAACTGCTTCTGCAATGG
SEQ ID NO: 15


 


ADAM10
NM_001110.1
Forward Primer
CCCATCAACTTGTGCCAGTA
SEQ ID NO: 16




Probe
TGCCTACTCCACTGCACAGACCCT
SEQ ID NO: 17




Reverse Primer
GGTGATGGTTCGACCACTG
SEQ ID NO: 18


 


ADAM17
NM_003183.3
Forward Primer
GAAGTGCCAGGAGGCGATTA
SEQ ID NO: 19




Probe
TGCTACTTGCAAAGGCGTGTCCTACTGC
SEQ ID NO: 20




Reverse Primer
CGGGCACTCACTGCTATTACC
SEQ ID NO: 21


 


ADAMTS12
NM_030955.2
Forward Primer
GGAGAAGGGTGGAGTGCAG
SEQ ID NO: 22




Probe
CGCACAGTCAGAATCCATCTGGGT
SEQ ID NO: 23




Reverse Primer
CAGGGTCAGGTCTCTGGATG
SEQ ID NO: 24


 


ADPRT
NM_001618.2
Forward Primer
TTGACAACCTGCTGGACATC
SEQ ID NO: 25




Probe
CCCTGAGCAGACTGTAGGCCACCT
SEQ ID NO: 26




Reverse Primer
ATGGGATCCTTGCTGCTATC
SEQ ID NO: 27


 


AGXT
NM_000030.1
Forward Primer
CTTTTCCCTCCAGTGGCA
SEQ ID NO: 28




Probe
CTCCTGGAAACAGTCCACTTGGGC
SEQ ID NO: 29




Reverse Primer
ATTTGGAAGGCACTGGGTTT
SEQ ID NO: 30


 


AKAP12
NM_005100.2
Forward Primer
TAGAGAGCCCCTGACAATCC
SEQ ID NO: 31




Probe
TGGCTCTAGCTCCTGATGAAGCCTC
SEQ ID NO: 32




Reverse Primer
GGTTGGTCTTGGAAAGAGGA
SEQ ID NO: 33


 


AKT1
NM_005163.1
Forward Primer
CGCTTCTATGGCGCTGAGAT
SEQ ID NO: 34




Probe
CAGCCCTGGACTACCTGCACTCGG
SEQ ID NO: 35




Reverse Primer
TCCCGGTACACCACGTTCTT
SEQ ID NO: 36


 


AKT2
NM_001626.2
Forward Primer
TCCTGCCACCCTTCAAACC
SEQ ID NO: 37




Probe
CAGGTCACGTCCGAGGTCGACACA
SEQ ID NO: 38




Reverse Primer
GGCGGTAAATTCATCATCGAA
SEQ ID NO: 39


 


AKT3
NM_005465.1
Forward Primer
TTGTCTCTGCCTTGGACTATCTACA
SEQ ID NO: 40




Probe
TCACGGTACACAATCTTTCCGGA
SEQ ID NO: 41




Reverse Primer
CCAGCATTAGATTCTCCAACTTGA
SEQ ID NO: 42


 


AL137428
AL137428.1
Forward Primer
CAAGAAGAGGCTCTACCCTGG
SEQ ID NO: 43




Probe
ACTGGGAATTTCCAAGGCCACCTT
SEQ ID NO: 44




Reverse Primer
AAATGAGCTCTGCGATCCTC
SEQ ID NO: 45


 


ALCAM
NM_001627.1
Forward Primer
GAGGAATATGGAATCCAAGGG
SEQ ID NO: 46




Probe
CCAGTTCCTGCCGTCTGCTCTTCT
SEQ ID NO: 47




Reverse Primer
GTGGCGGAGATCAAGAGG
SEQ ID NO: 48


 


ALDH1A1
NM_000689.1
Forward Primer
GAAGGAGATAAGGAGGATGTTGACA
SEQ ID NO: 49




Probe
AGTGAAGGCCGCAAGACAGGCTTTTC
SEQ ID NO: 50




Reverse Primer
CGCCACGGAGATCCAATC
SEQ ID NO: 51


 


ALDOA
NM_000034.2
Forward Primer
GCCTGTACGTGCCAGCTC
SEQ ID NO: 52




Probe
TGCCAGAGCCTCAACTGTCTCTGC
SEQ ID NO: 53




Reverse Primer
TCATCGGAGCTTGATCTCG
SEQ ID NO: 54


 


AMFR
NM_001144.2
Forward Primer
GATGGTTCAGCTCTGCAAGGA
SEQ ID NO: 55




Probe
CGATTTGAATATCTTTCCTTCTCGCCCACC
SEQ ID NO: 56




Reverse Primer
TCGACCGTGGCTGCTCAT
SEQ ID NO: 57


 


ANGPT2
NM_001147.1
Forward Primer
CCGTGAAAGCTGCTCTGTAA
SEQ ID NO: 58




Probe
AAGCTGACACAGCCCTCCCAAGTG
SEQ ID NO: 59




Reverse Primer
TTGCAGTGGGAAGAACAGTC
SEQ ID NO: 60


 


ANTXR1
NM_032208.1
Forward Primer
CTCCAGGTGTACCTCCAACC
SEQ ID NO: 61




Probe
AGCCTTCTCCCACAGCTGCCTACA
SEQ ID NO: 62




Reverse Primer
GAGAAGGCTGGGAGACTCTG
SEQ ID NO: 63


 


ANXA1
NM_000700.1
Forward Primer
GCCCCTATCCTACCTTCAATCC
SEQ ID NO: 64




Probe
TCCTCGGATGTCGCTGCCT
SEQ ID NO: 65




Reverse Primer
CCTTTAACCATTATGGCCTTATGC
SEQ ID NO: 66


 


ANXA2
NM_004039.1
Forward Primer
CAAGACACTAAGGGCGACTACCA
SEQ ID NO: 67




Probe
CCACCACACAGGTACAGCAGCGCT
SEQ ID NO: 68




Reverse Primer
CGTGTCGGGCTTCAGTCAT
SEQ ID NO: 69


 


ANXA5
NM_001154.2
Forward Primer
GCTCAAGCCTGGAAGATGAC
SEQ ID NO: 70




Probe
AGTACCCTGAAGTGTCCCCCACCA
SEQ ID NO: 71




Reverse Primer
AGAACCACCAACATCCGCT
SEQ ID NO: 72


 


AP-1 (JUN
NM_002228.2
Forward Primer
GACTGCAAAGATGGAAACGA
SEQ ID NO: 73


official)

Probe
CTATGACGATGCCCTCAACGCCTC
SEQ ID NO: 74




Reverse Primer
TAGCCATAAGGTCCGCTCTC
SEQ ID NO: 75


 


APC
NM_000038.1
Forward Primer
GGACAGCAGGAATGTGTTTC
SEQ ID NO: 76




Probe
CATTGGCTCCCCGTGACCTGTA
SEQ ID NO: 77




Reverse Primer
ACCCACTCGATTTGTTTCTG
SEQ ID NO: 78


 


APEX-1
NM_001641.2
Forward Primer
GATGAAGCCTTTCGCAAGTT
SEQ ID NO: 79




Probe
CTTTCGGGAAGCCAGGCCCTT
SEQ ID NO: 80




Reverse Primer
AGGTCTCCACACAGCACAAG
SEQ ID NO: 81


 


APG-1
NM_014278.2
Forward Primer
ACCCCGGCCTGTATATCAT
SEQ ID NO: 82




Probe
CCAATGGCTCGAGTTCTTGATCCC
SEQ ID NO: 83




Reverse Primer
CTATCTGGCTCTTTGCTGCAT
SEQ ID NO: 84


 


APN (ANPEP
NM_001150.1
Forward Primer
CCACCTTGGACCAAAGTAAAGC
SEQ ID NO: 85


official)

Probe
CTCCCCAACACGCTGAAACCCG
SEQ ID NO: 86




Reverse Primer
TCTCAGCGTCACCTGGTAGGA
SEQ ID NO: 87


 


APOC1
NM_001645.3
Forward Primer
GGAAACACACTGGAGGACAAG
SEQ ID NO: 88




Probe
TCATCAGCCGCATCAAACAGAGTG
SEQ ID NO: 89




Reverse Primer
CGCATCTTGGCAGAAAGTT
SEQ ID NO: 90


 


AREG
NM_001657.1
Forward Primer
TGTGAGTGAAATGCCTTCTAGTAGTGA
SEQ ID NO: 91




Probe
CCGTCCTCGGGAGCCGACTATGA
SEQ ID NO: 92




Reverse Primer
TTGTGGTTCGTTATCATACTCTTCTGA
SEQ ID NO: 93


 


ARG
NM_005158.2
Forward Primer
CGCAGTGCAGCTGAGTATCTG
SEQ ID NO: 94




Probe
TCGCACCAGGAAGCTGCCATTGA
SEQ ID NO: 95




Reverse Primer
TGCCCAGGGCTACTCTCACTT
SEQ ID NO: 96


 


ARHF
NM_019034.2
Forward Primer
ACTGGCCCACTTAGTCCTCA
SEQ ID NO: 97




Probe
CTCCCAACCTGCTGTCCCTCAAG
SEQ ID NO: 98




Reverse Primer
CTGAACTCCACAGGCTGGTA
SEQ ID NO: 99


 


ATOH1
NM_005172.1
Forward Primer
GCAGCCACCTGCAACTTT
SEQ ID NO: 100




Probe
CAGGCGAGAGAGCATCCCGTCTAC
SEQ ID NO: 101




Reverse Primer
TCCAGGAGGGACAGCTCA
SEQ ID NO: 102


 


ATP5A1
NM_004046.3
Forward Primer
GATGCTGCCACTCAACAACT
SEQ ID NO: 103




Probe
AGTTAGACGCACGCCACGACTCAA
SEQ ID NO: 104




Reverse Primer
TGTCCTTGCTTCAGCAACTC
SEQ ID NO: 105


 


ATP5E
NM_006886.2
Forward Primer
CCGCTTTCGCTACAGCAT
SEQ ID NO: 106




Probe
TCCAGCCTGTCTCCAGTAGGCCAC
SEQ ID NO: 107




Reverse Primer
TGGGAGTATCGGATGTAGCTG
SEQ ID NO: 108


 


AURKB
NM_004217.1
Forward Primer
AGCTGCAGAAGAGCTGCACAT
SEQ ID NO: 109




Probe
TGACGAGCAGCGAACAGCCACG
SEQ ID NO: 110




Reverse Primer
GCATCTGCCAACTCCTCCAT
SEQ ID NO: 111


 


Axin 2
NM_004655.2
Forward Primer
GGCTATGTCTTTGCACCAGC
SEQ ID NO: 112




Probe
ACCAGCGCCAACGACAGTGAGATA
SEQ ID NO: 113




Reverse Primer
ATCCGTCAGCGCATCACT
SEQ ID NO: 114


 


axin1
NM_003502.2
Forward Primer
CCGTGTGACAGCATCGTT
SEQ ID NO: 115




Probe
CGTACTACTTCTGCGGGGAACCCA
SEQ ID NO: 116




Reverse Primer
CTCACCAGGGTGCGGTAG
SEQ ID NO: 117


 


B-Catenin
NM_001904.1
Forward Primer
GGCTCTTGTGCGTACTGTCCTT
SEQ ID NO: 118




Probe
AGGCTCAGTGATGTCTTCCCTGTCACCAG
SEQ ID NO: 119




Reverse Primer
TCAGATGACGAAGAGCACAGATG
SEQ ID NO: 120


 


BAD
NM_032989.1
Forward Primer
GGGTCAGGTGCCTCGAGAT
SEQ ID NO: 121




Probe
TGGGCCCAGAGCATGTTCCAGATC
SEQ ID NO: 122




Reverse Primer
CTGCTCACTCGGCTCAAACTC
SEQ ID NO: 123


 


BAG1
NM_004323.2
Forward Primer
CGTTGTCAGCACTTGGAATACAA
SEQ ID NO: 124




Probe
CCCAATTAACATGACCCGGCAACCAT
SEQ ID NO: 125




Reverse Primer
GTTCAACCTCTTCCTGTGGACTGT
SEQ ID NO: 126


 


BAG2
NM_004282.2
Forward Primer
CTAGGGGCAAAAAGCATGA
SEQ ID NO: 127




Probe
TTCCATGCCAGACAGGAAAAAGCA
SEQ ID NO: 128




Reverse Primer
CTAAATGCCCAAGGTGACTG
SEQ ID NO: 129


 


BAG3
NM_004281.2
Forward Primer
GAAAGTAAGCCAGGCCCAGTT
SEQ ID NO: 130




Probe
CAGAACTCCCTCCTGGACACATCCCAA
SEQ ID NO: 131




Reverse Primer
ACCTCTTTGCGGATCACTTGA
SEQ ID NO: 132


 


Bak
NM_001188.1
Forward Primer
CCATTCCCACCATTCTACCT
SEQ ID NO: 133




Probe
ACACCCCAGACGTCCTGGCCT
SEQ ID NO: 134




Reverse Primer
GGGAACATAGACCCACCAAT
SEQ ID NO: 135


 


Bax
NM_004324.1
Forward Primer
CCGCCGTGGACACAGACT
SEQ ID NO: 136




Probe
TGCCACTCGGAAAAAGACCTCTCGG
SEQ ID NO: 137




Reverse Primer
TTGCCGTCAGAAAACATGTCA
SEQ ID NO: 138


 


BBC3
NM_014417.1
Forward Primer
CCTGGAGGGTCCTGTACAAT
SEQ ID NO: 139




Probe
CATCATGGGACTCCTGCCCTTACC
SEQ ID NO: 140




Reverse Primer
CTAATTGGGCTCCATCTCG
SEQ ID NO: 141


 


BCAS1
NM_003657.1
Forward Primer
CCCCGAGACAACGGAGATAA
SEQ ID NO: 142




Probe
CTTTCCGTTGGCATCCGCAACAG
SEQ ID NO: 143




Reverse Primer
CTCGGGTTTGGCCTCTTTC
SEQ ID NO: 144


 


Bcl2
NM_000633.1
Forward Primer
CAGATGGACCTAGTACCCACTGAGA
SEQ ID NO: 145




Probe
TTCCACGCCGAAGGACAGCGAT
SEQ ID NO: 146




Reverse Primer
CCTATGATTTAAGGGCATTTTTCC
SEQ ID NO: 147


 


BCL2L10
NM_020396.2
Forward Primer
GCTGGGATGGCTTTTGTCA
SEQ ID NO: 148




Probe
TCTTCAGGACCCCCTTTCCACTGGC
SEQ ID NO: 149




Reverse Primer
GCCTGGACCAGCTGTTTTCTC
SEQ ID NO: 150


 


BCL2L11
NM_138621.1
Forward Primer
AATTACCAAGCAGCCGAAGA
SEQ ID NO: 151




Probe
CCACCCACGAATGGTTATCTTACGACTG
SEQ ID NO: 152




Reverse Primer
CAGGCGGACAATGTAACGTA
SEQ ID NO: 153


 


BCL2L12
NM_138639.1
Forward Primer
AACCCACCCCTGTCTTGG
SEQ ID NO: 154




Probe
TCCGGGTAGCTCTCAAACTCGAGG
SEQ ID NO: 155




Reverse Primer
CTCAGCTGACGGGAAAGG
SEQ ID NO: 156


 


Bclx
NM_001191.1
Forward Primer
CTTTTGTGGAACTCTATGGGAACA
SEQ ID NO: 157




Probe
TTCGGCTCTCGGCTGCTGCA
SEQ ID NO: 158




Reverse Primer
CAGCGGTTGAAGCGTTCCT
SEQ ID NO: 159


 


BCRP
NM_004827.1
Forward Primer
TGTACTGGCGAAGAATATTTGGTAAA
SEQ ID NO: 160




Probe
CAGGGCATCGATCTCTCACCCTGG
SEQ ID NO: 161




Reverse Primer
GCCACGTGATTCTTCCACAA
SEQ ID NO: 162


 


BFGF
NM_007083.1
Forward Primer
CCAGGAAGAATGCTTAAGATGTGA
SEQ ID NO: 163




Probe
TTCGCCAGGTCATTGAGATCCATCCA
SEQ ID NO: 164




Reverse Primer
TGGTGATGGGAGTTGTATTTTCAG
SEQ ID NO: 165


 


BGN
NM_001711.3
Forward Primer
GAGCTCCGCAAGGATGAC
SEQ ID NO: 166




Probe
CAAGGGTCTCCAGCACCTCTACGC
SEQ ID NO: 167




Reverse Primer
CTTGTTGTTCACCAGGACGA
SEQ ID NO: 168


 


BID
NM_001196.2
Forward Primer
GGACTGTGAGGTCAACAACG
SEQ ID NO: 169




Probe
TGTGATGCACTCATCCCTGAGGCT
SEQ ID NO: 170




Reverse Primer
GGAAGCCAAACACCAGTAGG
SEQ ID NO: 171


 


BIK
NM_001197.3
Forward Primer
ATTCCTATGGCTCTGCAATTGTC
SEQ ID NO: 172




Probe
CCGGTTAACTGTGGCCTGTGCCC
SEQ ID NO: 173




Reverse Primer
GGCAGGAGTGAATGGCTCTTC
SEQ ID NO: 174


 


BIN1
NM_004305.1
Forward Primer
CCTGCAAAAGGGAACAAGAG
SEQ ID NO: 175




Probe
CTTCGCCTCCAGATGGCTCCC
SEQ ID NO: 176




Reverse Primer
CGTGGTTGACTCTGATCTCG
SEQ ID NO: 177


 


BLMH
NM_000386.2
Forward Primer
GGTTGCTGCCTCCATCAAAG
SEQ ID NO: 178




Probe
ACATCACAGCCAAACCACACAGCCTCT
SEQ ID NO: 179




Reverse Primer
CCAGCTTGCTATTGAAGTGTTTTC
SEQ ID NO: 180


 


BMP2
NM_001200.1
Forward Primer
ATGTGGACGCTCTTTCAATG
SEQ ID NO: 181




Probe
ACCGCAGTCCGTCTAAGAAGCACG
SEQ ID NO: 182




Reverse Primer
ACCATGGTCGACCTTTAGGA
SEQ ID NO: 183


 


BMP4
NM_001202.2
Forward Primer
GGGCTAGCCATTGAGGTG
SEQ ID NO: 184




Probe
CTCACCTCCATCAGACTCGGACCC
SEQ ID NO: 185




Reverse Primer
GCTAATCCTGACATGCTGGC
SEQ ID NO: 186


 


BMP7
NM_001719.1
Forward Primer
TCGTGGAACATGACAAGGAATT
SEQ ID NO: 187




Probe
TTCCACCCACGCTACCACCATCG
SEQ ID NO: 188




Reverse Primer
TGGAAAGATCAAACCGGAACTC
SEQ ID NO: 189


 


BMPR1A
NM_004329.2
Forward Primer
TTGGTTCAGCGAACTATTGC
SEQ ID NO: 190




Probe
CAAACAGATTCAGATGGTCCGGCA
SEQ ID NO: 191




Reverse Primer
TCTCCATATCGGCCTTTACC
SEQ ID NO: 192


 


BRAF
NM_004333.1
Forward Primer
CCTTCCGACCAGCAGATGAA
SEQ ID NO: 193




Probe
CAATTTGGGCAACGAGACCGATCCT
SEQ ID NO: 194




Reverse Primer
TTTATATGCACATTGGGAGCTGAT
SEQ ID NO: 195


 


BRCA1
NM_007295.1
Forward Primer
TCAGGGGGCTAGAAATCTGT
SEQ ID NO: 196




Probe
CTATGGGCCCTTCACCAACATGC
SEQ ID NO: 197




Reverse Primer
CCATTCCAGTTGATCTGTGG
SEQ ID NO: 198


 


BRCA2
NM_000059.1
Forward Primer
AGTTCGTGCTTTGCAAGATG
SEQ ID NO: 199




Probe
CATTCTTCACTGCTTCATAAAGCTCTGCA
SEQ ID NO: 200




Reverse Primer
AAGGTAAGCTGGGTCTGCTG
SEQ ID NO: 201


 


BRK
NM_005975.1
Forward Primer
GTGCAGGAAAGGTTCACAAA
SEQ ID NO: 202




Probe
AGTGTCTGCGTCCAATACACGCGT
SEQ ID NO: 203




Reverse Primer
GCACACACGATGGAGTAAGG
SEQ ID NO: 204


 


BTF3
NM_001207.2
Forward Primer
CAGTGATCCACTTTAACAACCCTAAAG
SEQ ID NO: 205




Probe
TCAGGCATCTCTGGCAGCGAACAC
SEQ ID NO: 206




Reverse Primer
AGCATGGCCTGTAATGGTGAA
SEQ ID NO: 207


 


BTRC
NM_033637.2
Forward Primer
GTTGGGACACAGTTGGTCTG
SEQ ID NO: 208




Probe
CAGTCGGCCCAGGACGGTCTACT
SEQ ID NO: 209




Reverse Primer
TGAAGCAGTCAGTTGTGCTG
SEQ ID NO: 210


 


BUB1
NM_004336.1
Forward Primer
CCGAGGTTAATCCAGCACGTA
SEQ ID NO: 211




Probe
TGCTGGGAGCCTACACTTGGCCC
SEQ ID NO: 212




Reverse Primer
AAGACATGGCGCTCTCAGTTC
SEQ ID NO: 213


 


BUB1B
NM_001211.3
Forward Primer
TCAACAGAAGGCTGAACCACTAGA
SEQ ID NO: 214




Probe
TACAGTCCCAGCACCGACAATTCC
SEQ ID NO: 215




Reverse Primer
CAACAGAGTTTGCCGAGACACT
SEQ ID NO: 216


 


BUB3
NM_004725.1
Forward Primer
CTGAAGCAGATGGTTCATCATT
SEQ ID NO: 217




Probe
CCTCGCTTTGTTTAACAGCCCAGG
SEQ ID NO: 218




Reverse Primer
GCTGATTCCCAAGAGTCTAACC
SEQ ID NO: 219


 


c-abl
NM_005157.2
Forward Primer
CCATCTCGCTGAGATACGAA
SEQ ID NO: 220




Probe
GGGAGGGTGTACCATTACAGGATCAACA
SEQ ID NO: 221




Reverse Primer
AGACGTAGAGCTTGCCATCA
SEQ ID NO: 222


 


c-kit
NM_000222.1
Forward Primer
GAGGCAACTGCTTATGGCTTAATTA
SEQ ID NO: 223




Probe
TTACAGCGACAGTCATGGCCGCAT
SEQ ID NO: 224




Reverse Primer
GGCACTCGGCTTGAGCAT
SEQ ID NO: 225


 


c-myb (MYB
NM_005375.1
Forward Primer
AACTCAGACTTGGAAATGCCTTCT
SEQ ID NO: 226


official)

Probe
AACTTCCACCCCCCTCATTGGTCACA
SEQ ID NO: 227




Reverse Primer
CTGGTCTCTATGAAATGGTGTTGTAAC
SEQ ID NO: 228


 


c-Src
NM_005417.3
Forward Primer
TGAGGAGTGGTATTTTGGCAAGA
SEQ ID NO: 229




Probe
AACCGCTCTGACTCCCGTCTGGTG
SEQ ID NO: 230




Reverse Primer
CTCTCGGGTTCTCTGCATTGA
SEQ ID NO: 231


 


C20 orf1
NM_012112.2
Forward Primer
TCAGCTGTGAGCTGCGGATA
SEQ ID NO: 232




Probe
CAGGTCCCATTGCCGGGCG
SEQ ID NO: 233




Reverse Primer
ACGGTCCTAGGTTTGAGGTTAAGA
SEQ ID NO: 234


 


C20ORF126
NM_030815.2
Forward Primer
CCAGCACTGCTCGTTACTGT
SEQ ID NO: 235




Probe
TGGGACCTCAGACCACTGAAGGC
SEQ ID NO: 236




Reverse Primer
TTGACTTCACGGCAGTTCATA
SEQ ID NO: 237


 


C8orf4
NM_020130.2
Forward Primer
CTACGAGTCAGCCCATCCAT
SEQ ID NO: 238




Probe
CATGGCTACCACTTCGACACAGCC
SEQ ID NO: 239




Reverse Primer
TGCCCACGGCTTTCTTAC
SEQ ID NO: 240


 


CA9
NM_001216.1
Forward Primer
ATCCTAGCCCTGGTTTTTGG
SEQ ID NO: 241




Probe
TTTGCTGTCACCAGCGTCGC
SEQ ID NO: 242




Reverse Primer
CTGCCTTCTCATCTGCACAA
SEQ ID NO: 243


 


Cad17
NM_004063.2
Forward Primer
GAAGGCCAAGAACCGAGTCA
SEQ ID NO: 244




Probe
TTATATTCCAGTTTAAGGCCAATCCTC
SEQ ID NO: 245




Reverse Primer
TCCCCAGTTAGTTCAAAAGTCACA
SEQ ID NO: 246


 


CALD1
NM_004342.4
Forward Primer
CACTAAGGTTTGAGACAGTTCCAGAA
SEQ ID NO: 247




Probe
AACCCAAGCTCAAGACGCAGGACGAG
SEQ ID NO: 248




Reverse Primer
GCGAATTAGCCCTCTACAACTGA
SEQ ID NO: 249


 


CAPG
NM_001747.1
Forward Primer
GATTGTCACTGATGGGGAGG
SEQ ID NO: 250




Probe
AGGACCTGGATCATCTCAGCAGGC
SEQ ID NO: 251




Reverse Primer
CCTTCAGAGCAGGCTTGG
SEQ ID NO: 252


 


CAPN1
NM_005186.2
Forward Primer
CAAGAAGCTGTACGAGCTCATCA
SEQ ID NO: 253




Probe
CCGCTACTCGGAGCCCGACCTG
SEQ ID NO: 254




Reverse Primer
GCAGCAAACGAAATTGTCAAAG
SEQ ID NO: 255


 


CASP8
NM_033357.1
Forward Primer
CCTCGGGGATACTGTCTGAT
SEQ ID NO: 256




Probe
CAACAATCACAATTTTGCAAAAGCACG
SEQ ID NO: 257




Reverse Primer
GAAGTTTGGGCACTTTCTCC
SEQ ID NO: 258


 


CASP9
NM_001229.2
Forward Primer
TGAATGCCGTGGATTGCA
SEQ ID NO: 259




Probe
CACTAGCCCTGGACCAGCCACTGCT
SEQ ID NO: 260




Reverse Primer
ACAGGGATCATGGGACACAAG
SEQ ID NO: 261


 


CAT
NM_001752.1
Forward Primer
ATCCATTCGATCTCACCAAGGT
SEQ ID NO: 262




Probe
TGGCCTCACAAGGACTACCCTCTCATCC
SEQ ID NO: 263




Reverse Primer
TCCGGTTTAAGACCAGTTTACCA
SEQ ID NO: 264


 


CAV1
NM_001753.3
Forward Primer
GTGGCTCAACATTGTGTTCC
SEQ ID NO: 265




Probe
ATTTCAGCTGATCAGTGGGCCTCC
SEQ ID NO: 266




Reverse Primer
CAATGGCCTCCATTTTACAG
SEQ ID NO: 267


 


CBL
NM_005188.1
Forward Primer
TCATTCACAAACCTGGCAGT
SEQ ID NO: 268




Probe
TTCCGGCTGAGCTGTACTCGTCTG
SEQ ID NO: 269




Reverse Primer
CATACCCAATAGCCCACTGA
SEQ ID NO: 270


 


CCL20
NM_004591.1
Forward Primer
CCATGTGCTGTACCAAGAGTTTG
SEQ ID NO: 271




Probe
CAGCACTGACATCAAAGCAGCCAGGA
SEQ ID NO: 272




Reverse Primer
CGCCGCAGAGGTGGAGTA
SEQ ID NO: 273


 


CCL3
NM_002983.1
Forward Primer
AGCAGACAGTGGTCAGTCCTT
SEQ ID NO: 274




Probe
CTCTGCTGACACTCGAGCCCACAT
SEQ ID NO: 275




Reverse Primer
CTGCATGATTCTGAGCAGGT
SEQ ID NO: 276


 


CCNA2
NM_001237.2
Forward Primer
CCATACCTCAAGTATTTGCCATCAG
SEQ ID NO: 277




Probe
ATTGCTGGAGCTGCCTTTCATTTAGCACT
SEQ ID NO: 278




Reverse Primer
AGCTTTGTCCCGTGACTGTGTA
SEQ ID NO: 279


 


CCNB1
NM_031966.1
Forward Primer
TTCAGGTTGTTGCAGGAGAC
SEQ ID NO: 280




Probe
TGTCTCCATTATTGATCGGTTCATGCA
SEQ ID NO: 281




Reverse Primer
CATCTTCTTGGGCACACAAT
SEQ ID NO: 282


 


CCNB2
NM_004701.2
Forward Primer
AGGCTTCTGCAGGAGACTCTGT
SEQ ID NO: 283




Probe
TCGATCCATAATGCCAACGCACATG
SEQ ID NO: 284




Reverse Primer
GGGAAACTGGCTGAACCTGTAA
SEQ ID NO: 285


 


CCND1
NM_001758.1
Forward Primer
GCATGTTCGTGGCCTCTAAGA
SEQ ID NO: 286




Probe
AAGGAGACCATCCCCCTGACGGC
SEQ ID NO: 287




Reverse Primer
CGGTGTAGATGCACAGCTTCTC
SEQ ID NO: 288


 


CCND3
NM_001760.2
Forward Primer
CCTCTGTGCTACAGATTATACCTTTGC
SEQ ID NO: 289




Probe
TACCCGCCATCCATGATCGCCA
SEQ ID NO: 290




Reverse Primer
CACTGCAGCCCCAATGCT
SEQ ID NO: 291


 


CCNE1
NM_001238.1
Forward Primer
AAAGAAGATGATGACCGGGTTTAC
SEQ ID NO: 292




Probe
CAAACTCAACGTGCAAGCCTCGGA
SEQ ID NO: 293




Reverse Primer
GAGCCTCTGGATGGTGCAAT
SEQ ID NO: 294


 


CCNE2
NM_057749.1
Forward Primer
GGTCACCAAGAAACATCAGTATGAA
SEQ ID NO: 295




Probe
CCCAGATAATACAGGTGGCCAACAATTCCT
SEQ ID NO: 296




Reverse Primer
TTCAATGATAATGCAAGGACTGATC
SEQ ID NO: 297


 


CCNE2
NM_057749var1
Forward Primer
ATGCTGTGGCTCCTTCCTAACT
SEQ ID NO: 298


variant 1

Probe
TACCAAGCAACCTACATGTCAAGAAAGCCC
SEQ ID NO: 299




Reverse Primer
ACCCAAATTGTGATATACAAAAAGGTT
SEQ ID NO: 300


 


CCR7
NM_001838.2
Forward Primer
GGATGACATGCACTCAGCTC
SEQ ID NO: 301




Probe
CTCCCATCCCAGTGGAGCCAA
SEQ ID NO: 302




Reverse Primer
CCTGACATTTCCCTTGTCCT
SEQ ID NO: 303


 


CD105
NM_000118.1
Forward Primer
GCAGGTGTCAGCAAGTATGATCAG
SEQ ID NO: 304




Probe
CGACAGGATATTGACCACCGCCTCATT
SEQ ID NO: 305




Reverse Primer
TTTTTCCGCTGTGGTGATGA
SEQ ID NO: 306


 


CD134
NM_003327.1
Forward Primer
GCCCAGTGCGGAGAACAG
SEQ ID NO: 307


(TNFRSF4

Probe
CCAGCTTGATTCTCGTCTCTGCACTTAAGC
SEQ ID NO: 308


official)

Reverse Primer
AATCACACGCACCTGGAGAAC
SEQ ID NO: 309


 


CD18
NM_000211.1
Forward Primer
CGTCAGGACCCACCATGTCT
SEQ ID NO: 310




Probe
CGCGGCCGAGACATGGCTTG
SEQ ID NO: 311




Reverse Primer
GGTTAATTGGTGACATCCTCAAGA
SEQ ID NO: 312


 


CD24
NM_013230.1
Forward Primer
TCCAACTAATGCCACCACCAA
SEQ ID NO: 313




Probe
CTGTTGACTGCAGGGCACCACCA
SEQ ID NO: 314




Reverse Primer
GAGAGAGTGAGACCACGAAGAGACT
SEQ ID NO: 315


 


CD28
NM_006139.1
Forward Primer
TGTGAAAGGGAAACACCTTTG
SEQ ID NO: 316




Probe
CCAAGTCCCCTATTTCCCGGACCT
SEQ ID NO: 317




Reverse Primer
AGCACCCAAAAGGGCTTAG
SEQ ID NO: 318


 


CD31
NM_000442.1
Forward Primer
TGTATTTCAAGACCTCTGTGCACTT
SEQ ID NO: 319




Probe
TTTATGAACCTGCCCTGCTCCCACA
SEQ ID NO: 320




Reverse Primer
TTAGCCTGAGGAATTGCTGTGTT
SEQ ID NO: 321


 


CD34
NM_001773.1
Forward Primer
CCACTGCACACACCTCAGA
SEQ ID NO: 322




Probe
CTGTTCTTGGGGCCCTACACCTTG
SEQ ID NO: 323




Reverse Primer
CAGGAGTTTACCTGCCCCT
SEQ ID NO: 324


 


CD3z
NM_000734.1
Forward Primer
AGATGAAGTGGAAGGCGCTT
SEQ ID NO: 325




Probe
CACCGCGGCCATCCTGCA
SEQ ID NO: 326




Reverse Primer
TGCCTCTGTAATCGGCAACTG
SEQ ID NO: 327


 


CD44E
X55150
Forward Primer
ATCACCGACAGCACAGACA
SEQ ID NO: 328




Probe
CCCTGCTACCAATATGGACTCCAGTCA
SEQ ID NO: 329




Reverse Primer
ACCTGTGTTTGGATTTGCAG
SEQ ID NO: 330


 


CD44s
M59040.1
Forward Primer
GACGAAGACAGTCCCTGGAT
SEQ ID NO: 331




Probe
CACCGACAGCACAGACAGAATCCC
SEQ ID NO: 332




Reverse Primer
ACTGGGGTGGAATGTGTCTT
SEQ ID NO: 333


 


CD44v3
AJ251595v3
Forward Primer
CACACAAAACAGAACCAGGACT
SEQ ID NO: 334




Probe
ACCCAGTGGAACCCAAGCCATTC
SEQ ID NO: 335




Reverse Primer
CTGAAGTAGCACTTCCGGATT
SEQ ID NO: 336


 


CD44v6
AJ251595v6
Forward Primer
CTCATACCAGCCATCCAATG
SEQ ID NO: 337




Probe
CACCAAGCCCAGAGGACAGTTCCT
SEQ ID NO: 338




Reverse Primer
TTGGGTTGAAGAAATCAGTCC
SEQ ID NO: 339


 


CD68
NM_001251.1
Forward Primer
TGGTTCCCAGCCCTGTGT
SEQ ID NO: 340




Probe
CTCCAAGCCCAGATTCAGATTCGAGTCA
SEQ ID NO: 341




Reverse Primer
CTCCTCCACCCTGGGTTGT
SEQ ID NO: 342


 


CD80
NM_005191.2
Forward Primer
TTCAGTTGCTTTGCAGGAAG
SEQ ID NO: 343




Probe
TTCTGTGCCCACCATATTCCTCTAGACA
SEQ ID NO: 344




Reverse Primer
TTGATCAAGGTCACCAGAGC
SEQ ID NO: 345


 


CD82
NM_002231.2
Forward Primer
GTGCAGGCTCAGGTGAAGTG
SEQ ID NO: 346




Probe
TCAGCTTCTACAACTGGACAGACAACGCTG
SEQ ID NO: 347




Reverse Primer
GACCTCAGGGCGATTCATGA
SEQ ID NO: 348


 


CD8A
NM_171827.1
Forward Primer
AGGGTGAGGTGCTTGAGTCT
SEQ ID NO: 349




Probe
CCAACGGCAAGGGAACAAGTACTTCT
SEQ ID NO: 350




Reverse Primer
GGGCACAGTATCCCAGGTA
SEQ ID NO: 351


 


CD9
NM_001769.1
Forward Primer
GGGCGTGGAACAGTTTATCT
SEQ ID NO: 352




Probe
AGACATCTGCCCCAAGAAGGACGT
SEQ ID NO: 353




Reverse Primer
CACGGTGAAGGTTTCGAGT
SEQ ID NO: 354


 


CDC2
NM_001786.2
Forward Primer
GAGAGCGACGCGGTTGTT
SEQ ID NO: 355




Probe
TAGCTGCCGCTGCGGCCG
SEQ ID NO: 356




Reverse Primer
GTATGGTAGATCCCGGCTTATTATTC
SEQ ID NO: 357


 


CDC20
NM_001255.1
Forward Primer
TGGATTGGAGTTCTGGGAATG
SEQ ID NO: 358




Probe
ACTGGCCGTGGCACTGGACAACA
SEQ ID NO: 359




Reverse Primer
GCTTGCACTCCACAGGTACACA
SEQ ID NO: 360


 


cdc25A
NM_001789.1
Forward Primer
TCTTGCTGGCTACGCCTCTT
SEQ ID NO: 361




Probe
TGTCCCTGTTAGACGTCCTCCGTCCATA
SEQ ID NO: 362




Reverse Primer
CTGCATTGTGGCACAGTTCTG
SEQ ID NO: 363


 


CDC25B
NM_021874.1
Forward Primer
AAACGAGCAGTTTGCCATCAG
SEQ ID NO: 364




Probe
CCTCACCGGCATAGACTGGAAGCG
SEQ ID NO: 365




Reverse Primer
GTTGGTGATGTTCCGAAGCA
SEQ ID NO: 366


 


CDC25C
NM_001790.2
Forward Primer
GGTGAGCAGAAGTGGCCTAT
SEQ ID NO: 367




Probe
CTCCCCGTCGATGCCAGAGAACT
SEQ ID NO: 368




Reverse Primer
CTTCAGTCTTGGCCTGTTCA
SEQ ID NO: 369


 


CDC4
NM_018315.2
Forward Primer
GCAGTCCGCTGTGTTCAA
SEQ ID NO: 370




Probe
TGCTCCACTAACAACCCTCCTGCC
SEQ ID NO: 371




Reverse Primer
GGATCCCACACCTTTACCATAA
SEQ ID NO: 372


 


CDC42
NM_001791.2
Forward Primer
TCCAGAGACTGCTGAAAA
SEQ ID NO: 373




Probe
CCCGTGACCTGAAGGCTGTCAAG
SEQ ID NO: 374




Reverse Primer
TGTGTAAGTGCAGAACAC
SEQ ID NO: 375


 


CDC42BPA
NM_003607.2
Forward Primer
GAGCTGAAAGACGCACACTG
SEQ ID NO: 376




Probe
AATTCCTGCATGGCCAGTTTCCTC
SEQ ID NO: 377




Reverse Primer
GCCGCTCATTGATCTCCA
SEQ ID NO: 378


 


CDC6
NM_001254.2
Forward Primer
GCAACACTCCCCATTTACCTC
SEQ ID NO: 379




Probe
TTGTTCTCCACCAAAGCAAGGCAA
SEQ ID NO: 380




Reverse Primer
TGAGGGGGACCATTCTCTTT
SEQ ID NO: 381


 


CDCA7 v2
NM_145810.1
Forward Primer
AAGACCGTGGATGGCTACAT
SEQ ID NO: 382




Probe
ATGAAGATGACCTGCCCAGAAGCC
SEQ ID NO: 383




Reverse Primer
AGGGTCACGGATGATCTGG
SEQ ID NO: 384


 


CDH1
NM_004360.2
Forward Primer
TGAGTGTCCCCCGGTATCTTC
SEQ ID NO: 385




Probe
TGCCAATCCCGATGAAATTGGAAATTT
SEQ ID NO: 386




Reverse Primer
CAGCCGCTTTCAGATTTTCAT
SEQ ID NO: 387


 


CDH11
NM_001797.2
Forward Primer
GTCGGCAGAAGCAGGACT
SEQ ID NO: 388




Probe
CCTTCTGCCCATAGTGATCAGCGA
SEQ ID NO: 389




Reverse Primer
CTACTCATGGGCGGGATG
SEQ ID NO: 390


 


CDH3
NM_001793.3
Forward Primer
ACCCATGTACCGTCCTCG
SEQ ID NO: 391




Probe
CCAACCCAGATGAAATCGGCAACT
SEQ ID NO: 392




Reverse Primer
CCGCCTTCAGGTTCTCAAT
SEQ ID NO: 393


 


CDK2
NM_001798.2
Forward Primer
AATGCTGCACTACGACCCTA
SEQ ID NO: 394




Probe
CCTTGGCCGAAATCCGCTTGT
SEQ ID NO: 395




Reverse Primer
TTGGTCACATCCTGGAAGAA
SEQ ID NO: 396


 


CDX1
NM_001804.1
Forward Primer
AGCAACACCAGCCTCCTG
SEQ ID NO: 397




Probe
CACCTCCTCTCCAATGCCTGTGAA
SEQ ID NO: 398




Reverse Primer
GGGCTATGGCAGAAACTCCT
SEQ ID NO: 399


 


Cdx2
NM_001265.2
Forward Primer
GGGCAGGCAAGGTTTACA
SEQ ID NO: 400




Probe
ATCTTAGCTGCCTTTGGCTTCCGC
SEQ ID NO: 401




Reverse Primer
GTCTTTGGTCAGTCCAGCTTTC
SEQ ID NO: 402


 


CEACAM1
NM_001712.2
Forward Primer
ACTTGCCTGTTCAGAGCACTCA
SEQ ID NO: 403




Probe
TCCTTCCCACCCCCAGTCCTGTC
SEQ ID NO: 404




Reverse Primer
TGGCAAATCCGAATTAGAGTGA
SEQ ID NO: 405


 


CEACAM6
NM_002483.2
Forward Primer
CACAGCCTCACTTCTAACCTTCTG
SEQ ID NO: 406




Probe
ACCCACCCACCACTGCCAAGCTC
SEQ ID NO: 407




Reverse Primer
TTGAATGGCGTGGATTCAATAG
SEQ ID NO: 408


 


CEBPB
NM_005194.2
Forward Primer
GCAACCCACGTGTAACTGTC
SEQ ID NO: 409




Probe
CCGGGCCCTGAGTAATCGCTTAA
SEQ ID NO: 410




Reverse Primer
ACAAGCCCGTAGGAACATCT
SEQ ID NO: 411


 


CEGP1
NM_020974.1
Forward Primer
TGACAATCAGCACACCTGCAT
SEQ ID NO: 412




Probe
CAGGCCCTCTTCCGAGCGGT
SEQ ID NO: 413




Reverse Primer
TGTGACTACAGCCGTGATCCTTA
SEQ ID NO: 414


 


CENPA
NM_001809.2
Forward Primer
TAAATTCACTCGTGGTGTGGA
SEQ ID NO: 415




Probe
CTTCAATTGGCAAGCCCAGGC
SEQ ID NO: 416




Reverse Primer
GCCTCTTGTAGGGCCAATAG
SEQ ID NO: 417


 


CENPE
NM_001813.1
Forward Primer
GGATGCTGGTGACCTCTTCT
SEQ ID NO: 418




Probe
TCCCTCACGTTGCAACAGGAATTAA
SEQ ID NO: 419




Reverse Primer
GCCAAGGCACCAAGTAACTC
SEQ ID NO: 420


 


CENPF
NM_016343.2
Forward Primer
CTCCCGTCAACAGCGTTC
SEQ ID NO: 421




Probe
ACACTGGACCAGGAGTGCATCCAG
SEQ ID NO: 422




Reverse Primer
GGGTGAGTCTGGCCTTCA
SEQ ID NO: 423


 


CES2
NM_003869.4
Forward Primer
ACTTTGCGAGAAATGGGAAC
SEQ ID NO: 424




Probe
AGTGTGGCAGACCCTCGCCATT
SEQ ID NO: 425




Reverse Primer
CAGGTATTGCTCCTCCTGGT
SEQ ID NO: 426


 


CGA (CHGA
NM_001275.2
Forward Primer
CTGAAGGAGCTCCAAGACCT
SEQ ID NO: 427


official)

Probe
TGCTGATGTGCCCTCTCCTTGG
SEQ ID NO: 428




Reverse Primer
CAAAACCGCTGTGTTTCTTC
SEQ ID NO: 429


 


CGB
NM_000737.2
Forward Primer
CCACCATAGGCAGAGGCA
SEQ ID NO: 430




Probe
ACACCCTACTCCCTGTGCCTCCAG
SEQ ID NO: 431




Reverse Primer
AGTCGTCGAGTGCTAGGGAC
SEQ ID NO: 432


 


CHAF1B
NM_005441.1
Forward Primer
GAGGCCAGTGGTGGAAACAG
SEQ ID NO: 433




Probe
AGCTGATGAGTCTGCCCTACCGCCTG
SEQ ID NO: 434




Reverse Primer
TCCGAGGCCACAGCAAAC
SEQ ID NO: 435


 


CHD2
NM_001271.1
Forward Primer
CTCTGTGCGAGGCTGTCA
SEQ ID NO: 436




Probe
ACCCATCTCGGGATCCCTGATACC
SEQ ID NO: 437




Reverse Primer
GGTAAGGACTGTGGGCTGG
SEQ ID NO: 438


 


CHFR
NM_018223.1
Forward Primer
AAGGAAGTGGTCCCTCTGTG
SEQ ID NO: 439




Probe
TGAAGTCTCCAGCTTTGCCTCAGC
SEQ ID NO: 440




Reverse Primer
GACGCAGTCTTTCTGTCTGG
SEQ ID NO: 441


 


Chk1
NM_001274.1
Forward Primer
GATAAATTGGTACAAGGGATCAGCTT
SEQ ID NO: 442




Probe
CCAGCCCACATGTCCTGATCATATGC
SEQ ID NO: 443




Reverse Primer
GGGTGCCAAGTAACTGACTATTCA
SEQ ID NO: 444


 


Chk2
NM_007194.1
Forward Primer
ATGTGGAACCCCCACCTACTT
SEQ ID NO: 445




Probe
AGTCCCAACAGAAACAAGAACTTCAGGCG
SEQ ID NO: 446




Reverse Primer
CAGTCCACAGCACGGTTATACC
SEQ ID NO: 447


 


CIAP1
NM_001166.2
Forward Primer
TGCCTGTGGTGGGAAGCT
SEQ ID NO: 448




Probe
TGACATAGCATCATCCTTTGGTTCCCAGTT
SEQ ID NO: 449




Reverse Primer
GGAAAATGCCTCCGGTGTT
SEQ ID NO: 450


 


cIAP2
NM_001165.2
Forward Primer
GGATATTTCCGTGGCTCTTATTCA
SEQ ID NO: 451




Probe
TCTCCATCAAATCCTGTAAACTCCAGAGCA
SEQ ID NO: 452




Reverse Primer
CTTCTCATCAAGGCAGAAAAATCTT
SEQ ID NO: 453


 


CKS1B
NM_001826.1
Forward Primer
GGTCCCTAAAACCCATCTGA
SEQ ID NO: 454




Probe
TGAACGCCAAGATTCCTCCATTCA
SEQ ID NO: 455




Reverse Primer
TAATGGACCCATCCCTGACT
SEQ ID NO: 456


 


CKS2
NM_001827.1
Forward Primer
GGCTGGACGTGGTTTTGTCT
SEQ ID NO: 457




Probe
CTGCGCCCGCTCTTCGCG
SEQ ID NO: 458




Reverse Primer
CGCTGCAGAAAATGAAACGA
SEQ ID NO: 459


 


Claudin 4
NM_001305.2
Forward Primer
GGCTGCTTTGCTGCAACTG
SEQ ID NO: 460




Probe
CGCACAGACAAGCCTTACTCCGCC
SEQ ID NO: 461




Reverse Primer
CAGAGCGGGCAGCAGAATA
SEQ ID NO: 462


 


CLDN1
NM_021101.3
Forward Primer
TCTGGGAGGTGCCCTACTT
SEQ ID NO: 463




Probe
TGTTCCTGTCCCCGAAAAACAACC
SEQ ID NO: 464




Reverse Primer
TGGATAGGGCCTTGGTGTT
SEQ ID NO: 465


 


CLDN7
NM_001307.3
Forward Primer
GGTCTGCCCTAGTCATCCTG
SEQ ID NO: 466




Probe
TGCACTGCTCTCCTGTTCCTGTCC
SEQ ID NO: 467




Reverse Primer
GTACCCAGCCTTGCTCTCAT
SEQ ID NO: 468


 


CLIC1
NM_001288.3
Forward Primer
CGGTACTTGAGCAATGCCTA
SEQ ID NO: 469




Probe
CGGGAAGAATTCGCTTCCACCTG
SEQ ID NO: 470




Reverse Primer
TCGATCTCCTCATCATCTGG
SEQ ID NO: 471


 


CLTC
NM_004859.1
Forward Primer
ACCGTATGGACAGCCACAG
SEQ ID NO: 472




Probe
TCTCACATGCTGTACCCAAAGCCA
SEQ ID NO: 473




Reverse Primer
TGACTACAGGATCAGCGCTTC
SEQ ID NO: 474


 


CLU
NM_001831.1
Forward Primer
CCCCAGGATACCTACCACTACCT
SEQ ID NO: 475




Probe
CCCTTCAGCCTGCCCCACCG
SEQ ID NO: 476




Reverse Primer
TGCGGGACTTGGGAAAGA
SEQ ID NO: 477


 


cMet
NM_000245.1
Forward Primer
GACATTTCCAGTCCTGCAGTCA
SEQ ID NO: 478




Probe
TGCCTCTCTGCCCCACCCTTTGT
SEQ ID NO: 479




Reverse Primer
CTCCGATCGCACACATTTGT
SEQ ID NO: 480


 


cMYC
NM_002467.1
Forward Primer
TCCCTCCACTCGGAAGGACTA
SEQ ID NO: 481




Probe
TCTGACACTGTCCAACTTGACCCTCTT
SEQ ID NO: 482




Reverse Primer
CGGTTGTTGCTGATCTGTCTCA
SEQ ID NO: 483


 


CNN
NM_001299.2
Forward Primer
TCCACCCTCCTGGCTTTG
SEQ ID NO: 484




Probe
TCCTTTCGTCTTCGCCATGCTGG
SEQ ID NO: 485




Reverse Primer
TCACTCCCACGTTCACCTTGT
SEQ ID NO: 486


 


COL1A1
NM_000088.2
Forward Primer
GTGGCCATCCAGCTGACC
SEQ ID NO: 487




Probe
TCCTGCGCCTGATGTCCACCG
SEQ ID NO: 488




Reverse Primer
CAGTGGTAGGTGATGTTCTGGGA
SEQ ID NO: 489


 


COL1A2
NM_000089.2
Forward Primer
CAGCCAAGAACTGGTATAGGAGCT
SEQ ID NO: 490




Probe
TCTCCTAGCCAGACGTGTTTCTTGTCCTTG
SEQ ID NO: 491




Reverse Primer
AAACTGGCTGCCAGCATTG
SEQ ID NO: 492


 


COPS3
NM_003653.2
Forward Primer
ATGCCCAGTGTTCCTGACTT
SEQ ID NO: 493




Probe
CGAAACGCTATTCTCACAGGTTCAGC
SEQ ID NO: 494




Reverse Primer
CTCCCCATTACAAGTGCTGA
SEQ ID NO: 495


 


COX2
NM_000963.1
Forward Primer
TCTGCAGAGTTGGAAGCACTCTA
SEQ ID NO: 496




Probe
CAGGATACAGCTCCACAGCATCGATGTC
SEQ ID NO: 497




Reverse Primer
GCCGAGGCTTTTCTACCAGAA
SEQ ID NO: 498


 


COX3
MITO_COX3
Forward Primer
TCGAGTCTCCCTTCACCATT
SEQ ID NO: 499




Probe
CGACGGCATCTACGGCTCAACAT
SEQ ID NO: 500




Reverse Primer
GACGTGAAGTCCGTGGAAG
SEQ ID NO: 501


 


CP
NM_000096.1
Forward Primer
CGTGAGTACACAGATGCCTCC
SEQ ID NO: 502




Probe
TCTTCAGGGCCTCTCTCCTTTCGA
SEQ ID NO: 503




Reverse Primer
CCAGGATGCCAAGATGCT
SEQ ID NO: 504


 


CRBP
NM_002899.2
Forward Primer
TGGTCTGCAAGCAAGTATTCAAG
SEQ ID NO: 505




Probe
TCTGCTTGGGCCTCACTGCACCT
SEQ ID NO: 506




Reverse Primer
GCTGATTGGTTGGGACAAGGT
SEQ ID NO: 507


 


CREBBP
NM_004380.1
Forward Primer
TGGGAAGCAGCTGTGTACCAT
SEQ ID NO: 508




Probe
CCTCGCGATGCTGCCTACTACAGCTATC
SEQ ID NO: 509




Reverse Primer
GAAACACTTCTCACAGAAATGATACCTATT
SEQ ID NO: 510


 


CRIP2
NM_001312.1
Forward Primer
GTGCTACGCCACCCTGTT
SEQ ID NO: 511




Probe
CCGATGTTCACGCCTTTGGGTC
SEQ ID NO: 512




Reverse Primer
CAGGGGCTTCTCGTAGATGT
SEQ ID NO: 513


 


cripto
NM_003212.1
Forward Primer
GGGTCTGTGCCCCATGAC
SEQ ID NO: 514


(TDGF1

Probe
CCTGGCTGCCCAAGAAGTGTTCCCT
SEQ ID NO: 515


official)

Reverse Primer
TGACCGTGCCAGCATTTACA
SEQ ID NO: 516


 


CRK(a)
NM_016823.2
Forward Primer
CTCCCTAACCTCCAGAATGG
SEQ ID NO: 517




Probe
ACTCGCTTCTGGATAACCCTGGCA
SEQ ID NO: 518




Reverse Primer
TGTCTTGTCGTAGGCATTGG
SEQ ID NO: 519


 


CRMP1
NM_001313.1
Forward Primer
AAGGTTTTTGGATTGCAAGG
SEQ ID NO: 520




Probe
ACCGTCATACATGCCCCTGGAAAC
SEQ ID NO: 521




Reverse Primer
GGGTGTAGCTGGTACCTCGT
SEQ ID NO: 522


 


CRYAB
NM_001885.1
Forward Primer
GATGTGATTGAGGTGCATGG
SEQ ID NO: 523




Probe
TGTTCATCCTGGCGCTCTTCATGT
SEQ ID NO: 524




Reverse Primer
GAACTCCCTGGAGATGAAACC
SEQ ID NO: 525


 


CSEL1
NM_001316.2
Forward Primer
TTACGCAGCTCATGCTCTTG
SEQ ID NO: 526




Probe
ACGGCTCTTTACTATGCGAGGGCC
SEQ ID NO: 527




Reverse Primer
GCAGCTGTAAAGAGAGTGGCAT
SEQ ID NO: 528


 


CSF1
NM_000757.3
Forward Primer
TGCAGCGGCTGATTGACA
SEQ ID NO: 529




Probe
TCAGATGGAGACCTCGTGCCAAATTACA
SEQ ID NO: 530




Reverse Primer
CAACTGTTCCTGGTCTACAAACTCA
SEQ ID NO: 531


 


CSK (SRC)
NM_004383.1
Forward Primer
CCTGAACATGAAGGAGCTGA
SEQ ID NO: 532




Probe
TCCCGATGGTCTGCAGCAGCT
SEQ ID NO: 533




Reverse Primer
CATCACGTCTCCGAACTCC
SEQ ID NO: 534


 


CTAG1B
NM_001327.1
Forward Primer
GCTCTCCATCAGCTCCTGTC
SEQ ID NO: 535




Probe
CCACATCAACAGGGAAAGCTGCTG
SEQ ID NO: 536




Reverse Primer
AACACGGGCAGAAAGCACT
SEQ ID NO: 537


 


CTGF
NM_001901.1
Forward Primer
GAGTTCAAGTGCCCTGACG
SEQ ID NO: 538




Probe
AACATCATGTTCTTCTTCATGACCTCGC
SEQ ID NO: 539




Reverse Primer
AGTTGTAATGGCAGGCACAG
SEQ ID NO: 540


 


CTHRC1
NM_138455.2
Forward Primer
GCTCACTTCGGCTAAAATGC
SEQ ID NO: 541




Probe
ACCAACGCTGACAGCATGCATTTC
SEQ ID NO: 542




Reverse Primer
TCAGCTCCATTGAATGTGAAA
SEQ ID NO: 543


 


CTLA4
NM_005214.2
Forward Primer
CACTGAGGTCCGGGTGACA
SEQ ID NO: 544




Probe
CACCTGGCTGTCAGCCTGCCG
SEQ ID NO: 545




Reverse Primer
GTAGGTTGCCGCACAGACTTC
SEQ ID NO: 546


 


CTNNBIP1
NM_020248.2
Forward Primer
GTTTTCCAGGTCGGAGACG
SEQ ID NO: 547




Probe
CTTTGCAGCTACTGCCTCCGGTCT
SEQ ID NO: 548




Reverse Primer
AGCATCCAGGGTGTTCCA
SEQ ID NO: 549


 


CTSB
NM_001908.1
Forward Primer
GGCCGAGATCTACAAAAACG
SEQ ID NO: 550




Probe
CCCCGTGGAGGGAGCTTTCTC
SEQ ID NO: 551




Reverse Primer
GCAGGAAGTCCGAATACACA
SEQ ID NO: 552


 


CTSD
NM_001909.1
Forward Primer
GTACATGATCCCCTGTGAGAAGGT
SEQ ID NO: 553




Probe
ACCCTGCCCGCGATCACACTGA
SEQ ID NO: 554




Reverse Primer
GGGACAGCTTGTAGCCTTTGC
SEQ ID NO: 555


 


CTSH
NM_004390.1
Forward Primer
GCAAGTTCCAACCTGGAAAG
SEQ ID NO: 556




Probe
TGGCTACATCCTTGACAAAGCCGA
SEQ ID NO: 557




Reverse Primer
CATCGCTTCCTCGTCATAGA
SEQ ID NO: 558


 


CTSL
NM_001912.1
Forward Primer
GGGAGGCTTATCTCACTGAGTGA
SEQ ID NO: 559




Probe
TTGAGGCCCAGAGCAGTCTACCAGATTCT
SEQ ID NO: 560




Reverse Primer
CCATTGCAGCCTTCATTGC
SEQ ID NO: 561


 


CTSL2
NM_001333.2
Forward Primer
TGTCTCACTGAGCGAGCAGAA
SEQ ID NO: 562




Probe
CTTGAGGACGCGAACAGTCCACCA
SEQ ID NO: 563




Reverse Primer
ACCATTGCAGCCCTGATTG
SEQ ID NO: 564


 


CUL1
NM_003592.2
Forward Primer
ATGCCCTGGTAATGTCTGCAT
SEQ ID NO: 565




Probe
CAGCCACAAAGCCAGCGTCATTGT
SEQ ID NO: 566




Reverse Primer
GCGACCACAAGCCTTATCAAG
SEQ ID NO: 567


 


CUL4A
NM_003589.1
Forward Primer
AAGCATCTTCCTGTTCTTGGA
SEQ ID NO: 568




Probe
TATGTGCTGCAGAACTCCACGCTG
SEQ ID NO: 569




Reverse Primer
AATCCCATATCCCAGATGGA
SEQ ID NO: 570


 


CXCL12
NM_000609.3
Forward Primer
GAGCTACAGATGCCCATGC
SEQ ID NO: 571




Probe
TTCTTCGAAAGCCATGTTGCCAGA
SEQ ID NO: 572




Reverse Primer
TTTGAGATGCTTGACGTTGG
SEQ ID NO: 573


 


CXCR4
NM_003467.1
Forward Primer
TGACCGCTTCTACCCCAATG
SEQ ID NO: 574




Probe
CTGAAACTGGAACACAACCACCCACAAG
SEQ ID NO: 575




Reverse Primer
AGGATAAGGCCAACCATGATGT
SEQ ID NO: 576


 


CYBA
NM_000101.1
Forward Primer
GGTGCCTACTCCATTGTGG
SEQ ID NO: 577




Probe
TACTCCAGCAGGCACACAAACACG
SEQ ID NO: 578




Reverse Primer
GTGGAGCCCTTCTTCCTCTT
SEQ ID NO: 579


 


CYP1B1
NM_000104.2
Forward Primer
CCAGCTTTGTGCCTGTCACTAT
SEQ ID NO: 580




Probe
CTCATGCCACCACTGCCAACACCTC
SEQ ID NO: 581




Reverse Primer
GGGAATGTGGTAGCCCAAGA
SEQ ID NO: 582


 


CYP2C8
NM_000770.2
Forward Primer
CCGTGTTCAAGAGGAAGCTC
SEQ ID NO: 583




Probe
TTTTCTCAACTCCTCCACAAGGCA
SEQ ID NO: 584




Reverse Primer
AGTGGGATCACAGGGTGAAG
SEQ ID NO: 585


 


CYP3A4
NM_017460.3
Forward Primer
AGAACAAGGACAACATAGATCCTTACATAT
SEQ ID NO: 586




Probe
CACACCCTTTGGAAGTGGACCCAGAA
SEQ ID NO: 587




Reverse Primer
GCAAACCTCATGCCAATGC
SEQ ID NO: 588


 


CYR61
NM_001554.3
Forward Primer
TGCTCATTCTTGAGGAGCAT
SEQ ID NO: 589




Probe
CAGCACCCTTGGCAGTTTCGAAAT
SEQ ID NO: 590




Reverse Primer
GTGGCTGCATTAGTGTCCAT
SEQ ID NO: 591


 


DAPK1
NM_004938.1
Forward Primer
CGCTGACATCATGAATGTTCCT
SEQ ID NO: 592




Probe
TCATATCCAAACTCGCCTCCAGCCG
SEQ ID NO: 593




Reverse Primer
TCTCTTTCAGCAACGATGTGTCTT
SEQ ID NO: 594


 


DCC
NM_005215.1
Forward Primer
AAATGTCCTCCTCGACTGCT
SEQ ID NO: 595




Probe
ATCACTGGAACTCCTCGGTCGGAC
SEQ ID NO: 596




Reverse Primer
TGAATGCCATCTTTCTTCCA
SEQ ID NO: 597


 


DCC_exons18-23
X76132_18-23
Forward Primer
GGTCACCGTTGGTGTCATCA
SEQ ID NO: 598




Probe
CAGCCACGATGACCACTACCAGCACT
SEQ ID NO: 599




Reverse Primer
GAGCGTCGGGTGCAAATC
SEQ ID NO: 600


 


DCC_exons6-7
X76132_6-7
Forward Primer
ATGGAGATGTGGTCATTCCTAGTG
SEQ ID NO: 601




Probe
TGCTTCCTCCCACTATCTGAAAATAA
SEQ ID NO: 602




Reverse Primer
CACCACCCCAAGTATCCGTAAG
SEQ ID NO: 603


 


DCK
NM_000788.1
Forward Primer
GCCGCCACAAGACTAAGGAAT
SEQ ID NO: 604




Probe
AGCTGCCCGTCTTTCTCAGCCAGC
SEQ ID NO: 605




Reverse Primer
CGATGTTCCCTTCGATGGAG
SEQ ID NO: 606


 


DDB1
NM_001923.2
Forward Primer
TGCGGATCATCCGGAATG
SEQ ID NO: 607




Probe
AATTGGAATCCACGAGCATGCCAGC
SEQ ID NO: 608




Reverse Primer
TCCTTTGATGCCTGGTAAGTCA
SEQ ID NO: 609


 


DET1
NM_017996.2
Forward Primer
CTTGTGGAGATCACCCAATCAG
SEQ ID NO: 610




Probe
CTATGCCCGGGACTCGGGCCT
SEQ ID NO: 611




Reverse Primer
CCCGCCTGGATCTCAAACT
SEQ ID NO: 612


 


DHFR
NM_000791.2
Forward Primer
TTGCTATAACTAAGTGCTTCTCCAAGA
SEQ ID NO: 613




Probe
CCCAACTGAGTCCCCAGCACCT
SEQ ID NO: 614




Reverse Primer
GTGGAATGGCAGCTCACTGTAG
SEQ ID NO: 615


 


DHPS
NM_013407.1
Forward Primer
GGGAGAACGGGATCAATAGGAT
SEQ ID NO: 616




Probe
CTCATTGGGCACCAGCAGGTTTCC
SEQ ID NO: 617




Reverse Primer
GCATCAGCCAGTCCTCAAACT
SEQ ID NO: 618


 


DIABLO
NM_019887.1
Forward Primer
CACAATGGCGGCTCTGAAG
SEQ ID NO: 619




Probe
AAGTTACGCTGCGCGACAGCCAA
SEQ ID NO: 620




Reverse Primer
ACACAAACACTGTCTGTACCTGAAGA
SEQ ID NO: 621


 


DIAPH1
NM_005219.2
Forward Primer
CAAGCAGTCAAGGAGAACCA
SEQ ID NO: 622




Probe
TTCTTCTGTCTCCCGCCGCTTC
SEQ ID NO: 623




Reverse Primer
AGTTTTGCTCGCCTCATCTT
SEQ ID NO: 624


 


DICER1
NM_177438.1
Forward Primer
TCCAATTCCAGCATCACTGT
SEQ ID NO: 625




Probe
AGAAAAGCTGTTTGTCTCCCCAGCA
SEQ ID NO: 626




Reverse Primer
GGCAGTGAAGGCGATAAAGT
SEQ ID NO: 627


 


DKK1
NM_012242.1
Forward Primer
TGACAACTACCAGCCGTACC
SEQ ID NO: 628




Probe
AGTGCCGCACTCCTCGTCCTCT
SEQ ID NO: 629




Reverse Primer
GGGACTAGCGCAGTACTCATC
SEQ ID NO: 630


 


DLC1
NM_006094.3
Forward Primer
GATTCAGACGAGGATGAGCC
SEQ ID NO: 631




Probe
AAAGTCCATTTGCCACTGATGGCA
SEQ ID NO: 632




Reverse Primer
CACCTCTTGCTGTCCCTTTG
SEQ ID NO: 633


 


DPYD
NM_000110.2
Forward Primer
AGGACGCAAGGAGGGTTTG
SEQ ID NO: 634




Probe
CAGTGCCTACAGTCTCGAGTCTGCCAGTG
SEQ ID NO: 635




Reverse Primer
GATGTCCGCCGAGTCCTTACT
SEQ ID NO: 636


 


DR4
NM_003844.1
Forward Primer
TGCACAGAGGGTGTGGGTTAC
SEQ ID NO: 637




Probe
CAATGCTTCCAACAATTTGTTTGCTTGCC
SEQ ID NO: 638




Reverse Primer
TCTTCATCTGATTTACAAGCTGTACATG
SEQ ID NO: 639


 


DR5
NM_003842.2
Forward Primer
CTCTGAGACAGTGCTTCGATGACT
SEQ ID NO: 640




Probe
CAGACTTGGTGCCCTTTGACTCC
SEQ ID NO: 641




Reverse Primer
CCATGAGGCCCAACTTCCT
SEQ ID NO: 642


 


DRG1
NM_004147.3
Forward Primer
CCTGGATCTCCCAGGTATCA
SEQ ID NO: 643




Probe
ACCTTTCCCATCCTTGGCACCTTC
SEQ ID NO: 644




Reverse Primer
TGCAATGACTTGACGACCTC
SEQ ID NO: 645


 


DSP
NM_004415.1
Forward Primer
TGGCACTACTGCATGATTGACA
SEQ ID NO: 646




Probe
CAGGGCCATGACAATCGCCAA
SEQ ID NO: 647




Reverse Primer
CCTGCCGCATTGTTTTCAG
SEQ ID NO: 648


 


DTYMK
NM_012145.1
Forward Primer
AAATCGCTGGGAACAAGTG
SEQ ID NO: 649




Probe
CGCCCTGGCTCAACTTTTCCTTAA
SEQ ID NO: 650




Reverse Primer
AATGCGTATCTGTCCACGAC
SEQ ID NO: 651


 


DUSP1
NM_004417.2
Forward Primer
AGACATCAGCTCCTGGTTCA
SEQ ID NO: 652




Probe
CGAGGCCATTGACTTCATAGACTCCA
SEQ ID NO: 653




Reverse Primer
GACAAACACCCTTCCTCCAG
SEQ ID NO: 654


 


DUSP2
NM_004418.2
Forward Primer
TATCCCTGTGGAGGACAACC
SEQ ID NO: 655




Probe
CCTCCTGGAACCAGGCACTGATCT
SEQ ID NO: 656




Reverse Primer
CACCCAGTCAATGAAGCCTA
SEQ ID NO: 657


 


DUT
NM_001948.2
Forward Primer
ACACATGGAGTGCTTCTGGA
SEQ ID NO: 658




Probe
ATCAGCCCACTTGACCACCCAGTT
SEQ ID NO: 659




Reverse Primer
CTCTTGCCTGTGCTTCCAC
SEQ ID NO: 660


 


DYRK1B
NM_004714.1
Forward Primer
AGCATGACACGGAGATGAAG
SEQ ID NO: 661




Probe
CACCTGAAGCGGCACTTCATGTTC
SEQ ID NO: 662




Reverse Primer
AATACCAGGCACAGGTGGTT
SEQ ID NO: 663


 


E2F1
NM_005225.1
Forward Primer
ACTCCCTCTACCCTTGAGCA
SEQ ID NO: 664




Probe
CAGAAGAACAGCTCAGGGACCCCT
SEQ ID NO: 665




Reverse Primer
CAGGCCTCAGTTCCTTCAGT
SEQ ID NO: 666


 


EDN1
NM_001955.1
Forward Primer
TGCCACCTGGACATCATTTG
SEQ ID NO: 667


endothelin

Probe
CACTCCCGAGCACGTTGTTCCGT
SEQ ID NO: 668




Reverse Primer
TGGACCTAGGGCTTCCAAGTC
SEQ ID NO: 669


 


EFNA1
NM_004428.2
Forward Primer
TACATCTCCAAACCCATCCA
SEQ ID NO: 670




Probe
CAACCTCAAGCAGCGGTCTTCATG
SEQ ID NO: 671




Reverse Primer
TTGCCACTGACAGTCACCTT
SEQ ID NO: 672


 


EFNA3
NM_004952.3
Forward Primer
ACTACATCTCCACGCCCACT
SEQ ID NO: 673




Probe
CCTCAGACACTTCCAGTGCAGGTTG
SEQ ID NO: 674




Reverse Primer
CAGCAGACGAACACCTTCAT
SEQ ID NO: 675


 


EFNB1
NM_004429.3
Forward Primer
GGAGCCCGTATCCTGGAG
SEQ ID NO: 676




Probe
CCCTCAACCCCAAGTTCCTGAGTG
SEQ ID NO: 677




Reverse Primer
GGATAGATCACCAAGCCCTTC
SEQ ID NO: 678


 


EFNB2
NM_004093.2
Forward Primer
TGACATTATCATCCCGCTAAGGA
SEQ ID NO: 679




Probe
CGGACAGCGTCTTCTGCCCTCACT
SEQ ID NO: 680




Reverse Primer
GTAGTCCCCGCTGACCTTCTC
SEQ ID NO: 681


 


EFP
NM_005082.2
Forward Primer
TTGAACAGAGCCTGACCAAG
SEQ ID NO: 682




Probe
TGATGCTTTCTCCAGAAACTCGAACTCA
SEQ ID NO: 683




Reverse Primer
TGTTGAGATTCCTCGCAGTT
SEQ ID NO: 684


 


EGFR
NM_005228.1
Forward Primer
TGTCGATGGACTTCCAGAAC
SEQ ID NO: 685




Probe
CACCTGGGCAGCTGCCAA
SEQ ID NO: 686




Reverse Primer
ATTGGGACAGCTTGGATCA
SEQ ID NO: 687


 


EGLN1
NM_022051.1
Forward Primer
TCAATGGCCGGACGAAAG
SEQ ID NO: 688




Probe
CATTGCCCGGATAACAAGCAACCATG
SEQ ID NO: 689




Reverse Primer
TTTGGATTATCAACATGACGTACATAAC
SEQ ID NO: 690


 


EGLN3
NM_022073.2
Forward Primer
GCTGGTCCTCTACTGCGG
SEQ ID NO: 691




Probe
CCGGCTGGGCAAATACTACGTCAA
SEQ ID NO: 692




Reverse Primer
CCACCATTGCCTTAGACCTC
SEQ ID NO: 693


 


EGR1
NM_001964.2
Forward Primer
GTCCCCGCTGCAGATCTCT
SEQ ID NO: 694




Probe
CGGATCCTTTCCTCACTCGCCCA
SEQ ID NO: 695




Reverse Primer
CTCCAGCTTAGGGTAGTTGTCCAT
SEQ ID NO: 696


 


EGR3
NM_004430.2
Forward Primer
CCATGTGGATGAATGAGGTG
SEQ ID NO: 697




Probe
ACCCAGTCTCACCTTCTCCCCACC
SEQ ID NO: 698




Reverse Primer
TGCCTGAGAAGAGGTGAGGT
SEQ ID NO: 699


 


EI24
NM_004879.2
Forward Primer
AAAGTGGTGAATGCCATTTG
SEQ ID NO: 700




Probe
CCTCAAATGCCAGGTCAGCTATATCCTG
SEQ ID NO: 701




Reverse Primer
GTGAGGCTTCCTCCCTGATA
SEQ ID NO: 702


 


EIF4E
NM_001968.1
Forward Primer
GATCTAAGATGGCGACTGTCGAA
SEQ ID NO: 703




Probe
ACCACCCCTACTCCTAATCCCCCGACT
SEQ ID NO: 704




Reverse Primer
TTAGATTCCGTTTTCTCCTCTTCTG
SEQ ID NO: 705


 


EIF4EL3
NM_004846.1
Forward Primer
AAGCCGCGGTTGAATGTG
SEQ ID NO: 706




Probe
TGACCCTCTCCCTCTCTGGATGGCA
SEQ ID NO: 707




Reverse Primer
TGACGCCAGCTTCAATGATG
SEQ ID NO: 708


 


ELAVL1
NM_001419.2
Forward Primer
GACAGGAGGCCTCTATCCTG
SEQ ID NO: 709




Probe
CACCCCACCCTCCACCTCAATC
SEQ ID NO: 710




Reverse Primer
GTGAGGTAGGTCTGGGGAAG
SEQ ID NO: 711


 


EMP1
NM_001423.1
Forward Primer
GCTAGTACTTTGATGCTCCCTTGAT
SEQ ID NO: 712




Probe
CCAGAGAGCCTCCCTGCAGCCA
SEQ ID NO: 713




Reverse Primer
GAACAGCTGGAGGCCAAGTC
SEQ ID NO: 714


 


EMR3
NM_032571.2
Forward Primer
TGGCCTACCTCTTCACCATC
SEQ ID NO: 715




Probe
TCAACAGCCTCCAAGGCTTCTTCA
SEQ ID NO: 716




Reverse Primer
TGAGGAGGCAGTAGACCAAGA
SEQ ID NO: 717


 


EMS1
NM_005231.2
Forward Primer
GGCAGTGTCACTGAGTCCTTGA
SEQ ID NO: 718




Probe
ATCCTCCCCTGCCCCGCG
SEQ ID NO: 719




Reverse Primer
TGCACTGTGCGTCCCAAT
SEQ ID NO: 720


 


ENO1
NM_001428.2
Forward Primer
CAAGGCCGTGAACGAGAAGT
SEQ ID NO: 721




Probe
CTGCAACTGCCTCCTGCTCAAAGTCA
SEQ ID NO: 722




Reverse Primer
CGGTCACGGAGCCAATCT
SEQ ID NO: 723


 


EP300
NM_001429.1
Forward Primer
AGCCCCAGCAACTACAGTCT
SEQ ID NO: 724




Probe
CACTGACATCATGGCTGGCCTTG
SEQ ID NO: 725




Reverse Primer
TGTTCAAAGGTTGACCATGC
SEQ ID NO: 726


 


EPAS1
NM_001430.3
Forward Primer
AAGCCTTGGAGGGTTTCATTG
SEQ ID NO: 727




Probe
TGTCGCCATCTTGGGTCACCACG
SEQ ID NO: 728




Reverse Primer
TGCTGATGTTTTCTGACAGAAAGAT
SEQ ID NO: 729


 


EpCAM
NM_002354.1
Forward Primer
GGGCCCTCCAGAACAATGAT
SEQ ID NO: 730




Probe
CCGCTCTCATCGCAGTCAGGATCAT
SEQ ID NO: 731




Reverse Primer
TGCACTGCTTGGCCTTAAAGA
SEQ ID NO: 732


 


EPHA2
NM_004431.2
Forward Primer
CGCCTGTTCACCAAGATTGAC
SEQ ID NO: 733




Probe
TGCGCCCGATGAGATCACCG
SEQ ID NO: 734




Reverse Primer
GTGGCGTGCCTCGAAGTC
SEQ ID NO: 735


 


EPHB2
NM_004442.4
Forward Primer
CAACCAGGCAGCTCCATC
SEQ ID NO: 736




Probe
CACCTGATGCATGATGGACACTGC
SEQ ID NO: 737




Reverse Primer
GTAATGCTGTCCACGGTGC
SEQ ID NO: 738


 


EPHB4
NM_004444.3
Forward Primer
TGAACGGGGTATCCTCCTTA
SEQ ID NO: 739




Probe
CGTCCCATTTGAGCCTGTCAATGT
SEQ ID NO: 740




Reverse Primer
AGGTACCTCTCGGTCAGTGG
SEQ ID NO: 741


 


EphB6
NM_004445.1
Forward Primer
ACTGGTCCTCCATCGGCT
SEQ ID NO: 742




Probe
CCTTGCACCTCAAACCAAAGCTCC
SEQ ID NO: 743




Reverse Primer
CCAGTGTAGCATGAGTGCTGA
SEQ ID NO: 744


 


EPM2A
NM_005670.2
Forward Primer
ACTGTGGCACTTAGGGGAGA
SEQ ID NO: 745




Probe
CTGCCTCTGCCCAAAGCAAATGTC
SEQ ID NO: 746




Reverse Primer
AGTGGAAATGTGTCCTGGCT
SEQ ID NO: 747


 


ErbB3
NM_001982.1
Forward Primer
CGGTTATGTCATGCCAGATACAC
SEQ ID NO: 748




Probe
CCTCAAAGGTACTCCCTCCTCCCGG
SEQ ID NO: 749




Reverse Primer
GAACTGAGACCCACTGAAGAAAGG
SEQ ID NO: 750


 


ERCC1
NM_001983.1
Forward Primer
GTCCAGGTGGATGTGAAAGA
SEQ ID NO: 751




Probe
CAGCAGGCCCTCAAGGAGCTG
SEQ ID NO: 752




Reverse Primer
CGGCCAGGATACACATCTTA
SEQ ID NO: 753


 


ERCC2
NM_000400.2
Forward Primer
TGGCCTTCTTCACCAGCTA
SEQ ID NO: 754




Probe
AGGCCACGGTGCTCTCCATGTACT
SEQ ID NO: 755




Reverse Primer
CAAGGATCCCCTGCTCATAC
SEQ ID NO: 756


 


EREG
NM_001432.1
Forward Primer
ATAACAAAGTGTAGCTCTGACATGAATG
SEQ ID NO: 757




Probe
TTGTTTGCATGGACAGTGCATCTATCTGGT
SEQ ID NO: 758




Reverse Primer
CACACCTGCAGTAGTTTTGACTCA
SEQ ID NO: 759


 


ERK1
Z11696.1
Forward Primer
ACGGATCACAGTGGAGGAAG
SEQ ID NO: 760




Probe
CGCTGGCTCACCCCTACCTG
SEQ ID NO: 761




Reverse Primer
CTCATCCGTCGGGTCATAGT
SEQ ID NO: 762


 


ERK2
NM_002745.1
Forward Primer
AGTTCTTGACCCCTGGTCCT
SEQ ID NO: 763




Probe
TCTCCAGCCCGTCTTGGCTT
SEQ ID NO: 764




Reverse Primer
AAACGGCTCAAAGGAGTCAA
SEQ ID NO: 765


 


ESPL1
NM_012291.1
Forward Primer
ACCCCCAGACCGGATCAG
SEQ ID NO: 766




Probe
CTGGCCCTCATGTCCCCTTCACG
SEQ ID NO: 767




Reverse Primer
TGTAGGGCAGACTTCCTCAAACA
SEQ ID NO: 768


 


EstR1
NM_000125.1
Forward Primer
CGTGGTGCCCCTCTATGAC
SEQ ID NO: 769




Probe
CTGGAGATGCTGGACGCCC
SEQ ID NO: 770




Reverse Primer
GGCTAGTGGGCGCATGTAG
SEQ ID NO: 771


 


ETV4
NM_001986.1
Forward Primer
TCCAGTGCCTATGACCCC
SEQ ID NO: 772




Probe
CAGACAAATCGCCATCAAGTCCCC
SEQ ID NO: 773




Reverse Primer
ACTGTCCAAGGGCACCAG
SEQ ID NO: 774


 


F3
NM_001993.2
Forward Primer
GTGAAGGATGTGAAGCAGACGTA
SEQ ID NO: 775




Probe
TGGCACGGGTCTTCTCCTACC
SEQ ID NO: 776




Reverse Primer
AACCGGTGCTCTCCACATTC
SEQ ID NO: 777


 


FABP4
NM_001442.1
Forward Primer
GCTTTGCCACCAGGAAAGT
SEQ ID NO: 778




Probe
CTGGCATGGCCAAACCTAACATGA
SEQ ID NO: 779




Reverse Primer
CATCCCCATTCACACTGATG
SEQ ID NO: 780


 


FAP
NM_004460.2
Forward Primer
CTGACCAGAACCACGGCT
SEQ ID NO: 781




Probe
CGGCCTGTCCACGAACCACTTATA
SEQ ID NO: 782




Reverse Primer
GGAAGTGGGTCATGTGGG
SEQ ID NO: 783


 


fas
NM_000043.1
Forward Primer
GGATTGCTCAACAACCATGCT
SEQ ID NO: 784




Probe
TCTGGACCCTCCTACCTCTGGTTCTTACGT
SEQ ID NO: 785




Reverse Primer
GGCATTAACACTTTTGGACGATAA
SEQ ID NO: 786


 


fasI
NM_000639.1
Forward Primer
GCACTTTGGGATTCTTTCCATTAT
SEQ ID NO: 787




Probe
ACAACATTCTCGGTGCCTGTAACAAAGAA
SEQ ID NO: 788




Reverse Primer
GCATGTAAGAAGACCCTCACTGAA
SEQ ID NO: 789


 


FASN
NM_004104.4
Forward Primer
GCCTCTTCCTGTTCGACG
SEQ ID NO: 790




Probe
TCGCCCACCTACGTACTGGCCTAC
SEQ ID NO: 791




Reverse Primer
GCTTTGCCCGGTAGCTCT
SEQ ID NO: 792


 


FBXO5
NM_012177.2
Forward Primer
GGCTATTCCTCATTTTCTCTACAAAGTG
SEQ ID NO: 793




Probe
CCTCCAGGAGGCTACCTTCTTCATGTTCAC
SEQ ID NO: 794




Reverse Primer
GGATTGTAGACTGTCACCGAAATTC
SEQ ID NO: 795


 


FBXW7
NM_033632.1
Forward Primer
CCCCAGTTTCAACGAGACTT
SEQ ID NO: 796




Probe
TCATTGCTCCCTAAAGAGTTGGCACTC
SEQ ID NO: 797




Reverse Primer
GTTCCAGGAATGAAAGCACA
SEQ ID NO: 798


 


FDXR
NM_004110.2
Forward Primer
GAGATGATTCAGTTACCGGGAG
SEQ ID NO: 799




Probe
AATCCACAGGATCCAAAATGGGCC
SEQ ID NO: 800




Reverse Primer
ATCTTGTCCTGGAGACCCAA
SEQ ID NO: 801


 


FES
NM_002005.2
Forward Primer
CTCTGCAGGCCTAGGTGC
SEQ ID NO: 802




Probe
CTCCTCAGCGGCTCCAGCTCATAT
SEQ ID NO: 803




Reverse Primer
CCAGGACTGTGAAGAGCTGTC
SEQ ID NO: 804


 


FGF18
NM_003862.1
Forward Primer
CGGTAGTCAAGTCCGGATCAA
SEQ ID NO: 805




Probe
CAAGGAGACGGAATTCTACCTGTGC
SEQ ID NO: 806




Reverse Primer
GCTTGCCTTTGCGGTTCA
SEQ ID NO: 807


 


FGF2
NM_002006.2
Forward Primer
AGATGCAGGAGAGAGGAAGC
SEQ ID NO: 808




Probe
CCTGCAGACTGCTTTTTGCCCAAT
SEQ ID NO: 809




Reverse Primer
GTTTTGCAGCCTTACCCAAT
SEQ ID NO: 810


 


FGFR1
NM_023109.1
Forward Primer
CACGGGACATTCACCACATC
SEQ ID NO: 811




Probe
ATAAAAAGACAACCAACGGCCGACTGC
SEQ ID NO: 812




Reverse Primer
GGGTGCCATCCACTTCACA
SEQ ID NO: 813


 


FGFR2
NM_000141.2
Forward Primer
GAGGGACTGTTGGCATGCA
SEQ ID NO: 814


isoform 1

Probe
TCCCAGAGACCAACGTTCAAGCAGTTG
SEQ ID NO: 815




Reverse Primer
GAGTGAGAATTCGATCCAAGTCTTC
SEQ ID NO: 816


 


FHIT
NM_002012.1
Forward Primer
CCAGTGGAGCGCTTCCAT
SEQ ID NO: 817




Probe
TCGGCCACTTCATCAGGACGCAG
SEQ ID NO: 818




Reverse Primer
CTCTCTGGGTCGTCTGAAACAA
SEQ ID NO: 819


 


FIGF
NM_004469.2
Forward Primer
GGTTCCAGCTTTCTGTAGCTGT
SEQ ID NO: 820




Probe
ATTGGTGGCCACACCACCTCCTTA
SEQ ID NO: 821




Reverse Primer
GCCGCAGGTTCTAGTTGCT
SEQ ID NO: 822


 


FLJ12455
NM_022078.1
Forward Primer
CCACCAGCATGAAGTTTCG
SEQ ID NO: 823




Probe
ACCCCTCACAAAGGCCATGTCTGT
SEQ ID NO: 824




Reverse Primer
GGCTGTCTGAAGCACAACTG
SEQ ID NO: 825


 


FLJ20712
AK000719.1
Forward Primer
GCCACACAAACATGCTCCT
SEQ ID NO: 826




Probe
ATGTCTTTCCCAGCAGCTCTGCCT
SEQ ID NO: 827




Reverse Primer
GCCACAGGAAACTTCCGA
SEQ ID NO: 828


 


FLT1
NM_002019.1
Forward Primer
GGCTCCCGAATCTATCTTTG
SEQ ID NO: 829




Probe
CTACAGCACCAAGAGCGACGTGTG
SEQ ID NO: 830




Reverse Primer
TCCCACAGCAATACTCCGTA
SEQ ID NO: 831


 


FLT4
NM_002020.1
Forward Primer
ACCAAGAAGCTGAGGACCTG
SEQ ID NO: 832




Probe
AGCCCGCTGACCATGGAAGATCT
SEQ ID NO: 833




Reverse Primer
CCTGGAAGCTGTAGCAGACA
SEQ ID NO: 834


 


FOS
NM_005252.2
Forward Primer
CGAGCCCTTTGATGACTTCCT
SEQ ID NO: 835




Probe
TCCCAGCATCATCCAGGCCCAG
SEQ ID NO: 836




Reverse Primer
GGAGCGGGCTGTCTCAGA
SEQ ID NO: 837


 


FOXO3A
NM_001455.1
Forward Primer
TGAAGTCCAGGACGATGATG
SEQ ID NO: 838




Probe
CTCTACAGCAGCTCAGCCAGCCTG
SEQ ID NO: 839




Reverse Primer
ACGGCTTGCTTACTGAAGGT
SEQ ID NO: 840


 


FPGS
NM_004957.3
Forward Primer
CAGCCCTGCCAGTTTGAC
SEQ ID NO: 841




Probe
ATGCCGTCTTCTGCCCTAACCTGA
SEQ ID NO: 842




Reverse Primer
GTTGCCTGTGGATGACACC
SEQ ID NO: 843


 


FRP1
NM_003012.2
Forward Primer
TTGGTACCTGTGGGTTAGCA
SEQ ID NO: 844




Probe
TCCCCAGGGTAGAATTCAATCAGAGC
SEQ ID NO: 845




Reverse Primer
CACATCCAAATGCAAACTGG
SEQ ID NO: 846


 


FST
NM_006350.2
Forward Primer
GTAAGTCGGATGAGCCTGTCTGT
SEQ ID NO: 847




Probe
CCAGTGACAATGCCACTTATGCCAGC
SEQ ID NO: 848




Reverse Primer
CAGCTTCCTTCATGGCACACT
SEQ ID NO: 849


 


Furin
NM_002569.1
Forward Primer
AAGTCCTCGATACGCACTATAGCA
SEQ ID NO: 850




Probe
CCCGGATGGTCTCCACGTCAT
SEQ ID NO: 851




Reverse Primer
CTGGCATGTGGCACATGAG
SEQ ID NO: 852


 


FUS
NM_004960.1
Forward Primer
GGATAATTCAGACAACAACACCATCT
SEQ ID NO: 853




Probe
TCAATTGTAACATTCTCACCCAGGCCTTG
SEQ ID NO: 854




Reverse Primer
TGAAGTAATCAGCCACAGACTCAAT
SEQ ID NO: 855


 


FUT1
NM_000148.1
Forward Primer
CCGTGCTCATTGCTAACCA
SEQ ID NO: 856




Probe
TCTGTCCCTGAACTCCCAGAACCA
SEQ ID NO: 857




Reverse Primer
CTGCCCAAAGCCAGATGTA
SEQ ID NO: 858


 


FUT3
NM_000149.1
Forward Primer
CAGTTCGGTCCAACAGAGAA
SEQ ID NO: 859




Probe
AGCAGGCAACCACCATGTCATTTG
SEQ ID NO: 860




Reverse Primer
TGCGAATTATATCCCGATGA
SEQ ID NO: 861


 


FUT6
NM_000150.1
Forward Primer
CGTGTGTCTCAAGACGATCC
SEQ ID NO: 862




Probe
TGTGTACCCTAATGGGTCCCGCTT
SEQ ID NO: 863




Reverse Primer
GGTCCCTGTGCTGTCTGG
SEQ ID NO: 864


 


FXYD5
NM_014164.4
Forward Primer
AGAGCACCAAAGCAGCTCAT
SEQ ID NO: 865




Probe
CACTGATGACACCACGACGCTCTC
SEQ ID NO: 866




Reverse Primer
GTGCTTGGGGATGGTCTCT
SEQ ID NO: 867


 


FYN
NM_002037.3
Forward Primer
GAAGCGCAGATCATGAAGAA
SEQ ID NO: 868




Probe
CTGAAGCACGACAAGCTGGTCCAG
SEQ ID NO: 869




Reverse Primer
CTCCTCAGACACCACTGCAT
SEQ ID NO: 870


 


FZD1
NM_003505.1
Forward Primer
GGTGCACCAGTTCTACCCTC
SEQ ID NO: 871




Probe
ACTTGAGCTCAGCGGAACACTGCA
SEQ ID NO: 872




Reverse Primer
GCGTACATGGAGCACAGGA
SEQ ID NO: 873


 


FZD2
NM_001466.2
Forward Primer
TGGATCCTCACCTGGTCG
SEQ ID NO: 874




Probe
TGCGCTTCCACCTTCTTCACTGTC
SEQ ID NO: 875




Reverse Primer
GCGCTGCATGTCTACCAA
SEQ ID NO: 876


 


FZD6
NM_003506.2
Forward Primer
AATGAGAGAGGTGAAAGCGG
SEQ ID NO: 877




Probe
CGGAGCTAGCACCCCCAGGTTAAG
SEQ ID NO: 878




Reverse Primer
AGGTTCACCACAGTCCTGTTC
SEQ ID NO: 879


 


G-Catenin
NM_002230.1
Forward Primer
TCAGCAGCAAGGGCATCAT
SEQ ID NO: 880




Probe
CGCCCGCAGGCCTCATCCT
SEQ ID NO: 881




Reverse Primer
GGTGGTTTTCTTGAGCGTGTACT
SEQ ID NO: 882


 


G1P2
NM_005101.1
Forward Primer
CAACGAATTCCAGGTGTCC
SEQ ID NO: 883




Probe
CTGAGCAGCTCCATGTCGGTGTC
SEQ ID NO: 884




Reverse Primer
GATCTGCGCCTTCAGCTC
SEQ ID NO: 885


 


GADD45
NM_001924.2
Forward Primer
GTGCTGGTGACGAATCCA
SEQ ID NO: 886




Probe
TTCATCTCAATGGAAGGATCCTGCC
SEQ ID NO: 887




Reverse Primer
CCCGGCAAAAACAAATAAGT
SEQ ID NO: 888


 


GADD45B
NM_015675.1
Forward Primer
ACCCTCGACAAGACCACACT
SEQ ID NO: 889




Probe
AACTTCAGCCCCAGCTCCCAAGTC
SEQ ID NO: 890




Reverse Primer
TGGGAGTTCATGGGTACAGA
SEQ ID NO: 891


 


GADD45G
NM_006705.2
Forward Primer
CGCGCTGCAGATCCATTT
SEQ ID NO: 892




Probe
CGCTGATCCAGGCTTTCTGCTGC
SEQ ID NO: 893




Reverse Primer
CGCACTATGTCGATGTCGTTCT
SEQ ID NO: 894


 


GAGE4
NM_001474.1
Forward Primer
GGAACAGGGTCACCCACAGA
SEQ ID NO: 895




Probe
TCAGGACCATCTTCACACTCACACCCA
SEQ ID NO: 896




Reverse Primer
GATTTGGCGGGTCCATCTC
SEQ ID NO: 897


 


GBP1
NM_002053.1
Forward Primer
TTGGGAAATATTTGGGCATT
SEQ ID NO: 898




Probe
TTGGGACATTGTAGACTTGGCCAGAC
SEQ ID NO: 899




Reverse Primer
AGAAGCTAGGGTGGTTGTCC
SEQ ID NO: 900


 


GBP2
NM_004120.2
Forward Primer
GCATGGGAACCATCAACCA
SEQ ID NO: 901




Probe
CCATGGACCAACTTCACTATGTGACAGAGC
SEQ ID NO: 902




Reverse Primer
TGAGGAGTTTGCCTTGATTCG
SEQ ID NO: 903


 


GCLC
NM_001498.1
Forward Primer
CTGTTGCAGGAAGGCATTGA
SEQ ID NO: 904




Probe
CATCTCCTGGCCCAGCATGTT
SEQ ID NO: 905




Reverse Primer
GTCAGTGGGTCTCTAATAAAGAGATGAG
SEQ ID NO: 906


 


GCLM
NM_002061.1
Forward Primer
TGTAGAATCAAACTCTTCATCATCAACTAG
SEQ ID NO: 907




Probe
TGCAGTTGACATGGCCTGTTCAGTCC
SEQ ID NO: 908




Reverse Primer
CACAGAATCCAGCTGTGCAACT
SEQ ID NO: 909


 


GCNT1
NM_001490.3
Forward Primer
TGGTGCTTGGAGCATAGAAG
SEQ ID NO: 910




Probe
TGCCCTTCACAAAGGAAATCCCTG
SEQ ID NO: 911




Reverse Primer
GCAACGTCCTCAGCATTTC
SEQ ID NO: 912


 


GDF15
NM_004864.1
Forward Primer
CGCTCCAGACCTATGATGACT
SEQ ID NO: 913




Probe
TGTTAGCCAAAGACTGCCACTGCA
SEQ ID NO: 914




Reverse Primer
ACAGTGGAAGGACCAGGACT
SEQ ID NO: 915


 


GIT1
NM_014030.2
Forward Primer
GTGTATGACGAGGTGGATCG
SEQ ID NO: 916




Probe
AGCCAGCCACACTGCATCATTTTC
SEQ ID NO: 917




Reverse Primer
ACCAGAGTGCTGTGGTTTTG
SEQ ID NO: 918


 


GJA1
NM_000165.2
Forward Primer
GTTCACTGGGGGTGTATGG
SEQ ID NO: 919




Probe
ATCCCCTCCCTCTCCACCCATCTA
SEQ ID NO: 920




Reverse Primer
AAATACCAACATGCACCTCTCTT
SEQ ID NO: 921


 


GJB2
NM_004004.3
Forward Primer
TGTCATGTACGACGGCTTCT
SEQ ID NO: 922




Probe
AGGCGTTGCACTTCACCAGCC
SEQ ID NO: 923




Reverse Primer
AGTCCACAGTGTTGGGACAA
SEQ ID NO: 924


 


GPX1
NM_000581.2
Forward Primer
GCTTATGACCGACCCCAA
SEQ ID NO: 925




Probe
CTCATCACCTGGTCTCCGGTGTGT
SEQ ID NO: 926




Reverse Primer
AAAGTTCCAGGCAACATCGT
SEQ ID NO: 927


 


GPX2
NM_002083.1
Forward Primer
CACACAGATCTCCTACTCCATCCA
SEQ ID NO: 928




Probe
CATGCTGCATCCTAAGGCTCCTCAGG
SEQ ID NO: 929




Reverse Primer
GGTCCAGCAGTGTCTCCTGAA
SEQ ID NO: 930


 


Grb10
NM_005311.2
Forward Primer
CTTCGCCTTTGCTGATTGC
SEQ ID NO: 931




Probe
CTCCAAACGCCTGCCTGACGACTG
SEQ ID NO: 932




Reverse Primer
CCATAACGCACATGCTCCAA
SEQ ID NO: 933


 


GRB14
NM_004490.1
Forward Primer
TCCCACTGAAGCCCTTTCAG
SEQ ID NO: 934




Probe
CCTCCAAGCGAGTCCTTCTTCAACCG
SEQ ID NO: 935




Reverse Primer
AGTGCCCAGGCGTAAACATC
SEQ ID NO: 936


 


GRB2
NM_002086.2
Forward Primer
GTCCATCAGTGCATGACGTT
SEQ ID NO: 937




Probe
AGGCCACGTATAGTCCTAGCTGACGC
SEQ ID NO: 938




Reverse Primer
AGCCCACTTGGTTTCTTGTT
SEQ ID NO: 939


 


GRB7
NM_005310.1
Forward Primer
CCATCTGCATCCATCTTGTT
SEQ ID NO: 940




Probe
CTCCCCACCCTTGAGAAGTGCCT
SEQ ID NO: 941




Reverse Primer
GGCCACCAGGGTATTATCTG
SEQ ID NO: 942


 


GRIK1
NM_000830.2
Forward Primer
GTTGGGTGCATCTCTCGG
SEQ ID NO: 943




Probe
AATTCATGCCGAGATACAGCCGCT
SEQ ID NO: 944




Reverse Primer
CGTGCTCCATCTTCCTAGCTT
SEQ ID NO: 945


 


GRO1
NM_001511.1
Forward Primer
CGAAAAGATGCTGAACAGTGACA
SEQ ID NO: 946




Probe
CTTCCTCCTCCCTTCTGGTCAGTTGGAT
SEQ ID NO: 947




Reverse Primer
TCAGGAACAGCCACCAGTGA
SEQ ID NO: 948


 


GRP
NM_002091.1
Forward Primer
CTGGGTCTCATAGAAGCAAAGGA
SEQ ID NO: 949




Probe
AGAAACCACCAGCCACCTCAACCCA
SEQ ID NO: 950




Reverse Primer
CCACGAAGGCTGCTGATTG
SEQ ID NO: 951


 


GRPR
NM_005314.1
Forward Primer
ATGCTGCTGGCCATTCCA
SEQ ID NO: 952




Probe
CCGTGTTTTCTGACCTCCATCCCTTCC
SEQ ID NO: 953




Reverse Primer
AGGTCTGGTTGGTGCTTTCCT
SEQ ID NO: 954


 


GSK3B
NM_002093.2
Forward Primer
GACAAGGACGGCAGCAAG
SEQ ID NO: 955




Probe
CCAGGAGTTGCCACCACTGTTGTC
SEQ ID NO: 956




Reverse Primer
TTGTGGCCTGTCTGGACC
SEQ ID NO: 957


 


GSTA3
NM_000847.3
Forward Primer
TCTCCAACTTCCCTCTGCTG
SEQ ID NO: 958




Probe
AGGCCCTGAAAACCAGAATCAGCA
SEQ ID NO: 959




Reverse Primer
ACTTCTTCACCGTGGGCA
SEQ ID NO: 960


 


GSTM1
NM_000561.1
Forward Primer
AAGCTATGAGGAAAAGAAGTACACGAT
SEQ ID NO: 961




Probe
TCAGCCACTGGCTTCTGTCATAATCAGGAG
SEQ ID NO: 962




Reverse Primer
GGCCCAGCTTGAATTTTTCA
SEQ ID NO: 963


 


GSTM3
NM_000849.3
Forward Primer
CAATGCCATCTTGCGCTACAT
SEQ ID NO: 964




Probe
CTCGCAAGCACAACATGTGTGGTGAGA
SEQ ID NO: 965




Reverse Primer
GTCCACTCGAATCTTTTCTTCTTCA
SEQ ID NO: 966


 


GSTp
NM_000852.2
Forward Primer
GAGACCCTGCTGTCCCAGAA
SEQ ID NO: 967




Probe
TCCCACAATGAAGGTCTTGCCTCCCT
SEQ ID NO: 968




Reverse Primer
GGTTGTAGTCAGCGAAGGAGATC
SEQ ID NO: 969


 


GSTT1
NM_000853.1
Forward Primer
CACCATCCCCACCCTGTCT
SEQ ID NO: 970




Probe
CACAGCCGCCTGAAAGCCACAAT
SEQ ID NO: 971




Reverse Primer
GGCCTCAGTGTGCATCATTCT
SEQ ID NO: 972


 


H2AFZ
NM_002106.2
Forward Primer
CCGGAAAGGCCAAGACAA
SEQ ID NO: 973




Probe
CCCGCTCGCAGAGAGCCGG
SEQ ID NO: 974




Reverse Primer
AATACGGCCCACTGGGAACT
SEQ ID NO: 975


 


HB-EGF
NM_001945.1
Forward Primer
GACTCCTTCGTCCCCAGTTG
SEQ ID NO: 976




Probe
TTGGGCCTCCCATAATTGCTTTGCC
SEQ ID NO: 977




Reverse Primer
TGGCACTTGAAGGCTCTGGTA
SEQ ID NO: 978


 


hCRA a
U78556.1
Forward Primer
TGACACCCTTACCTTCCTGAGAA
SEQ ID NO: 979




Probe
TCTGCTTTCCGCGCTCCCAGG
SEQ ID NO: 980




Reverse Primer
AAAAACACGAGTCAAAAATAGAAGTCACT
SEQ ID NO: 981


 


HDAC1
NM_004964.2
Forward Primer
CAAGTACCACAGCGATGACTACATTAA
SEQ ID NO: 982




Probe
TTCTTGCGCTCCATCCGTCCAGA
SEQ ID NO: 983




Reverse Primer
GCTTGCTGTACTCCGACATGTT
SEQ ID NO: 984


 


HDAC2
NM_001527.1
Forward Primer
GGTGGCTACACAATCCGTAA
SEQ ID NO: 985




Probe
TGCAGTCTCATATGTCCAACATCGAGC
SEQ ID NO: 986




Reverse Primer
TGGGAATCTCACAATCAAGG
SEQ ID NO: 987


 


HDGF
NM_004494.1
Forward Primer
TCCTAGGCATTCTGGACCTC
SEQ ID NO: 988




Probe
CATTCCTACCCCTGATCCCAACCC
SEQ ID NO: 989




Reverse Primer
GCTGTTGATGCTCCATCCTT
SEQ ID NO: 990


 


hENT1
NM_004955.1
Forward Primer
AGCCGTGACTGTTGAGGTC
SEQ ID NO: 991




Probe
AAGTCCAGCATCGCAGGCAGC
SEQ ID NO: 992




Reverse Primer
AAGTAACGTTCCCAGGTGCT
SEQ ID NO: 993


 


Hepsin
NM_002151.1
Forward Primer
AGGCTGCTGGAGGTCATCTC
SEQ ID NO: 994




Probe
CCAGAGGCCGTTTCTTGGCCG
SEQ ID NO: 995




Reverse Primer
CTTCCTGCGGCCACAGTCT
SEQ ID NO: 996


 


HER2
NM_004448.1
Forward Primer
CGGTGTGAGAAGTGCAGCAA
SEQ ID NO: 997




Probe
CCAGACCATAGCACACTCGGGCAC
SEQ ID NO: 998




Reverse Primer
CCTCTCGCAAGTGCTCCAT
SEQ ID NO: 999


 


Herstatin
AF177761.2
Forward Primer
CACCCTGTCCTATCCTTCCT
SEQ ID NO: 1000




Probe
CCCTCTTGGGACCTAGTCTCTGCCT
SEQ ID NO: 1001




Reverse Primer
GGCCAGGGGTAGAGAGTAGA
SEQ ID NO: 1002


 


HES6
NM_018645.3
Forward Primer
TTAGGGACCCTGCAGCTCT
SEQ ID NO: 1003




Probe
TAGCTCCCTCCCTCCACCCACTC
SEQ ID NO: 1004




Reverse Primer
CTACAAAATTCTTCCTCCTGCC
SEQ ID NO: 1005


 


HGF
M29145.1
Forward Primer
CCGAAATCCAGATGATGATG
SEQ ID NO: 1006




Probe
CTCATGGACCCTGGTGCTACACG
SEQ ID NO: 1007




Reverse Primer
CCCAAGGAATGAGTGGATTT
SEQ ID NO: 1008


 


HIF1A
NM_001530.1
Forward Primer
TGAACATAAAGTCTGCAACATGGA
SEQ ID NO: 1009




Probe
TTGCACTGCACAGGCCACATTCAC
SEQ ID NO: 1010




Reverse Primer
TGAGGTTGGTTACTGTTGGTATCATATA
SEQ ID NO: 1011


 


HK1
NM_000188.1
Forward Primer
TACGCACAGAGGCAAGCA
SEQ ID NO: 1012




Probe
TAAGAGTCCGGGATCCCCAGCCTA
SEQ ID NO: 1013




Reverse Primer
GAGAGAAGTGCTGGAGAGGC
SEQ ID NO: 1014


 


HLA-DPB1
NM_002121.4
Forward Primer
TCCATGATGGTTCTGCAGGTT
SEQ ID NO: 1015




Probe
CCCCGGACAGTGGCTCTGACG
SEQ ID NO: 1016




Reverse Primer
TGAGCAGCACCATCAGTAACG
SEQ ID NO: 1017


 


HLA-DRA
NM_019111.3
Forward Primer
GACGATTTGCCAGCTTTGAG
SEQ ID NO: 1018




Probe
TCAAGGTGCATTGGCCAACATAGC
SEQ ID NO: 1019




Reverse Primer
TCCAGGTTGGCTTTGTCC
SEQ ID NO: 1020


 


HLA-DRB1
NM_002124.1
Forward Primer
GCTTTCTCAGGACCTGGTTG
SEQ ID NO: 1021




Probe
CATTTTCTGCAGTTGCCGAACCAG
SEQ ID NO: 1022




Reverse Primer
AGGAAGCCACAAGGGAGG
SEQ ID NO: 1023


 


HLA-G
NM_002127.2
Forward Primer
CCTGCGCGGCTACTACAAC
SEQ ID NO: 1024




Probe
CGAGGCCAGTTCTCACACCCTCCAG
SEQ ID NO: 1025




Reverse Primer
CAGGTCGCAGCCAATCATC
SEQ ID NO: 1026


 


HMGB1
NM_002128.3
Forward Primer
TGGCCTGTCCATTGGTGAT
SEQ ID NO: 1027




Probe
TTCCACATCTCTCCCAGTTTCTTCGCAA
SEQ ID NO: 1028




Reverse Primer
GCTTGTCATCTGCAGCAGTGTT
SEQ ID NO: 1029


 


hMLH
NM_000249.2
Forward Primer
CTACTTCCAGCAACCCCAGA
SEQ ID NO: 1030




Probe
TCCACATCAGAATCTTCCCG
SEQ ID NO: 1031




Reverse Primer
CTTTCGGGAATCATCTTCCA
SEQ ID NO: 1032


 


HNRPAB
NM_004499.2
Forward Primer
CAAGGGAGCGACCAACTGA
SEQ ID NO: 1033




Probe
CTCCATATCCAAACAAAGCATGTGTGCG
SEQ ID NO: 1034




Reverse Primer
GTTTGCCAAGTTAAATTTGGTACATAAT
SEQ ID NO: 1035


 


HNRPD
NM_031370.2
Forward Primer
GCCAGTAAGAACGAGGAGGA
SEQ ID NO: 1036




Probe
AAGGCCATTCAAACTCCTCCCCAC
SEQ ID NO: 1037




Reverse Primer
CGTCGCTGCTTCAGAGTGT
SEQ ID NO: 1038


 


HoxA1
NM_005522.3
Forward Primer
AGTGACAGATGGACAATGCAAGA
SEQ ID NO: 1039




Probe
TGAACTCCTTCCTGGAATACCCCA
SEQ ID NO: 1040




Reverse Primer
CCGAGTCGCCACTGCTAAGT
SEQ ID NO: 1041


 


HoxA5
NM_019102.2
Forward Primer
TCCCTTGTGTTCCTTCTGTGAA
SEQ ID NO: 1042




Probe
AGCCCTGTTCTCGTTGCCCTAATTCATC
SEQ ID NO: 1043




Reverse Primer
GGCAATAAACAGGCTCATGATTAA
SEQ ID NO: 1044


 


HOXB13
NM_006361.2
Forward Primer
CGTGCCTTATGGTTACTTTGG
SEQ ID NO: 1045




Probe
ACACTCGGCAGGAGTAGTACCCGC
SEQ ID NO: 1046




Reverse Primer
CACAGGGTTTCAGCGAGC
SEQ ID NO: 1047


 


HOXB7
NM_004502.2
Forward Primer
CAGCCTCAAGTTCGGTTTTC
SEQ ID NO: 1048




Probe
ACCGGAGCCTTCCCAGAACAAACT
SEQ ID NO: 1049




Reverse Primer
GTTGGAAGCAAACGCACA
SEQ ID NO: 1050


 


HRAS
NM_005343.2
Forward Primer
GGACGAATACGACCCCACT
SEQ ID NO: 1051




Probe
ACCACCTGCTTCCGGTAGGAATCC
SEQ ID NO: 1052




Reverse Primer
GCACGTCTCCCCATCAAT
SEQ ID NO: 1053


 


HSBP1
NM_001537.1
Forward Primer
GGAGATGGCCGAGACTGAC
SEQ ID NO: 1054




Probe
CAAGACCGTGCAGGACCTCACCT
SEQ ID NO: 1055




Reverse Primer
CTGCAGGAGTGTCTGCACC
SEQ ID NO: 1056


 


HSD17B1
NM_000413.1
Forward Primer
CTGGACCGCACGGACATC
SEQ ID NO: 1057




Probe
ACCGCTTCTACCAATACCTCGCCCA
SEQ ID NO: 1058




Reverse Primer
CGCCTCGCGAAAGACTTG
SEQ ID NO: 1059


 


HSD17B2
NM_002153.1
Forward Primer
GCTTTCCAAGTGGGGAATTA
SEQ ID NO: 1060




Probe
AGTTGCTTCCATCCAACCTGGAGG
SEQ ID NO: 1061




Reverse Primer
TGCCTGCGATATTTGTTAGG
SEQ ID NO: 1062


 


HSPA1A
NM_005345.4
Forward Primer
CTGCTGCGACAGTCCACTA
SEQ ID NO: 1063




Probe
AGAGTGACTCCCGTTGTCCCAAGG
SEQ ID NO: 1064




Reverse Primer
CAGGTTCGCTCTGGGAAG
SEQ ID NO: 1065


 


HSPA1B
NM_005346.3
Forward Primer
GGTCCGCTTCGTCTTTCGA
SEQ ID NO: 1066




Probe
TGACTCCCGCGGTCCCAAGG
SEQ ID NO: 1067




Reverse Primer
GCACAGGTTCGCTCTGGAA
SEQ ID NO: 1068


 


HSPA4
NM_002154.3
Forward Primer
TTCAGTGTGTCCAGTGCATC
SEQ ID NO: 1069




Probe
CATTTTCCTCAGACTTGTGAACCTCCACT
SEQ ID NO: 1070




Reverse Primer
ATCTGTTTCCATTGGCTCCT
SEQ ID NO: 1071


 


HSPA5
NM_005347.2
Forward Primer
GGCTAGTAGAACTGGATCCCAACA
SEQ ID NO: 1072




Probe
TAATTAGACCTAGGCCTCAGCTGCACTGCC
SEQ ID NO: 1073




Reverse Primer
GGTCTGCCCAAATGCTTTTC
SEQ ID NO: 1074


 


HSPA8
NM_006597.3
Forward Primer
CCTCCCTCTGGTGGTGCTT
SEQ ID NO: 1075




Probe
CTCAGGGCCCACCATTGAAGAGGTTG
SEQ ID NO: 1076




Reverse Primer
GCTACATCTACACTTGGTTGGCTTAA
SEQ ID NO: 1077


 


HSPB1
NM_001540.2
Forward Primer
CCGACTGGAGGAGCATAAA
SEQ ID NO: 1078




Probe
CGCACTTTTCTGAGCAGACGTCCA
SEQ ID NO: 1079




Reverse Primer
ATGCTGGCTGACTCTGCTC
SEQ ID NO: 1080


 


HSPCA
NM_005348.2
Forward Primer
CAAAAGGCAGAGGCTGATAA
SEQ ID NO: 1081




Probe
TGACCAGATCCTTCACAGACTTGTCGT
SEQ ID NO: 1082




Reverse Primer
AGCGCAGTTTCATAAAGCAA
SEQ ID NO: 1083


 


HSPE1
NM_002157.1
Forward Primer
GCAAGCAACAGTAGTCGCTG
SEQ ID NO: 1084




Probe
TCTCCACCCTTTCCTTTAGAACCCG
SEQ ID NO: 1085




Reverse Primer
CCAACTTTCACGCTAACTGGT
SEQ ID NO: 1086


 


HSPG2
NM_005529.2
Forward Primer
GAGTACGTGTGCCGAGTGTT
SEQ ID NO: 1087




Probe
CAGCTCCGTGCCTCTAGAGGCCT
SEQ ID NO: 1088




Reverse Primer
CTCAATGGTGACCAGGACA
SEQ ID NO: 1089


 


ICAM1
NM_000201.1
Forward Primer
GCAGACAGTGACCATCTACAGCTT
SEQ ID NO: 1090




Probe
CCGGCGCCCAACGTGATTCT
SEQ ID NO: 1091




Reverse Primer
CTTCTGAGACCTCTGGCTTCGT
SEQ ID NO: 1092


 


ICAM2
NM_000873.2
Forward Primer
GGTCATCCTGACACTGCAAC
SEQ ID NO: 1093




Probe
TTGCCCACAGCCACCAAAGTG
SEQ ID NO: 1094




Reverse Primer
TGCACTCAATGGTGAAGGAC
SEQ ID NO: 1095


 


ID1
NM_002165.1
Forward Primer
AGAACCGCAAGGTGAGCAA
SEQ ID NO: 1096




Probe
TGGAGATTCTCCAGCACGTCATCGAC
SEQ ID NO: 1097




Reverse Primer
TCCAACTGAAGGTCCCTGATG
SEQ ID NO: 1098


 


ID2
NM_002166.1
Forward Primer
AACGACTGCTACTCCAAGCTCAA
SEQ ID NO: 1099




Probe
TGCCCAGCATCCCCCAGAACAA
SEQ ID NO: 1100




Reverse Primer
GGATTTCCATCTTGCTCACCTT
SEQ ID NO: 1101


 


ID3
NM_002167.2
Forward Primer
CTTCACCAAATCCCTTCCTG
SEQ ID NO: 1102




Probe
TCACAGTCCTTCGCTCCTGAGCAC
SEQ ID NO: 1103




Reverse Primer
CTCTGGCTCTTCAGGCTACA
SEQ ID NO: 1104


 


ID4
NM_001546.2
Forward Primer
TGGCCTGGCTCTTAATTTG
SEQ ID NO: 1105




Probe
CTTTTGTTTTGCCCAGTATAGACTCGGAAG
SEQ ID NO: 1106




Reverse Primer
TGCAATCATGCAAGACCAC
SEQ ID NO: 1107


 


IFIT1
NM_001548.1
Forward Primer
TGACAACCAAGCAAATGTGA
SEQ ID NO: 1108




Probe
AAGTTGCCCCAGGTCACCAGACTC
SEQ ID NO: 1109




Reverse Primer
CAGTCTGCCCATGTGGTAAT
SEQ ID NO: 1110


 


IGF1
NM_000618.1
Forward Primer
TCCGGAGCTGTGATCTAAGGA
SEQ ID NO: 1111




Probe
TGTATTGCGCACCCCTCAAGCCTG
SEQ ID NO: 1112




Reverse Primer
CGGACAGAGCGAGCTGACTT
SEQ ID NO: 1113


 


IGF1R
NM_000875.2
Forward Primer
GCATGGTAGCCGAAGATTTCA
SEQ ID NO: 1114




Probe
CGCGTCATACCAAAATCTCCGATTTTGA
SEQ ID NO: 1115




Reverse Primer
TTTCCGGTAATAGTCTGTCTCATAGATATC
SEQ ID NO: 1116


 


IGF2
NM_000612.2
Forward Primer
CCGTGCTTCCGGACAACTT
SEQ ID NO: 1117




Probe
TACCCCGTGGGCAAGTTCTTCCAA
SEQ ID NO: 1118




Reverse Primer
TGGACTGCTTCCAGGTGTCA
SEQ ID NO: 1119


 


IGFBP2
NM_000597.1
Forward Primer
GTGGACAGCACCATGAACA
SEQ ID NO: 1120




Probe
CTTCCGGCCAGCACTGCCTC
SEQ ID NO: 1121




Reverse Primer
CCTTCATACCCGACTTGAGG
SEQ ID NO: 1122


 


IGFBP3
NM_000598.1
Forward Primer
ACGCACCGGGTGTCTGA
SEQ ID NO: 1123




Probe
CCCAAGTTCCACCCCCTCCATTCA
SEQ ID NO: 1124




Reverse Primer
TGCCCTTTCTTGATGATGATTATC
SEQ ID NO: 1125


 


IGFBP5
NM_000599.1
Forward Primer
TGGACAAGTACGGGATGAAGCT
SEQ ID NO: 1126




Probe
CCCGTCAACGTACTCCATGCCTGG
SEQ ID NO: 1127




Reverse Primer
CGAAGGTGTGGCACTGAAAGT
SEQ ID NO: 1128


 


IGFBP6
NM_002178.1
Forward Primer
TGAACCGCAGAGACCAACAG
SEQ ID NO: 1129




Probe
ATCCAGGCACCTCTACCACGCCCTC
SEQ ID NO: 1130




Reverse Primer
GTCTTGGACACCCGCAGAAT
SEQ ID NO: 1131


 


IGFBP7
NM_001553
Forward Primer
GGGTCACTATGGAGTTCAAAGGA
SEQ ID NO: 1132




Probe
CCCGGTCACCAGGCAGGAGTTCT
SEQ ID NO: 1133




Reverse Primer
GGGTCTGAATGGCCAGGTT
SEQ ID NO: 1134


 


IHH
NM_002181.1
Forward Primer
AAGGACGAGGAGAACACAGG
SEQ ID NO: 1135




Probe
ATGACCCAGCGCTGCAAGGAC
SEQ ID NO: 1136




Reverse Primer
AGATAGCCAGCGAGTTCAGG
SEQ ID NO: 1137


 


IL-8
NM_000584.2
Forward Primer
AAGGAACCATCTCACTGTGTGTAAAC
SEQ ID NO: 1138




Probe
TGACTTCCAAGCTGGCCGTGGC
SEQ ID NO: 1139




Reverse Primer
ATCAGGAAGGCTGCCAAGAG
SEQ ID NO: 1140


 


IL10
NM_000572.1
Forward Primer
GGCGCTGTCATCGATTTCTT
SEQ ID NO: 1141




Probe
CTGCTCCACGGCCTTGCTCTTG
SEQ ID NO: 1142




Reverse Primer
TGGAGCTTATTAAAGGCATTCTTCA
SEQ ID NO: 1143


 


IL1B
NM_000576.2
Forward Primer
AGCTGAGGAAGATGCTGGTT
SEQ ID NO: 1144




Probe
TGCCCACAGACCTTCCAGGAGAAT
SEQ ID NO: 1145




Reverse Primer
GGAAAGAAGGTGCTCAGGTC
SEQ ID NO: 1146


 


IL6
NM_000600.1
Forward Primer
CCTGAACCTTCCAAAGATGG
SEQ ID NO: 1147




Probe
CCAGATTGGAAGCATCCATCTTTTTCA
SEQ ID NO: 1148




Reverse Primer
ACCAGGCAAGTCTCCTCATT
SEQ ID NO: 1149


 


IL6ST
NM_002184.2
Forward Primer
GGCCTAATGTTCCAGATCCT
SEQ ID NO: 1150




Probe
CATATTGCCCAGTGGTCACCTCACA
SEQ ID NO: 1151




Reverse Primer
AAAATTGTGCCTTGGAGGAG
SEQ ID NO: 1152


 


ILT-2
NM_006669.1
Forward Primer
AGCCATCACTCTCAGTGCAG
SEQ ID NO: 1153




Probe
CAGGTCCTATCGTGGCCCCTGA
SEQ ID NO: 1154




Reverse Primer
ACTGCAGAGTCAGGGTCTCC
SEQ ID NO: 1155


 


IMP-1
NM_006546.2
Forward Primer
GAAAGTGTTTGCGGAGCAC
SEQ ID NO: 1156




Probe
CTCCTACAGCGGCCAGTTCTTGGT
SEQ ID NO: 1157




Reverse Primer
GAAGGCGTAGCCGGATTT
SEQ ID NO: 1158


 


IMP2
NM_006548.3
Forward Primer
CAATCTGATCCCAGGGTTGAA
SEQ ID NO: 1159




Probe
CTCAGCGCACTTGGCATCTTTTCAACA
SEQ ID NO: 1160




Reverse Primer
GGCCCTGCTGGTGGAGATA
SEQ ID NO: 1161


 


ING1L
NM_001564.1
Forward Primer
TGTTTCCAAGATCCTGCTGA
SEQ ID NO: 1162




Probe
CCATCTTTGCTTTATCTGAGGCTCGTTC
SEQ ID NO: 1163




Reverse Primer
TCTTTCTGGTTGGCTGGAAT
SEQ ID NO: 1164


 


ING5
NM_032329.4
Forward Primer
CCTACAGCAAGTGCAAGGAA
SEQ ID NO: 1165




Probe
CCAGCTGCACTTTGTCGTCACTGT
SEQ ID NO: 1166




Reverse Primer
CATCTCGTAGGTCTGCATGG
SEQ ID NO: 1167


 


INHA
NM_002191.2
Forward Primer
CCTCCCAGTTTCATCTTCCACTA
SEQ ID NO: 1168




Probe
ATGTGCAGCCCACAACCACCATGA
SEQ ID NO: 1169




Reverse Primer
AGGGACTGGAAGGGACAGGTT
SEQ ID NO: 1170


 


INHBA
NM_002192.1
Forward Primer
GTGCCCGAGCCATATAGCA
SEQ ID NO: 1171




Probe
ACGTCCGGGTCCTCACTGTCCTTCC
SEQ ID NO: 1172




Reverse Primer
CGGTAGTGGTTGATGACTGTTGA
SEQ ID NO: 1173


 


INHBB
NM_002193.1
Forward Primer
AGCCTCCAGGATACCAGCAA
SEQ ID NO: 1174




Probe
AGCTAAGCTGCCATTTGTCACCG
SEQ ID NO: 1175




Reverse Primer
TCTCCGACTGACAGGCATTTG
SEQ ID NO: 1176


 


IRS1
NM_005544.1
Forward Primer
CCACAGCTCACCTTCTGTCA
SEQ ID NO: 1177




Probe
TCCATCCCAGCTCCAGCCAG
SEQ ID NO: 1178




Reverse Primer
CCTCAGTGCCAGTCTCTTCC
SEQ ID NO: 1179


 


ITGA3
NM_002204.1
Forward Primer
CCATGATCCTCACTCTGCTG
SEQ ID NO: 1180




Probe
CACTCCAGACCTCGCTTAGCATGG
SEQ ID NO: 1181




Reverse Primer
GAAGCTTTGTAGCCGGTGAT
SEQ ID NO: 1182


 


ITGA4
NM_000885.2
Forward Primer
CAACGCTTCAGTGATCAATCC
SEQ ID NO: 1183




Probe
CGATCCTGCATCTGTAAATCGCCC
SEQ ID NO: 1184




Reverse Primer
GTCTGGCCGGGATTCTTT
SEQ ID NO: 1185


 


ITGA5
NM_002205.1
Forward Primer
AGGCCAGCCCTACATTATCA
SEQ ID NO: 1186




Probe
TCTGAGCCTTGTCCTCTATCCGGC
SEQ ID NO: 1187




Reverse Primer
GTCTTCTCCACAGTCCAGCA
SEQ ID NO: 1188


 


ITGA6
NM_000210.1
Forward Primer
CAGTGACAAACAGCCCTTCC
SEQ ID NO: 1189




Probe
TCGCCATCTTTTGTGGGATTCCTT
SEQ ID NO: 1190




Reverse Primer
GTTTAGCCTCATGGGCGTC
SEQ ID NO: 1191


 


ITGA7
NM_002206.1
Forward Primer
GATATGATTGGTCGCTGCTTTG
SEQ ID NO: 1192




Probe
CAGCCAGGACCTGGCCATCCG
SEQ ID NO: 1193




Reverse Primer
AGAACTTCCATTCCCCACCAT
SEQ ID NO: 1194


 


ITGAV
NM_002210.2
Forward Primer
ACTCGGACTGCACAAGCTATT
SEQ ID NO: 1195




Probe
CCGACAGCCACAGAATAACCCAAA
SEQ ID NO: 1196




Reverse Primer
TGCCATCACCATTGAAATCT
SEQ ID NO: 1197


 


ITGB1
NM_002211.2
Forward Primer
TCAGAATTGGATTTGGCTCA
SEQ ID NO: 1198




Probe
TGCTAATGTAAGGCATCACAGTCTTTTCCA
SEQ ID NO: 1199




Reverse Primer
CCTGAGCTTAGCTGGTGTTG
SEQ ID NO: 1200


 


ITGB3
NM_000212.1
Forward Primer
ACCGGGAGCCCTACATGAC
SEQ ID NO: 1201




Probe
AAATACCTGCAACCGTTACTGCCGTGAC
SEQ ID NO: 1202




Reverse Primer
CCTTAAGCTCTTTCACTGACTCAATCT
SEQ ID NO: 1203


 


ITGB4
NM_000213.2
Forward Primer
CAAGGTGCCCTCAGTGGA
SEQ ID NO: 1204




Probe
CACCAACCTGTACCCGTATTGCGA
SEQ ID NO: 1205




Reverse Primer
GCGCACACCTTCATCTCAT
SEQ ID NO: 1206


 


ITGB5
NM_002213.3
Forward Primer
TCGTGAAAGATGACCAGGAG
SEQ ID NO: 1207




Probe
TGCTATGTTTCTACAAAACCGCCAAGG
SEQ ID NO: 1208




Reverse Primer
GGTGAACATCATGACGCAGT
SEQ ID NO: 1209


 


K-ras
NM_033360.2
Forward Primer
GTCAAAATGGGGAGGGACTA
SEQ ID NO: 1210




Probe
TGTATCTTGTTGAGCTATCCAAACTGCCC
SEQ ID NO: 1211




Reverse Primer
CAGGACCACCACAGAGTGAG
SEQ ID NO: 1212


 


KCNH2 iso
NM_000238.2
Forward Primer
GAGCGCAAAGTGGAAATCG
SEQ ID NO: 1213


a/b

Probe
TAGGAAGCAGCTCCCATCTTTCCGGTA
SEQ ID NO: 1214




Reverse Primer
TCTTCACGGGCACCACATC
SEQ ID NO: 1215


 


KCNH2 iso
NM_172057.1
Forward Primer
TCCTGCTGCTGGTCATCTAC
SEQ ID NO: 1216


a/c

Probe
TGTCTTCACACCCTACTCGGCTGC
SEQ ID NO: 1217




Reverse Primer
CCTTCTTCCGTCTCCTTCAG
SEQ ID NO: 1218


 


KCNK4
NM_016611.2
Forward Primer
CCTATCAGCCGCTGGTGT
SEQ ID NO: 1219




Probe
ATCCTGCTCGGCCTGGCTTACTTC
SEQ ID NO: 1220




Reverse Primer
TGGTGGTGAGCACTGAGG
SEQ ID NO: 1221


 


KDR
NM_002253.1
Forward Primer
GAGGACGAAGGCCTCTACAC
SEQ ID NO: 1222




Probe
CAGGCATGCAGTGTTCTTGGCTGT
SEQ ID NO: 1223




Reverse Primer
AAAAATGCCTCCACTTTTGC
SEQ ID NO: 1224


 


Ki-67
NM_002417.1
Forward Primer
CGGACTTTGGGTGCGACTT
SEQ ID NO: 1225




Probe
CCACTTGTCGAACCACCGCTCGT
SEQ ID NO: 1226




Reverse Primer
TTACAACTCTTCCACTGGGACGAT
SEQ ID NO: 1227


 


KIAA0125
NM_014792.2
Forward Primer
GTGTCCTGGTCCATGTGGT
SEQ ID NO: 1228




Probe
CACGTGTCTCCACCTCCAAGGAGA
SEQ ID NO: 1229




Reverse Primer
GGGAGGTGCACACTGAGG
SEQ ID NO: 1230


 


KIF22
NM_007317.1
Forward Primer
CTAAGGCACTTGCTGGAAGG
SEQ ID NO: 1231




Probe
TCCATAGGCAAGCACACTGGCATT
SEQ ID NO: 1232




Reverse Primer
TCTTCCCAGCTCCTGTGG
SEQ ID NO: 1233


 


KIF2C
NM_006845.2
Forward Primer
AATTCCTGCTCCAAAAGAAAGTCTT
SEQ ID NO: 1234




Probe
AAGCCGCTCCACTCGCATGTCC
SEQ ID NO: 1235




Reverse Primer
CGTGATGCGAAGCTCTGAGA
SEQ ID NO: 1236


 


KIFC1
XM_371813.1
Forward Primer
CCACAGGGTTGAAGAACCAG
SEQ ID NO: 1237




Probe
AGCCAGTTCCTGCTGTTCCTGTCC
SEQ ID NO: 1238




Reverse Primer
CACCTGATGTGCCAGACTTC
SEQ ID NO: 1239


 


Kitlng
NM_000899.1
Forward Primer
GTCCCCGGGATGGATGTT
SEQ ID NO: 1240




Probe
CATCTCGCTTATCCAACAATGACTTGGCA
SEQ ID NO: 1241




Reverse Primer
GATCAGTCAAGCTGTCTGACAATTG
SEQ ID NO: 1242


 


KLF5
NM_001730.3
Forward Primer
GTGCAACCGCAGCTTCTC
SEQ ID NO: 1243




Probe
CTCTGACCACCTGGCCCTGCATAT
SEQ ID NO: 1244




Reverse Primer
CGGGCAGTGCTCAGTTCT
SEQ ID NO: 1245


 


KLF6
NM_001300.4
Forward Primer
CACGAGACCGGCTACTTCTC
SEQ ID NO: 1246




Probe
AGTACTCCTCCAGAGACGGCAGCG
SEQ ID NO: 1247




Reverse Primer
GCTCTAGGCAGGTCTGTTGC
SEQ ID NO: 1248


 


KLK10
NM_002776.1
Forward Primer
GCCCAGAGGCTCCATCGT
SEQ ID NO: 1249




Probe
CCTCTTCCTCCCCAGTCGGCTGA
SEQ ID NO: 1250




Reverse Primer
CAGAGGTTTGAACAGTGCAGACA
SEQ ID NO: 1251


 


KLK6
NM_002774.2
Forward Primer
GACGTGAGGGTCCTGATTCT
SEQ ID NO: 1252




Probe
TTACCCCAGCTCCATCCTTGCATC
SEQ ID NO: 1253




Reverse Primer
TCCTCACTCATCACGTCCTC
SEQ ID NO: 1254


 


KLRK1
NM_007360.1
Forward Primer
TGAGAGCCAGGCTTCTTGTA
SEQ ID NO: 1255




Probe
TGTCTCAAAATGCCAGCCTTCTGAA
SEQ ID NO: 1256




Reverse Primer
ATCCTGGTCCTCTTTGCTGT
SEQ ID NO: 1257


 


KNTC2
NM_006101.1
Forward Primer
ATGTGCCAGTGAGCTTGAGT
SEQ ID NO: 1258




Probe
CCTTGGAGAAACACAAGCACCTGC
SEQ ID NO: 1259




Reverse Primer
TGAGCCCCTGGTTAACAGTA
SEQ ID NO: 1260


 


KRAS2
NM_004985.3
Forward Primer
GAGACCAAGGTTGCAAGGC
SEQ ID NO: 1261




Probe
AAGCTCAAAGGTTCACACAGGGCC
SEQ ID NO: 1262




Reverse Primer
CAGTCCATGCTGTGAAACTCTC
SEQ ID NO: 1263


 


KRT19
NM_002276.1
Forward Primer
TGAGCGGCAGAATCAGGAGTA
SEQ ID NO: 1264




Probe
CTCATGGACATCAAGTCGCGGCTG
SEQ ID NO: 1265




Reverse Primer
TGCGGTAGGTGGCAATCTC
SEQ ID NO: 1266


 


KRT8
NM_002273.1
Forward Primer
GGATGAAGCTTACATGAACAAGGTAGA
SEQ ID NO: 1267




Probe
CGTCGGTCAGCCCTTCCAGGC
SEQ ID NO: 1268




Reverse Primer
CATATAGCTGCCTGAGGAAGTTGAT
SEQ ID NO: 1269


 


LAMA3
NM_000227.2
Forward Primer
CAGATGAGGCACATGGAGAC
SEQ ID NO: 1270




Probe
CTGATTCCTCAGGTCCTTGGCCTG
SEQ ID NO: 1271




Reverse Primer
TTGAAATGGCAGAACGGTAG
SEQ ID NO: 1272


 


LAMB3
NM_000228.1
Forward Primer
ACTGACCAAGCCTGAGACCT
SEQ ID NO: 1273




Probe
CCACTCGCCATACTGGGTGCAGT
SEQ ID NO: 1274




Reverse Primer
GTCACACTTGCAGCATTTCA
SEQ ID NO: 1275


 


LAMC2
NM_005562.1
Forward Primer
ACTCAAGCGGAAATTGAAGCA
SEQ ID NO: 1276




Probe
AGGTCTTATCAGCACAGTCTCCGCCTCC
SEQ ID NO: 1277




Reverse Primer
ACTCCCTGAAGCCGAGACACT
SEQ ID NO: 1278


 


LAT
NM_014387.2
Forward Primer
GTGAACGTTCCGGAGAGC
SEQ ID NO: 1279




Probe
ATCCAGAGACGCTTCTGCGCTCTC
SEQ ID NO: 1280




Reverse Primer
ACATTCACATACTCCCGGCT
SEQ ID NO: 1281


 


LCN2
NM_005564.2
Forward Primer
CGCTGGGCAACATTAAGAG
SEQ ID NO: 1282




Probe
TCACCACTCGGACGAGGTAACTCG
SEQ ID NO: 1283




Reverse Primer
AGCATGCTGGTTGTAGTTGGT
SEQ ID NO: 1284


 


LDLRAP1
NM_015627.1
Forward Primer
CAGTGCCTCTCGCCTGTC
SEQ ID NO: 1285




Probe
ACTGGGACAAGCCTGACAGCAGC
SEQ ID NO: 1286




Reverse Primer
TGAAGAGGTCATCCTGCTCTG
SEQ ID NO: 1287


 


LEF
NM_016269.2
Forward Primer
GATGACGGAAAGCATCCAG
SEQ ID NO: 1288




Probe
TGGAGGCCTCTACAACAAGGGACC
SEQ ID NO: 1289




Reverse Primer
CCCGGAATAACTCGAGTAGGA
SEQ ID NO: 1290


 


LGALS3
NM_002306.1
Forward Primer
AGCGGAAAATGGCAGACAAT
SEQ ID NO: 1291




Probe
ACCCAGATAACGCATCATGGAGCGA
SEQ ID NO: 1292




Reverse Primer
CTTGAGGGTTTGGGTTTCCA
SEQ ID NO: 1293


 


LGMN
NM_001008530.1
Forward Primer
TTGGTGCCGTTCCTATAGATG
SEQ ID NO: 1294




Probe
CAGTGCTTGCCTCCATCTTCAGGA
SEQ ID NO: 1295




Reverse Primer
GAACCTGCCACGATCACC
SEQ ID NO: 1296


 


LILRB3
NM_006864.1
Forward Primer
CACCTGGTCTGGGAAGATACC
SEQ ID NO: 1297




Probe
ACCGAGACCCCAATCAAAACCTCC
SEQ ID NO: 1298




Reverse Primer
AAGAGCAGCAGGACGAAGG
SEQ ID NO: 1299


 


LMNB1
NM_005573.1
Forward Primer
TGCAAACGCTGGTGTCACA
SEQ ID NO: 1300




Probe
CAGCCCCCCAACTGACCTCATC
SEQ ID NO: 1301




Reverse Primer
CCCCACGAGTTCTGGTTCTTC
SEQ ID NO: 1302


 


LMYC
NM_012421.1
Forward Primer
CCCATCCAGAACACTGATTG
SEQ ID NO: 1303




Probe
TGACCTCCATCCCTTTCACTTGAATG
SEQ ID NO: 1304




Reverse Primer
CTGCTTTCTATGCACCCTTTC
SEQ ID NO: 1305


 


LOX
NM_002317.3
Forward Primer
CCAATGGGAGAACAACGG
SEQ ID NO: 1306




Probe
CAGGCTCAGCAAGCTGAACACCTG
SEQ ID NO: 1307




Reverse Primer
CGCTGAGGCTGGTACTGTG
SEQ ID NO: 1308


 


LOXL2
NM_002318.1
Forward Primer
TCAGCGGGCTCTTAAACAA
SEQ ID NO: 1309




Probe
CAGCTGTCCCCGCAGTAAAGAAGC
SEQ ID NO: 1310




Reverse Primer
AAGACAGGAGTTGACCACGC
SEQ ID NO: 1311


 


LRP5
NM_002335.1
Forward Primer
CGACTATGACCCACTGGACA
SEQ ID NO: 1312




Probe
CGCCCATCCACCCAGTAGATGAAC
SEQ ID NO: 1313




Reverse Primer
CTTGGCTCGCTTGATGTTC
SEQ ID NO: 1314


 


LRP6
NM_002336.1
Forward Primer
GGATGTAGCCATCTCTGCCT
SEQ ID NO: 1315




Probe
ATAGACCTCAGGGCCTTCGCTGTG
SEQ ID NO: 1316




Reverse Primer
AGTTCAAAGCCAATAGGGCA
SEQ ID NO: 1317


 


LY6D
NM_003695.2
Forward Primer
AATGCTGATGACTTGGAGCAG
SEQ ID NO: 1318




Probe
CACAGACCCCACAGAGGATGAAGC
SEQ ID NO: 1319




Reverse Primer
CTGCATCCTCTGTGGGGT
SEQ ID NO: 1320


 


MAD
NM_002357.1
Forward Primer
TGGTTCTGATTAGGTAACGTATTGGA
SEQ ID NO: 1321




Probe
CTGCCCACAACTCCCTTGCACGTAA
SEQ ID NO: 1322




Reverse Primer
GGTCAAGGTGGGACACTGAAG
SEQ ID NO: 1323


 


MAD1L1
NM_003550.1
Forward Primer
AGAAGCTGTCCCTGCAAGAG
SEQ ID NO: 1324




Probe
CATGTTCTTCACAATCGCTGCATCC
SEQ ID NO: 1325




Reverse Primer
AGCCGTACCAGCTCAGACTT
SEQ ID NO: 1326


 


MAD2L1
NM_002358.2
Forward Primer
CCGGGAGCAGGGAATCAC
SEQ ID NO: 1327




Probe
CGGCCACGATTTCGGCGCT
SEQ ID NO: 1328




Reverse Primer
ATGCTGTTGATGCCGAATGA
SEQ ID NO: 1329


 


MADH2
NM_005901.2
Forward Primer
GCTGCCTTTGGTAAGAACATGTC
SEQ ID NO: 1330




Probe
TCCATCTTGCCATTCACGCCGC
SEQ ID NO: 1331




Reverse Primer
ATCCCAGCAGTCTCTTCACAACT
SEQ ID NO: 1332


 


MADH4
NM_005359.3
Forward Primer
GGACATTACTGGCCTGTTCACA
SEQ ID NO: 1333




Probe
TGCATTCCAGCCTCCCATTTCCA
SEQ ID NO: 1334




Reverse Primer
ACCAATACTCAGGAGCAGGATGA
SEQ ID NO: 1335


 


MADH7
NM_005904.1
Forward Primer
TCCATCAAGGCTTTCGACTA
SEQ ID NO: 1336




Probe
CTGCAGGCTGTACGCCTTCTCG
SEQ ID NO: 1337




Reverse Primer
CTGCTGCATAAACTCGTGGT
SEQ ID NO: 1338


 


MAP2
NM_031846.1
Forward Primer
CGGACCACCAGGTCAGAG
SEQ ID NO: 1339




Probe
CCACTCTTCCCTGCTCTGCGAATT
SEQ ID NO: 1340




Reverse Primer
CAGGGGTAGTGGGTGTTGAG
SEQ ID NO: 1341


 


MAP2K1
NM_002755.2
Forward Primer
GCCTTTCTTACCCAGAAGCAGAA
SEQ ID NO: 1342




Probe
TCTCAAAGTCGTCATCCTTCAGTTCTCCCA
SEQ ID NO: 1343




Reverse Primer
CAGCCCCCAGCTCACTGAT
SEQ ID NO: 1344


 


MAP3K1
XM_042066.8
Forward Primer
GGTTGGCATCAAAAGGAACT
SEQ ID NO: 1345




Probe
AATTGTCCCTGAAACTCTCCTGCACC
SEQ ID NO: 1346




Reverse Primer
TGCCATAAATGCAATTGTCC
SEQ ID NO: 1347


 


MAPK14
NM_139012.1
Forward Primer
TGAGTGGAAAAGCCTGACCTATG
SEQ ID NO: 1348




Probe
TGAAGTCATCAGCTTTGTGCCACCACC
SEQ ID NO: 1349




Reverse Primer
GGACTCCATCTCTTCTTGGTCAA
SEQ ID NO: 1350


 


Maspin
NM_002639.1
Forward Primer
CAGATGGCCACTTTGAGAACATT
SEQ ID NO: 1351




Probe
AGCTGACAACAGTGTGAACGACCAGACC
SEQ ID NO: 1352




Reverse Primer
GGCAGCATTAACCACAAGGATT
SEQ ID NO: 1353


 


MAX
NM_002382.3
Forward Primer
CAAACGGGCTCATCATAATGC
SEQ ID NO: 1354




Probe
TGATGTGGTCCCTACGTTTTCGTTCCA
SEQ ID NO: 1355




Reverse Primer
TCCCGCAAACTGTGAAAGCT
SEQ ID NO: 1356


 


MCM2
NM_004526.1
Forward Primer
GACTTTTGCCCGCTACCTTTC
SEQ ID NO: 1357




Probe
ACAGCTCATTGTTGTCACGCCGGA
SEQ ID NO: 1358




Reverse Primer
GCCACTAACTGCTTCAGTATGAAGAG
SEQ ID NO: 1359


 


MCM3
NM_002388.2
Forward Primer
GGAGAACAATCCCCTTGAGA
SEQ ID NO: 1360




Probe
TGGCCTTTCTGTCTACAAGGATCACCA
SEQ ID NO: 1361




Reverse Primer
ATCTCCTGGATGGTGATGGT
SEQ ID NO: 1362


 


MCM6
NM_005915.2
Forward Primer
TGATGGTCCTATGTGTCACATTCA
SEQ ID NO: 1363




Probe
CAGGTTTCATACCAACACAGGCTTCAGCAC
SEQ ID NO: 1364




Reverse Primer
TGGGACAGGAAACACACCAA
SEQ ID NO: 1365


 


MCP1
NM_002982.1
Forward Primer
CGCTCAGCCAGATGCAATC
SEQ ID NO: 1366




Probe
TGCCCCAGTCACCTGCTGTTA
SEQ ID NO: 1367




Reverse Primer
GCACTGAGATCTTCCTATTGGTGAA
SEQ ID NO: 1368


 


MDK
NM_002391.2
Forward Primer
GGAGCCGACTGCAAGTACA
SEQ ID NO: 1369




Probe
ATCACACGCACCCCAGTTCTCAAA
SEQ ID NO: 1370




Reverse Primer
GACTTTGGTGCCTGTGCC
SEQ ID NO: 1371


 


MDM2
NM_002392.1
Forward Primer
CTACAGGGACGCCATCGAA
SEQ ID NO: 1372




Probe
CTTACACCAGCATCAAGATCCGG
SEQ ID NO: 1373




Reverse Primer
ATCCAACCAATCACCTGAATGTT
SEQ ID NO: 1374


 


MGAT5
NM_002410.2
Forward Primer
GGAGTCGAAGGTGGACAATC
SEQ ID NO: 1375




Probe
AATGGCACCGGAACAAACTCAACC
SEQ ID NO: 1376




Reverse Primer
TGGGAACAGCTGTAGTGGAGT
SEQ ID NO: 1377


 


MGMT
NM_002412.1
Forward Primer
GTGAAATGAAACGCACCACA
SEQ ID NO: 1378




Probe
CAGCCCTTTGGGGAAGCTGG
SEQ ID NO: 1379




Reverse Primer
GACCCTGCTCACAACCAGAC
SEQ ID NO: 1380


 


mGST1
NM_020300.2
Forward Primer
ACGGATCTACCACACCATTGC
SEQ ID NO: 1381




Probe
TTTGACACCCCTTCCCCAGCCA
SEQ ID NO: 1382




Reverse Primer
TCCATATCCAACAAAAAAACTCAAAG
SEQ ID NO: 1383


 


MMP1
NM_002421.2
Forward Primer
GGGAGATCATCGGGACAACTC
SEQ ID NO: 1384




Probe
AGCAAGATTTCCTCCAGGTCCATCAAAAGG
SEQ ID NO: 1385




Reverse Primer
GGGCCTGGTTGAAAAGCAT
SEQ ID NO: 1386


 


MMP12
NM_002426.1
Forward Primer
CCAACGCTTGCCAAATCCT
SEQ ID NO: 1387




Probe
AACCAGCTCTCTGTGACCCCAATT
SEQ ID NO: 1388




Reverse Primer
ACGGTAGTGACAGCATCAAAACTC
SEQ ID NO: 1389


 


MMP2
NM_004530.1
Forward Primer
CCATGATGGAGAGGCAGACA
SEQ ID NO: 1390




Probe
CTGGGAGCATGGCGATGGATACCC
SEQ ID NO: 1391




Reverse Primer
GGAGTCCGTCCTTACCGTCAA
SEQ ID NO: 1392


 


MMP7
NM_002423.2
Forward Primer
GGATGGTAGCAGTCTAGGGATTAACT
SEQ ID NO: 1393




Probe
CCTGTATGCTGCAACTCATGAACTTGGC
SEQ ID NO: 1394




Reverse Primer
GGAATGTCCCATACCCAAAGAA
SEQ ID NO: 1395


 


MMP9
NM_004994.1
Forward Primer
GAGAACCAATCTCACCGACA
SEQ ID NO: 1396




Probe
ACAGGTATTCCTCTGCCAGCTGCC
SEQ ID NO: 1397




Reverse Primer
CACCCGAGTGTAACCATAGC
SEQ ID NO: 1398


 


MRP1
NM_004996.2
Forward Primer
TCATGGTGCCCGTCAATG
SEQ ID NO: 1399




Probe
ACCTGATACGTCTTGGTCTTCATCGCCAT
SEQ ID NO: 1400




Reverse Primer
CGATTGTCTTTGCTCTTCATGTG
SEQ ID NO: 1401


 


MRP2
NM_000392.1
Forward Primer
AGGGGATGACTTGGACACAT
SEQ ID NO: 1402




Probe
CTGCCATTCGACATGACTGCAATTT
SEQ ID NO: 1403




Reverse Primer
AAAACTGCATGGCTTTGTCA
SEQ ID NO: 1404


 


MRP3
NM_003786.2
Forward Primer
TCATCCTGGCGATCTACTTCCT
SEQ ID NO: 1405




Probe
TCTGTCCTGGCTGGAGTCGCTTTCAT
SEQ ID NO: 1406




Reverse Primer
CCGTTGAGTGGAATCAGCAA
SEQ ID NO: 1407


 


MRP4
NM_005845.1
Forward Primer
AGCGCCTGGAATCTACAACT
SEQ ID NO: 1408




Probe
CGGAGTCCAGTGTTTTCCCACTTG
SEQ ID NO: 1409




Reverse Primer
AGAGCCCCTGGAGAGAAGAT
SEQ ID NO: 1410


 


MRPL40
NM_003776.2
Forward Primer
ACTTGCAGGCTGCTATCCTT
SEQ ID NO: 1411




Probe
TTCCTACTCTCAGGGGCAGCATGTT
SEQ ID NO: 1412




Reverse Primer
AGCAGACTTGAACCCTGGTC
SEQ ID NO: 1413


 


MSH2
NM_000251.1
Forward Primer
GATGCAGAATTGAGGCAGAC
SEQ ID NO: 1414




Probe
CAAGAAGATTTACTTCGTCGATTCCCAGA
SEQ ID NO: 1415




Reverse Primer
TCTTGGCAAGTCGGTTAAGA
SEQ ID NO: 1416


 


MSH3
NM_002439.1
Forward Primer
TGATTACCATCATGGCTCAGA
SEQ ID NO: 1417




Probe
TCCCAATTGTCGCTTCTTCTGCAG
SEQ ID NO: 1418




Reverse Primer
CTTGTGAAAATGCCATCCAC
SEQ ID NO: 1419


 


MSH6
NM_000179.1
Forward Primer
TCTATTGGGGGATTGGTAGG
SEQ ID NO: 1420




Probe
CCGTTACCAGCTGGAAATTCCTGAGA
SEQ ID NO: 1421




Reverse Primer
CAAATTGCGAGTGGTGAAAT
SEQ ID NO: 1422


 


MT3
NM_005954.1
Forward Primer
GTGTGAGAAGTGTGCCAAGG
SEQ ID NO: 1423




Probe
CTCTCCGCCTTTGCACACACAGT
SEQ ID NO: 1424




Reverse Primer
CTGCACTTCTCTGCTTCTGC
SEQ ID NO: 1425


 


MTA1
NM_004689.2
Forward Primer
CCGCCCTCACCTGAAGAGA
SEQ ID NO: 1426




Probe
CCCAGTGTCCGCCAAGGAGCG
SEQ ID NO: 1427




Reverse Primer
GGAATAAGTTAGCCGCGCTTCT
SEQ ID NO: 1428


 


MUC1
NM_002456.1
Forward Primer
GGCCAGGATCTGTGGTGGTA
SEQ ID NO: 1429




Probe
CTCTGGCCTTCCGAGAAGGTACC
SEQ ID NO: 1430




Reverse Primer
CTCCACGTCGTGGACATTGA
SEQ ID NO: 1431


 


MUC2
NM_002457.1
Forward Primer
CTATGAGCCATGTGGGAACC
SEQ ID NO: 1432




Probe
AGCTTCGAGACCTGCAGGACCATC
SEQ ID NO: 1433




Reverse Primer
ATGTTGGAGTGGATGCCG
SEQ ID NO: 1434


 


MUC5B
XM_039877.11
Forward Primer
TGCCCTTGCACTGTCCTAA
SEQ ID NO: 1435




Probe
TCAGCCATCCTGCACACCTACACC
SEQ ID NO: 1436




Reverse Primer
CAGCCACACTCATCCACG
SEQ ID NO: 1437


 


MUTYH
NM_012222.1
Forward Primer
GTACGACCAAGAGAAACGGG
SEQ ID NO: 1438




Probe
TCTGCCCGTCTTCTCCATGGTAGG
SEQ ID NO: 1439




Reverse Primer
CCTGTCCAGGTCCATCTCA
SEQ ID NO: 1440


 


MVP
NM_017458.1
Forward Primer
ACGAGAACGAGGGCATCTATGT
SEQ ID NO: 1441




Probe
CGCACCTTTCCGGTCTTGACATCCT
SEQ ID NO: 1442




Reverse Primer
GCATGTAGGTGCTTCCAATCAC
SEQ ID NO: 1443


 


MX1
NM_002462.2
Forward Primer
GAAGGAATGGGAATCAGTCATGA
SEQ ID NO: 1444




Probe
TCACCCTGGAGATCAGCTCCCGA
SEQ ID NO: 1445




Reverse Primer
GTCTATTAGAGTCAGATCCGGGACAT
SEQ ID NO: 1446


 


MXD4
NM_006454.2
Forward Primer
AGAAACTGGAGGAGCAGGAC
SEQ ID NO: 1447




Probe
TGCAGCTGCTCCTTGATGCTCAGT
SEQ ID NO: 1448




Reverse Primer
CTTCAGGAAACGATGCTCCT
SEQ ID NO: 1449


 


MYBL2
NM_002466.1
Forward Primer
GCCGAGATCGCCAAGATG
SEQ ID NO: 1450




Probe
CAGCATTGTCTGTCCTCCCTGGCA
SEQ ID NO: 1451




Reverse Primer
CTTTTGATGGTAGAGTTCCAGTGATTC
SEQ ID NO: 1452


 


MYH11
NM_002474.1
Forward Primer
CGGTACTTCTCAGGGCTAATATATACG
SEQ ID NO: 1453




Probe
CTCTTCTGCGTGGTGGTCAACCCCTA
SEQ ID NO: 1454




Reverse Primer
CCGAGTAGATGGGCAGGTGTT
SEQ ID NO: 1455


 


MYLK
NM_053025.1
Forward Primer
TGACGGAGCGTGAGTGCAT
SEQ ID NO: 1456




Probe
CCCTCCGAGATCTGCCGCATGTACT
SEQ ID NO: 1457




Reverse Primer
ATGCCCTGCTTGTGGATGTAC
SEQ ID NO: 1458


 


NAT2
NM_000015.1
Forward Primer
TAACTGACATTCTTGAGCACCAGAT
SEQ ID NO: 1459




Probe
CGGGCTGTTCCCTTTGAGAACCTTAACA
SEQ ID NO: 1460




Reverse Primer
ATGGCTTGCCCACAATGC
SEQ ID NO: 1461


 


NAV2
NM_182964.3
Forward Primer
CTCTCCCAGCACAGCTTGA
SEQ ID NO: 1462




Probe
CCTCACTGAGTCAACCAGCCTGGA
SEQ ID NO: 1463




Reverse Primer
CACCAGTGTCATCCAGCAAC
SEQ ID NO: 1464


 


NCAM1
NM_000615.1
Forward Primer
TAGTTCCCAGCTGACCATCA
SEQ ID NO: 1465




Probe
CTCAGCCTCGTCGTTCTTATCCACC
SEQ ID NO: 1466




Reverse Primer
CAGCCTTGTTCTCAGCAATG
SEQ ID NO: 1467


 


NDE1
NM_017668.1
Forward Primer
CTACTGCGGAAAGTCGGG
SEQ ID NO: 1468




Probe
CTGGAGTCCAAACTCGCTTCCTGC
SEQ ID NO: 1469




Reverse Primer
GGACTGATCGTACACGAGGTT
SEQ ID NO: 1470


 


NDRG1
NM_006096.2
Forward Primer
AGGGCAACATTCCACAGC
SEQ ID NO: 1471




Probe
CTGCAAGGACACTCATCACAGCCA
SEQ ID NO: 1472




Reverse Primer
CAGTGCTCCTACTCCGGC
SEQ ID NO: 1473


 


NDUFS3
NM_004551.1
Forward Primer
TATCCATCCTGATGGCGTC
SEQ ID NO: 1474




Probe
CCCAGTGCTGACTTTCCTCAGGGA
SEQ ID NO: 1475




Reverse Primer
TTGAACTGTGCATTGGTGTG
SEQ ID NO: 1476


 


NEDD8
NM_006156.1
Forward Primer
TGCTGGCTACTGGGTGTTAGT
SEQ ID NO: 1477




Probe
TGCAGTCCTGTGTGCTTCCCTCTC
SEQ ID NO: 1478




Reverse Primer
GACAACCAGGGACACAGTCA
SEQ ID NO: 1479


 


NEK2
NM_002497.1
Forward Primer
GTGAGGCAGCGCGACTCT
SEQ ID NO: 1480




Probe
TGCCTTCCCGGGCTGAGGACT
SEQ ID NO: 1481




Reverse Primer
TGCCAATGGTGTACAACACTTCA
SEQ ID NO: 1482


 


NF2
NM_000268.2
Forward Primer
ACTCCAGAGCTGACCTCCAC
SEQ ID NO: 1483




Probe
CTACAATGACTTCCCAGGCTGGGC
SEQ ID NO: 1484




Reverse Primer
TCAGGGCTTCAGTGTCTCAC
SEQ ID NO: 1485


 


NFKBp50
NM_003998.1
Forward Primer
CAGACCAAGGAGATGGACCT
SEQ ID NO: 1486




Probe
AAGCTGTAAACATGAGCCGCACCA
SEQ ID NO: 1487




Reverse Primer
AGCTGCCAGTGCTATCCG
SEQ ID NO: 1488


 


NFKBp65
NM_021975.1
Forward Primer
CTGCCGGGATGGCTTCTAT
SEQ ID NO: 1489




Probe
CTGAGCTCTGCCCGGACCGCT
SEQ ID NO: 1490




Reverse Primer
CCAGGTTCTGGAAACTGTGGAT
SEQ ID NO: 1491


 


NISCH
NM_007184.1
Forward Primer
CCAAGGAATCATGTTCGTTCAG
SEQ ID NO: 1492




Probe
TGGCCAGCAGCCTCTCGTCCAC
SEQ ID NO: 1493




Reverse Primer
TGGTGCTCGGGAGTCAGACT
SEQ ID NO: 1494


 


Nkd-1
NM_033119.3
Forward Primer
GAGAGAGTGAGCGAACCCTG
SEQ ID NO: 1495




Probe
CCAGGCTCCAAGAAGCAGCTGAAG
SEQ ID NO: 1496




Reverse Primer
CGTCGCACTGGAGCTCTT
SEQ ID NO: 1497


 


NMB
NM_021077.1
Forward Primer
GGCTGCTGGTACAAATACTGC
SEQ ID NO: 1498




Probe
TGTCTGCCCCTATTATTGGTGTCATTTCT
SEQ ID NO: 1499




Reverse Primer
CAATCTAAGCCACGCTGTTG
SEQ ID NO: 1500


 


NMBR
NM_002511.1
Forward Primer
TGATCCATCTCTAGGCCACA
SEQ ID NO: 1501




Probe
TTGTCACCTTAGTTGCCCGGGTTC
SEQ ID NO: 1502




Reverse Primer
GAGCAAATGGGTTGACACAA
SEQ ID NO: 1503


 


NME1
NM_000269.1
Forward Primer
CCAACCCTGCAGACTCCAA
SEQ ID NO: 1504




Probe
CCTGGGACCATCCGTGGAGACTTCT
SEQ ID NO: 1505




Reverse Primer
ATGTATAATGTTCCTGCCAACTTGTATG
SEQ ID NO: 1506


 


NOS3
NM_000603.2
Forward Primer
ATCTCCGCCTCGCTCATG
SEQ ID NO: 1507




Probe
TTCACTCGCTTCGCCATCACCG
SEQ ID NO: 1508




Reverse Primer
TCGGAGCCATACAGGATTGTC
SEQ ID NO: 1509


 


NOTCH1
NM_017617.2
Forward Primer
CGGGTCCACCAGTTTGAATG
SEQ ID NO: 1510




Probe
CCGCTCTGCAGCCGGGACA
SEQ ID NO: 1511




Reverse Primer
GTTGTATTGGTTCGGCACCAT
SEQ ID NO: 1512


 


NOTCH2
NM_024408.2
Forward Primer
CACTTCCCTGCTGGGATTAT
SEQ ID NO: 1513




Probe
CCGTGTTGCACAGCTCATCACACT
SEQ ID NO: 1514




Reverse Primer
AGTTGTCAAACAGGCACTCG
SEQ ID NO: 1515


 


NPM1
NM_002520.2
Forward Primer
AATGTTGTCCAGGTTCTATTGC
SEQ ID NO: 1516




Probe
AACAGGCATTTTGGACAACACATTCTTG
SEQ ID NO: 1517




Reverse Primer
CAAGCAAAGGGTGGAGTTC
SEQ ID NO: 1518


 


NR4A1
NM_002135.2
Forward Primer
CACAGCTTGCTTGTCGATGTC
SEQ ID NO: 1519




Probe
CCTTCGCCTGCCTCTCTGCCC
SEQ ID NO: 1520




Reverse Primer
ATGCCGGTCGGTGATGAG
SEQ ID NO: 1521


 


NRG1
NM_013957.1
Forward Primer
CGAGACTCTCCTCATAGTGAAAGGTAT
SEQ ID NO: 1522




Probe
ATGACCACCCCGGCTCGTATGTCA
SEQ ID NO: 1523




Reverse Primer
CTTGGCGTGTGGAAATCTACAG
SEQ ID NO: 1524


 


NRP1
NM_003873.1
Forward Primer
CAGCTCTCTCCACGCGATTC
SEQ ID NO: 1525




Probe
CAGGATCTACCCCGAGAGAGCCACTCAT
SEQ ID NO: 1526




Reverse Primer
CCCAGCAGCTCCATTCTGA
SEQ ID NO: 1527


 


NRP2
NM_003872.1
Forward Primer
CTACAGCCTAAACGGCAAGG
SEQ ID NO: 1528




Probe
AGGACCCCAGGACCCAGCAG
SEQ ID NO: 1529




Reverse Primer
GTTCCCTTCGAACAGCTTTG
SEQ ID NO: 1530


 


NTN1
NM_004822.1
Forward Primer
AGAAGGACTATGCCGTCCAG
SEQ ID NO: 1531




Probe
ATCCACATCCTGAAGGCGGACAAG
SEQ ID NO: 1532




Reverse Primer
CCGTGAACTTCCACCAGTC
SEQ ID NO: 1533


 


NUFIP1
NM_012345.1
Forward Primer
GCTTCCACATCGTGGTATTG
SEQ ID NO: 1534




Probe
CTTCTGATAGGTTTCCTCGGCATCAGA
SEQ ID NO: 1535




Reverse Primer
AACTGCAGGGTTGAAGGACT
SEQ ID NO: 1536


 


ODC1
NM_002539.1
Forward Primer
AGAGATCACCGGCGTAATCAA
SEQ ID NO: 1537




Probe
CCAGCGTTGGACAAATACTTTCCGTCA
SEQ ID NO: 1538




Reverse Primer
CGGGCTCAGCTATGATTCTCA
SEQ ID NO: 1539


 


OPN,
NM_000582.1
Forward Primer
CAACCGAAGTTTTCACTCCAGTT
SEQ ID NO: 1540


osteopontin

Probe
TCCCCACAGTAGACACATATGATGGCCG
SEQ ID NO: 1541




Reverse Primer
CCTCAGTCCATAAACCACACTATCA
SEQ ID NO: 1542


 


ORC1L
NM_004153.2
Forward Primer
TCCTTGACCATACCGGAGG
SEQ ID NO: 1543




Probe
TGCATGTACATCTCCGGTGTCCCT
SEQ ID NO: 1544




Reverse Primer
CAGTGGCAGTCTTCCCTGTC
SEQ ID NO: 1545


 


OSM
NM_020530.3
Forward Primer
GTTTCTGAAGGGGAGGTCAC
SEQ ID NO: 1546




Probe
CTGAGCTGGCCTCCTATGCCTCAT
SEQ ID NO: 1547




Reverse Primer
AGGTGTCTGGTTTGGGACA
SEQ ID NO: 1548


 


OSMR
NM_003999.1
Forward Primer
GCTCATCATGGTCATGTGCT
SEQ ID NO: 1549




Probe
CAGGTCTCCTTGATCCACTGACTTTTCA
SEQ ID NO: 1550




Reverse Primer
TGTAAGGGTCAGGGATGTCA
SEQ ID NO: 1551


 


P14ARF
S78535.1
Forward Primer
CCCTCGTGCTGATGCTACT
SEQ ID NO: 1552




Probe
CTGCCCTAGACGCTGGCTCCTC
SEQ ID NO: 1553




Reverse Primer
CATCATGACCTGGTCTTCTAGG
SEQ ID NO: 1554


 


p16-INK4
L27211.1
Forward Primer
GCGGAAGGTCCCTCAGACA
SEQ ID NO: 1555




Probe
CTCAGAGCCTCTCTGGTTCTTTCAATCGG
SEQ ID NO: 1556




Reverse Primer
TGATGATCTAAGTTTCCCGAGGTT
SEQ ID NO: 1557


 


p21
NM_000389.1
Forward Primer
TGGAGACTCTCAGGGTCGAAA
SEQ ID NO: 1558




Probe
CGGCGGCAGACCAGCATGAC
SEQ ID NO: 1559




Reverse Primer
GGCGTTTGGAGTGGTAGAAATC
SEQ ID NO: 1560


 


p27
NM_004064.1
Forward Primer
CGGTGGACCACGAAGAGTTAA
SEQ ID NO: 1561




Probe
CCGGGACTTGGAGAAGCACTGCA
SEQ ID NO: 1562




Reverse Primer
GGCTCGCCTCTTCCATGTC
SEQ ID NO: 1563


 


P53
NM_000546.2
Forward Primer
CTTTGAACCCTTGCTTGCAA
SEQ ID NO: 1564




Probe
AAGTCCTGGGTGCTTCTGACGCACA
SEQ ID NO: 1565




Reverse Primer
CCCGGGACAAAGCAAATG
SEQ ID NO: 1566


 


p53R2
AB036063.1
Forward Primer
CCCAGCTAGTGTTCCTCAGA
SEQ ID NO: 1567




Probe
TCGGCCAGCTTTTTCCAATCTTTG
SEQ ID NO: 1568




Reverse Primer
CCGTAAGCCCTTCCTCTATG
SEQ ID NO: 1569


 


PADI4
NM_012387.1
Forward Primer
AGCAGTGGCTTGCTTTCTTC
SEQ ID NO: 1570




Probe
CCTGTGATGTCCCAGTTTCCCACTC
SEQ ID NO: 1571




Reverse Primer
TGCTAGGACCATGTTGGGAT
SEQ ID NO: 1572


 


PAI1
NM_000602.1
Forward Primer
CCGCAACGTGGTTTTCTCA
SEQ ID NO: 1573




Probe
CTCGGTGTTGGCCATGCTCCAG
SEQ ID NO: 1574




Reverse Primer
TGCTGGGTTTCTCCTCCTGTT
SEQ ID NO: 1575


 


Pak1
NM_002576.3
Forward Primer
GAGCTGTGGGTTGTTATGGA
SEQ ID NO: 1576




Probe
ACATCTGTCAAGGAGCCTCCAGCC
SEQ ID NO: 1577




Reverse Primer
CCATGCAAGTTTCTGTCACC
SEQ ID NO: 1578


 


PARC
NM_015089.1
Forward Primer
GGAGCTGACCTGCTTCCTAC
SEQ ID NO: 1579




Probe
TCCTTATGCATCGAGGCCAGGC
SEQ ID NO: 1580




Reverse Primer
AGCAGAGCACCACAGCATAG
SEQ ID NO: 1581


 


PCAF
NM_003884.3
Forward Primer
AGGTGGCTGTGTTACTGCAA
SEQ ID NO: 1582




Probe
TGCCACAGTTCTGCGACAGTCTACC
SEQ ID NO: 1583




Reverse Primer
CACCTGTGTGGTTTCGTACC
SEQ ID NO: 1584


 


PCNA
NM_002592.1
Forward Primer
GAAGGTGTTGGAGGCACTCAAG
SEQ ID NO: 1585




Probe
ATCCCAGCAGGCCTCGTTGATGAG
SEQ ID NO: 1586




Reverse Primer
GGTTTACACCGCTGGAGCTAA
SEQ ID NO: 1587


 


PDGFA
NM_002607.2
Forward Primer
TTGTTGGTGTGCCCTGGTG
SEQ ID NO: 1588




Probe
TGGTGGCGGTCACTCCCTCTGC
SEQ ID NO: 1589




Reverse Primer
TGGGTTCTGTCCAAACACTGG
SEQ ID NO: 1590


 


PDGFB
NM_002608.1
Forward Primer
ACTGAAGGAGACCCTTGGAG
SEQ ID NO: 1591




Probe
TCTCCTGCCGATGCCCCTAGG
SEQ ID NO: 1592




Reverse Primer
TAAATAACCCTGCCCACACA
SEQ ID NO: 1593


 


PDGFC
NM_016205.1
Forward Primer
AGTTACTAAAAAATACCACGAGGTCCTT
SEQ ID NO: 1594




Probe
CCCTGACACCGGTCTTTGGTCTCAACT
SEQ ID NO: 1595




Reverse Primer
GTCGGTGAGTGATTTGTGCAA
SEQ ID NO: 1596


 


PDGFD
NM_025208.2
Forward Primer
TATCGAGGCAGGTCATACCA
SEQ ID NO: 1597




Probe
TCCAGGTCAACTTTTGACTTCCGGT
SEQ ID NO: 1598




Reverse Primer
TAACGCTTGGCATCATCATT
SEQ ID NO: 1599


 


PDGFRa
NM_006206.2
Forward Primer
GGGAGTTTCCAAGAGATGGA
SEQ ID NO: 1600




Probe
CCCAAGACCCGACCAAGCACTAG
SEQ ID NO: 1601




Reverse Primer
CTTCAACCACCTTCCCAAAC
SEQ ID NO: 1602


 


PDGFRb
NM_002609.2
Forward Primer
CCAGCTCTCCTTCCAGCTAC
SEQ ID NO: 1603




Probe
ATCAATGTCCCTGTCCGAGTGCTG
SEQ ID NO: 1604




Reverse Primer
GGGTGGCTCTCACTTAGCTC
SEQ ID NO: 1605


 


PFN1
NM_005022.2
Forward Primer
GGAAAACGTTCGTCAACATC
SEQ ID NO: 1606




Probe
CAACCAGGACACCCACCTCAGCT
SEQ ID NO: 1607




Reverse Primer
AAAACTTGACCGGTCTTTGC
SEQ ID NO: 1608


 


PFN2
NM_053024.1
Forward Primer
TCTATACGTCGATGGTGACTGC
SEQ ID NO: 1609




Probe
CTCCCCACCTTGACTCTTTGTCCG
SEQ ID NO: 1610




Reverse Primer
GCCGACAGCCACATTGTAT
SEQ ID NO: 1611


 


PGK1
NM_000291.1
Forward Primer
AGAGCCAGTTGCTGTAGAACTCAA
SEQ ID NO: 1612




Probe
TCTCTGCTGGGCAAGGATGTTCTGTTC
SEQ ID NO: 1613




Reverse Primer
CTGGGCCTACACAGTCCTTCA
SEQ ID NO: 1614


 


PI3K
NM_002646.2
Forward Primer
TGCTACCTGGACAGCCCG
SEQ ID NO: 1615




Probe
TCCTCCTGAAACGAGCTGTGTCTGACTT
SEQ ID NO: 1616




Reverse Primer
AGGCCGTCCTTCAGTAACCA
SEQ ID NO: 1617


 


PI3KC2A
NM_002645.1
Forward Primer
ATACCAATCACCGCACAAACC
SEQ ID NO: 1618




Probe
TGCGCTGTGACTGGACTTAACAAATAGCCT
SEQ ID NO: 1619




Reverse Primer
CACACTAGCATTTTCTCCGCATA
SEQ ID NO: 1620


 


PIK3CA
NM_006218.1
Forward Primer
GTGATTGAAGAGCATGCCAA
SEQ ID NO: 1621




Probe
TCCTGCTTCTCGGGATACAGACCA
SEQ ID NO: 1622




Reverse Primer
GTCCTGCGTGGGAATAGC
SEQ ID NO: 1623


 


PIM1
NM_002648.2
Forward Primer
CTGCTCAAGGACACCGTCTA
SEQ ID NO: 1624




Probe
TACACTCGGGTCCCATCGAAGTCC
SEQ ID NO: 1625




Reverse Primer
GGATCCACTCTGGAGGGC
SEQ ID NO: 1626


 


Pin1
NM_006221.1
Forward Primer
GATCAACGGCTACATCCAGA
SEQ ID NO: 1627




Probe
TCAAAGTCCTCCTCTCCCGACTTGA
SEQ ID NO: 1628




Reverse Primer
TGAACTGTGAGGCCAGAGAC
SEQ ID NO: 1629


 


PKD1
NM_000296.2
Forward Primer
CAGCACCAGCGATTACGAC
SEQ ID NO: 1630




Probe
AGCCATTGTGAGGACTCTCCCAGC
SEQ ID NO: 1631




Reverse Primer
CTGAATAGGCCCACGTCC
SEQ ID NO: 1632


 


PKR2
NM_002654.3
Forward Primer
CCGCCTGGACATTGATTCAC
SEQ ID NO: 1633




Probe
ACCCATCACAGCCCGGAACACTG
SEQ ID NO: 1634




Reverse Primer
CTGGGCCAATGGTACAGATGA
SEQ ID NO: 1635


 


PLA2G2A
NM_000300.2
Forward Primer
GCATCCCTCACCCATCCTA
SEQ ID NO: 1636




Probe
AGGCCAGGCAGGAGCCCTTCTATA
SEQ ID NO: 1637




Reverse Primer
GCTGGAAATCTGCTGGATGT
SEQ ID NO: 1638


 


PLAUR
NM_002659.1
Forward Primer
CCCATGGATGCTCCTCTGAA
SEQ ID NO: 1639




Probe
CATTGACTGCCGAGGCCCCATG
SEQ ID NO: 1640




Reverse Primer
CCGGTGGCTACCAGACATTG
SEQ ID NO: 1641


 


PLK
NM_005030.2
Forward Primer
AATGAATACAGTATTCCCAAGCACAT
SEQ ID NO: 1642




Probe
AACCCCGTGGCCGCCTCC
SEQ ID NO: 1643




Reverse Primer
TGTCTGAAGCATCTTCTGGATGA
SEQ ID NO: 1644


 


PLK3
NM_004073.2
Forward Primer
TGAAGGAGACGTACCGCTG
SEQ ID NO: 1645




Probe
CAAGCAGGTTCACTACACGCTGCC
SEQ ID NO: 1646




Reverse Primer
CAGGCAGTGAGAGGCTGG
SEQ ID NO: 1647


 


PLOD2
NM_000935.2
Forward Primer
CAGGGAGGTGGTTGCAAAT
SEQ ID NO: 1648




Probe
TCCAGCCTTTTCGTGGTGACTCAA
SEQ ID NO: 1649




Reverse Primer
TCTCCCAGGATGCATGAAG
SEQ ID NO: 1650


 


PMS1
NM_000534.2
Forward Primer
CTTACGGTTTTCGTGGAGAAG
SEQ ID NO: 1651




Probe
CCTCAGCTATACAACAAATTGACCCCAAG
SEQ ID NO: 1652




Reverse Primer
AGCAGCCGTTCTTGTTGTAA
SEQ ID NO: 1653


 


PMS2
NM_000535.2
Forward Primer
GATGTGGACTGCCATTCAAA
SEQ ID NO: 1654




Probe
TCGAAATTTACATCCGGTATCTTCCTGG
SEQ ID NO: 1655




Reverse Primer
TGCGAGATTAGTTGGCTGAG
SEQ ID NO: 1656


 


PPARG
NM_005037.3
Forward Primer
TGACTTTATGGAGCCCAAGTT
SEQ ID NO: 1657




Probe
TTCCAGTGCATTGAACTTCACAGCA
SEQ ID NO: 1658




Reverse Primer
GCCAAGTCGCTGTCATCTAA
SEQ ID NO: 1659


 


PPID
NM_005038.1
Forward Primer
TCCTCATTTGGATGGGAAAC
SEQ ID NO: 1660




Probe
TTCCTTTAATTACTTGGCCAAACACCACA
SEQ ID NO: 1661




Reverse Primer
CCAATATCCTTGCCACTCCTA
SEQ ID NO: 1662


 


PPM1D
NM_003620.1
Forward Primer
GCCATCCGCAAAGGCTTT
SEQ ID NO: 1663




Probe
TCGCTTGTCACCTTGCCATGTGG
SEQ ID NO: 1664




Reverse Primer
GGCCATTCCGCCAGTTTC
SEQ ID NO: 1665


 


PPP2R4
NM_178001.1
Forward Primer
GGCTCAGAGCATAAGGCTTC
SEQ ID NO: 1666




Probe
TTGGTCACTTCTCCCAACTTGGGC
SEQ ID NO: 1667




Reverse Primer
ACGGGAACTCAGAAAACTGG
SEQ ID NO: 1668


 


PR
NM_000926.2
Forward Primer
GCATCAGGCTGTCATTATGG
SEQ ID NO: 1669




Probe
TGTCCTTACCTGTGGGAGCTGTAAGGTC
SEQ ID NO: 1670




Reverse Primer
AGTAGTTGTGCTGCCCTTCC
SEQ ID NO: 1671


 


PRDX2
NM_005809.4
Forward Primer
GGTGTCCTTCGCCAGATCAC
SEQ ID NO: 1672




Probe
TTAATGATTTGCCTGTGGGACGCTCC
SEQ ID NO: 1673




Reverse Primer
CAGCCGCAGAGCCTCATC
SEQ ID NO: 1674


 


PRDX3
NM_006793.2
Forward Primer
TGACCCCAATGGAGTCATCA
SEQ ID NO: 1675




Probe
CATTTGAGCGTCAACGATCTCCCAGTG
SEQ ID NO: 1676




Reverse Primer
CCAAGCGGAGGGTTTCTTC
SEQ ID NO: 1677


 


PRDX4
NM_006406.1
Forward Primer
TTACCCATTTGGCCTGGATTAA
SEQ ID NO: 1678




Probe
CCAAGTCCTCCTTGTCTTCGAGGGGT
SEQ ID NO: 1679




Reverse Primer
CTGAAAGAAGTGGAATCCTTATTGG
SEQ ID NO: 1680


 


PRDX6
NM_004905.2
Forward Primer
CTGTGAGCCAGAGGATGTCA
SEQ ID NO: 1681




Probe
CTGCCAATTGTGTTTTCCTGCAGC
SEQ ID NO: 1682




Reverse Primer
TGTGATGACACCAGGATGTG
SEQ ID NO: 1683


 


PRKCA
NM_002737.1
Forward Primer
CAAGCAATGCGTCATCAATGT
SEQ ID NO: 1684




Probe
CAGCCTCTGCGGAATGGATCACACT
SEQ ID NO: 1685




Reverse Primer
GTAAATCCGCCCCCTCTTCT
SEQ ID NO: 1686


 


PRKCB1
NM_002738.5
Forward Primer
GACCCAGCTCCACTCCTG
SEQ ID NO: 1687




Probe
CCAGACCATGGACCGCCTGTACTT
SEQ ID NO: 1688




Reverse Primer
CCCATTCACGTACTCCATCA
SEQ ID NO: 1689


 


PRKCD
NM_006254.1
Forward Primer
CTGACACTTGCCGCAGAGAA
SEQ ID NO: 1690




Probe
CCCTTTCTCACCCACCTCATCTGCAC
SEQ ID NO: 1691




Reverse Primer
AGGTGGTCCTTGGTCTGGAA
SEQ ID NO: 1692


 


PRKR
NM_002759.1
Forward Primer
GCGATACATGAGCCCAGAACA
SEQ ID NO: 1693




Probe
AGGTCCACTTCCTTTCCATAGTCTTGCGA
SEQ ID NO: 1694




Reverse Primer
TCAGCAAGAATTAGCCCCAAAG
SEQ ID NO: 1695


 


pS2
NM_003225.1
Forward Primer
GCCCTCCCAGTGTGCAAAT
SEQ ID NO: 1696




Probe
TGCTGTTTCGACGACACCGTTCG
SEQ ID NO: 1697




Reverse Primer
CGTCGATGGTATTAGGATAGAAGCA
SEQ ID NO: 1698


 


PTCH
NM_000264.2
Forward Primer
CCACGACAAAGCCGACTAC
SEQ ID NO: 1699




Probe
CCTGAAACAAGGCTGAGAATCCCG
SEQ ID NO: 1700




Reverse Primer
TACTCGATGGGCTCTGCTG
SEQ ID NO: 1701


 


PTEN
NM_000314.1
Forward Primer
TGGCTAAGTGAAGATGACAATCATG
SEQ ID NO: 1702




Probe
CCTTTCCAGCTTTACAGTGAATTGCTGCA
SEQ ID NO: 1703




Reverse Primer
TGCACATATCATTACACCAGTTCGT
SEQ ID NO: 1704


 


PTGER3
NM_000957.2
Forward Primer
TAACTGGGGCAACCTTTTCT
SEQ ID NO: 1705




Probe
CCTTTGCCTTCCTGGGGCTCTT
SEQ ID NO: 1706




Reverse Primer
TTGCAGGAAAAGGTGACTGT
SEQ ID NO: 1707


 


PTHLH
NM_002820.1
Forward Primer
AGTGACTGGGAGTGGGCTAGAA
SEQ ID NO: 1708




Probe
TGACACCTCCACAACGTCGCTGGA
SEQ ID NO: 1709




Reverse Primer
AAGCCTGTTACCGTGAATCGA
SEQ ID NO: 1710


 


PTHR1
NM_000316.1
Forward Primer
CGAGGTACAAGCTGAGATCAAGAA
SEQ ID NO: 1711




Probe
CCAGTGCCAGTGTCCAGCGGCT
SEQ ID NO: 1712




Reverse Primer
GCGTGCCTTTCGCTTGAA
SEQ ID NO: 1713


 


PTK2
NM_005607.3
Forward Primer
GACCGGTCGAATGATAAGGT
SEQ ID NO: 1714




Probe
ACCAGGCCCGTCACATTCTCGTAC
SEQ ID NO: 1715




Reverse Primer
CTGGACATCTCGATGACAGC
SEQ ID NO: 1716


 


PTK2B
NM_004103.3
Forward Primer
CAAGCCCAGCCGACCTAAG
SEQ ID NO: 1717




Probe
CTCCGCAAACCAACCTCCTGGCT
SEQ ID NO: 1718




Reverse Primer
GAACCTGGAACTGCAGCTTTG
SEQ ID NO: 1719


 


PTP4A3
NM_007079.2
Forward Primer
CCTGTTCTCGGCACCTTAAA
SEQ ID NO: 1720




Probe
ACCTGACTGCCCCGGGGTCTAATA
SEQ ID NO: 1721




Reverse Primer
TATTGCCTTCGGGTGTCC
SEQ ID NO: 1722


 


PTP4A3 v2
NM_032611.1
Forward Primer
AATATTTGTGCGGGGTATGG
SEQ ID NO: 1723




Probe
CCAAGAGAAACGAGATTTAAAAACCCACC
SEQ ID NO: 1724




Reverse Primer
AACGAGATCCCTGTGCTTGT
SEQ ID NO: 1725


 


PTPD1
NM_007039.2
Forward Primer
CGCTTGCCTAACTCATACTTTCC
SEQ ID NO: 1726




Probe
TCCACGCAGCGTGGCACTG
SEQ ID NO: 1727




Reverse Primer
CCATTCAGACTGCGCCACTT
SEQ ID NO: 1728


 


PTPN1
NM_002827.2
Forward Primer
AATGAGGAAGTTTCGGATGG
SEQ ID NO: 1729




Probe
CTGATCCAGACAGCCGACCAGCT
SEQ ID NO: 1730




Reverse Primer
CTTCGATCACAGCCAGGTAG
SEQ ID NO: 1731


 


PTPRF
NM_002840.2
Forward Primer
TGTTTTAGCTGAGGGACGTG
SEQ ID NO: 1732




Probe
CCGACGTCCCCAAACCTAGCTAGG
SEQ ID NO: 1733




Reverse Primer
TACCAACCCTGGAATGTTGA
SEQ ID NO: 1734


 


PTPRJ
NM_002843.2
Forward Primer
AACTTCCGGTACCTCGTTCGT
SEQ ID NO: 1735




Probe
ACTACATGAAGCAGAGTCCTCCCGAATCG
SEQ ID NO: 1736




Reverse Primer
AGCACTGCAATGCACCAGAA
SEQ ID NO: 1737


 


PTPRO
NM_030667.1
Forward Primer
CATGGCCTGATCATGGTGT
SEQ ID NO: 1738




Probe
CCCACAGCAAATGCTGCAGAAAGT
SEQ ID NO: 1739




Reverse Primer
CCATGTGTACAAACTGCAGGA
SEQ ID NO: 1740


 


PTTG1
NM_004219.2
Forward Primer
GGCTACTCTGATCTATGTTGATAAGGAA
SEQ ID NO: 1741




Probe
CACACGGGTGCCTGGTTCTCCA
SEQ ID NO: 1742




Reverse Primer
GCTTCAGCCCATCCTTAGCA
SEQ ID NO: 1743


 


RAB32
NM_006834.2
Forward Primer
CCTGCAGCTGTGGGACAT
SEQ ID NO: 1744




Probe
CGATTTGGCAACATGACCCGAGTA
SEQ ID NO: 1745




Reverse Primer
AGCACCAACAGCTTCCTTG
SEQ ID NO: 1746


 


RAB6C
NM_032144.1
Forward Primer
GCGACAGCTCCTCTAGTTCCA
SEQ ID NO: 1747




Probe
TTCCCGAAGTCTCCGCCCG
SEQ ID NO: 1748




Reverse Primer
GGAACACCAGCTTGAATTTCCT
SEQ ID NO: 1749


 


RAC1
NM_006908.3
Forward Primer
TGTTGTAAATGTCTCAGCCCC
SEQ ID NO: 1750




Probe
CGTTCTTGGTCCTGTCCCTTGGA
SEQ ID NO: 1751




Reverse Primer
TTGAGCAAAGCGTACAAAGG
SEQ ID NO: 1752


 


RAD51C
NM_058216.1
Forward Primer
GAACTTCTTGAGCAGGAGCATACC
SEQ ID NO: 1753




Probe
AGGGCTTCATAATCACCTTCTGTTC
SEQ ID NO: 1754




Reverse Primer
TCCACCCCCAAGAATATCATCTAGT
SEQ ID NO: 1755


 


RAD54L
NM_003579.2
Forward Primer
AGCTAGCCTCAGTGACACACATG
SEQ ID NO: 1756




Probe
ACACAACGTCGGCAGTGCAACCTG
SEQ ID NO: 1757




Reverse Primer
CCGGATCTGACGGCTGTT
SEQ ID NO: 1758


 


RAF1
NM_002880.1
Forward Primer
CGTCGTATGCGAGAGTCTGT
SEQ ID NO: 1759




Probe
TCCAGGATGCCTGTTAGTTCTCAGCA
SEQ ID NO: 1760




Reverse Primer
TGAAGGCGTGAGGTGTAGAA
SEQ ID NO: 1761


 


RALBP1
NM_006788.2
Forward Primer
GGTGTCAGATATAAATGTGCAAATGC
SEQ ID NO: 1762




Probe
TGCTGTCCTGTCGGTCTCAGTACGTTCA
SEQ ID NO: 1763




Reverse Primer
TTCGATATTGCCAGCAGCTATAAA
SEQ ID NO: 1764


 


RANBP2
NM_006267.3
Forward Primer
TCCTTCAGCTTTCACACTGG
SEQ ID NO: 1765




Probe
TCCAGAAGAGTCATGCAACTTCATTTCTG
SEQ ID NO: 1766




Reverse Primer
AAATCCTGTTCCCACCTGAC
SEQ ID NO: 1767


 


ranBP7
NM_006391.1
Forward Primer
AACATGATTATCCAAGCCGC
SEQ ID NO: 1768




Probe
AAGCCAATTTTGTCCACAATGGCA
SEQ ID NO: 1769




Reverse Primer
GCCAACAAGCACTGTTATCG
SEQ ID NO: 1770


 


RANBP9
NM_005493.2
Forward Primer
CAAGTCAGTTGAGACGCCAGTT
SEQ ID NO: 1771




Probe
TTCTATGGCGGCCTGACTTCCTCCA
SEQ ID NO: 1772




Reverse Primer
TGCAGCTCTCGTCCAAAGTG
SEQ ID NO: 1773


 


RAP1GDS1
NM_021159.3
Forward Primer
TGTGGATGCTGGATTGATTT
SEQ ID NO: 1774




Probe
CCACTGGTGCAGCTGCTAAATAGCA
SEQ ID NO: 1775




Reverse Primer
AAGCAGCACTTCCTGGTCTT
SEQ ID NO: 1776


 


RARA
NM_000964.1
Forward Primer
AGTCTGTGAGAAACGACCGAAAC
SEQ ID NO: 1777




Probe
TCGGGCTTGGGCACCTCCTTCTT
SEQ ID NO: 1778




Reverse Primer
CGGCGTCAGCGTGTAGCT
SEQ ID NO: 1779


 


RARB
NM_016152.2
Forward Primer
TGCCTGGACATCCTGATTCT
SEQ ID NO: 1780




Probe
TGCACCAGGTATACCCCAGAACAAGA
SEQ ID NO: 1781




Reverse Primer
AAGGCCGTCTGAGAAAGTCA
SEQ ID NO: 1782


 


RASSF1
NM_007182.3
Forward Primer
AGTGGGAGACACCTGACCTT
SEQ ID NO: 1783




Probe
TTGATCTTCTGCTCAATCTCAGCTTGAGA
SEQ ID NO: 1784




Reverse Primer
TGATCTGGGCATTGTACTCC
SEQ ID NO: 1785


 


RBM5
NM_005778.1
Forward Primer
CGAGAGGGAGAGCAAGACCAT
SEQ ID NO: 1786




Probe
CTGCGCGGCCTTCCCATCA
SEQ ID NO: 1787




Reverse Primer
TCTCGAATATCGCTCTCTGTGATG
SEQ ID NO: 1788


 


RBX1
NM_014248.2
Forward Primer
GGAACCACATTATGGATCTTTGC
SEQ ID NO: 1789




Probe
TAGAATGTCAAGCTAACCAGGCGTCCGC
SEQ ID NO: 1790




Reverse Primer
CATGCGACAGTACACTCTTCTGAA
SEQ ID NO: 1791


 


RCC1
NM_001269.2
Forward Primer
GGGCTGGGTGAGAATGTG
SEQ ID NO: 1792




Probe
ATACCAGGGCCGGCTTCTTCCTCT
SEQ ID NO: 1793




Reverse Primer
CACAACATCCTCCGGAATG
SEQ ID NO: 1794


 


REG4
NM_032044.2
Forward Primer
TGCTAACTCCTGCACAGCC
SEQ ID NO: 1795




Probe
TCCTCTTCCTTTCTGCTAGCCTGGC
SEQ ID NO: 1796




Reverse Primer
TGCTAGGTTTCCCCTCTGAA
SEQ ID NO: 1797


 


RFC
NM_003056.1
Forward Primer
TCAAGACCATCATCACTTTCATTGT
SEQ ID NO: 1798




Probe
CCTCCCGGTCCGCAAGCAGTT
SEQ ID NO: 1799




Reverse Primer
GGATCAGGAAGTACACGGAGTATAACT
SEQ ID NO: 1800


 


RhoB
NM_004040.2
Forward Primer
AAGCATGAACAGGACTTGACC
SEQ ID NO: 1801




Probe
CTTTCCAACCCCTGGGGAAGACAT
SEQ ID NO: 1802




Reverse Primer
CCTCCCCAAGTCAGTTGC
SEQ ID NO: 1803


 


rhoC
NM_175744.1
Forward Primer
CCCGTTCGGTCTGAGGAA
SEQ ID NO: 1804




Probe
TCCGGTTCGCCATGTCCCG
SEQ ID NO: 1805




Reverse Primer
GAGCACTCAAGGTAGCCAAAGG
SEQ ID NO: 1806


 


RIZ1
NM_012231.1
Forward Primer
CCAGACGAGCGATTAGAAGC
SEQ ID NO: 1807




Probe
TGTGAGGTGAATGATTTGGGGGA
SEQ ID NO: 1808




Reverse Primer
TCCTCCTCTTCCTCCTCCTC
SEQ ID NO: 1809


 


RNF11
NM_014372.3
Forward Primer
ACCCTGGAAGAGATGGATCA
SEQ ID NO: 1810




Probe
CCATCATACAGATCACACACTCCCGG
SEQ ID NO: 1811




Reverse Primer
ATTGGGTCCCCATAAACAAA
SEQ ID NO: 1812


 


ROCK1
NM_005406.1
Forward Primer
TGTGCACATAGGAATGAGCTTC
SEQ ID NO: 1813




Probe
TCACTCTCTTTGCTGGCCAACTGC
SEQ ID NO: 1814




Reverse Primer
GTTTAGCACGCAATTGCTCA
SEQ ID NO: 1815


 


ROCK2
NM_004850.3
Forward Primer
GATCCGAGACCCTCGCTC
SEQ ID NO: 1816




Probe
CCCATCAACGTGGAGAGCTTGCT
SEQ ID NO: 1817




Reverse Primer
AGGACCAAGGAATTTAAGCCA
SEQ ID NO: 1818


 


RPLPO
NM_001002.2
Forward Primer
CCATTCTATCATCAACGGGTACAA
SEQ ID NO: 1819




Probe
TCTCCACAGACAAGGCCAGGACTCG
SEQ ID NO: 1820




Reverse Primer
TCAGCAAGTGGGAAGGTGTAATC
SEQ ID NO: 1821


 


RPS13
NM_001017.2
Forward Primer
CAGTCGGCTTTACCCTATCG
SEQ ID NO: 1822




Probe
CAACTTCAACCAAGTGGGGACGCT
SEQ ID NO: 1823




Reverse Primer
TCTGCTCCTTCACGTCGTC
SEQ ID NO: 1824


 


RRM1
NM_001033.1
Forward Primer
GGGCTACTGGCAGCTACATT
SEQ ID NO: 1825




Probe
CATTGGAATTGCCATTAGTCCCAGC
SEQ ID NO: 1826




Reverse Primer
CTCTCAGCATCGGTACAAGG
SEQ ID NO: 1827


 


RRM2
NM_001034.1
Forward Primer
CAGCGGGATTAAACAGTCCT
SEQ ID NO: 1828




Probe
CCAGCACAGCCAGTTAAAAGATGCA
SEQ ID NO: 1829




Reverse Primer
ATCTGCGTTGAAGCAGTGAG
SEQ ID NO: 1830


 


RTN4
NM_007008.1
Forward Primer
GACTGGAGTGGTGTTTGGTG
SEQ ID NO: 1831




Probe
CCAGCCTATTCCTGCTGCTTTCATTG
SEQ ID NO: 1832




Reverse Primer
CTGTTACGCTCACAATGCTG
SEQ ID NO: 1833


 


RUNX1
NM_001754.2
Forward Primer
AACAGAGACATTGCCAACCA
SEQ ID NO: 1834




Probe
TTGGATCTGCTTGCTGTCCAAACC
SEQ ID NO: 1835




Reverse Primer
GTGATTTGCCCAGGAAGTTT
SEQ ID NO: 1836


 


RXRA
NM_002957.3
Forward Primer
GCTCTGTTGTGTCCTGTTGC
SEQ ID NO: 1837




Probe
TCAGTCACAGGAAGGCCAGAGCC
SEQ ID NO: 1838




Reverse Primer
GTACGGAGAAGCCACTTCACA
SEQ ID NO: 1839


 


S100A1
NM_006271.1
Forward Primer
TGGACAAGGTGATGAAGGAG
SEQ ID NO: 1840




Probe
CCTCCCCGTCTCCATTCTCGTCTA
SEQ ID NO: 1841




Reverse Primer
AGCACCACATACTCCTGGAA
SEQ ID NO: 1842


 


S100A2
NM_005978.2
Forward Primer
TGGCTGTGCTGGTCACTACCT
SEQ ID NO: 1843




Probe
CACAAGTACTCCTGCCAAGAGGGCGAC
SEQ ID NO: 1844




Reverse Primer
TCCCCCTTACTCAGCTTGAACT
SEQ ID NO: 1845


 


S100A4
NM_002961.2
Forward Primer
GACTGCTGTCATGGCGTG
SEQ ID NO: 1846




Probe
ATCACATCCAGGGCCTTCTCCAGA
SEQ ID NO: 1847




Reverse Primer
CGAGTACTTGTGGAAGGTGGAC
SEQ ID NO: 1848


 


S100A8
NM_002964.3
Forward Primer
ACTCCCTGATAAAGGGGAATTT
SEQ ID NO: 1849




Probe
CATGCCGTCTACAGGGATGACCTG
SEQ ID NO: 1850




Reverse Primer
TGAGGACACTCGGTCTCTAGC
SEQ ID NO: 1851


 


S100A9
NM_002965.2
Forward Primer
CTTTGGGACAGAGTGCAAGA
SEQ ID NO: 1852




Probe
CGATGACTTGCAAAATGTCGCAGC
SEQ ID NO: 1853




Reverse Primer
TGGTCTCTATGTTGCGTTCC
SEQ ID NO: 1854


 


S100P
NM_005980.2
Forward Primer
AGACAAGGATGCCGTGGATAA
SEQ ID NO: 1855




Probe
TTGCTCAAGGACCTGGACGCCAA
SEQ ID NO: 1856




Reverse Primer
GAAGTCCACCTGGGCATCTC
SEQ ID NO: 1857


 


SAT
NM_002970.1
Forward Primer
CCTTTTACCACTGCCTGGTT
SEQ ID NO: 1858




Probe
TCCAGTGCTCTTTCGGCACTTCTG
SEQ ID NO: 1859




Reverse Primer
ACAATGCTGTGTCCTTCCG
SEQ ID NO: 1860


 


SBA2
NM_018639.3
Forward Primer
GGACTCAACGATGGGCAG
SEQ ID NO: 1861




Probe
CCCTGTCTGCACCTCCCAGATCTT
SEQ ID NO: 1862




Reverse Primer
CGGAAAGATTCAAAAGCAGG
SEQ ID NO: 1863


 


SDC1
NM_002997.1
Forward Primer
GAAATTGACGAGGGGTGTCT
SEQ ID NO: 1864




Probe
CTCTGAGCGCCTCCATCCAAGG
SEQ ID NO: 1865




Reverse Primer
AGGAGCTAACGGAGAACCTG
SEQ ID NO: 1866


 


SEMA3B
NM_004636.1
Forward Primer
GCTCCAGGATGTGTTTCTGTTG
SEQ ID NO: 1867




Probe
TCGCGGGACCACCGGACC
SEQ ID NO: 1868




Reverse Primer
ACGTGGAGAAGACGGCATAGA
SEQ ID NO: 1869


 


SEMA3F
NM_004186.1
Forward Primer
CGCGAGCCCCTCATTATACA
SEQ ID NO: 1870




Probe
CTCCCCACAGCGCATCGAGGAA
SEQ ID NO: 1871




Reverse Primer
CACTCGCCGTTGACATCCT
SEQ ID NO: 1872


 


SEMA4B
NM_020210.1
Forward Primer
TTCCAGCCCAACACAGTGAA
SEQ ID NO: 1873




Probe
ACTTTGGCCTGCCCGCTCCTCT
SEQ ID NO: 1874




Reverse Primer
GAGTCGGGTCGCCAGGTT
SEQ ID NO: 1875


 


SFRP2
NM_003013.2
Forward Primer
CAAGCTGAACGGTGTGTCC
SEQ ID NO: 1876




Probe
CAGCACCGATTTCTTCAGGTCCCT
SEQ ID NO: 1877




Reverse Primer
TGCAAGCTGTCTTTGAGCC
SEQ ID NO: 1878


 


SFRP4
NM_003014.2
Forward Primer
TACAGGATGAGGCTGGGC
SEQ ID NO: 1879




Probe
CCTGGGACAGCCTATGTAAGGCCA
SEQ ID NO: 1880




Reverse Primer
GTTGTTAGGGCAAGGGGC
SEQ ID NO: 1881


 


SGCB
NM_000232.1
Forward Primer
CAGTGGAGACCAGTTGGGTAGTG
SEQ ID NO: 1882




Probe
CACACATGCAGAGCTTGTAGCGTACCCA
SEQ ID NO: 1883




Reverse Primer
CCTTGAAGAGCGTCCCATCA
SEQ ID NO: 1884


 


SHC1
NM_003029.3
Forward Primer
CCAACACCTTCTTGGCTTCT
SEQ ID NO: 1885




Probe
CCTGTGTTCTTGCTGAGCACCCTC
SEQ ID NO: 1886




Reverse Primer
CTGTTATCCCAACCCAAACC
SEQ ID NO: 1887


 


SHH
NM_000193.2
Forward Primer
GTCCAAGGCACATATCCACTG
SEQ ID NO: 1888




Probe
CACCGAGTTCTCTGCTTTCACCGA
SEQ ID NO: 1889




Reverse Primer
GAAGCAGCCTCCCGATTT
SEQ ID NO: 1890


 


SI
NM_001041.1
Forward Primer
AACGGACTCCCTCAATTTGT
SEQ ID NO: 1891




Probe
TGTCCATGGTCATGCAAATCTTGC
SEQ ID NO: 1892




Reverse Primer
GAAATTGCAGGGTCCAAGAT
SEQ ID NO: 1893


 


Siah-1
NM_003031.2
Forward Primer
TTGGCATTGGAACTACATTCA
SEQ ID NO: 1894




Probe
TCCGCGGTATCCTCGGATTAGTTC
SEQ ID NO: 1895




Reverse Primer
GGTATGGAGAAGGGGGTCC
SEQ ID NO: 1896


 


SIAT4A
NM_003033.2
Forward Primer
AACCACAGTTGGAGGAGGAC
SEQ ID NO: 1897




Probe
CAGAGACAGTTTCCCTCCCCGCT
SEQ ID NO: 1898




Reverse Primer
CGAAGGAAGGGTGTTGGTAT
SEQ ID NO: 1899


 


SIAT7B
NM_006456.1
Forward Primer
TCCAGCCCAAATCCTCCT
SEQ ID NO: 1900




Probe
TGGCACATCCTACCCCAGATGCTA
SEQ ID NO: 1901




Reverse Primer
GGTGTCCTGGAGTCCTTGAA
SEQ ID NO: 1902


 


SIM2
NM_005069.2
Forward Primer
GATGGTAGGAAGGGATGTGC
SEQ ID NO: 1903




Probe
CGCCTCTCCACGCACTCAGCTAT
SEQ ID NO: 1904




Reverse Primer
CACAAGGAGCTGTGAATGAGG
SEQ ID NO: 1905


 


SIN3A
NM_015477.1
Forward Primer
CCAGAGTCATGCTCATCCAG
SEQ ID NO: 1906




Probe
CTGTCCCTGCACTGGTGCAACTG
SEQ ID NO: 1907




Reverse Primer
CCACCTTCAGCCTCTGAAAT
SEQ ID NO: 1908


 


SIR2
NM_012238.3
Forward Primer
AGCTGGGGTGTCTGTTTCAT
SEQ ID NO: 1909




Probe
CCTGACTTCAGGTCAAGGGATGG
SEQ ID NO: 1910




Reverse Primer
ACAGCAAGGCGAGCATAAAT
SEQ ID NO: 1911


 


SKP1A
NM_006930.2
Forward Primer
CCATTGCCTTTGCTTTGTTCAT
SEQ ID NO: 1912




Probe
TCCCATGGTTTTTATTCTGCCCTGCTG
SEQ ID NO: 1913




Reverse Primer
TTCCGGATTTCCTTTCTTTGC
SEQ ID NO: 1914


 


SKP2
NM_005983.2
Forward Primer
AGTTGCAGAATCTAAGCCTGGAA
SEQ ID NO: 1915




Probe
CCTGCGGCTTTCGGATCCCA
SEQ ID NO: 1916




Reverse Primer
TGAGTTTTTTGCGAGAGTATTGACA
SEQ ID NO: 1917


 


SLC25A3
NM_213611.1
Forward Primer
TCTGCCAGTGCTGAATTCTT
SEQ ID NO: 1918




Probe
TGCTGACATTGCCCTGGCTCCTAT
SEQ ID NO: 1919




Reverse Primer
TTCGAACCTTAGCAGCTTCC
SEQ ID NO: 1920


 


SLC2A1
NM_006516.1
Forward Primer
GCCTGAGTCTCCTGTGCC
SEQ ID NO: 1921




Probe
ACATCCCAGGCTTCACCCTGAATG
SEQ ID NO: 1922




Reverse Primer
AGTCTCCACCCTCAGGCAT
SEQ ID NO: 1923


 


SLC31A1
NM_001859.2
Forward Primer
CCGTTCGAAGAGTCGTGAG
SEQ ID NO: 1924




Probe
TCTCCGAATCTTAACCCGTCACCC
SEQ ID NO: 1925




Reverse Primer
AGTCCAGCCACTAGCACCTC
SEQ ID NO: 1926


 


SLC5A8
NM_145913.2
Forward Primer
CCTGCTTTCAACCACATTGA
SEQ ID NO: 1927




Probe
TCCCATTGCTCTTGCCACTCTGAT
SEQ ID NO: 1928




Reverse Primer
AGAGCAGCTTCACAAACGAG
SEQ ID NO: 1929


 


SLC7A5
NM_003486.4
Forward Primer
GCGCAGAGGCCAGTTAAA
SEQ ID NO: 1930




Probe
AGATCACCTCCTCGAACCCACTCC
SEQ ID NO: 1931




Reverse Primer
AGCTGAGCTGTGGGTTGC
SEQ ID NO: 1932


 


SLPI
NM_003064.2
Forward Primer
ATGGCCAATGTTTGATGCT
SEQ ID NO: 1933




Probe
TGGCCATCCATCTCACAGAAATTGG
SEQ ID NO: 1934




Reverse Primer
ACACTTCAAGTCACGCTTGC
SEQ ID NO: 1935


 


SMARCA3
NM_003071.2
Forward Primer
AGGGACTGTCCTGGCACAT
SEQ ID NO: 1936




Probe
AGCAAAAGACCCAGGACATCTGCA
SEQ ID NO: 1937




Reverse Primer
CAACAAATTTGCCGCAGTC
SEQ ID NO: 1938


 


SNAI1
NM_005985.2
Forward Primer
CCCAATCGGAAGCCTAACTA
SEQ ID NO: 1939




Probe
TCTGGATTAGAGTCCTGCAGCTCGC
SEQ ID NO: 1940




Reverse Primer
GTAGGGCTGCTGGAAGGTAA
SEQ ID NO: 1941


 


SNAI2
NM_003068.3
Forward Primer
GGCTGGCCAAACATAAGCA
SEQ ID NO: 1942




Probe
CTGCACTGCGATGCCCAGTCTAGAAAATC
SEQ ID NO: 1943




Reverse Primer
TCCTTGTCACAGTATTTACAGCTGAA
SEQ ID NO: 1944


 


SNRPF
NM_003095.1
Forward Primer
GGCTGGTCGGCAGAGAGTAG
SEQ ID NO: 1945




Probe
AAACTCATGTAAACCACGGCCGAATGTTG
SEQ ID NO: 1946




Reverse Primer
TGAGGAAAGGTTTGGGATTGA
SEQ ID NO: 1947


 


SOD1
NM_000454.3
Forward Primer
TGAAGAGAGGCATGTTGGAG
SEQ ID NO: 1948




Probe
TTTGTCAGCAGTCACATTGCCCAA
SEQ ID NO: 1949




Reverse Primer
AATAGACACATCGGCCACAC
SEQ ID NO: 1950


 


SOD2
NM_000636.1
Forward Primer
GCTTGTCCAAATCAGGATCCA
SEQ ID NO: 1951




Probe
AACAACAGGCCTTATTCCACTGCTGGG
SEQ ID NO: 1952




Reverse Primer
AGCGTGCTCCCACACATCA
SEQ ID NO: 1953


 


SOS1
NM_005633.2
Forward Primer
TCTGCACCAAATTCTCCAAG
SEQ ID NO: 1954




Probe
AACACCGTTAACACCTCCGCCTG
SEQ ID NO: 1955




Reverse Primer
GTGGTACTGGAAGCACCAGA
SEQ ID NO: 1956


 


SOX17
NM_022454.2
Forward Primer
TCGTGTGCAAGCCTGAGA
SEQ ID NO: 1957




Probe
CTCCCCTACCAGGGGCATGACTC
SEQ ID NO: 1958




Reverse Primer
CTGTCGGGGAGATTCACAC
SEQ ID NO: 1959


 


SPARC
NM_003118.1
Forward Primer
TCTTCCCTGTACACTGGCAGTTC
SEQ ID NO: 1960




Probe
TGGACCAGCACCCCATTGACGG
SEQ ID NO: 1961




Reverse Primer
AGCTCGGTGTGGGAGAGGTA
SEQ ID NO: 1962


 


SPINT2
NM_021102.1
Forward Primer
AGGAATGCAGCGGATTCCT
SEQ ID NO: 1963




Probe
CCCAAGTGCTCCCAGAAGGCAGG
SEQ ID NO: 1964




Reverse Primer
TCGCTGGAGTGGTCTTCAGA
SEQ ID NO: 1965


 


SPRY1
AK026960.1
Forward Primer
CAGACCAGTCCCTGGTCATAGG
SEQ ID NO: 1966




Probe
CTGGGTCCGGATTGCCCTTTCAG
SEQ ID NO: 1967




Reverse Primer
CCTTCAAGTCATCCACAATCAGTT
SEQ ID NO: 1968


 


SPRY2
NM_005842.1
Forward Primer
TGTGGCAAGTGCAAATGTAA
SEQ ID NO: 1969




Probe
CAGAGGCCTTGGGTAGGTGCACTC
SEQ ID NO: 1970




Reverse Primer
GTCGCAGATCCAGTCTGATG
SEQ ID NO: 1971


 


SR-A1
NM_021228.1
Forward Primer
AGATGGAAGAAGCCAACCTG
SEQ ID NO: 1972




Probe
CTGGATCAGCTCCTGGGCCTTC
SEQ ID NO: 1973




Reverse Primer
CTGTGGCTGAGGATCTGGT
SEQ ID NO: 1974


 


ST14
NM_021978.2
Forward Primer
TGACTGCACATGGAACATTG
SEQ ID NO: 1975




Probe
AGGTGCCCAACAACCAGCATGT
SEQ ID NO: 1976




Reverse Primer
AAGAATTTGAAGCGCACCTT
SEQ ID NO: 1977


 


STAT1
NM_007315.1
Forward Primer
GGGCTCAGCTTTCAGAAGTG
SEQ ID NO: 1978




Probe
TGGCAGTTTTCTTCTGTCACCAAAA
SEQ ID NO: 1979




Reverse Primer
ACATGTTCAGCTGGTCCACA
SEQ ID NO: 1980


 


STAT3
NM_003150.1
Forward Primer
TCACATGCCACTTTGGTGTT
SEQ ID NO: 1981




Probe
TCCTGGGAGAGATTGACCAGCA
SEQ ID NO: 1982




Reverse Primer
CTTGCAGGAAGCGGCTATAC
SEQ ID NO: 1983


 


STAT5A
NM_003152.1
Forward Primer
GAGGCGCTCAACATGAAATTC
SEQ ID NO: 1984




Probe
CGGTTGCTCTGCACTTCGGCCT
SEQ ID NO: 1985




Reverse Primer
GCCAGGAACACGAGGTTCTC
SEQ ID NO: 1986


 


STAT5B
NM_012448.1
Forward Primer
CCAGTGGTGGTGATCGTTCA
SEQ ID NO: 1987




Probe
CAGCCAGGACAACAATGCGACGG
SEQ ID NO: 1988




Reverse Primer
GCAAAAGCATTGTCCCAGAGA
SEQ ID NO: 1989


 


STC1
NM_003155.1
Forward Primer
CTCCGAGGTGAGGAGGACT
SEQ ID NO: 1990




Probe
CACATCAAACGCACATCCCATGAG
SEQ ID NO: 1991




Reverse Primer
ACCTCTCCCTGGTTATGCAC
SEQ ID NO: 1992


 


STK11
NM_000455.3
Forward Primer
GGACTCGGAGACGCTGTG
SEQ ID NO: 1993




Probe
TTCTTGAGGATCTTGACGGCCCTC
SEQ ID NO: 1994




Reverse Primer
GGGATCCTTCGCAACTTCTT
SEQ ID NO: 1995


 


STK15
NM_003600.1
Forward Primer
CATCTTCCAGGAGGACCACT
SEQ ID NO: 1996




Probe
CTCTGTGGCACCCTGGACTACCTG
SEQ ID NO: 1997




Reverse Primer
TCCGACCTTCAATCATTTCA
SEQ ID NO: 1998


 


STMN1
NM_005563.2
Forward Primer
AATACCCAACGCACAAATGA
SEQ ID NO: 1999




Probe
CACGTTCTCTGCCCCGTTTCTTG
SEQ ID NO: 2000




Reverse Primer
GGAGACAATGCAAACCACAC
SEQ ID NO: 2001


 


STMY3
NM_005940.2
Forward Primer
CCTGGAGGCTGCAACATACC
SEQ ID NO: 2002




Probe
ATCCTCCTGAAGCCCTTTTCGCAGC
SEQ ID NO: 2003




Reverse Primer
TACAATGGCTTTGGAGGATAGCA
SEQ ID NO: 2004


 


STS
NM_000351.2
Forward Primer
GAAGATCCCTTTCCTCCTACTGTTC
SEQ ID NO: 2005




Probe
CTTCGTGGCTCTCGGCTTCCCA
SEQ ID NO: 2006




Reverse Primer
GGATGATGTTCGGCCTTGAT
SEQ ID NO: 2007


 


SURV
NM_001168.1
Forward Primer
TGTTTTGATTCCCGGGCTTA
SEQ ID NO: 2008




Probe
TGCCTTCTTCCTCCCTCACTTCTCACCT
SEQ ID NO: 2009




Reverse Primer
CAAAGCTGTCAGCTCTAGCAAAAG
SEQ ID NO: 2010


 


TAGLN
NM_003186.2
Forward Primer
GATGGAGCAGGTGGCTCAGT
SEQ ID NO: 2011




Probe
CCCAGAGTCCTCAGCCGCCTTCAG
SEQ ID NO: 2012




Reverse Primer
AGTCTGGAACATGTCAGTCTTGATG
SEQ ID NO: 2013


 


TBP
NM_003194.1
Forward Primer
GCCCGAAACGCCGAATATA
SEQ ID NO: 2014




Probe
TACCGCAGCAAACCGCTTGGG
SEQ ID NO: 2015




Reverse Primer
CGTGGCTCTCTTATCCTCATGAT
SEQ ID NO: 2016


 


TCF-1
NM_000545.3
Forward Primer
GAGGTCCTGAGCACTGCC
SEQ ID NO: 2017




Probe
CTGGGTTCACAGGCTCCTTTGTCC
SEQ ID NO: 2018




Reverse Primer
GATGTGGGACCATGCTTGT
SEQ ID NO: 2019


 


TCF-7
NM_003202.2
Forward Primer
GCAGCTGCAGTCAACAGTTC
SEQ ID NO: 2020




Probe
AAGTCATGGCCCAAATCCAGTGTG
SEQ ID NO: 2021




Reverse Primer
CTGTGAATGGGGAGGGGT
SEQ ID NO: 2022


 


TCF7L1
NM_031283.1
Forward Primer
CCGGGACACTTTCCAGAAG
SEQ ID NO: 2023




Probe
TCTCACTTCGGCGAAATAGTCCCG
SEQ ID NO: 2024




Reverse Primer
AGAACGCGCTGTCCTGAG
SEQ ID NO: 2025


 


TCF7L2
NM_030756.1
Forward Primer
CCAATCACGACAGGAGGATT
SEQ ID NO: 2026




Probe
AGACACCCCTACCCCACAGCTCTG
SEQ ID NO: 2027




Reverse Primer
TGGACACGGAAGCATTGAC
SEQ ID NO: 2028


 


TCFL4
NM_170607.2
Forward Primer
CTGACTGCTCTGCTTAAAGGTGAA
SEQ ID NO: 2029




Probe
TAGCAGGAACAACAACAAAAGCCAACCAA
SEQ ID NO: 2030




Reverse Primer
ATGTCTTGCACTGGCTACCTTGT
SEQ ID NO: 2031


 


TEK
NM_000459.1
Forward Primer
ACTTCGGTGCTACTTAACAACTTACATC
SEQ ID NO: 2032




Probe
AGCTCGGACCACGTACTGCTCCCTG
SEQ ID NO: 2033




Reverse Primer
CCTGGGCCTTGGTGTTGAC
SEQ ID NO: 2034


 


TERC
U86046.1
Forward Primer
AAGAGGAACGGAGCGAGTC
SEQ ID NO: 2035




Probe
CACGTCCCACAGCTCAGGGAATC
SEQ ID NO: 2036




Reverse Primer
ATGTGTGAGCCGAGTCCTG
SEQ ID NO: 2037


 


TERT
NM_003219.1
Forward Primer
GACATGGAGAACAAGCTGTTTGC
SEQ ID NO: 2038




Probe
ACCAAACGCAGGAGCAGCCCG
SEQ ID NO: 2039




Reverse Primer
GAGGTGTCACCAACAAGAAATCAT
SEQ ID NO: 2040


 


TFF3
NM_003226.1
Forward Primer
AGGCACTGTTCATCTCAGTTTTTCT
SEQ ID NO: 2041




Probe
CAGAAAGCTTGCCGGGAGCAAAGG
SEQ ID NO: 2042




Reverse Primer
CATCAGGCTCCAGATATGAACTTTC
SEQ ID NO: 2043


 


TGFA
NM_003236.1
Forward Primer
GGTGTGCCACAGACCTTCCT
SEQ ID NO: 2044




Probe
TTGGCCTGTAATCACCTGTGCAGCCTT
SEQ ID NO: 2045




Reverse Primer
ACGGAGTTCTTGACAGAGTTTTGA
SEQ ID NO: 2046


 


TGFB2
NM_003238.1
Forward Primer
ACCAGTCCCCCAGAAGACTA
SEQ ID NO: 2047




Probe
TCCTGAGCCCGAGGAAGTCCC
SEQ ID NO: 2048




Reverse Primer
CCTGGTGCTGTTGTAGATGG
SEQ ID NO: 2049


 


TGFB3
NM_003239.1
Forward Primer
GGATCGAGCTCTTCCAGATCCT
SEQ ID NO: 2050




Probe
CGGCCAGATGAGCACATTGCC
SEQ ID NO: 2051




Reverse Primer
GCCACCGATATAGCGCTGTT
SEQ ID NO: 2052


 


TGFBI
NM_000358.1
Forward Primer
GCTACGAGTGCTGTCCTGG
SEQ ID NO: 2053




Probe
CCTTCTCCCCAGGGACCTTTTCAT
SEQ ID NO: 2054




Reverse Primer
AGTGGTAGGGCTGCTGGAC
SEQ ID NO: 2055


 


TGFBR1
NM_004612.1
Forward Primer
GTCATCACCTGGCCTTGG
SEQ ID NO: 2056




Probe
AGCAATGACAGCTGCCAGTTCCAC
SEQ ID NO: 2057




Reverse Primer
GCAGACGAAGCACACTGGT
SEQ ID NO: 2058


 


TGFBR2
NM_003242.2
Forward Primer
AACACCAATGGGTTCCATCT
SEQ ID NO: 2059




Probe
TTCTGGGCTCCTGATTGCTCAAGC
SEQ ID NO: 2060




Reverse Primer
CCTCTTCATCAGGCCAAACT
SEQ ID NO: 2061


 


THBS1
NM_003246.1
Forward Primer
CATCCGCAAAGTGACTGAAGAG
SEQ ID NO: 2062




Probe
CCAATGAGCTGAGGCGGCCTCC
SEQ ID NO: 2063




Reverse Primer
GTACTGAACTCCGTTGTGATAGCATAG
SEQ ID NO: 2064


 


THY1
NM_006288.2
Forward Primer
GGACAAGACCCTCTCAGGCT
SEQ ID NO: 2065




Probe
CAAGCTCCCAAGAGCTTCCAGAGC
SEQ ID NO: 2066




Reverse Primer
TTGGAGGCTGTGGGTCAG
SEQ ID NO: 2067


 


TIMP1
NM_003254.1
Forward Primer
TCCCTGCGGTCCCAGATAG
SEQ ID NO: 2068




Probe
ATCCTGCCCGGAGTGGAACTGAAGC
SEQ ID NO: 2069




Reverse Primer
GTGGGAACAGGGTGGACACT
SEQ ID NO: 2070


 


TIMP2
NM_003255.2
Forward Primer
TCACCCTCTGTGACTTCATCGT
SEQ ID NO: 2071




Probe
CCCTGGGACACCCTGAGCACCA
SEQ ID NO: 2072




Reverse Primer
TGTGGTTCAGGCTCTTCTTCTG
SEQ ID NO: 2073


 


TIMP3
NM_000362.2
Forward Primer
CTACCTGCCTTGCTTTGTGA
SEQ ID NO: 2074




Probe
CCAAGAACGAGTGTCTCTGGACCG
SEQ ID NO: 2075




Reverse Primer
ACCGAAATTGGAGAGCATGT
SEQ ID NO: 2076


 


TJP1
NM_003257.1
Forward Primer
ACTTTGCTGGGACAAAGGTC
SEQ ID NO: 2077




Probe
CTCGGGCCTGCCCACTTCTTC
SEQ ID NO: 2078




Reverse Primer
CACATGGACTCCTCAGCATC
SEQ ID NO: 2079


 


TK1
NM_003258.1
Forward Primer
GCCGGGAAGACCGTAATTGT
SEQ ID NO: 2080




Probe
CAAATGGCTTCCTCTGGAAGGTCCCA
SEQ ID NO: 2081




Reverse Primer
CAGCGGCACCAGGTTCAG
SEQ ID NO: 2082


 


TLN1
NM_006289.2
Forward Primer
AAGCAGAAGGGAGAGCGTAAGA
SEQ ID NO: 2083




Probe
CTTCCAGGCACACAAGAATTGTGGGC
SEQ ID NO: 2084




Reverse Primer
CCTTGGCCTCAATCTCACTCA
SEQ ID NO: 2085


 


TMEPAI
NM_020182.3
Forward Primer
CAGAAGGATGCCTGTGGC
SEQ ID NO: 2086




Probe
ATTCCGTTGCCTGACACTGTGCTC
SEQ ID NO: 2087




Reverse Primer
GTAGACCTGCGGCTCTGG
SEQ ID NO: 2088


 


TMSB10
NM_021103.2
Forward Primer
GAAATCGCCAGCTTCGATAA
SEQ ID NO: 2089




Probe
CGTCTCCGTTTTCTTCAGCTTGGC
SEQ ID NO: 2090




Reverse Primer
GTCGGCAGGGTGTTCTTTT
SEQ ID NO: 2091


 


TMSB4X
NM_021109.2
Forward Primer
CACATCAAAGAACTACTGACAACGAA
SEQ ID NO: 2092




Probe
CCGCGCCTGCCTTTCCCA
SEQ ID NO: 2093




Reverse Primer
CCTGCCAGCCAGATAGATAGACA
SEQ ID NO: 2094


 


TNC
NM_002160.1
Forward Primer
AGCTCGGAACCTCACCGT
SEQ ID NO: 2095




Probe
CAGCCTTCGGGCTGTGGACATAC
SEQ ID NO: 2096




Reverse Primer
GTAGCAGCCTTGAGGCCC
SEQ ID NO: 2097


 


TNF
NM_000594.1
Forward Primer
GGAGAAGGGTGACCGACTCA
SEQ ID NO: 2098




Probe
CGCTGAGATCAATCGGCCCGACTA
SEQ ID NO: 2099




Reverse Primer
TGCCCAGACTCGGCAAAG
SEQ ID NO: 2100


 


TNFRSF5
NM_001250.3
Forward Primer
TCTCACCTCGCTATGGTTCGT
SEQ ID NO: 2101




Probe
TGCCTCTGCAGTGCGTCCTCTGG
SEQ ID NO: 2102




Reverse Primer
GATGGACAGCGGTCAGCAA
SEQ ID NO: 2103


 


TNFRSF6B
NM_003823.2
Forward Primer
CCTCAGCACCAGGGTACCA
SEQ ID NO: 2104




Probe
TGACGGCACGCTCACACTCCTCAG
SEQ ID NO: 2105




Reverse Primer
TGTCCTGGAAAGCCACAAAGT
SEQ ID NO: 2106


 


TNFSF4
NM_003326.2
Forward Primer
CTTCATCTTCCCTCTACCCAGA
SEQ ID NO: 2107




Probe
CAGGGGTTGGACCCTTTCCATCTT
SEQ ID NO: 2108




Reverse Primer
GCTGCATTTCCCACATTCTC
SEQ ID NO: 2109


 


TOP2A
NM_001067.1
Forward Primer
AATCCAAGGGGGAGAGTGAT
SEQ ID NO: 2110




Probe
CATATGGACTTTGACTCAGCTGTGGC
SEQ ID NO: 2111




Reverse Primer
GTACAGATTTTGCCCGAGGA
SEQ ID NO: 2112


 


TOP2B
NM_001068.1
Forward Primer
TGTGGACATCTTCCCCTCAGA
SEQ ID NO: 2113




Probe
TTCCCTACTGAGCCACCTTCTCTG
SEQ ID NO: 2114




Reverse Primer
CTAGCCCGACCGGTTCGT
SEQ ID NO: 2115


 


TP
NM_001953.2
Forward Primer
CTATATGCAGCCAGAGATGTGACA
SEQ ID NO: 2116




Probe
ACAGCCTGCCACTCATCACAGCC
SEQ ID NO: 2117




Reverse Primer
CCACGAGTTTCTTACTGAGAATGG
SEQ ID NO: 2118


 


TP53BP1
NM_005657.1
Forward Primer
TGCTGTTGCTGAGTCTGTTG
SEQ ID NO: 2119




Probe
CCAGTCCCCAGAAGACCATGTCTG
SEQ ID NO: 2120




Reverse Primer
CTTGCCTGGCTTCACAGATA
SEQ ID NO: 2121


 


TP53BP2
NM_005426.1
Forward Primer
GGGCCAAATATTCAGAAGC
SEQ ID NO: 2122




Probe
CCACCATAGCGGCCATGGAG
SEQ ID NO: 2123




Reverse Primer
GGATGGGTATGATGGGACAG
SEQ ID NO: 2124


 


TP53I3
NM_004881.2
Forward Primer
GCGGACTTAATGCAGAGACA
SEQ ID NO: 2125




Probe
CAGTATGACCCACCTCCAGGAGCC
SEQ ID NO: 2126




Reverse Primer
TCAAGTCCCAAAATGTTGCT
SEQ ID NO: 2127


 


TRAG3
NM_004909.1
Forward Primer
GACGCTGGTCTGGTGAAGATG
SEQ ID NO: 2128




Probe
CCAGGAAACCACGAGCCTCCAGC
SEQ ID NO: 2129




Reverse Primer
TGGGTGGTTGTTGGACAATG
SEQ ID NO: 2130


 


TRAIL
NM_003810.1
Forward Primer
CTTCACAGTGCTCCTGCAGTCT
SEQ ID NO: 2131




Probe
AAGTACACGTAAGTTACAGCCACACA
SEQ ID NO: 2132




Reverse Primer
CATCTGCTTCAGCTCGTTGGT
SEQ ID NO: 2133


 


TS
NM_001071.1
Forward Primer
GCCTCGGTGTGCCTTTCA
SEQ ID NO: 2134




Probe
CATCGCCAGCTACGCCCTGCTC
SEQ ID NO: 2135




Reverse Primer
CGTGATGTGCGCAATCATG
SEQ ID NO: 2136


 


TST
NM_003312.4
Forward Primer
GGAGCCGGATGCAGTAGGA
SEQ ID NO: 2137




Probe
ACCACGGATATGGCCCGAGTCCA
SEQ ID NO: 2138




Reverse Primer
AAGTCCATGAAAGGCATGTTGA
SEQ ID NO: 2139


 


TUBA1
NM_006000.1
Forward Primer
TGTCACCCCGACTCAACGT
SEQ ID NO: 2140




Probe
AGACGCACCGCCCGGACTCAC
SEQ ID NO: 2141




Reverse Primer
ACGTGGACTGAGATGCATTCAC
SEQ ID NO: 2142


 


TUBB
NM_001069.1
Forward Primer
CGAGGACGAGGCTTAAAAAC
SEQ ID NO: 2143




Probe
TCTCAGATCAATCGTGCATCCTTAGTGAA
SEQ ID NO: 2144




Reverse Primer
ACCATGCTTGAGGACAACAG
SEQ ID NO: 2145


 


TUFM
NM_003321.3
Forward Primer
GTATCACCATCAATGCGGC
SEQ ID NO: 2146




Probe
CATGTGGAGTATAGCACTGCCGCC
SEQ ID NO: 2147




Reverse Primer
CAGTCTGTGTGGGCGTAGTG
SEQ ID NO: 2148


 


TULP3
NM_003324.2
Forward Primer
TGTGTATAGTCCTGCCCCTCAA
SEQ ID NO: 2149




Probe
CCGGATTATCCGACATCTTACTGTGA
SEQ ID NO: 2150




Reverse Primer
CCCGATCCATTCCCCTTTTA
SEQ ID NO: 2151


 


tusc4
NM_006545.4
Forward Primer
GGAGGAGCTAAATGCCTCAG
SEQ ID NO: 2152




Probe
ACTCATCAATGGGCAGAGTGCACC
SEQ ID NO: 2153




Reverse Primer
CCTTCAAGTGGATGGTGTTG
SEQ ID NO: 2154


 


UBB
NM_018955.1
Forward Primer
GAGTCGACCCTGCACCTG
SEQ ID NO: 2155




Probe
AATTAACAGCCACCCCTCAGGCG
SEQ ID NO: 2156




Reverse Primer
GCGAATGCCATGACTGAA
SEQ ID NO: 2157


 


UBC
NM_021009.2
Forward Primer
ACGCACCCTGTCTGACTACA
SEQ ID NO: 2158




Probe
CATCCAGAAAGAGTCCACCCTGCA
SEQ ID NO: 2159




Reverse Primer
ACCTCTAAGACGGAGCACCA
SEQ ID NO: 2160


 


UBE2C
NM_007019.2
Forward Primer
TGTCTGGCGATAAAGGGATT
SEQ ID NO: 2161




Probe
TCTGCCTTCCCTGAATCAGACAACC
SEQ ID NO: 2162




Reverse Primer
ATGGTCCCTACCCATTTGAA
SEQ ID NO: 2163


 


UBE2M
NM_003969.1
Forward Primer
CTCCATAATTTATGGCCTGCAGTA
SEQ ID NO: 2164




Probe
TCTTCTTGGAGCCCAACCCCGAG
SEQ ID NO: 2165




Reverse Primer
TGCGGCCTCCTTGTTCAG
SEQ ID NO: 2166


 


UBL1
NM_003352.3
Forward Primer
GTGAAGCCACCGTCATCATG
SEQ ID NO: 2167




Probe
CTGACCAGGAGGCAAAACCTTCAACTGA
SEQ ID NO: 2168




Reverse Primer
CCTTCCTTCTTATCCCCCAAGT
SEQ ID NO: 2169


 


UCP2
NM_003355.2
Forward Primer
ACCATGCTCCAGAAGGAGG
SEQ ID NO: 2170




Probe
CCCCGAGCCTTCTACAAAGGGTTC
SEQ ID NO: 2171




Reverse Primer
AACCCAAGCGGAGAAAGG
SEQ ID NO: 2172


 


UGT1A1
NM_000463.2
Forward Primer
CCATGCAGCCTGGAATTTG
SEQ ID NO: 2173




Probe
CTACCCAGTGCCCCAACCCATTCTC
SEQ ID NO: 2174




Reverse Primer
GAGAGGCCTGGGCACGTA
SEQ ID NO: 2175


 


UMPS
NM_000373.1
Forward Primer
TGCGGAAATGAGCTCCAC
SEQ ID NO: 2176




Probe
CCCTGGCCACTGGGGACTACACTA
SEQ ID NO: 2177




Reverse Primer
CCTCAGCCATTCTAACCGC
SEQ ID NO: 2178


 


UNC5A
XM_030300.7
Forward Primer
GACAGCTGATCCAGGAGCC
SEQ ID NO: 2179




Probe
CGGGTCCTGCACTTCAAGGACAGT
SEQ ID NO: 2180




Reverse Primer
ATGGATAGGCGCAGGTTG
SEQ ID NO: 2181


 


UNC5B
NM_170744.2
Forward Primer
AGAACGGAGGCCGTGACT
SEQ ID NO: 2182




Probe
CGGGACGCTGCTCGACTCTAAGAA
SEQ ID NO: 2183




Reverse Primer
CATGCACAGCCCATCTGT
SEQ ID NO: 2184


 


UNC5C
NM_003728.2
Forward Primer
CTGAACACAGTGGAGCTGGT
SEQ ID NO: 2185




Probe
ACCTGCCGCACACAGAGTTTGC
SEQ ID NO: 2186




Reverse Primer
CTGGAAGATCTGCCCTTCTC
SEQ ID NO: 2187


 


upa
NM_002658.1
Forward Primer
GTGGATGTGCCCTGAAGGA
SEQ ID NO: 2188




Probe
AAGCCAGGCGTCTACACGAGAGTCTCAC
SEQ ID NO: 2189




Reverse Primer
CTGCGGATCCAGGGTAAGAA
SEQ ID NO: 2190


 


UPP1
NM_003364.2
Forward Primer
ACGGGTCCTGCCTCAGTT
SEQ ID NO: 2191




Probe
TCAGCTTTCTCTGCATTGGCTCCC
SEQ ID NO: 2192




Reverse Primer
CGGGGCAATCATTGTGAC
SEQ ID NO: 2193


 


VCAM1
NM_001078.2
Forward Primer
TGGCTTCAGGAGCTGAATACC
SEQ ID NO: 2194




Probe
CAGGCACACACAGGTGGGACACAAAT
SEQ ID NO: 2195




Reverse Primer
TGCTGTCGTGATGAGAAAATAGTG
SEQ ID NO: 2196


 


VCL
NM_003373.2
Forward Primer
GATACCACAACTCCCATCAAGCT
SEQ ID NO: 2197




Probe
AGTGGCAGCCACGGCGCC
SEQ ID NO: 2198




Reverse Primer
TCCCTGTTAGGCGCATCAG
SEQ ID NO: 2199


 


VCP
NM_007126.2
Forward Primer
GGCTTTGGCAGCTTCAGAT
SEQ ID NO: 2200




Probe
AGCTCCACCCTGGTTCCCTGAAG
SEQ ID NO: 2201




Reverse Primer
CTCCACTGCCCTGACTGG
SEQ ID NO: 2202


 


VDAC1
NM_003374.1
Forward Primer
GCTGCGACATGGATTTCGA
SEQ ID NO: 2203




Probe
TTGCTGGGCCTTCCATCCGG
SEQ ID NO: 2204




Reverse Primer
CCAGCCCTCGTAACCTAGCA
SEQ ID NO: 2205


 


VDAC2
NM_003375.2
Forward Primer
ACCCACGGACAGACTTGC
SEQ ID NO: 2206




Probe
CGCGTCCAATGTGTATTCCTCCAT
SEQ ID NO: 2207




Reverse Primer
AGCTTTGCCAAGGTCAGC
SEQ ID NO: 2208


 


VDR
NM_000376.1
Forward Primer
GCCCTGGATTTCAGAAAGAG
SEQ ID NO: 2209




Probe
CAAGTCTGGATCTGGGACCCTTTCC
SEQ ID NO: 2210




Reverse Primer
AGTTACAAGCCAGGGAAGGA
SEQ ID NO: 2211


 


VEGF
NM_003376.3
Forward Primer
CTGCTGTCTTGGGTGCATTG
SEQ ID NO: 2212




Probe
TTGCCTTGCTGCTCTACCTCCACCA
SEQ ID NO: 2213




Reverse Primer
GCAGCCTGGGACCACTTG
SEQ ID NO: 2214


 


VEGF_altsplice1
AF486837.1
Forward Primer
TGTGAATGCAGACCAAAGAAAGA
SEQ ID NO: 2215




Probe
AGAGCAAGACAAGAAAATCCCTGTGGGC
SEQ ID NO: 2216




Reverse Primer
GCTTTCTCCGCTCTGAGCAA
SEQ ID NO: 2217


 


VEGF_altsplice2
AF214570.1
Forward Primer
AGCTTCCTACAGCACAACAAAT
SEQ ID NO: 2218




Probe
TGTCTTGCTCTATCTTTCTTTGGTCTGCA
SEQ ID NO: 2219




Reverse Primer
CTCGGCTTGTCACATTTTTC
SEQ ID NO: 2220


 


VEGFB
NM_003377.2
Forward Primer
TGACGATGGCCTGGAGTGT
SEQ ID NO: 2221




Probe
CTGGGCAGCACCAAGTCCGGA
SEQ ID NO: 2222




Reverse Primer
GGTACCGGATCATGAGGATCTG
SEQ ID NO: 2223


 


VEGFC
NM_005429.2
Forward Primer
CCTCAGCAAGACGTTATTTGAAATT
SEQ ID NO: 2224




Probe
CCTCTCTCTCAAGGCCCCAAACCAGT
SEQ ID NO: 2225




Reverse Primer
AAGTGTGATTGGCAAAACTGATTG
SEQ ID NO: 2226


 


VIM
NM_003380.1
Forward Primer
TGCCCTTAAAGGAACCAATGA
SEQ ID NO: 2227




Probe
ATTTCACGCATCTGGCGTTCCA
SEQ ID NO: 2228




Reverse Primer
GCTTCAACGGCAAAGTTCTCTT
SEQ ID NO: 2229


 


WIF
NM_007191.2
Forward Primer
TACAAGCTGAGTGCCCAGG
SEQ ID NO: 2230




Probe
TACAAAAGCCTCCATTTCGGCACC
SEQ ID NO: 2231




Reverse Primer
CACTCGCAGATGCGTCTTT
SEQ ID NO: 2232


 


WISP1
NM_003882.2
Forward Primer
AGAGGCATCCATGAACTTCACA
SEQ ID NO: 2233




Probe
CGGGCTGCATCAGCACACGC
SEQ ID NO: 2234




Reverse Primer
CAAACTCCACAGTACTTGGGTTGA
SEQ ID NO: 2235


 


Wnt-3a
NM_033131.2
Forward Primer
ACAAAGCTACCAGGGAGTCG
SEQ ID NO: 2236




Probe
TTTGTCCACGCCATTGCCTCAG
SEQ ID NO: 2237




Reverse Primer
TGAGCGTGTCACTGCAAAG
SEQ ID NO: 2238


 


Wnt-5a
NM_003392.2
Forward Primer
GTATCAGGACCACATGCAGTACATC
SEQ ID NO: 2239




Probe
TTGATGCCTGTCTTCGCGCCTTCT
SEQ ID NO: 2240




Reverse Primer
TGTCGGAATTGATACTGGCATT
SEQ ID NO: 2241


 


Wnt-5b
NM_032642.2
Forward Primer
TGTCTTCAGGGTCTTGTCCA
SEQ ID NO: 2242




Probe
TTCCGTAAGAGGCCTGGTGCTCTC
SEQ ID NO: 2243




Reverse Primer
GTGCACGTGGATGAAAGAGT
SEQ ID NO: 2244


 


WNT2
NM_003391.1
Forward Primer
CGGTGGAATCTGGCTCTG
SEQ ID NO: 2245




Probe
CTCCCTCTGCTCTTGACCTGGCTC
SEQ ID NO: 2246




Reverse Primer
CCATGAAGAGTTGACCTCGG
SEQ ID NO: 2247


 


WWOX
NM_016373.1
Forward Primer
ATCGCAGCTGGTGGGTGTA
SEQ ID NO: 2248




Probe
CTGCTGTTTACCTTGGCGAGGCCTTT
SEQ ID NO: 2249




Reverse Primer
AGCTCCCTGTTGCATGGACTT
SEQ ID NO: 2250


 


XPA
NM_000380.2
Forward Primer
GGGTAGAGGGAAAAGGGTTC
SEQ ID NO: 2251




Probe
CAAAGGCTGAACTGGATTCTTAACCAAGA
SEQ ID NO: 2252




Reverse Primer
TGCACCACCATTGCTATTATT
SEQ ID NO: 2253


 


XPC
NM_004628.2
Forward Primer
GATACATCGTCTGCGAGGAA
SEQ ID NO: 2254




Probe
TTCAAAGACGTGCTCCTGACTGCC
SEQ ID NO: 2255




Reverse Primer
CTTTCAATGACTGCCTGCTC
SEQ ID NO: 2256


 


XRCC1
NM_006297.1
Forward Primer
GGAGATGAAGCCCCCAAG
SEQ ID NO: 2257




Probe
AGAAGCAACCCCAGACCAAAACCA
SEQ ID NO: 2258




Reverse Primer
GTCCAGCTGCCTGAGTGG
SEQ ID NO: 2259


 


YB-1
NM_004559.1
Forward Primer
AGACTGTGGAGTTTGATGTTGTTGA
SEQ ID NO: 2260




Probe
TTGCTGCCTCCGCACCCTTTTCT
SEQ ID NO: 2261




Reverse Primer
GGAACACCACCAGGACCTGTAA
SEQ ID NO: 2262


 


YWHAH
NM_003405.2
Forward Primer
CATGGCCTCCGCTATGAA
SEQ ID NO: 2263




Probe
AGGTTCATTCAGCTCTGTCACCGC
SEQ ID NO: 2264




Reverse Primer
GGAGATTTCGATCTTCATTGGA
SEQ ID NO: 2265


 


zbtb7
NM_015898.2
Forward Primer
CTGCGTTCACACCCCAGT
SEQ ID NO: 2266




Probe
TCTCTCCAGAACAGCTCGCCCTGT
SEQ ID NO: 2267




Reverse Primer
CTCAGCCACGACAGATGGT
SEQ ID NO: 2268


 


ZG16
NM_152338.1
Forward Primer
TGCTGAGCCTCCTCTCCTT
SEQ ID NO: 2269




Probe
TACTCCTCATCACAGTGCCCCTGC
SEQ ID NO: 2270




Reverse Primer
GGATGGGGGTTAGTGATAAGG
SEQ ID NO: 2271




















TABLE B






Locus

Sequence ID



Gene
Link
Sequence
Number







A-Catenin
NM_001903.1
CGTTCCGATCCTCTATACTGCATCCCAGGCATGCCTACAGCACCCTGATGTCGCAGCCTATAAGGCCAACAGGGACCT
SEQ ID NO: 2272



 


ABCB1
NM_000927.2
AAACACCACTGGAGCATTGACTACCAGGCTCGCCAATGATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTG
SEQ ID NO: 2273


 


ABCC5
NM_005688.1
TGCAGACTGTACCATGCTGACCATTGCCCATCGCCTGCACACGGTTCTAGGCTCCGATAGGATTATGGTGCTGGCC
SEQ ID NO: 2274


 


ABCC6
NM_001171.2
GGATGAACCTCGACCTGCTGCAGGAGCACTCGGACGAGGCTATCTGGGCAGCCCTGGAGACGGTGCAGCTC
SEQ ID NO: 2275


 


ACP1
NM_004300.2
GCTACCAAGTCCGTGCTGTTTGTGTGTCTGGGTAACATTTGTCGATCACCCATTGCAGAAGCAGTTTTC
SEQ ID NO: 2276


 


ADAM10
NM_001110.1
CCCATCAACTTGTGCCAGTACAGGGTCTGTGCAGTGGAGTAGGCACTTCAGTGGTCGAACCATCACC
SEQ ID NO: 2277


 


ADAM17
NM_003183.3
GAAGTGCCAGGAGGCGATTAATGCTACTTGCAAAGGCGTGTCCTACTGCACAGGTAATAGCAGTGAGTGCCCG
SEQ ID NO: 2278


 


ADAMTS12
NM_030955.2
GGAGAAGGGTGGAGTGCAGCACCCAGATGGATTCTGACTGTGCGGCCATCCAGAGACCTGACCCTG
SEQ ID NO: 2279


 


ADPRT
NM_001618.2
TTGACAACCTGCTGGACATCGAGGTGGCCTACAGTCTGCTCAGGGGAGGGTCTGATGATAGCAGCAAGGATCCCAT
SEQ ID NO: 2280


 


AGXT
NM_000030.1
CTTTTCCCTCCAGTGGCACCTCCTGGAAACAGTCCACTTGGGCGCAAAACCCAGTGCCTTCCAAAT
SEQ ID NO: 2281


 


AKAP12
NM_005100.2
TAGAGAGCCCCTGACAATCCTGAGGCTTCATCAGGAGCTAGAGCCATTTAACATTTCCTCTTTCCAAGACCAACC
SEQ ID NO: 2282


 


AKT1
NM_005163.1
CGCTTCTATGGCGCTGAGATTGTGTCAGCCCTGGACTACCTGCACTCGGAGAAGAACGTGGTGTACCGGGA
SEQ ID NO: 2283


 


AKT2
NM_001626.2
TCCTGCCACCCTTCAAACCTCAGGTCACGTCCGAGGTCGACACAAGGTACTTCGATGATGAATTTACCGCC
SEQ ID NO: 2284


 


AKT3
NM_005465.1
TTGTCTCTGCCTTGGACTATCTACATTCCGGAAAGATTGTGTACCGTGATCTCAAGTTGGAGAATCTAATGCTGG
SEQ ID NO: 2285


 


AL137428
AL137428.1
CAAGAAGAGGCTCTACCCTGGGACTGGGAATTTCCAAGGCCACCTTTGAGGATCGCAGAGCTCATTT
SEQ ID NO: 2286


 


ALCAM
NM_001627.1
GAGGAATATGGAATCCAAGGGGGCCAGTTCCTGCCGTCTGCTCTTCTGCCTCTTGATCTCCGCCAC
SEQ ID NO: 2287


 


ALDH1A1
NM_000689.1
GAAGGAGATAAGGAGGATGTTGACAAGGCAGTGAAGGCCGCAAGACAGGCTTTTCAGATTGGATCTCCGTGGCG
SEQ ID NO: 2288


 


ALDOA
NM_000034.2
GCCTGTACGTGCCAGCTCCCCGACTGCCAGAGCCTCAACTGTCTCTGCTTCGAGATCAAGCTCCGATGA
SEQ ID NO: 2289


 


AMFR
NM_001144.2
GATGGTTCAGCTCTGCAAGGATCGATTTGAATATCTTTCCTTCTCGCCCACCACGCCGATGAGCAGCCACGGTCGA
SEQ ID NO: 2290


 


ANGPT2
NM_001147.1
CCGTGAAAGCTGCTCTGTAAAAGCTGACACAGCCCTCCCAAGTGAGCAGGACTGTTCTTCCCACTGCAA
SEQ ID NO: 2291


 


ANTXR1
NM_032208.1
CTCCAGGTGTACCTCCAACCCTAGCCTTCTCCCACAGCTGCCTACAACAGAGTCTCCCAGCCTTCTC
SEQ ID NO: 2292


 


ANXA1
NM_000700.1
GCCCCTATCCTACCTTCAATCCATCCTCGGATGTCGCTGCCTTGCATAAGGCCATAATGGTTAAAGG
SEQ ID NO: 2293


 


ANXA2
NM_004039.1
CAAGACACTAAGGGCGACTACCAGAAAGCGCTGCTGTACCTGTGTGGTGGAGATGACTGAAGCCCGACACG
SEQ ID NO: 2294


 


ANXA5
NM_001154.2
GCTCAAGCCTGGAAGATGACGTGGTGGGGGACACTTCAGGGTACTACCAGCGGATGTTGGTGGTTCT
SEQ ID NO: 2295


 


AP-1 (JUN
NM_002228.2
GACTGCAAAGATGGAAACGACCTTCTATGACGATGCCCTCAACGCCTCGTTCCTCCCGTCCGAGAGCGGACCTTATGGCTA
SEQ ID NO: 2296


official)


 


APC
NM_000038.1
GGACAGCAGGAATGTGTTTCTCCATACAGGTCACGGGGAGCCAATGGTTCAGAAACAAATCGAGTGGGT
SEQ ID NO: 2297


 


APEX-1
NM_001641.2
GATGAAGCCTTTCGCAAGTTCCTGAAGGGCCTGGCTTCCCGAAAGCCCCTTGTGCTGTGTGGAGACCT
SEQ ID NO: 2298


 


APG-1
NM_014278.2
ACCCCGGCCTGTATATCATTGGGATCAAGAACTCGAGCCATTGGAAATGCAGCAAAGAGCCAGATAG
SEQ ID NO: 2299


 


APN (ANPEP
NM_001150.1
CCACCTTGGACCAAAGTAAAGCGTGGAATCGTTACCGCCTCCCCAACACGCTGAAACCCGATTCCTACCAGGTGACGCTGAGA
SEQ ID NO: 2300


official)


 


APOC1
NM_001645.3
GGAAACACACTGGAGGACAAGGCTCGGGAACTCATCAGCCGCATCAAACAGAGTGAACTTTCTGCCAAGATGCG
SEQ ID NO: 2301


 


AREG
NM_001657.1
TGTGAGTGAAATGCCTTCTAGTAGTGAACCGTCCTCGGGAGCCGACTATGACTACTCAGAAGAGTATGATAACGAACCACAA
SEQ ID NO: 2302


 


ARG
NM_005158.2
CGCAGTGCAGCTGAGTATCTGCTCAGCAGTCTAATCAATGGCAGCTTCCTGGTGCGAGAAAGTGAGAGTAGCCCTGGGCA
SEQ ID NO: 2303


 


ARHF
NM_019034.2
ACTGGCCCACTTAGTCCTCAAGCTCCCAACCTGCTGTCCCTCAAGCCCCGCTTCTACCAGCCTGTGGAGTTCAG
SEQ ID NO: 2304


 


ATOH1
NM_005172.1
GCAGCCACCTGCAACTTTGCAGGCGAGAGAGCATCCCGTCTACCCGCCTGAGCTGTCCCTCCTGGA
SEQ ID NO: 2305


 


ATP5A1
NM_004046.3
GATGCTGCCACTCAACAACTTTTGAGTCGTGGCGTGCGTCTAACTGAGTTGCTGAAGCAAGGACA
SEQ ID NO: 2306


 


ATP5E
NM_006886.2
CCGCTTTCGCTACAGCATGGTGGCCTACTGGAGACAGGCTGGACTCAGCTACATCCGATACTCCCA
SEQ ID NO: 2307


 


AURKB
NM_004217.1
AGCTGCAGAAGAGCTGCACATTTGACGAGCAGCGAACAGCCACGATCATGGAGGAGTTGGCAGATGC
SEQ ID NO: 2308


 


Axin 2
NM_004655.2
GGCTATGTCTTTGCACCAGCCACCAGCGCCAACGACAGTGAGATATCCAGTGATGCGCTGACGGAT
SEQ ID NO: 2309


 


axin1
NM_003502.2
CCGTGTGACAGCATCGTTGTGGCGTACTACTTCTGCGGGGAACCCATCCCCTACCGCACCCTGGTGAG
SEQ ID NO: 2310


 


B-Catenin
NM_001904.1
GGCTCTTGTGCGTACTGTCCTTCGGGCTGGTGACAGGGAAGACATCACTGAGCCTGCCATCTGTGCTCTTCGTCATCTGA
SEQ ID NO: 2311


 


BAD
NM_032989.1
GGGTCAGGTGCCTCGAGATCGGGCTTGGGCCCAGAGCATGTTCCAGATCCCAGAGTTTGAGCCGAGTGAGCAG
SEQ ID NO: 2312


 


BAG1
NM_004323.2
CGTTGTCAGCACTTGGAATACAAGATGGTTGCCGGGTCATGTTAATTGGGAAAAAGAACAGTCCACAGGAAGAGGTTGAAC
SEQ ID NO: 2313


 


BAG2
NM_004282.2
CTAGGGGCAAAAAGCATGACTGCTTTTTCCTGTCTGGCATGGAATCACGCAGTCACCTTGGGCATTTAG
SEQ ID NO: 2314


 


BAG3
NM_004281.2
GAAAGTAAGCCAGGCCCAGTTGGACCAGAACTCCCTCCTGGACACATCCCAATTCAAGTGATCCGCAAAGAGGT
SEQ ID NO: 2315


 


Bak
NM_001188.1
CCATTCCCACCATTCTACCTGAGGCCAGGACGTCTGGGGTGTGGGGATTGGTGGGTCTATGTTCCC
SEQ ID NO: 2316


 


Bax
NM_004324.1
CCGCCGTGGACACAGACTCCCCCCGAGAGGTCTTTTTCCGAGTGGCAGCTGACATGTTTTCTGACGGCAA
SEQ ID NO: 2317


 


BBC3
NM_014417.1
CCTGGAGGGTCCTGTACAATCTCATCATGGGACTCCTGCCCTTACCCAGGGGCCACAGAGCCCCCGAGATGGAGCCCAATTAG
SEQ ID NO: 2318


 


BCAS1
NM_003657.1
CCCCGAGACAACGGAGATAAGTGCTGTTGCGGATGCCAACGGAAAGAATCTTGGGAAAGAGGCCAAACCCGAG
SEQ ID NO: 2319


 


Bcl2
NM_000633.1
CAGATGGACCTAGTACCCACTGAGATTTCCACGCCGAAGGACAGCGATGGGAAAAATGCCCTTAAATCATAGG
SEQ ID NO: 2320


 


BCL2L10
NM_020396.2
GCTGGGATGGCTTTTGTCACTTCTTCAGGACCCCCTTTCCACTGGCTTTTTGGAGAAAACAGCTGGTCCAGGC
SEQ ID NO: 2321


 


BCL2L11
NM_138621.1
AATTACCAAGCAGCCGAAGACCACCCACGAATGGTTATCTTACGACTGTTACGTTACATTGTCCGCCTG
SEQ ID NO: 2322


 


BCL2L12
NM_138639.1
AACCCACCCCTGTCTTGGAGCTCCGGGTAGCTCTCAAACTCGAGGCTGCGCACCCCCTTTCCCGTCAGCTGAG
SEQ ID NO: 2323


 


Bclx
NM_001191.1
CTTTTGTGGAACTCTATGGGAACAATGCAGCAGCCGAGAGCCGAAAGGGCCAGGAACGCTTCAACCGCTG
SEQ ID NO: 2324


 


BCRP
NM_004827.1
TGTACTGGCGAAGAATATTTGGTAAAGCAGGGCATCGATCTCTCACCCTGGGGCTTGTGGAAGAATCACGTGGC
SEQ ID NO: 2325


 


BFGF
NM_007083.1
CCAGGAAGAATGCTTAAGATGTGAGTGGATGGATCTCAATGACCTGGCGAAGACTGAAAATACAACTCCCATCACCA
SEQ ID NO: 2326


 


BGN
NM_001711.3
GAGCTCCGCAAGGATGACTTCAAGGGTCTCCAGCACCTCTACGCCCTCGTCCTGGTGAACAACAAG
SEQ ID NO: 2327


 


BID
NM_001196.2
GGACTGTGAGGTCAACAACGGTTCCAGCCTCAGGGATGAGTGCATCACAAACCTACTGGTGTTTGGCTTCC
SEQ ID NO: 2328


 


BIK
NM_001197.3
ATTCCTATGGCTCTGCAATTGTCACCGGTTAACTGTGGCCTGTGCCCAGGAAGAGCCATTCACTCCTGCC
SEQ ID NO: 2329


 


BIN1
NM_004305.1
CCTGCAAAAGGGAACAAGAGCCCTTCGCCTCCAGATGGCTCCCCTGCCGCCACCCCCGAGATCAGAGTCAACCACG
SEQ ID NO: 2330


 


BLMH
NM_000386.2
GGTTGCTGCCTCCATCAAAGATGGAGAGGCTGTGTGGTTTGGCTGTGATGTTGGAAAACACTTCAATAGCAAGCTGG
SEQ ID NO: 2331


 


BMP2
NM_001200.1
ATGTGGACGCTCTTTCAATGGACGTGTCCCCGCGTGCTTCTTAGACGGACTGCGGTCTCCTAAAGGTCGACCATGGT
SEQ ID NO: 2332


 


BMP4
NM_001202.2
GGGCTAGCCATTGAGGTGACTCACCTCCATCAGACTCGGACCCACCAGGGCCAGCATGTCAGGATTAGC
SEQ ID NO: 2333


 


BMP7
NM_001719.1
TCGTGGAACATGACAAGGAATTCTTCCACCCACGCTACCACCATCGAGAGTTCCGGTTTGATCTTTCCA
SEQ ID NO: 2334


 


BMPR1A
NM_004329.2
TTGGTTCAGCGAACTATTGCCAAACAGATTCAGATGGTCCGGCAAGTTGGTAAAGGCCGATATGGAGA
SEQ ID NO: 2335


 


BRAF
NM_004333.1
CCTTCCGACCAGCAGATGAAGATCATCGAAATCAATTTGGGCAACGAGACCGATCCTCATCAGCTCCCAATGTGCATATAAA
SEQ ID NO: 2336


 


BRCA1
NM_007295.1
TCAGGGGGCTAGAAATCTGTTGCTATGGGCCCTTCACCAACATGCCCACAGATCAACTGGAATGG
SEQ ID NO: 2337


 


BRCA2
NM_000059.1
AGTTCGTGCTTTGCAAGATGGTGCAGAGCTTTATGAAGCAGTGAAGAATGCAGCAGACCCAGCTTACCTT
SEQ ID NO: 2338


 


BRK
NM_005975.1
GTGCAGGAAAGGTTCACAAATGTGGAGTGTCTGCGTCCAATACACGCGTGTGCTCCTCTCCTTACTCCATCGTGTGTGC
SEQ ID NO: 2339


 


BTF3
NM_001207.2
CAGTGATCCACTTTAACAACCCTAAAGTTCAGGCATCTCTGGCAGCGAACACTTTCACCATTACAGGCCATGCT
SEQ ID NO: 2340


 


BTRC
NM_033637.2
GTTGGGACACAGTTGGTCTGCAGTCGGCCCAGGACGGTCTACTCAGCACAACTGACTGCTTCA
SEQ ID NO: 2341


 


BUB1
NM_004336.1
CCGAGGTTAATCCAGCACGTATGGGGCCAAGTGTAGGCTCCCAGCAGGAACTGAGAGCGCCATGTCTT
SEQ ID NO: 2342


 


BUB1B
NM_001211.3
TCAACAGAAGGCTGAACCACTAGAAAGACTACAGTCCCAGCACCGACAATTCCAAGCTCGAGTGTCTCGGCAAACTCTGTTG
SEQ ID NO: 2343


 


BUB3
NM_004725.1
CTGAAGCAGATGGTTCATCATTTCCTGGGCTGTTAAACAAAGCGAGGTTAAGGTTAGACTCTTGGGAATCAGC
SEQ ID NO: 2344


 


c-abl
NM_005157.2
CCATCTCGCTGAGATACGAAGGGAGGGTGTACCATTACAGGATCAACACTGCTTCTGATGGCAAGCTCTACGTCT
SEQ ID NO: 2345


 


c-kit
NM_000222.1
GAGGCAACTGCTTATGGCTTAATTAAGTCAGATGCGGCCATGACTGTCGCTGTAAAGATGCTCAAGCCGAGTGCC
SEQ ID NO: 2346


 


c-myb (MYB
NM_005375.1
AACTCAGACTTGGAAATGCCTTCTTTAACTTCCACCCCCCTCATTGGTCACAAATTGACTGTTACAACACCATTTCATAGAGACCAG
SEQ ID NO: 2347


official)


 


c-Src
NM_005417.3
TGAGGAGTGGTATTTTGGCAAGATCACCAGACGGGAGTCAGAGCGGTTACTGCTCAATGCAGAGAACCCGAGAG
SEQ ID NO: 2348


 


C20 orf1
NM_012112.2
TCAGCTGTGAGCTGCGGATACCGCCCGGCAATGGGACCTGCTCTTAACCTCAAACCTAGGACCGT
SEQ ID NO: 2349


 


C20ORF126
NM_030815.2
CCAGCACTGCTCGTTACTGTCTGCCTTCAGTGGTCTGAGGTCCCAGTATGAACTGCCGTGAAGTCAA
SEQ ID NO: 2350


 


C8orf4
NM_020130.2
CTACGAGTCAGCCCATCCATCCATGGCTACCACTTCGACACAGCCTCTCGTAAGAAAGCCGTGGGCA
SEQ ID NO: 2351


 


CA9
NM_001216.1
ATCCTAGCCCTGGTTTTTGGCCTCCTTTTTGCTGTCACCAGCGTCGCGTTCCTTGTGCAGATGAGAAGGCAG
SEQ ID NO: 2352


 


Cad17
NM_004063.2
GAAGGCCAAGAACCGAGTCAAATTATATTCCAGTTTAAGGCCAATCCTCCTGCTGTGACTTTTGAACTAACTGGGGA
SEQ ID NO: 2353


 


CALD1
NM_004342.4
CACTAAGGTTTGAGACAGTTCCAGAAAGAACCCAAGCTCAAGACGCAGGACGAGCTCAGTTGTAGAGGGCTAATTCGC
SEQ ID NO: 2354


 


CAPG
NM_001747.1
GATTGTCACTGATGGGGAGGAGCCTGCTGAGATGATCCAGGTCCTGGGCCCCAAGCCTGCTCTGAAGG
SEQ ID NO: 2355


 


CAPN1
NM_005186.2
CAAGAAGCTGTACGAGCTCATCATCACCCGCTACTCGGAGCCCGACCTGGCGGTCGACTTTGACAATTTCGTTTGCTGC
SEQ ID NO: 2356


 


CASP8
NM_033357.1
CCTCGGGGATACTGTCTGATCATCAACAATCACAATTTTGCAAAAGCACGGGAGAAAGTGCCCAAACTTC
SEQ ID NO: 2357


 


CASP9
NM_001229.2
TGAATGCCGTGGATTGCACGTGGCCTCTTGAGCAGTGGCTGGTCCAGGGCTAGTGACTTGTGTCCCATGATCCCTGT
SEQ ID NO: 2358


 


CAT
NM_001752.1
ATCCATTCGATCTCACCAAGGTTTGGCCTCACAAGGACTACCCTCTCATCCCAGTTGGTAAACTGGTCTTAAACCGGA
SEQ ID NO: 2359


 


CAV1
NM_001753.3
GTGGCTCAACATTGTGTTCCCATTTCAGCTGATCAGTGGGCCTCCAAGGAGGGGCTGTAAAATGGAGGCCATTG
SEQ ID NO: 2360


 


CBL
NM_005188.1
TCATTCACAAACCTGGCAGTTATATCTTCCGGCTGAGCTGTACTCGTCTGGGTCAGTGGGCTATTGGGTATG
SEQ ID NO: 2361


 


CCL20
NM_004591.1
CCATGTGCTGTACCAAGAGTTTGCTCCTGGCTGCTTTGATGTCAGTGCTGCTACTCCACCTCTGCGGCG
SEQ ID NO: 2362


 


CCL3
NM_002983.1
AGCAGACAGTGGTCAGTCCTTTCTTGGCTCTGCTGACACTCGAGCCCACATTCCGTCACCTGCTCAGAATCATGCAG
SEQ ID NO: 2363


 


CCNA2
NM_001237.2
CCATACCTCAAGTATTTGCCATCAGTTATTGCTGGAGCTGCCTTTCATTTAGCACTCTACACAGTCACGGGACAAAGCT
SEQ ID NO: 2364


 


CCNB1
NM_031966.1
TTCAGGTTGTTGCAGGAGACCATGTACATGACTGTCTCCATTATTGATCGGTTCATGCAGAATAATTGTGTGCCCAAGAAGATG
SEQ ID NO: 2365


 


CCNB2
NM_004701.2
AGGCTTCTGCAGGAGACTCTGTACATGTGCGTTGGCATTATGGATCGATTTTTACAGGTTCAGCCAGTTTCCC
SEQ ID NO: 2366


 


CCND1
NM_001758.1
GCATGTTCGTGGCCTCTAAGATGAAGGAGACCATCCCCCTGACGGCCGAGAAGCTGTGCATCTACACCG
SEQ ID NO: 2367


 


CCND3
NM_001760.2
CCTCTGTGCTACAGATTATACCTTTGCCATGTACCCGCCATCCATGATCGCCACGGGCAGCATTGGGGCTGCAGTG
SEQ ID NO: 2368


 


CCNE1
NM_001238.1
AAAGAAGATGATGACCGGGTTTACCCAAACTCAACGTGCAAGCCTCGGATTATTGCACCATCCAGAGGCTC
SEQ ID NO: 2369


 


CCNE2
NM_057749.1
ATGCTGTGGCTCCTTCCTAACTGGGGCTTTCTTGACATGTAGGTTGCTTGGTAATAACCTTTTTGTATATCACAATTTGGGT
SEQ ID NO: 2370


 


CCNE2
NM_057749var1
GGTCACCAAGAAACATCAGTATGAAATTAGGAATTGTTGGCCACCTGTATTATCTGGGGGGATCAGTCCTTGCATTATCATTGAA
SEQ ID NO: 2371


variant 1


 


CCR7
NM_001838.2
GGATGACATGCACTCAGCTCTTGGCTCCACTGGGATGGGAGGAGAGGACAAGGGAAATGTCAGG
SEQ ID NO: 2372


 


CD105
NM_000118.1
GCAGGTGTCAGCAAGTATGATCAGCAATGAGGCGGTGGTCAATATCCTGTCGAGCTCATCACCACAGCGGAAAAA
SEQ ID NO: 2373


 


CD134
NM_003327.1
GCCCAGTGCGGAGAACAGGTCCAGCTTGATTCTCGTCTCTGCACTTAAGCTGTTCTCCAGGTGCGTGTGATT
SEQ ID NO: 2374


(TNFRSF4


official)


 


CD18
NM_000211.1
CGTCAGGACCCACCATGTCTGCCCCATCACGCGGCCGAGACATGGCTTGGCCACAGCTCTTGAGGATGTCACCAATTAACC
SEQ ID NO: 2375


 


CD24
NM_013230.1
TCCAACTAATGCCACCACCAAGGCGGCTGGTGGTGCCCTGCAGTCAACAGCCAGTCTCTTCGTGGTCTCACTCTCTC
SEQ ID NO: 2376


 


CD28
NM_006139.1
TGTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTTCCCGGACCTTCTAAGCCCTTTTGGGTGCT
SEQ ID NO: 2377


 


CD31
NM_000442.1
TGTATTTCAAGACCTCTGTGCACTTATTTATGAACCTGCCCTGCTCCCACAGAACACAGCAATTCCTCAGGCTAA
SEQ ID NO: 2378


 


CD34
NM_001773.1
CCACTGCACACACCTCAGAGGCTGTTCTTGGGGCCCTACACCTTGAGGAGGGGCAGGTAAACTCCTG
SEQ ID NO: 2379


 


CD3z
NM_000734.1
AGATGAAGTGGAAGGCGCTTTTCACCGCGGCCATCCTGCAGGCACAGTTGCCGATTACAGAGGCA
SEQ ID NO: 2380


 


CD44E
X55150
ATCACCGACAGCACAGACAGAATCCCTGCTACCAATATGGACTCCAGTCATAGTACAACGCTTCAGCCTACTGCAAATCCAAACACAGGT
SEQ ID NO: 2381


 


CD44s
M59040.1
GACGAAGACAGTCCCTGGATCACCGACAGCACAGACAGAATCCCTGCTACCAGAGACCAAGACACATTCCACCCCAGT
SEQ ID NO: 2382


 


CD44v3
AJ251595v3
CACACAAAACAGAACCAGGACTGGACCCAGTGGAACCCAAGCCATTCAAATCCGGAAGTGCTACTTCAG
SEQ ID NO: 2383


 


CD44v6
AJ251595v6
CTCATACCAGCCATCCAATGCAAGGAAGGACAACACCAAGCCCAGAGGACAGTTCCTGGACTGATTTCTTC
SEQ ID NO: 2384




AACCCAA


 


CD68
NM_001251.1
TGGTTCCCAGCCCTGTGTCCACCTCCAAGCCCAGATTCAGATTCGAGTCATGTACACAACCCAGGGTGGAGGAG
SEQ ID NO: 2385


 


CD80
NM_005191.2
TTCAGTTGCTTTGCAGGAAGTGTCTAGAGGAATATGGTGGGCACAGAAGTAGCTCTGGTGACCTTGATCAA
SEQ ID NO: 2386


 


CD82
NM_002231.2
GTGCAGGCTCAGGTGAAGTGCTGCGGCTGGGTCAGCTTCTACAACTGGACAGACAACGCTGAGCTCATGAATCGCCCTGAGGTC
SEQ ID NO: 2387


 


CD8A
NM_171827.1
AGGGTGAGGTGCTTGAGTCTCCAACGGCAAGGGAACAAGTACTTCTTGATACCTGGGATACTGTGCCC
SEQ ID NO: 2388


 


CD9
NM_001769.1
GGGCGTGGAACAGTTTATCTCAGACATCTGCCCCAAGAAGGACGTACTCGAAACCTTCACCGTG
SEQ ID NO: 2389


 


CDC2
NM_001786.2
GAGAGCGACGCGGTTGTTGTAGCTGCCGCTGCGGCCGCCGCGGAATAATAAGCCGGGATCTACCATAC
SEQ ID NO: 2390


 


CDC20
NM_001255.1
TGGATTGGAGTTCTGGGAATGTACTGGCCGTGGCACTGGACAACAGTGTGTACCTGTGGAGTGCAAGC
SEQ ID NO: 2391


 


cdc25A
NM_001789.1
TCTTGCTGGCTACGCCTCTTCTGTCCCTGTTAGACGTCCTCCGTCCATATCAGAACTGTGCCACAATGCAG
SEQ ID NO: 2392


 


CDC25B
NM_021874.1
AAACGAGCAGTTTGCCATCAGACGCTTCCAGTCTATGCCGGTGAGGCTGCTGGGCCACAGCCCCGTGCTTCGGAACATCACCAAC
SEQ ID NO: 2393


 


CDC25C
NM_001790.2
GGTGAGCAGAAGTGGCCTATATCGCTCCCCGTCGATGCCAGAGAACTTGAACAGGCCAAGACTGAAG
SEQ ID NO: 2394


 


CDC4
NM_018315.2
GCAGTCCGCTGTGTTCAATATGATGGCAGGAGGGTTGTTAGTGGAGCATATGATTTTATGGTAAAGGTGTGGGATCC
SEQ ID NO: 2395


 


CDC42
NM_001791.2
TCCAGAGACTGCTGAAAAGCTGGCCCGTGACCTGAAGGCTGTCAAGTATGTGGAGTGTTCTGCACTTACACA
SEQ ID NO: 2396


 


CDC42BPA
NM_003607.2
GAGCTGAAAGACGCACACTGTCAGAGGAAACTGGCCATGCAGGAATTCATGGAGATCAATGAGCGGC
SEQ ID NO: 2397


 


CDC6
NM_001254.2
GCAACACTCCCCATTTACCTCCTTGTTCTCCACCAAAGCAAGGCAAGAAAGAGAATGGTCCCCCTCA
SEQ ID NO: 2398


 


CDCA7 v2
NM_145810.1
AAGACCGTGGATGGCTACATGAATGAAGATGACCTGCCCAGAAGCCGTCGCTCCAGATCATCCGTGACCCT
SEQ ID NO: 2399


 


CDH1
NM_004360.2
TGAGTGTCCCCCGGTATCTTCCCCGCCCTGCCAATCCCGATGAAATTGGAAATTTTATTGATGAAAATCTGAAAGCGGCTG
SEQ ID NO: 2400


 


CDH11
NM_001797.2
GTCGGCAGAAGCAGGACTTGTACCTTCTGCCCATAGTGATCAGCGATGGCGGCATCCCGCCCATGAGTAG
SEQ ID NO: 2401


 


CDH3
NM_001793.3
ACCCATGTACCGTCCTCGGCCAGCCAACCCAGATGAAATCGGCAACTTTATAATTGAGAACCTGAAGGCGG
SEQ ID NO: 2402


 


CDK2
NM_001798.2
AATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCCCTGGCTCACCCTTTCTTCCAGGATGTGACCAA
SEQ ID NO: 2403


 


CDX1
NM_001804.1
AGCAACACCAGCCTCCTGGCCACCTCCTCTCCAATGCCTGTGAAAGAGGAGTTTCTGCCATAGCCC
SEQ ID NO: 2404


 


Cdx2
NM_001265.2
GGGCAGGCAAGGTTTACACTGCGGAAGCCAAAGGCAGCTAAGATAGAAAGCTGGACTGACCAAAGAC
SEQ ID NO: 2405


 


CEACAM1
NM_001712.2
ACTTGCCTGTTCAGAGCACTCATTCCTTCCCACCCCCAGTCCTGTCCTATCACTCTAATTCGGATTTGCCA
SEQ ID NO: 2406


 


CEACAM6
NM_002483.2
CACAGCCTCACTTCTAACCTTCTGGAACCCACCCACCACTGCCAAGCTCACTATTGAATCCACGCCATTCAA
SEQ ID NO: 2407


 


CEBPB
NM_005194.2
GCAACCCACGTGTAACTGTCAGCCGGGCCCTGAGTAATCGCTTAAAGATGTTCCTACGGGCTTGT
SEQ ID NO: 2408


 


CEGP1
NM_020974.1
TGACAATCAGCACACCTGCATTCACCGCTCGGAAGAGGGCCTGAGCTGCATGAATAAGGATCACGGCTGTAGTCACA
SEQ ID NO: 2409


 


CENPA
NM_001809.2
TAAATTCACTCGTGGTGTGGACTTCAATTGGCAAGCCCAGGCCCTATTGGCCCTACAAGAGGC
SEQ ID NO: 2410


 


CENPE
NM_001813.1
GGATGCTGGTGACCTCTTCTTCCCTCACGTTGCAACAGGAATTAAAGGCTAAAAGAAAACGAAGAGTTACTT
SEQ ID NO: 2411




GGTGCCTTGGC


 


CENPF
NM_016343.2
CTCCCGTCAACAGCGTTCTTTCCAAACACTGGACCAGGAGTGCATCCAGATGAAGGCCAGACTCACCC
SEQ ID NO: 2412


 


CES2
NM_003869.4
ACTTTGCGAGAAATGGGAACCCCAATGGCGAGGGTCTGCCACACTGGCCGCTGTTCGACCAGGAGGAGCAATACCTG
SEQ ID NO: 2413


 


CGA (CHGA
NM_001275.2
CTGAAGGAGCTCCAAGACCTCGCTCTCCAAGGCGCCAAGGAGAGGGCACATCAGCAGAAGAAACACAGCGGTTTTG
SEQ ID NO: 2414


official)


 


CGB
NM_000737.2
CCACCATAGGCAGAGGCAGGCCTTCCTACACCCTACTCCCTGTGCCTCCAGCCTCGACTAGTCCCTAGCACTCGACGACT
SEQ ID NO: 2415


 


CHAF1B
NM_005441.1
GAGGCCAGTGGTGGAAACAGGTGTGGAGCTGATGAGTCTGCCCTACCGCCTGGTGTTTGCTGTGGCCTCGGA
SEQ ID NO: 2416


 


CHD2
NM_001271.1
CTCTGTGCGAGGCTGTCAGCCACACTAGGTATCAGGGATCCCGAGATGGGTACCAGCCCACAGTCCTTACC
SEQ ID NO: 2417


 


CHFR
NM_018223.1
AAGGAAGTGGTCCCTCTGTGGCAAGTGATGAAGTCTCCAGCTTTGCCTCAGCTCTCCCAGACAGAAAGACTGCGTC
SEQ ID NO: 2418


 


Chk1
NM_001274.1
GATAAATTGGTACAAGGGATCAGCTTTTCCCAGCCCACATGTCCTGATCATATGCTTTTGAATAGTCAGTTACTTGGCACCC
SEQ ID NO: 2419


 


Chk2
NM_007194.1
ATGTGGAACCCCCACCTACTTGGCGCCTGAAGTTCTTGTTTCTGTTGGGACTGCTGGGTATAACCGTGCTGTGGACTG
SEQ ID NO: 2420


 


CIAP1
NM_001166.2
TGCCTGTGGTGGGAAGCTCAGTAACTGGGAACCAAAGGATGATGCTATGTCAGAACACCGGAGGCATTTTCC
SEQ ID NO: 2421


 


cIAP2
NM_001165.2
GGATATTTCCGTGGCTCTTATTCAAACTCTCCATCAAATCCTGTAAACTCCAGAGCAAATCAAGATTTTTCTGCCTTGATGAGAAG
SEQ ID NO: 2422


 


CKS1B
NM_001826.1
GGTCCCTAAAACCCATCTGATGTCTGAATCTGAATGGAGGAATCTTGGCGTTCAGCAGAGTCAGGGATGGGTCCATTA
SEQ ID NO: 2423


 


CKS2
NM_001827.1
GGCTGGACGTGGTTTTGTCTGCTGCGCCCGCTCTTCGCGCTCTCGTTTCATTTTCTGCAGCG
SEQ ID NO: 2424


 


Claudin 4
NM_001305.2
GGCTGCTTTGCTGCAACTGTCCACCCCGCACAGACAAGCCTTACTCCGCCAAGTATTCTGCTGCCCGCTCTG
SEQ ID NO: 2425


 


CLDN1
NM_021101.3
TCTGGGAGGTGCCCTACTTTGCTGTTCCTGTCCCCGAAAAACAACCTCTTACCCAACACCAAGGCCCTATCCA
SEQ ID NO: 2426


 


CLDN7
NM_001307.3
GGTCTGCCCTAGTCATCCTGGGAGGTGCACTGCTCTCCTGTTCCTGTCCTGGGAATGAGAGCAAGGCTGGGTAC
SEQ ID NO: 2427


 


CLIC1
NM_001288.3
CGGTACTTGAGCAATGCCTACGCCCGGGAAGAATTCGCTTCCACCTGTCCAGATGATGAGGAGATCGA
SEQ ID NO: 2428


 


CLTC
NM_004859.1
ACCGTATGGACAGCCACAGCCTGGCTTTGGGTACAGCATGTGAGATGAAGCGCTGATCCTGTAGTCA
SEQ ID NO: 2429


 


CLU
NM_001831.1
CCCCAGGATACCTACCACTACCTGCCCTTCAGCCTGCCCCACCGGAGGCCTCACTTCTTCTTTCCCAAGTCCCGCA
SEQ ID NO: 2430


 


cMet
NM_000245.1
GACATTTCCAGTCCTGCAGTCAATGCCTCTCTGCCCCACCCTTTGTTCAGTGTGGCTGGTGCCACGACAAATGTGTGCGATCGGAG
SEQ ID NO: 2431


 


cMYC
NM_002467.1
TCCCTCCACTCGGAAGGACTATCCTGCTGCCAAGAGGGTCAAGTTGGACAGTGTCAGAGTCCTGAGACAGATCAGCAACAACCG
SEQ ID NO: 2432


 


CNN
NM_001299.2
TCCACCCTCCTGGCTTTGGCCAGCATGGCGAAGACGAAAGGAAACAAGGTGAACGTGGGAGTGA
SEQ ID NO: 2433


 


COL1A1
NM_000088.2
GTGGCCATCCAGCTGACCTTCCTGCGCCTGATGTCCACCGAGGCCTCCCAGAACATCACCTACCACTG
SEQ ID NO: 2434


 


COL1A2
NM_000089.2
CAGCCAAGAACTGGTATAGGAGCTCCAAGGACAAGAAACACGTCTGGCTAGGAGAAACTATCAATGCTGGCAGCCAGTTT
SEQ ID NO: 2435


 


COPS3
NM_003653.2
ATGCCCAGTGTTCCTGACTTCGAAACGCTATTCTCACAGGTTCAGCTCTTCATCAGCACTTGTAATGGGGAG
SEQ ID NO: 2436


 


COX2
NM_000963.1
TCTGCAGAGTTGGAAGCACTCTATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGC
SEQ ID NO: 2437


 


COX3
MITO_COX3
TCGAGTCTCCCTTCACCATTTCCGACGGCATCTACGGCTCAACATTTTTTGTAGCCACAGGCTTCCACGGACTTCACGTC
SEQ ID NO: 2438


 


CP
NM_000096.1
CGTGAGTACACAGATGCCTCCTTCACAAATCGAAAGGAGAGAGGCCCTGAAGAAGAGCATCTTGGCATCCTGG
SEQ ID NO: 2439


 


CRBP
NM_002899.2
TGGTCTGCAAGCAAGTATTCAAGAAGGTGCAGTGAGGCCCAAGCAGACAACCTTGTCCCAACCAATCAGC
SEQ ID NO: 2440


 


CREBBP
NM_004380.1
TGGGAAGCAGCTGTGTACCATTCCTCGCGATGCTGCCTACTACAGCTATCAGAATAGGTATCATTTCTGTGAGAAGTGTTTC
SEQ ID NO: 2441


 


CRIP2
NM_001312.1
GTGCTACGCCACCCTGTTCGGACCCAAAGGCGTGAACATCGGGGGCGCGGGCTCCTACATCTACGAGAAGCCCCTG
SEQ ID NO: 2442


 


cripto (TDGF1
NM_003212.1
GGGTCTGTGCCCCATGACACCTGGCTGCCCAAGAAGTGTTCCCTGTGTAAATGCTGGCACGGTCA
SEQ ID NO: 2443


official)


 


CRK(a)
NM_016823.2
CTCCCTAACCTCCAGAATGGGCCCATATATGCCAGGGTTATCCAGAAGCGAGTCCCCAATGCCTACGACAAGACA
SEQ ID NO: 2444


 


CRMP1
NM_001313.1
AAGGTTTTTGGATTGCAAGGGGTTTCCAGGGGCATGTATGACGGTCCTGTGTACGAGGTACCAGCTACACCC
SEQ ID NO: 2445


 


CRYAB
NM_001885.1
GATGTGATTGAGGTGCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTC
SEQ ID NO: 2446


 


CSEL1
NM_001316.2
TTACGCAGCTCATGCTCTTGAACGGCTCTTTACTATGCGAGGGCCTAACAATGCCACTCTCTTTACAGCTGC
SEQ ID NO: 2447


 


CSF1
NM_000757.3
TGCAGCGGCTGATTGACAGTCAGATGGAGACCTCGTGCCAAATTACATTTGAGTTTGTAGACCAGGAACAGTTG
SEQ ID NO: 2448


 


CSK (SRC)
NM_004383.1
CCTGAACATGAAGGAGCTGAAGCTGCTGCAGACCATCGGGAAGGGGGAGTTCGGAGACGTGATG
SEQ ID NO: 2449


 


CTAG1B
NM_001327.1
GCTCTCCATCAGCTCCTGTCTCCAGCAGCTTTCCCTGTTGATGTGGATCACGCAGTGCTTTCTGCCCGTGTT
SEQ ID NO: 2450


 


CTGF
NM_001901.1
GAGTTCAAGTGCCCTGACGGCGAGGTCATGAAGAAGAACATGATGTTCATCAAGACCTGTGCCTGCCATTACAACT
SEQ ID NO: 2451


 


CTHRC1
NM_138455.2
GCTCACTTCGGCTAAAATGCAGAAATGCATGCTGTCAGCGTTGGTATTTCACATTCAATGGAGCTGA
SEQ ID NO: 2452


 


CTLA4
NM_005214.2
CACTGAGGTCCGGGTGACAGTGCTTCGGCAGGCTGACAGCCAGGTGACTGAAGTCTGTGCGGCAACCTAC
SEQ ID NO: 2453


 


CTNNBIP1
NM_020248.2
GTTTTCCAGGTCGGAGACGGAAGACCGGAGGCAGTAGCTGCAAAGCCCTTGGAACACCCTGGATGCT
SEQ ID NO: 2454


 


CTSB
NM_001908.1
GGCCGAGATCTACAAAAACGGCCCCGTGGAGGGAGCTTTCTCTGTGTATTCGGACTTCCTGC
SEQ ID NO: 2455


 


CTSD
NM_001909.1
GTACATGATCCCCTGTGAGAAGGTGTCCACCCTGCCCGCGATCACACTGAAGCTGGGAGGCAAAGGCTACAAGCTGTCCC
SEQ ID NO: 2456


 


CTSH
NM_004390.1
GCAAGTTCCAACCTGGAAAGGCCATCGGCTTTGTCAAGGATGTAGCCAACATCACAATCTATGACGAGGAAGCGATG
SEQ ID NO: 2457


 


CTSL
NM_001912.1
GGGAGGCTTATCTCACTGAGTGAGCAGAATCTGGTAGACTGCTCTGGGCCTCAAGGCAATGAAGGCTGCAATGG
SEQ ID NO: 2458


 


CTSL2
NM_001333.2
TGTCTCACTGAGCGAGCAGAATCTGGTGGACTGTTCGCGTCCTCAAGGCAATCAGGGCTGCAATGGT
SEQ ID NO: 2459


 


CUL1
NM_003592.2
ATGCCCTGGTAATGTCTGCATTCAACAATGACGCTGGCTTTGTGGCTGCTCTTGATAAGGCTTGTGGTCGC
SEQ ID NO: 2460


 


CUL4A
NM_003589.1
AAGCATCTTCCTGTTCTTGGACCGCACCTATGTGCTGCAGAACTCCACGCTGCCCTCCATCTGGGATATGGGATT
SEQ ID NO: 2461


 


CXCL12
NM_000609.3
GAGCTACAGATGCCCATGCCGATTCTTCGAAAGCCATGTTGCCAGAGCCAACGTCAAGCATCTCAAA
SEQ ID NO: 2462


 


CXCR4
NM_003467.1
TGACCGCTTCTACCCCAATGACTTGTGGGTGGTTGTGTTCCAGTTTCAGCACATCATGGTTGGCCTTATCCT
SEQ ID NO: 2463


 


CYBA
NM_000101.1
GGTGCCTACTCCATTGTGGCGGGCGTGTTTGTGTGCCTGCTGGAGTACCCCCGGGGGAAGAGGAAGAAGGGCTCCAC
SEQ ID NO: 2464


 


CYP1B1
NM_000104.2
CCAGCTTTGTGCCTGTCACTATTCCTCATGCCACCACTGCCAACACCTCTGTCTTGGGCTACCACATTCCC
SEQ ID NO: 2465


 


CYP2C8
NM_000770.2
CCGTGTTCAAGAGGAAGCTCACTGCCTTGTGGAGGAGTTGAGAAAAACCAAGGCTTCACCCTGTGATCCCACT
SEQ ID NO: 2466


 


CYP3A4
NM_017460.3
AGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAACTGCATTGGCATGAGGTTTGC
SEQ ID NO: 2467


 


CYR61
NM_001554.3
TGCTCATTCTTGAGGAGCATTAAGGTATTTCGAAACTGCCAAGGGTGCTGGTGCGGATGGACACTAATGCAGCCAC
SEQ ID NO: 2468


 


DAPK1
NM_004938.1
CGCTGACATCATGAATGTTCCTCGACCGGCTGGAGGCGAGTTTGGATATGACAAAGACACATCGTTGCTGA
SEQ ID NO: 2469




AAGAGA


 


DCC
NM_005215.1
AAATGTCCTCCTCGACTGCTCCGCGGAGTCCGACCGAGGAGTTCCAGTGATCAAGTGGAAGAAAGATGGCATTCA
SEQ ID NO: 2470


 


DCC_exons18-23
X76132_18-23
GGTCACCGTTGGTGTCATCACAGTGCTGGTAGTGGTCATCGTGGCTGTGATTTGCACCCGACGCTC
SEQ ID NO: 2471


 


DCC_exons6-7
X76132_6-7
ATGGAGATGTGGTCATTCCTAGTGATTATTTTCAGATAGTGGGAGGAAGCAACTTACGGATACTTGGGGTGGTG
SEQ ID NO: 2472


 


DCK
NM_000788.1
GCCGCCACAAGACTAAGGAATGGCCACCCCGCCCAAGAGAAGCTGCCCGTCTTTCTCAGCCAGCTCTGAG
SEQ ID NO: 2473




GGGACCCGCATCAAGAAAATCTCCATCGAAGGGAACATCG


 


DDB1
NM_001923.2
TGCGGATCATCCGGAATGGAATTGGAATCCACGAGCATGCCAGCATTGACTTACCAGGCATCAAAGGA
SEQ ID NO: 2474


 


DET1
NM_017996.2
CTTGTGGAGATCACCCAATCAGGTTCTATGCCCGGGACTCGGGCCTGCTCAAGTTTGAGATCCAGGCGGG
SEQ ID NO: 2475


 


DHFR
NM_000791.2
TTGCTATAACTAAGTGCTTCTCCAAGACCCCAACTGAGTCCCCAGCACCTGCTACAGTGAGCTGCCATTCCAC
SEQ ID NO: 2476


 


DHPS
NM_013407.1
GGGAGAACGGGATCAATAGGATCGGAAACCTGCTGGTGCCCAATGAGAATTACTGCAAGTTTGAGGACTGGCTGATGC
SEQ ID NO: 2477


 


DIABLO
NM_019887.1
CACAATGGCGGCTCTGAAGAGTTGGCTGTCGCGCAGCGTAACTTCATTCTTCAGGTACAGACAGTGTTTGTGT
SEQ ID NO: 2478


 


DIAPH1
NM_005219.2
CAAGCAGTCAAGGAGAACCAGAAGCGGCGGGAGACAGAAGAAAAGATGAGGCGAGCAAAACT
SEQ ID NO: 2479


 


DICER1
NM_177438.1
TCCAATTCCAGCATCACTGTGGAGAAAAGCTGTTTGTCTCCCCAGCATACTTTATCGCCTTCACTGCC
SEQ ID NO: 2480


 


DKK1
NM_012242.1
TGACAACTACCAGCCGTACCCGTGCGCAGAGGACGAGGAGTGCGGCACTGATGAGTACTGCGCTAGTCCC
SEQ ID NO: 2481


 


DLC1
NM_006094.3
GATTCAGACGAGGATGAGCCTTGTGCCATCAGTGGCAAATGGACTTTCCAAAGGGACAGCAAGAGGTG
SEQ ID NO: 2482


 


DPYD
NM_000110.2
AGGACGCAAGGAGGGTTTGTCACTGGCAGACTCGAGACTGTAGGCACTGCCATGGCCCCTGTGCTCAGTAAGGACTCGGCGGACATC
SEQ ID NO: 2483


 


DR4
NM_003844.1
TGCACAGAGGGTGTGGGTTACACCAATGCTTCCAACAATTTGTTTGCTTGCCTCCCATGTACAGCTTGTAAATCAGATGAAGA
SEQ ID NO: 2484


 


DR5
NM_003842.2
CTCTGAGACAGTGCTTCGATGACTTTGCAGACTTGGTGCCCTTTGACTCCTGGGAGCCGCTCATGAGGAAGTTGGGCCTCATGG
SEQ ID NO: 2485


 


DRG1
NM_004147.3
CCTGGATCTCCCAGGTATCATTGAAGGTGCCAAGGATGGGAAAGGTAGAGGTCGTCAAGTCATTGCA
SEQ ID NO: 2486


 


DSP
NM_004415.1
TGGCACTACTGCATGATTGACATAGAGAAGATCAGGGCCATGACAATCGCCAAGCTGAAAACAATGCGGCAGG
SEQ ID NO: 2487


 


DTYMK
NM_012145.1
AAATCGCTGGGAACAAGTGCCGTTAATTAAGGAAAAGTTGAGCCAGGGCGTGACCCTCGTCGTGGACAGATACGCATT
SEQ ID NO: 2488


 


DUSP1
NM_004417.2
AGACATCAGCTCCTGGTTCAACGAGGCCATTGACTTCATAGACTCCATCAAGAATGCTGGAGGAAGGGTGTTTGTC
SEQ ID NO: 2489


 


DUSP2
NM_004418.2
TATCCCTGTGGAGGACAACCAGATGGTGGAGATCAGTGCCTGGTTCCAGGAGGCCATAGGCTTCATTGACTGGGTG
SEQ ID NO: 2490


 


DUT
NM_001948.2
ACACATGGAGTGCTTCTGGAACTATCAGCCCACTTGACCACCCAGTTTGTGGAAGCACAGGCAAGAG
SEQ ID NO: 2491


 


DYRK1B
NM_004714.1
AGCATGACACGGAGATGAAGTACTATATAGTACACCTGAAGCGGCACTTCATGTTCCGGAACCACCTGTGCCTGGTATT
SEQ ID NO: 2492


 


E2F1
NM_005225.1
ACTCCCTCTACCCTTGAGCAAGGGCAGGGGTCCCTGAGCTGTTCTTCTGCCCCATACTGAAGGAACTGAGGCCTG
SEQ ID NO: 2493


 


EDN1
NM_001955.1
TGCCACCTGGACATCATTTGGGTCAACACTCCCGAGCACGTTGTTCCGTATGGACTTGGAAGCCCTAGGTCCA
SEQ ID NO: 2494


endothelin


 


EFNA1
NM_004428.2
TACATCTCCAAACCCATCCACCAGCATGAAGACCGCTGCTTGAGGTTGAAGGTGACTGTCAGTGGCAA
SEQ ID NO: 2495


 


EFNA3
NM_004952.3
ACTACATCTCCACGCCCACTCACAACCTGCACTGGAAGTGTCTGAGGATGAAGGTGTTCGTCTGCTG
SEQ ID NO: 2496


 


EFNB1
NM_004429.3
GGAGCCCGTATCCTGGAGCTCCCTCAACCCCAAGTTCCTGAGTGGGAAGGGCTTGGTGATCTATCC
SEQ ID NO: 2497


 


EFNB2
NM_004093.2
TGACATTATCATCCCGCTAAGGACTGCGGACAGCGTCTTCTGCCCTCACTACGAGAAGGTCAGCGGGGACTAC
SEQ ID NO: 2498


 


EFP
NM_005082.2
TTGAACAGAGCCTGACCAAGAGGGATGAGTTCGAGTTTCTGGAGAAAGCATCAAAACTGCGAGGAATCTCAACA
SEQ ID NO: 2499


 


EGFR
NM_005228.1
TGTCGATGGACTTCCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAAT
SEQ ID NO: 2500


 


EGLN1
NM_022051.1
TCAATGGCCGGACGAAAGCCATGGTTGCTTGTTATCCGGGCAATGGAACGGGTTATGTACGTCATGTTGATAATCCAAA
SEQ ID NO: 2501


 


EGLN3
NM_022073.2
GCTGGTCCTCTACTGCGGGAGCCGGCTGGGCAAATACTACGTCAAGGAGAGGTCTAAGGCAATGGTGG
SEQ ID NO: 2502


 


EGR1
NM_001964.2
GTCCCCGCTGCAGATCTCTGACCCGTTCGGATCCTTTCCTCACTCGCCCACCATGGACAACTACCCTAAGCTGGAG
SEQ ID NO: 2503


 


EGR3
NM_004430.2
CCATGTGGATGAATGAGGTGTCTCCTTTCCATACCCAGTCTCACCTTCTCCCCACCCTACCTCACCTCTTCTCAGGCA
SEQ ID NO: 2504


 


EI24
NM_004879.2
AAAGTGGTGAATGCCATTTGGTTTCAGGATATAGCTGACCTGGCATTTGAGGTATCAGGGAGGAAGCCTCAC
SEQ ID NO: 2505


 


EIF4E
NM_001968.1
GATCTAAGATGGCGACTGTCGAACCGGAAACCACCCCTACTCCTAATCCCCCGACTACAGAAGAGGAGAAAACGGAATCTAA
SEQ ID NO: 2506


 


EIF4EL3
NM_004846.1
AAGCCGCGGTTGAATGTGCCATGACCCTCTCCCTCTCTGGATGGCACCATCATTGAAGCTGGCGTCA
SEQ ID NO: 2507


 


ELAVL1
NM_001419.2
GACAGGAGGCCTCTATCCTGTCCCTCCACCCCACCCTCCACCTCAATCCCCTCCCATCTTCCCCAGACCTACCTCAC
SEQ ID NO: 2508


 


EMP1
NM_001423.1
GCTAGTACTTTGATGCTCCCTTGATGGGGTCCAGAGAGCCTCCCTGCAGCCACCAGACTTGGCCTCCAGCTGTTC
SEQ ID NO: 2509


 


EMR3
NM_032571.2
TGGCCTACCTCTTCACCATCATCAACAGCCTCCAAGGCTTCTTCATCTTCTTGGTCTACTGCCTCCTCA
SEQ ID NO: 2510


 


EMS1
NM_005231.2
GGCAGTGTCACTGAGTCCTTGAAATCCTCCCCTGCCCCGCGGGTCTCTGGATTGGGACGCACAGTGCA
SEQ ID NO: 2511


 


ENO1
NM_001428.2
CAAGGCCGTGAACGAGAAGTCCTGCAACTGCCTCCTGCTCAAAGTCAACCAGATTGGCTCCGTGACCG
SEQ ID NO: 2512


 


EP300
NM_001429.1
AGCCCCAGCAACTACAGTCTGGGATGCCAAGGCCAGCCATGATGTCAGTGGCCCAGCATGGTCAACCTTTGAACA
SEQ ID NO: 2513


 


EPAS1
NM_001430.3
AAGCCTTGGAGGGTTTCATTGCCGTGGTGACCCAAGATGGCGACATGATCTTTCTGTCAGAAAACATCAGCA
SEQ ID NO: 2514


 


EpCAM
NM_002354.1
GGGCCCTCCAGAACAATGATGGGCTTTATGATCCTGACTGCGATGAGAGCGGGCTCTTTAAGGCCAAGCAGTGCA
SEQ ID NO: 2515


 


EPHA2
NM_004431.2
CGCCTGTTCACCAAGATTGACACCATTGCGCCCGATGAGATCACCGTCAGCAGCGACTTCGAGGCACGCCAC
SEQ ID NO: 2516


 


EPHB2
NM_004442.4
CAACCAGGCAGCTCCATCGGCAGTGTCCATCATGCATCAGGTGAGCCGCACCGTGGACAGCATTAC
SEQ ID NO: 2517


 


EPHB4
NM_004444.3
TGAACGGGGTATCCTCCTTAGCCACGGGGCCCGTCCCATTTGAGCCTGTCAATGTCACCACTGACCGAGAGGTACCT
SEQ ID NO: 2518


 


EphB6
NM_004445.1
ACTGGTCCTCCATCGGCTCCCCAGGAGCTTTGGTTTGAGGTGCAAGGCTCAGCACTCATGCTACACTGG
SEQ ID NO: 2519


 


EPM2A
NM_005670.2
ACTGTGGCACTTAGGGGAGATGACATTTGCTTTGGGCAGAGGCAGCTAGCCAGGACACATTTCCACT
SEQ ID NO: 2520


 


ErbB3
NM_001982.1
CGGTTATGTCATGCCAGATACACACCTCAAAGGTACTCCCTCCTCCCGGGAAGGCACCCTTTCTTCAGTGGGTCTCAGTTC
SEQ ID NO: 2521


 


ERCC1
NM_001983.1
GTCCAGGTGGATGTGAAAGATCCCCAGCAGGCCCTCAAGGAGCTGGCTAAGATGTGTATCCTGGCCG
SEQ ID NO: 2522


 


ERCC2
NM_000400.2
TGGCCTTCTTCACCAGCTACCAGTACATGGAGAGCACCGTGGCCTCCTGGTATGAGCAGGGGATCCTTG
SEQ ID NO: 2523


 


EREG
NM_001432.1
ATAACAAAGTGTAGCTCTGACATGAATGGCTATTGTTTGCATGGACAGTGCATCTATCTGGTGGACATGAGT
SEQ ID NO: 2524




CAAAACTACTGCAGGTGTG


 


ERK1
Z11696.1
ACGGATCACAGTGGAGGAAGCGCTGGCTCACCCCTACCTGGAGCAGTACTATGACCCGACGGATGAG
SEQ ID NO: 2525


 


ERK2
NM_002745.1
AGTTCTTGACCCCTGGTCCTGTCTCCAGCCCGTCTTGGCTTATCCACTTTGACTCCTTTGAGCCGTTT
SEQ ID NO: 2526


 


ESPL1
NM_012291.1
ACCCCCAGACCGGATCAGGCAAGCTGGCCCTCATGTCCCCTTCACGGTGTTTGAGGAAGTCTGCCCTACA
SEQ ID NO: 2527


 


EstR1
NM_000125.1
CGTGGTGCCCCTCTATGACCTGCTGCTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCC
SEQ ID NO: 2528


 


ETV4
NM_001986.1
TCCAGTGCCTATGACCCCCCCAGACAAATCGCCATCAAGTCCCCTGCCCCTGGTGCCCTTGGACAGT
SEQ ID NO: 2529


 


F3
NM_001993.2
GTGAAGGATGTGAAGCAGACGTACTTGGCACGGGTCTTCTCCTACCCGGCAGGGAATGTGGAGAGCACCGGTT
SEQ ID NO: 2530


 


FABP4
NM_001442.1
GCTTTGCCACCAGGAAAGTGGCTGGCATGGCCAAACCTAACATGATCATCAGTGTGAATGGGGATG
SEQ ID NO: 2531


 


FAP
NM_004460.2
CTGACCAGAACCACGGCTTATCCGGCCTGTCCACGAACCACTTATACACCCACATGACCCACTTCC
SEQ ID NO: 2532


 


fas
NM_000043.1
GGATTGCTCAACAACCATGCTGGGCATCTGGACCCTCCTACCTCTGGTTCTTACGTCTGTTGCTAGATTATC
SEQ ID NO: 2533




GTCCAAAAGTGTTAATGCC


 


fasI
NM_000639.1
GCACTTTGGGATTCTTTCCATTATGATTCTTTGTTACAGGCACCGAGAATGTTGTATTCAGTGAGGGTCTTCTTACATGC
SEQ ID NO: 2534


 


FASN
NM_004104.4
GCCTCTTCCTGTTCGACGGCTCGCCCACCTACGTACTGGCCTACACCCAGAGCTACCGGGCAAAGC
SEQ ID NO: 2535


 


FBXO5
NM_012177.2
GGCTATTCCTCATTTTCTCTACAAAGTGGCCTCAGTGAACATGAAGAAGGTAGCCTCCTGGAGGAGAATTTC
SEQ ID NO: 2536




GGTGACAGTCTACAATCC


 


FBXW7
NM_033632.1
CCCCAGTTTCAACGAGACTTCATTTCATTGCTCCCTAAAGAGTTGGCACTCTATGTGCTTTCATTCCTGGAAC
SEQ ID NO: 2537


 


FDXR
NM_004110.2
GAGATGATTCAGTTACCGGGAGCCCGGCCCATTTTGGATCCTGTGGATTTCTTGGGTCTCCAGGACAAGAT
SEQ ID NO: 2538


 


FES
NM_002005.2
CTCTGCAGGCCTAGGTGCAGCTCCTCAGCGGCTCCAGCTCATATGCTGACAGCTCTTCACAGTCCTGG
SEQ ID NO: 2539


 


FGF18
NM_003862.1
CGGTAGTCAAGTCCGGATCAAGGGCAAGGAGACGGAATTCTACCTGTGCATGAACCGCAAAGGCAAGC
SEQ ID NO: 2540


 


FGF2
NM_002006.2
AGATGCAGGAGAGAGGAAGCCTTGCAAACCTGCAGACTGCTTTTTGCCCAATATAGATTGGGTAAGGCTGCAAAAC
SEQ ID NO: 2541


 


FGFR1
NM_023109.1
CACGGGACATTCACCACATCGACTACTATAAAAAGACAACCAACGGCCGACTGCCTGTGAAGTGGATGGCACCC
SEQ ID NO: 2542


 


FGFR2
NM_000141.2
GAGGGACTGTTGGCATGCAGTGCCCTCCCAGAGACCAACGTTCAAGCAGTTGGTAGAAGACTTGGATCGA
SEQ ID NO: 2543


isoform 1

ATTCTCACTC


 


FHIT
NM_002012.1
CCAGTGGAGCGCTTCCATGACCTGCGTCCTGATGAAGTGGCCGATTTGTTTCAGACGACCCAGAGAG
SEQ ID NO: 2544


 


FIGF
NM_004469.2
GGTTCCAGCTTTCTGTAGCTGTAAGCATTGGTGGCCACACCACCTCCTTACAAAGCAACTAGAACCTGCGGC
SEQ ID NO: 2545


 


FLJ12455
NM_022078.1
CCACCAGCATGAAGTTTCGGACAGACATGGCCTTTGTGAGGGGTTCCAGTTGTGCTTCAGACAGCC
SEQ ID NO: 2546


 


FLJ20712
AK000719.1
GCCACACAAACATGCTCCTGCTCCTGGCGGAGGCAGAGCTGCTGGGAAAGACATTTCGGAAGTTTCCTGTGGC
SEQ ID NO: 2547


 


FLT1
NM_002019.1
GGCTCCCGAATCTATCTTTGACAAAATCTACAGCACCAAGAGCGACGTGTGGTCTTACGGAGTATTGCTGTGGGA
SEQ ID NO: 2548


 


FLT4
NM_002020.1
ACCAAGAAGCTGAGGACCTGTGGCTGAGCCCGCTGACCATGGAAGATCTTGTCTGCTACAGCTTCCAGG
SEQ ID NO: 2549


 


FOS
NM_005252.2
CGAGCCCTTTGATGACTTCCTGTTCCCAGCATCATCCAGGCCCAGTGGCTCTGAGACAGCCCGCTCC
SEQ ID NO: 2550


 


FOXO3A
NM_001455.1
TGAAGTCCAGGACGATGATGCGCCTCTCTCGCCCATGCTCTACAGCAGCTCAGCCAGCCTGTCACCTTCAG
SEQ ID NO: 2551




TAAGCAAGCCGT


 


FPGS
NM_004957.3
CAGCCCTGCCAGTTTGACTATGCCGTCTTCTGCCCTAACCTGACAGAGGTGTCATCCACAGGCAAC
SEQ ID NO: 2552


 


FRP1
NM_003012.2
TTGGTACCTGTGGGTTAGCATCAAGTTCTCCCCAGGGTAGAATTCAATCAGAGCTCCAGTTTGCATTTGGATGTG
SEQ ID NO: 2553


 


FST
NM_006350.2
GTAAGTCGGATGAGCCTGTCTGTGCCAGTGACAATGCCACTTATGCCAGCGAGTGTGCCATGAAGGAAGCTG
SEQ ID NO: 2554


 


Furin
NM_002569.1
AAGTCCTCGATACGCACTATAGCACCGAGAATGACGTGGAGACCATCCGGGCCAGCGTCTGCGCCCCCTG
SEQ ID NO: 2555




CCACGCCTCATGTGCCACATGCCAG


 


FUS
NM_004960.1
GGATAATTCAGACAACAACACCATCTTTGTGCAAGGCCTGGGTGAGAATGTTACAATTGAGTCTGTGGCTGATTACTTCA
SEQ ID NO: 2556


 


FUT1
NM_000148.1
CCGTGCTCATTGCTAACCACTGTCTGTCCCTGAACTCCCAGAACCACTACATCTGGCTTTGGGCAG
SEQ ID NO: 2557


 


FUT3
NM_000149.1
CAGTTCGGTCCAACAGAGAAAGCAGGCAACCACCATGTCATTTGAAAACAGTTTCATCGGGATATAATTCGCA
SEQ ID NO: 2558


 


FUT6
NM_000150.1
CGTGTGTCTCAAGACGATCCCACTGTGTACCCTAATGGGTCCCGCTTCCCAGACAGCACAGGGACC
SEQ ID NO: 2559


 


FXYD5
NM_014164.4
AGAGCACCAAAGCAGCTCATCCCACTGATGACACCACGACGCTCTCTGAGAGACCATCCCCAAGCAC
SEQ ID NO: 2560


 


FYN
NM_002037.3
GAAGCGCAGATCATGAAGAAGCTGAAGCACGACAAGCTGGTCCAGCTCTATGCAGTGGTGTCTGAGGAG
SEQ ID NO: 2561


 


FZD1
NM_003505.1
GGTGCACCAGTTCTACCCTCTAGTGAAAGTGCAGTGTTCCGCTGAGCTCAAGTTCTTCCTGTGCTCCATGTACGC
SEQ ID NO: 2562


 


FZD2
NM_001466.2
TGGATCCTCACCTGGTCGGTGCTGTGCTGCGCTTCCACCTTCTTCACTGTCACCACGTACTTGGTAGACATGCAGCGC
SEQ ID NO: 2563


 


FZD6
NM_003506.2
AATGAGAGAGGTGAAAGCGGACGGAGCTAGCACCCCCAGGTTAAGAGAACAGGACTGTGGTGAACCT
SEQ ID NO: 2564


 


G-Catenin
NM_002230.1
TCAGCAGCAAGGGCATCATGGAGGAGGATGAGGCCTGCGGGCGCCAGTACACGCTCAAGAAAACCACC
SEQ ID NO: 2565


 


G1P2
NM_005101.1
CAACGAATTCCAGGTGTCCCTGAGCAGCTCCATGTCGGTGTCAGAGCTGAAGGCGCAGATC
SEQ ID NO: 2566


 


GADD45
NM_001924.2
GTGCTGGTGACGAATCCACATTCATCTCAATGGAAGGATCCTGCCTTAAGTCAACTTATTTGTTTTTGCCGGG
SEQ ID NO: 2567


 


GADD45B
NM_015675.1
ACCCTCGACAAGACCACACTTTGGGACTTGGGAGCTGGGGCTGAAGTTGCTCTGTACCCATGAACTCCCA
SEQ ID NO: 2568


 


GADD45G
NM_006705.2
CGCGCTGCAGATCCATTTTACGCTGATCCAGGCTTTCTGCTGCGAGAACGACATCGACATAGTGCG
SEQ ID NO: 2569


 


GAGE4
NM_001474.1
GGAACAGGGTCACCCACAGACTGGGTGTGAGTGTGAAGATGGTCCTGATGGGCAGGAGATGGACCCGCCAAATC
SEQ ID NO: 2570


 


GBP1
NM_002053.1
TTGGGAAATATTTGGGCATTGGTCTGGCCAAGTCTACAATGTCCCAATATCAAGGACAACCACCCTAGCTTCT
SEQ ID NO: 2571


 


GBP2
NM_004120.2
GCATGGGAACCATCAACCAGCAGGCCATGGACCAACTTCACTATGTGACAGAGCTGACAGATCGAATCAAG
SEQ ID NO: 2572




GCAAACTCCTCA


 


GCLC
NM_001498.1
CTGTTGCAGGAAGGCATTGATCATCTCCTGGCCCAGCATGTTGCTCATCTCTTTATTAGAGACCCACTGAC
SEQ ID NO: 2573


 


GCLM
NM_002061.1
TGTAGAATCAAACTCTTCATCATCAACTAGAAGTGCAGTTGACATGGCCTGTTCAGTCCTTGGAGTTGCACA
SEQ ID NO: 2574




GCTGGATTCTGTG


 


GCNT1
NM_001490.3
TGGTGCTTGGAGCATAGAAGACTGCCCTTCACAAAGGAAATCCCTGATTATTGTTTGAAATGCTGAGGACGTTGC
SEQ ID NO: 2575


 


GDF15
NM_004864.1
CGCTCCAGACCTATGATGACTTGTTAGCCAAAGACTGCCACTGCATATGAGCAGTCCTGGTCCTTCCACTGT
SEQ ID NO: 2576


 


GIT1
NM_014030.2
GTGTATGACGAGGTGGATCGAAGAGAAAATGATGCAGTGTGGCTGGCTACCCAAAACCACAGCACTCTGGT
SEQ ID NO: 2577


 


GJA1
NM_000165.2
GTTCACTGGGGGTGTATGGGGTAGATGGGTGGAGAGGGAGGGGATAAGAGAGGTGCATGTTGGTATTT
SEQ ID NO: 2578


 


GJB2
NM_004004.3
TGTCATGTACGACGGCTTCTCCATGCAGCGGCTGGTGAAGTGCAACGCCTGGCCTTGTCCCAACACTGTGGACT
SEQ ID NO: 2579


 


GPX1
NM_000581.2
GCTTATGACCGACCCCAAGCTCATCACCTGGTCTCCGGTGTGTCGCAACGATGTTGCCTGGAACTTT
SEQ ID NO: 2580


 


GPX2
NM_002083.1
CACACAGATCTCCTACTCCATCCAGTCCTGAGGAGCCTTAGGATGCAGCATGCCTTCAGGAGACACTGCTGGACC
SEQ ID NO: 2581


 


Grb10
NM_005311.2
CTTCGCCTTTGCTGATTGCCTCTCCAAACGCCTGCCTGACGACTGCCTTGGAGCATGTGCGTTATGG
SEQ ID NO: 2582


 


GRB14
NM_004490.1
TCCCACTGAAGCCCTTTCAGTTGCGGTTGAAGAAGGACTCGCTTGGAGGAAAAAAGGATGTTTACGCCTGGGCACT
SEQ ID NO: 2583


 


GRB2
NM_002086.2
GTCCATCAGTGCATGACGTTTAAGGCCACGTATAGTCCTAGCTGACGCCAATAATAAAAAACAAGAAACCAAGTGGGCT
SEQ ID NO: 2584


 


GRB7
NM_005310.1
CCATCTGCATCCATCTTGTTTGGGCTCCCCACCCTTGAGAAGTGCCTCAGATAATACCCTGGTGGCC
SEQ ID NO: 2585


 


GRIK1
NM_000830.2
GTTGGGTGCATCTCTCGGGCGTCCGGCAGCGGCTGTATCTCGGCATGAATTAAGAAGCTAGGAAGATGGAGCACG
SEQ ID NO: 2586


 


GRO1
NM_001511.1
CGAAAAGATGCTGAACAGTGACAAATCCAACTGACCAGAAGGGAGGAGGAAGCTCACTGGTGGCTGTTCCTGA
SEQ ID NO: 2587


 


GRP
NM_002091.1
CTGGGTCTCATAGAAGCAAAGGAGAACAGAAACCACCAGCCACCTCAACCCAAGGCCTTGGGCAATCAGC
SEQ ID NO: 2588




AGCCTTCGTGG


 


GRPR
NM_005314.1
ATGCTGCTGGCCATTCCAGAGGCCGTGTTTTCTGACCTCCATCCCTTCCATGAGGAAAGCACCAACCAGACCT
SEQ ID NO: 2589


 


GSK3B
NM_002093.2
GACAAGGACGGCAGCAAGGTGACAACAGTGGTGGCAACTCCTGGGCAGGGTCCAGACAGGCCACAA
SEQ ID NO: 2590


 


GSTA3
NM_000847.3
TCTCCAACTTCCCTCTGCTGAAGGCCCTGAAAACCAGAATCAGCAACCTGCCCACGGTGAAGAAGT
SEQ ID NO: 2591


 


GSTM1
NM_000561.1
AAGCTATGAGGAAAAGAAGTACACGATGGGGGACGCTCCTGATTATGACAGAAGCCAGTGGCTGAATGAAA
SEQ ID NO: 2592




AATTCAAGCTGGGCC


 


GSTM3
NM_000849.3
CAATGCCATCTTGCGCTACATCGCTCGCAAGCACAACATGTGTGGTGAGACTGAAGAAGAAAAGATTCGAGTGGAC
SEQ ID NO: 2593


 


GSTp
NM_000852.2
GAGACCCTGCTGTCCCAGAACCAGGGAGGCAAGACCTTCATTGTGGGAGACCAGATCTCCTTCGCTGACTACAACC
SEQ ID NO: 2594


 


GSTT1
NM_000853.1
CACCATCCCCACCCTGTCTTCCACAGCCGCCTGAAAGCCACAATGAGAATGATGCACACTGAGGCC
SEQ ID NO: 2595


 


H2AFZ
NM_002106.2
CCGGAAAGGCCAAGACAAAGGCGGTTTCCCGCTCGCAGAGAGCCGGCTTGCAGTTCCCAGTGGGCCGTATT
SEQ ID NO: 2596


 


HB-EGF
NM_001945.1
GACTCCTTCGTCCCCAGTTGCCGTCTAGGATTGGGCCTCCCATAATTGCTTTGCCAAAATACCAGAGCCTTCAAGTGCCA
SEQ ID NO: 2597


 


hCRA a
U78556.1
TGACACCCTTACCTTCCTGAGAAATACCCCCTGGGAGCGCGGAAAGCAGAGCGGACAGGTCAGTGACTTC
SEQ ID NO: 2598




TATTTTTGACTCGTGTTTTT


 


HDAC1
NM_004964.2
CAAGTACCACAGCGATGACTACATTAAATTCTTGCGCTCCATCCGTCCAGATAACATGTCGGAGTACAGCAAGC
SEQ ID NO: 2599


 


HDAC2
NM_001527.1
GGTGGCTACACAATCCGTAATGTTGCTCGATGTTGGACATATGAGACTGCAGTTGCCCTTGATTGTGAGATTCCCA
SEQ ID NO: 2600


 


HDGF
NM_004494.1
TCCTAGGCATTCTGGACCTCTGGGTTGGGATCAGGGGTAGGAATGGAAGGATGGAGCATCAACAGC
SEQ ID NO: 2601


 


hENT1
NM_004955.1
AGCCGTGACTGTTGAGGTCAAGTCCAGCATCGCAGGCAGCAGCACCTGGGAACGTTACTT
SEQ ID NO: 2602


 


Hepsin
NM_002151.1
AGGCTGCTGGAGGTCATCTCCGTGTGTGATTGCCCCAGAGGCCGTTTCTTGGCCGCCATCTGCCAAGACT
SEQ ID NO: 2603




GTGGCCGCAGGAAG


 


HER2
NM_004448.1
CGGTGTGAGAAGTGCAGCAAGCCCTGTGCCCGAGTGTGCTATGGTCTGGGCATGGAGCACTTGCGAGAGG
SEQ ID NO: 2604


 


Herstatin
AF177761.2
CACCCTGTCCTATCCTTCCTCAGACCCTCTTGGGACCTAGTCTCTGCCTTCTACTCTCTACCCCTGGCC
SEQ ID NO: 2605


 


HES6
NM_018645.3
TTAGGGACCCTGCAGCTCTGGAGTGGGTGGAGGGAGGGAGCTACGGGCAGGAGGAAGAATTTTGTAG
SEQ ID NO: 2606


 


HGF
M29145.1
CCGAAATCCAGATGATGATGCTCATGGACCCTGGTGCTACACGGGAAATCCACTCATTCCTTGGG
SEQ ID NO: 2607


 


HIF1A
NM_001530.1
TGAACATAAAGTCTGCAACATGGAAGGTATTGCACTGCACAGGCCACATTCACGTATATGATACCAACAGTA
SEQ ID NO: 2608




ACCAACCTCA


 


HK1
NM_000188.1
TACGCACAGAGGCAAGCAGCTAAGAGTCCGGGATCCCCAGCCTACTGCCTCTCCAGCACTTCTCTC
SEQ ID NO: 2609


 


HLA-DPB1
NM_002121.4
TCCATGATGGTTCTGCAGGTTTCTGCGGCCCCCCGGACAGTGGCTCTGACGGCGTTACTGATGGTGCTGCTCA
SEQ ID NO: 2610


 


HLA-DRA
NM_019111.3
GACGATTTGCCAGCTTTGAGGCTCAAGGTGCATTGGCCAACATAGCTGTGGACAAAGCCAACCTGGA
SEQ ID NO: 2611


 


HLA-DRB1
NM_002124.1
GCTTTCTCAGGACCTGGTTGCTACTGGTTCGGCAACTGCAGAAAATGTCCTCCCTTGTGGCTTCCT
SEQ ID NO: 2612


 


HLA-G
NM_002127.2
CCTGCGCGGCTACTACAACCAGAGCGAGGCCAGTTCTCACACCCTCCAGTGGATGATTGGCTGCGACCTG
SEQ ID NO: 2613


 


HMGB1
NM_002128.3
TGGCCTGTCCATTGGTGATGTTGCGAAGAAACTGGGAGAGATGTGGAATAACACTGCTGCAGATGACAAGC
SEQ ID NO: 2614


 


hMLH
NM_000249.2
CTACTTCCAGCAACCCCAGAAAGAGACATCGGGAAGATTCTGATGTGGAAATGGTGGAAGATGATTCCCGAAAG
SEQ ID NO: 2615


 


HNRPAB
NM_004499.2
CAAGGGAGCGACCAACTGATCGCACACATGCTTTGTTTGGATATGGAGTGAACACAATTATGTACCAAATTT
SEQ ID NO: 2616




AACTTGGCAAAC


 


HNRPD
NM_031370.2
GCCAGTAAGAACGAGGAGGATGAAGGCCATTCAAACTCCTCCCCACGACACTCTGAAGCAGCGACG
SEQ ID NO: 2617


 


HoxA1
NM_005522.3
AGTGACAGATGGACAATGCAAGAATGAACTCCTTCCTGGAATACCCCATACTTAGCAGTGGCGACTCGG
SEQ ID NO: 2618


 


HoxA5
NM_019102.2
TCCCTTGTGTTCCTTCTGTGAAGAAGCCCTGTTCTCGTTGCCCTAATTCATCTTTTAATCATGAGCCTGTTTATTGCC
SEQ ID NO: 2619


 


HOXB13
NM_006361.2
CGTGCCTTATGGTTACTTTGGAGGCGGGTACTACTCCTGCCGAGTGTCCCGGAGCTCGCTGAAACCCTGTG
SEQ ID NO: 2620


 


HOXB7
NM_004502.2
CAGCCTCAAGTTCGGTTTTCGCTACCGGAGCCTTCCCAGAACAAACTTCTTGTGCGTTTGCTTCCAAC
SEQ ID NO: 2621


 


HRAS
NM_005343.2
GGACGAATACGACCCCACTATAGAGGATTCCTACCGGAAGCAGGTGGTCATTGATGGGGAGACGTGC
SEQ ID NO: 2622


 


HSBP1
NM_001537.1
GGAGATGGCCGAGACTGACCCCAAGACCGTGCAGGACCTCACCTCGGTGGTGCAGACACTCCTGCAG
SEQ ID NO: 2623


 


HSD17B1
NM_000413.1
CTGGACCGCACGGACATCCACACCTTCCACCGCTTCTACCAATACCTCGCCCACAGCAAGCAAGTCTTTCGCGAGGCG
SEQ ID NO: 2624


 


HSD17B2
NM_002153.1
GCTTTCCAAGTGGGGAATTAAAGTTGCTTCCATCCAACCTGGAGGCTTCCTAACAAATATCGCAGGCA
SEQ ID NO: 2625


 


HSPA1A
NM_005345.4
CTGCTGCGACAGTCCACTACCTTTTTCGAGAGTGACTCCCGTTGTCCCAAGGCTTCCCAGAGCGAACCTG
SEQ ID NO: 2626


 


HSPA1B
NM_005346.3
GGTCCGCTTCGTCTTTCGAGAGTGACTCCCGCGGTCCCAAGGCTTTCCAGAGCGAACCTGTGC
SEQ ID NO: 2627


 


HSPA4
NM_002154.3
TTCAGTGTGTCCAGTGCATCTTTAGTGGAGGTTCACAAGTCTGAGGAAAATGAGGAGCCAATGGAAACAGAT
SEQ ID NO: 2628


 


HSPA5
NM_005347.2
GGCTAGTAGAACTGGATCCCAACACCAAACTCTTAATTAGACCTAGGCCTCAGCTGCACTGCCCGAAAAGC
SEQ ID NO: 2629




ATTTGGGCAGACC


 


HSPA8
NM_006597.3
CCTCCCTCTGGTGGTGCTTCCTCAGGGCCCACCATTGAAGAGGTTGATTAAGCCAACCAAGTGTAGATGTAGC
SEQ ID NO: 2630


 


HSPB1
NM_001540.2
CCGACTGGAGGAGCATAAAAGCGCAGCCGAGCCCAGCGCCCCGCACTTTTCTGAGCAGACGTCCAGAGCA
SEQ ID NO: 2631




GAGTCAGCCAGCAT


 


HSPCA
NM_005348.2
CAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCT
SEQ ID NO: 2632


 


HSPE1
NM_002157.1
GCAAGCAACAGTAGTCGCTGTTGGATCGGGTTCTAAAGGAAAGGGTGGAGAGATTCAACCAGTTAGCGTGAAAGTTGG
SEQ ID NO: 2633


 


HSPG2
NM_005529.2
GAGTACGTGTGCCGAGTGTTGGGCAGCTCCGTGCCTCTAGAGGCCTCTGTCCTGGTCACCATTGAG
SEQ ID NO: 2634


 


ICAM1
NM_000201.1
GCAGACAGTGACCATCTACAGCTTTCCGGCGCCCAACGTGATTCTGACGAAGCCAGAGGTCTCAGAAG
SEQ ID NO: 2635


 


ICAM2
NM_000873.2
GGTCATCCTGACACTGCAACCCACTTTGGTGGCTGTGGGCAAGTCCTTCACCATTGAGTGCA
SEQ ID NO: 2636


 


ID1
NM_002165.1
AGAACCGCAAGGTGAGCAAGGTGGAGATTCTCCAGCACGTCATCGACTACATCAGGGACCTTCAGTTGGA
SEQ ID NO: 2637


 


ID2
NM_002166.1
AACGACTGCTACTCCAAGCTCAAGGAGCTGGTGCCCAGCATCCCCCAGAACAAGAAGGTGAGCAAGATGGAAATCC
SEQ ID NO: 2638


 


ID3
NM_002167.2
CTTCACCAAATCCCTTCCTGGAGACTAAACCTGGTGCTCAGGAGCGAAGGACTGTGAACTTGTAGCCTGAAGAGCCAGAG
SEQ ID NO: 2639


 


ID4
NM_001546.2
TGGCCTGGCTCTTAATTTGCTTTTGTTTTGCCCAGTATAGACTCGGAAGTAAGAGTTATAGCTAGTGGTCTTG
SEQ ID NO: 2640




CATGATTGCA


 


IFIT1
NM_001548.1
TGACAACCAAGCAAATGTGAGGAGTCTGGTGACCTGGGGCAACTTTGCCTGGATGTATTACCACATGGGCAGACTG
SEQ ID NO: 2641


 


IGF1
NM_000618.1
TCCGGAGCTGTGATCTAAGGAGGCTGGAGATGTATTGCGCACCCCTCAAGCCTGCCAAGTCAGCTCGCTCT
SEQ ID NO: 2642




GTCCG


 


IGF1R
NM_000875.2
GCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATCTATGAGACAGACT
SEQ ID NO: 2643




ATTACCGGAAA


 


IGF2
NM_000612.2
CCGTGCTTCCGGACAACTTCCCCAGATACCCCGTGGGCAAGTTCTTCCAATATGACACCTGGAAGCAGTCCA
SEQ ID NO: 2644


 


IGFBP2
NM_000597.1
GTGGACAGCACCATGAACATGTTGGGCGGGGGAGGCAGTGCTGGCCGGAAGCCCCTCAAGTCGGGTATGAAGG
SEQ ID NO: 2645


 


IGFBP3
NM_000598.1
ACGCACCGGGTGTCTGATCCCAAGTTCCACCCCCTCCATTCAAAGATAATCATCATCAAGAAAGGGCA
SEQ ID NO: 2646


 


IGFBP5
NM_000599.1
TGGACAAGTACGGGATGAAGCTGCCAGGCATGGAGTACGTTGACGGGGACTTTCAGTGCCACACCTTCG
SEQ ID NO: 2647


 


IGFBP6
NM_002178.1
TGAACCGCAGAGACCAACAGAGGAATCCAGGCACCTCTACCACGCCCTCCCAGCCCAATTCTGCGGGTGTCCAAGAC
SEQ ID NO: 2648


 


IGFBP7
NM_001553
GGGTCACTATGGAGTTCAAAGGACAGAACTCCTGCCTGGTGACCGGGACAACCTGGCCATTCAGACCC
SEQ ID NO: 2649


 


IHH
NM_002181.1
AAGGACGAGGAGAACACAGGCGCCGACCGCCTCATGACCCAGCGCTGCAAGGACCGCCTGAACTCGCTGGCTATCT
SEQ ID NO: 2650


 


IL-8
NM_000584.2
AAGGAACCATCTCACTGTGTGTAAACATGACTTCCAAGCTGGCCGTGGCTCTCTTGGCAGCCTTCCTGAT
SEQ ID NO: 2651


 


IL10
NM_000572.1
GGCGCTGTCATCGATTTCTTCCCTGTGAAAACAAGAGCAAGGCCGTGGAGCAGGTGAAGAATGCCTTTAATAAGCTCCA
SEQ ID NO: 2652


 


IL1B
NM_000576.2
AGCTGAGGAAGATGCTGGTTCCCTGCCCACAGACCTTCCAGGAGAATGACCTGAGCACCTTCTTTCC
SEQ ID NO: 2653


 


IL6
NM_000600.1
CCTGAACCTTCCAAAGATGGCTGAAAAAGATGGATGCTTCCAATCTGGATTCAATGAGGAGACTTGCCTGGT
SEQ ID NO: 2654


 


IL6ST
NM_002184.2
GGCCTAATGTTCCAGATCCTTCAAAGAGTCATATTGCCCAGTGGTCACCTCACACTCCTCCAAGGCACAATTTT
SEQ ID NO: 2655


 


ILT-2
NM_006669.1
AGCCATCACTCTCAGTGCAGCCAGGTCCTATCGTGGCCCCTGAGGAGACCCTGACTCTGCAGT
SEQ ID NO: 2656


 


IMP-1
NM_006546.2
GAAAGTGTTTGCGGAGCACAAGATCTCCTACAGCGGCCAGTTCTTGGTCAAATCCGGCTACGCCTTC
SEQ ID NO: 2657


 


IMP2
NM_006548.3
CAATCTGATCCCAGGGTTGAACCTCAGCGCACTTGGCATCTTTTCAACAGGACTGTCCGTGCTATCTCCACC
SEQ ID NO: 2658




AGCAGGGCC


 


ING1L
NM_001564.1
TGTTTCCAAGATCCTGCTGAAAGTGAACGAGCCTCAGATAAAGCAAAGATGGATTCCAGCCAACCAGAAAGA
SEQ ID NO: 2659


 


ING5
NM_032329.4
CCTACAGCAAGTGCAAGGAATACAGTGACGACAAAGTGCAGCTGGCCATGCAGACCTACGAGATG
SEQ ID NO: 2660


 


INHA
NM_002191.2
CCTCCCAGTTTCATCTTCCACTACTGTCATGGTGGTTGTGGGCTGCAGATCCCACCAAACCTGTCCCTTCCAGTCCCT
SEQ ID NO: 2661


 


INHBA
NM_002192.1
GTGCCCGAGCCATATAGCAGGCACGTCCGGGTCCTCACTGTCCTTCCACTCAACAGTCATCAACCACTACCG
SEQ ID NO: 2662


 


INHBB
NM_002193.1
AGCCTCCAGGATACCAGCAAATGGATGCGGTGACAAATGGCAGCTTAGCTACAAATGCCTGTCAGTCGGAGA
SEQ ID NO: 2663


 


IRS1
NM_005544.1
CCACAGCTCACCTTCTGTCAGGTGTCCATCCCAGCTCCAGCCAGCTCCCAGAGAGGAAGAGACTGGCACTGAGG
SEQ ID NO: 2664


 


ITGA3
NM_002204.1
CCATGATCCTCACTCTGCTGGTGGACTATACACTCCAGACCTCGCTTAGCATGGTAAATCACCGGCTACAAA
SEQ ID NO: 2665




GCTTC


 


ITGA4
NM_000885.2
CAACGCTTCAGTGATCAATCCCGGGGCGATTTACAGATGCAGGATCGGAAAGAATCCCGGCCAGAC
SEQ ID NO: 2666


 


ITGA5
NM_002205.1
AGGCCAGCCCTACATTATCAGAGCAAGAGCCGGATAGAGGACAAGGCTCAGATCTTGCTGGACTGTGGAGAAGAC
SEQ ID NO: 2667


 


ITGA6
NM_000210.1
CAGTGACAAACAGCCCTTCCAACCCAAGGAATCCCACAAAAGATGGCGATGACGCCCATGAGGCTAAAC
SEQ ID NO: 2668


 


ITGA7
NM_002206.1
GATATGATTGGTCGCTGCTTTGTGCTCAGCCAGGACCTGGCCATCCGGGATGAGTTGGATGGTGGGGAAT
SEQ ID NO: 2669




GGAAGTTCT


 


ITGAV
NM_002210.2
ACTCGGACTGCACAAGCTATTTTTGATGACAGCTATTTGGGTTATTCTGTGGCTGTCGGAGATTTCAATGGT
SEQ ID NO: 2670




GATGGCA


 


ITGB1
NM_002211.2
TCAGAATTGGATTTGGCTCATTTGTGGAAAAGACTGTGATGCCTTACATTAGCACAACACCAGCTAAGCTCAGG
SEQ ID NO: 2671


 


ITGB3
NM_000212.1
ACCGGGAGCCCTACATGACCGAAAATACCTGCAACCGTTACTGCCGTGACGAGATTGAGTCAGTGAAAGAGCTTAAGG
SEQ ID NO: 2672


 


ITGB4
NM_000213.2
CAAGGTGCCCTCAGTGGAGCTCACCAACCTGTACCCGTATTGCGACTATGAGATGAAGGTGTGCGC
SEQ ID NO: 2673


 


ITGB5
NM_002213.3
TCGTGAAAGATGACCAGGAGGCTGTGCTATGTTTCTACAAAACCGCCAAGGACTGCGTCATGATGTTCACC
SEQ ID NO: 2674


 


K-ras
NM_033360.2
GTCAAAATGGGGAGGGACTAGGGCAGTTTGGATAGCTCAACAAGATACAATCTCACTCTGTGGTGGTCCTG
SEQ ID NO: 2675


 


KCNH2 iso
NM_000238.2
GAGCGCAAAGTGGAAATCGCCTTCTACCGGAAAGATGGGAGCTGCTTCCTATGTCTGGTGGATGTGGTGCCCGTGAAGA
SEQ ID NO: 2676


a/b


 


KCNH2 iso
NM_172057.1
TCCTGCTGCTGGTCATCTACACGGCTGTCTTCACACCCTACTCGGCTGCCTTCCTGCTGAAGGAGACGGAAGAAGG
SEQ ID NO: 2677


a/c


 


KCNK4
NM_016611.2
CCTATCAGCCGCTGGTGTGGTTCTGGATCCTGCTCGGCCTGGCTTACTTCGCCTCAGTGCTCACCACCA
SEQ ID NO: 2678


 


KDR
NM_002253.1
GAGGACGAAGGCCTCTACACCTGCCAGGCATGCAGTGTTCTTGGCTGTGCAAAAGTGGAGGCATTTTT
SEQ ID NO: 2679


 


Ki-67
NM_002417.1
CGGACTTTGGGTGCGACTTGACGAGCGGTGGTTCGACAAGTGGCCTTGCGGGCCGGATCGTCCCAGTGG
SEQ ID NO: 2680




AAGAGTTGTAA


 


KIAA0125
NM_014792.2
GTGTCCTGGTCCATGTGGTGCACGTGTCTCCACCTCCAAGGAGAGGCTCCTCAGTGTGCACCTCCC
SEQ ID NO: 2681


 


KIF22
NM_007317.1
CTAAGGCACTTGCTGGAAGGGCAGAATGCCAGTGTGCTTGCCTATGGACCCACAGGAGCTGGGAAGA
SEQ ID NO: 2682


 


KIF2C
NM_006845.2
AATTCCTGCTCCAAAAGAAAGTCTTCGAAGCCGCTCCACTCGCATGTCCACTGTCTCAGAGCTTCGCATCACG
SEQ ID NO: 2683


 


KIFC1
XM_371813.1
CCACAGGGTTGAAGAACCAGAAGCCAGTTCCTGCTGTTCCTGTCCAGAAGTCTGGCACATCAGGTG
SEQ ID NO: 2684


 


Kitlng
NM_000899.1
GTCCCCGGGATGGATGTTTTGCCAAGTCATTGTTGGATAAGCGAGATGGTAGTACAATTGTCAGACAGCTTGACTGATC
SEQ ID NO: 2685


 


KLF5
NM_001730.3
GTGCAACCGCAGCTTCTCGCGCTCTGACCACCTGGCCCTGCATATGAAGAGGCACCAGAACTGAGCACTGCCCG
SEQ ID NO: 2686


 


KLF6
NM_001300.4
CACGAGACCGGCTACTTCTCGGCGCTGCCGTCTCTGGAGGAGTACTGGCAACAGACCTGCCTAGAGC
SEQ ID NO: 2687


 


KLK10
NM_002776.1
GCCCAGAGGCTCCATCGTCCATCCTCTTCCTCCCCAGTCGGCTGAACTCTCCCCTTGTCTGCACTGTTCAAACCTCTG
SEQ ID NO: 2688


 


KLK6
NM_002774.2
GACGTGAGGGTCCTGATTCTCCCTGGTTTTACCCCAGCTCCATCCTTGCATCACTGGGGAGGACGTGATGAGTGAGGA
SEQ ID NO: 2689


 


KLRK1
NM_007360.1
TGAGAGCCAGGCTTCTTGTATGTCTCAAAATGCCAGCCTTCTGAAAGTATACAGCAAAGAGGACCAGGAT
SEQ ID NO: 2690


 


KNTC2
NM_006101.1
ATGTGCCAGTGAGCTTGAGTCCTTGGAGAAACACAAGCACCTGCTAGAAAGTACTGTTAACCAGGGGCTCA
SEQ ID NO: 2691


 


KRAS2
NM_004985.3
GAGACCAAGGTTGCAAGGCCAGGCCCTGTGTGAACCTTTGAGCTTTCATAGAGAGTTTCACAGCATGGACTG
SEQ ID NO: 2692


 


KRT19
NM_002276.1
TGAGCGGCAGAATCAGGAGTACCAGCGGCTCATGGACATCAAGTCGCGGCTGGAGCAGGAGATTGCCACCTACCGCA
SEQ ID NO: 2693


 


KRT8
NM_002273.1
GGATGAAGCTTACATGAACAAGGTAGAGCTGGAGTCTCGCCTGGAAGGGCTGACCGACGAGATCAACTTC
SEQ ID NO: 2694




CTCAGGCAGCTATATG


 


LAMA3
NM_000227.2
CAGATGAGGCACATGGAGACCCAGGCCAAGGACCTGAGGAATCAGTTGCTCAACTACCGTTCTGCCATTTCAA
SEQ ID NO: 2695


 


LAMB3
NM_000228.1
ACTGACCAAGCCTGAGACCTACTGCACCCAGTATGGCGAGTGGCAGATGAAATGCTGCAAGTGTGAC
SEQ ID NO: 2696


 


LAMC2
NM_005562.1
ACTCAAGCGGAAATTGAAGCAGATAGGTCTTATCAGCACAGTCTCCGCCTCCTGGATTCAGTGTCTCGGCT
SEQ ID NO: 2697




TCAGGGAGT


 


LAT
NM_014387.2
GTGAACGTTCCGGAGAGCGGGGAGAGCGCAGAAGCGTCTCTGGATGGCAGCCGGGAGTATGTGAATGT
SEQ ID NO: 2698


 


LCN2
NM_005564.2
CGCTGGGCAACATTAAGAGTTACCCTGGATTAACGAGTTACCTCGTCCGAGTGGTGAGCACCAACTACAAC
SEQ ID NO: 2699




CAGCATGCT


 


LDLRAP1
NM_015627.1
CAGTGCCTCTCGCCTGTCGACTGGGACAAGCCTGACAGCAGCGGCACAGAGCAGGATGACCTCTTCA
SEQ ID NO: 2700


 


LEF
NM_016269.2
GATGACGGAAAGCATCCAGATGGAGGCCTCTACAACAAGGGACCCTCCTACTCGAGTTATTCCGGG
SEQ ID NO: 2701


 


LGALS3
NM_002306.1
AGCGGAAAATGGCAGACAATTTTTCGCTCCATGATGCGTTATCTGGGTCTGGAAACCCAAACCCTCAAG
SEQ ID NO: 2702


 


LGMN
NM_001008530.1
TTGGTGCCGTTCCTATAGATGATCCTGAAGATGGAGGCAAGCACTGGGTGGTGATCGTGGCAGGTTC
SEQ ID NO: 2703


 


LILRB3
NM_006864.1
CACCTGGTCTGGGAAGATACCTGGAGGTTTTGATTGGGGTCTCGGTGGCCTTCGTCCTGCTGCTCTT
SEQ ID NO: 2704


 


LMNB1
NM_005573.1
TGCAAACGCTGGTGTCACAGCCAGCCCCCCAACTGACCTCATCTGGAAGAACCAGAACTCGTGGGG
SEQ ID NO: 2705


 


LMYC
NM_012421.1
CCCATCCAGAACACTGATTGCTGTCATTCAAGTGAAAGGGATGGAGGTCAGAAAGGGTGCATAGAAAGCAG
SEQ ID NO: 2706


 


LOX
NM_002317.3
CCAATGGGAGAACAACGGGCAGGTGTTCAGCTTGCTGAGCCTGGGCTCACAGTACCAGCCTCAGCG
SEQ ID NO: 2707


 


LOXL2
NM_002318.1
TCAGCGGGCTCTTAAACAACCAGCTGTCCCCGCAGTAAAGAAGCCTGCGTGGTCAACTCCTGTCTT
SEQ ID NO: 2708


 


LRP5
NM_002335.1
CGACTATGACCCACTGGACAAGTTCATCTACTGGGTGGATGGGCGCCAGAACATCAAGCGAGCCAAG
SEQ ID NO: 2709


 


LRP6
NM_002336.1
GGATGTAGCCATCTCTGCCTCTATAGACCTCAGGGCCTTCGCTGTGCTTGCCCTATTGGCTTTGAACT
SEQ ID NO: 2710


 


LY6D
NM_003695.2
AATGCTGATGACTTGGAGCAGGCCCCACAGACCCCACAGAGGATGAAGCCACCCCACAGAGGATGCAG
SEQ ID NO: 2711


 


MAD
NM_002357.1
TGGTTCTGATTAGGTAACGTATTGGACCTGCCCACAACTCCCTTGCACGTAAACTTCAGTGTCCCACCTTGACC
SEQ ID NO: 2712


 


MAD1L1
NM_003550.1
AGAAGCTGTCCCTGCAAGAGCAGGATGCAGCGATTGTGAAGAACATGAAGTCTGAGCTGGTACGGCT
SEQ ID NO: 2713


 


MAD2L1
NM_002358.2
CCGGGAGCAGGGAATCACCCTGCGCGGGAGCGCCGAAATCGTGGCCGAGTTCTTCTCATTCGGCATCAACAGCAT
SEQ ID NO: 2714


 


MADH2
NM_005901.2
GCTGCCTTTGGTAAGAACATGTCGTCCATCTTGCCATTCACGCCGCCAGTTGTGAAGAGACTGCTGGGAT
SEQ ID NO: 2715


 


MADH4
NM_005359.3
GGACATTACTGGCCTGTTCACAATGAGCTTGCATTCCAGCCTCCCATTTCCAATCATCCTGCTCCTGAGTATTGGT
SEQ ID NO: 2716


 


MADH7
NM_005904.1
TCCATCAAGGCTTTCGACTACGAGAAGGCGTACAGCCTGCAGCGGCCCAATGACCACGAGTTTATGCAGCAG
SEQ ID NO: 2717


 


MAP2
NM_031846.1
CGGACCACCAGGTCAGAGCCAATTCGCAGAGCAGGGAAGAGTGGTACCTCAACACCCACTACCCCTG
SEQ ID NO: 2718


 


MAP2K1
NM_002755.2
GCCTTTCTTACCCAGAAGCAGAAGGTGGGAGAACTGAAGGATGACGACTTTGAGAAGATCAGTGAGCTGGGGGCTG
SEQ ID NO: 2719


 


MAP3K1
XM_042066.8
GGTTGGCATCAAAAGGAACTGGTGCAGGAGAGTTTCAGGGACAATTACTGGGGACAATTGCATTTATGGCA
SEQ ID NO: 2720


 


MAPK14
NM_139012.1
TGAGTGGAAAAGCCTGACCTATGATGAAGTCATCAGCTTTGTGCCACCACCCCTTGACCAAGAAGAGATGGAGTCC
SEQ ID NO: 2721


 


Maspin
NM_002639.1
CAGATGGCCACTTTGAGAACATTTTAGCTGACAACAGTGTGAACGACCAGACCAAAATCCTTGTGGTTAATGCTGCC
SEQ ID NO: 2722


 


MAX
NM_002382.3
CAAACGGGCTCATCATAATGCACTGGAACGAAAACGTAGGGACCACATCAAAGACAGCTTTCACAGTTTGCGGGA
SEQ ID NO: 2723


 


MCM2
NM_004526.1
GACTTTTGCCCGCTACCTTTCATTCCGGCGTGACAACAATGAGCTGTTGCTCTTCATACTGAAGCAGTTAGTGGC
SEQ ID NO: 2724


 


MCM3
NM_002388.2
GGAGAACAATCCCCTTGAGACAGAATATGGCCTTTCTGTCTACAAGGATCACCAGACCATCACCATCCAGGAGAT
SEQ ID NO: 2725


 


MCM6
NM_005915.2
TGATGGTCCTATGTGTCACATTCATCACAGGTTTCATACCAACACAGGCTTCAGCACTTCCTTTGGTGTGTTT
SEQ ID NO: 2726




CCTGTCCCA


 


MCP1
NM_002982.1
CGCTCAGCCAGATGCAATCAATGCCCCAGTCACCTGCTGTTATAACTTCACCAATAGGAAGATCTCAGTGC
SEQ ID NO: 2727


 


MDK
NM_002391.2
GGAGCCGACTGCAAGTACAAGTTTGAGAACTGGGGTGCGTGTGATGGGGGCACAGGCACCAAAGTC
SEQ ID NO: 2728


 


MDM2
NM_002392.1
CTACAGGGACGCCATCGAATCCGGATCTTGATGCTGGTGTAAGTGAACATTCAGGTGATTGGTTGGAT
SEQ ID NO: 2729


 


MGAT5
NM_002410.2
GGAGTCGAAGGTGGACAATCTTGTTGTCAATGGCACCGGAACAAACTCAACCAACTCCACTACAGCTGTTCCCA
SEQ ID NO: 2730


 


MGMT
NM_002412.1
GTGAAATGAAACGCACCACACTGGACAGCCCTTTGGGGAAGCTGGAGCTGTCTGGTTGTGAGCAGGGTC
SEQ ID NO: 2731


 


mGST1
NM_020300.2
ACGGATCTACCACACCATTGCATATTTGACACCCCTTCCCCAGCCAAATAGAGCTTTGAGTTTTTTTGTTGGATATGGA
SEQ ID NO: 2732


 


MMP1
NM_002421.2
GGGAGATCATCGGGACAACTCTCCTTTTGATGGACCTGGAGGAAATCTTGCTCATGCTTTTCAACCAGGCCC
SEQ ID NO: 2733


 


MMP12
NM_002426.1
CCAACGCTTGCCAAATCCTGACAATTCAGAACCAGCTCTCTGTGACCCCAATTTGAGTTTTGATGCTGTCACTACCGT
SEQ ID NO: 2734


 


MMP2
NM_004530.1
CCATGATGGAGAGGCAGACATCATGATCAACTTTGGCCGCTGGGAGCATGGCGATGGATACCCCTTTGAC
SEQ ID NO: 2735




GGTAAGGACGGACTCC


 


MMP7
NM_002423.2
GGATGGTAGCAGTCTAGGGATTAACTTCCTGTATGCTGCAACTCATGAACTTGGCCATTCTTTGGGTATGGGACATTCC
SEQ ID NO: 2736


 


MMP9
NM_004994.1
GAGAACCAATCTCACCGACAGGCAGCTGGCAGAGGAATACCTGTACCGCTATGGTTACACTCGGGTG
SEQ ID NO: 2737


 


MRP1
NM_004996.2
TCATGGTGCCCGTCAATGCTGTGATGGCGATGAAGACCAAGACGTATCAGGTGGCCCACATGAAGAGCAAA
SEQ ID NO: 2738




GACAATCG


 


MRP2
NM_000392.1
AGGGGATGACTTGGACACATCTGCCATTCGACATGACTGCAATTTTGACAAAGCCATGCAGTTTT
SEQ ID NO: 2739


 


MRP3
NM_003786.2
TCATCCTGGCGATCTACTTCCTCTGGCAGAACCTAGGTCCCTCTGTCCTGGCTGGAGTCGCTTTCATGGTC
SEQ ID NO: 2740




TTGCTGATTCCACTCAACGG


 


MRP4
NM_005845.1
AGCGCCTGGAATCTACAACTCGGAGTCCAGTGTTTTCCCACTTGTCATCTTCTCTCCAGGGGCTCT
SEQ ID NO: 2741


 


MRPL40
NM_003776.2
ACTTGCAGGCTGCTATCCTTAACATGCTGCCCCTGAGAGTAGGAATGACCAGGGTTCAAGTCTGCT
SEQ ID NO: 2742


 


MSH2
NM_000251.1
GATGCAGAATTGAGGCAGACTTTACAAGAAGATTTACTTCGTCGATTCCCAGATCTTAACCGACTTGCCAAGA
SEQ ID NO: 2743


 


MSH3
NM_002439.1
TGATTACCATCATGGCTCAGATTGGCTCCTATGTTCCTGCAGAAGAAGCGACAATTGGGATTGTGGATGGC
SEQ ID NO: 2744




ATTTTCACAAG


 


MSH6
NM_000179.1
TCTATTGGGGGATTGGTAGGAACCGTTACCAGCTGGAAATTCCTGAGAATTTCACCACTCGCAATTTG
SEQ ID NO: 2745


 


MT3
NM_005954.1
GTGTGAGAAGTGTGCCAAGGACTGTGTGTGCAAAGGCGGAGAGGCAGCTGAGGCAGAAGCAGAGAAGTGCAG
SEQ ID NO: 2746


 


MTA1
NM_004689.2
CCGCCCTCACCTGAAGAGAAACGCGCTCCTTGGCGGACACTGGGGGAGGAGAGGAAGAAGCGCGGCTAA
SEQ ID NO: 2747




CTTATTCC


 


MUC1
NM_002456.1
GGCCAGGATCTGTGGTGGTACAATTGACTCTGGCCTTCCGAGAAGGTACCATCAATGTCCACGACGTGGAG
SEQ ID NO: 2748


 


MUC2
NM_002457.1
CTATGAGCCATGTGGGAACCGGAGCTTCGAGACCTGCAGGACCATCAACGGCATCCACTCCAACAT
SEQ ID NO: 2749


 


MUC5B
XM_039877.11
TGCCCTTGCACTGTCCTAACGGCTCAGCCATCCTGCACACCTACACCCACGTGGATGAGTGTGGCTG
SEQ ID NO: 2750


 


MUTYH
NM_012222.1
GTACGACCAAGAGAAACGGGACCTACCATGGAGAAGACGGGCAGAAGATGAGATGGACCTGGACAGG
SEQ ID NO: 2751


 


MVP
NM_017458.1
ACGAGAACGAGGGCATCTATGTGCAGGATGTCAAGACCGGAAAGGTGCGCGCTGTGATTGGAAGCACCTACATGC
SEQ ID NO: 2752


 


MX1
NM_002462.2
GAAGGAATGGGAATCAGTCATGAGCTAATCACCCTGGAGATCAGCTCCCGAGATGTCCCGGATCTGACTCTAATAGAC
SEQ ID NO: 2753


 


MXD4
NM_006454.2
AGAAACTGGAGGAGCAGGACCGCCGGGCACTGAGCATCAAGGAGCAGCTGCAGCAGGAGCATCGTTTCCTGAAG
SEQ ID NO: 2754


 


MYBL2
NM_002466.1
GCCGAGATCGCCAAGATGTTGCCAGGGAGGACAGACAATGCTGTGAAGAATCACTGGAACTCTACCATCAAAAG
SEQ ID NO: 2755


 


MYH11
NM_002474.1
CGGTACTTCTCAGGGCTAATATATACGTACTCTGGCCTCTTCTGCGTGGTGGTCAACCCCTATAAACACCTG
SEQ ID NO: 2756




CCCATCTACTCGG


 


MYLK
NM_053025.1
TGACGGAGCGTGAGTGCATCAAGTACATGCGGCAGATCTCGGAGGGAGTGGAGTACATCCACAAGCAGGGCAT
SEQ ID NO: 2757


 


NAT2
NM_000015.1
TAACTGACATTCTTGAGCACCAGATCCGGGCTGTTCCCTTTGAGAACCTTAACATGCATTGTGGGCAAGCCAT
SEQ ID NO: 2758


 


NAV2
NM_182964.3
CTCTCCCAGCACAGCTTGAACCTCACTGAGTCAACCAGCCTGGACATGTTGCTGGATGACACTGGTG
SEQ ID NO: 2759


 


NCAM1
NM_000615.1
TAGTTCCCAGCTGACCATCAAAAAGGTGGATAAGAACGACGAGGCTGAGTACATCTGCATTGCTGAGAACAAGGCTG
SEQ ID NO: 2760


 


NDE1
NM_017668.1
CTACTGCGGAAAGTCGGGGCACTGGAGTCCAAACTCGCTTCCTGCCGGAACCTCGTGTACGATCAGTCC
SEQ ID NO: 2761


 


NDRG1
NM_006096.2
AGGGCAACATTCCACAGCTGCCCTGGCTGTGATGAGTGTCCTTGCAGGGGCCGGAGTAGGAGCACTG
SEQ ID NO: 2762


 


NDUFS3
NM_004551.1
TATCCATCCTGATGGCGTCATCCCAGTGCTGACTTTCCTCAGGGATCACACCAATGCACAGTTCAA
SEQ ID NO: 2763


 


NEDD8
NM_006156.1
TGCTGGCTACTGGGTGTTAGTTTGCAGTCCTGTGTGCTTCCCTCTCTTATGACTGTGTCCCTGGTTGTC
SEQ ID NO: 2764


 


NEK2
NM_002497.1
GTGAGGCAGCGCGACTCTGGCGACTGGCCGGCCATGCCTTCCCGGGCTGAGGACTATGAAGTGTTGTACA
SEQ ID NO: 2765




CCATTGGCA


 


NF2
NM_000268.2
ACTCCAGAGCTGACCTCCACCGCCCAGCCTGGGAAGTCATTGTAGGGAGTGAGACACTGAAGCCCTGA
SEQ ID NO: 2766


 


NFKBp50
NM_003998.1
CAGACCAAGGAGATGGACCTCAGCGTGGTGCGGCTCATGTTTACAGCTTTTCTTCCGGATAGCACTGGCAGCT
SEQ ID NO: 2767


 


NFKBp65
NM_021975.1
CTGCCGGGATGGCTTCTATGAGGCTGAGCTCTGCCCGGACCGCTGCATCCACAGTTTCCAGAACCTGG
SEQ ID NO: 2768


 


NISCH
NM_007184.1
CCAAGGAATCATGTTCGTTCAGGAGGAGGCCCTGGCCAGCAGCCTCTCGTCCACTGACAGTCTGACTCCC
SEQ ID NO: 2769




GAGCACCA


 


Nkd-1
NM_033119.3
GAGAGAGTGAGCGAACCCTGCCCAGGCTCCAAGAAGCAGCTGAAGTTTGAAGAGCTCCAGTGCGACG
SEQ ID NO: 2770


 


NMB
NM_021077.1
GGCTGCTGGTACAAATACTGCAGAAATGACACCAATAATAGGGGCAGACACAACAGCGTGGCTTAGATTG
SEQ ID NO: 2771


 


NMBR
NM_002511.1
TGATCCATCTCTAGGCCACATGATTGTCACCTTAGTTGCCCGGGTTCTCAGTTTTGGCAATTCTTGTGTCAA
SEQ ID NO: 2772




CCCATTTGCTC


 


NME1
NM_000269.1
CCAACCCTGCAGACTCCAAGCCTGGGACCATCCGTGGAGACTTCTGCATACAAGTTGGCAGGAACATTATACAT
SEQ ID NO: 2773


 


NOS3
NM_000603.2
ATCTCCGCCTCGCTCATGGGCACGGTGATGGCGAAGCGAGTGAAGGCGACAATCCTGTATGGCTCCGA
SEQ ID NO: 2774


 


NOTCH1
NM_017617.2
CGGGTCCACCAGTTTGAATGGTCAATGCGAGTGGCTGTCCCGGCTGCAGAGCGGCATGGTGCCGAACCAATACAAC
SEQ ID NO: 2775


 


NOTCH2
NM_024408.2
CACTTCCCTGCTGGGATTATATCAACAACCAGTGTGATGAGCTGTGCAACACGGTCGAGTGCCTGTTTGACAACT
SEQ ID NO: 2776


 


NPM1
NM_002520.2
AATGTTGTCCAGGTTCTATTGCCAAGAATGTGTTGTCCAAAATGCCTGTTTAGTTTTTAAAGATGGAACTCCA
SEQ ID NO: 2777




CCCTTTGCTTG


 


NR4A1
NM_002135.2
CACAGCTTGCTTGTCGATGTCCCTGCCTTCGCCTGCCTCTCTGCCCTTGTCCTCATCACCGACCGGCAT
SEQ ID NO: 2778


 


NRG1
NM_013957.1
CGAGACTCTCCTCATAGTGAAAGGTATGTGTCAGCCATGACCACCCCGGCTCGTATGTCACCTGTAGATTT
SEQ ID NO: 2779




CCACACGCCAAG


 


NRP1
NM_003873.1
CAGCTCTCTCCACGCGATTCATCAGGATCTACCCCGAGAGAGCCACTCATGGCGGACTGGGGCTCAGAAT
SEQ ID NO: 2780




GGAGCTGCTGGG


 


NRP2
NM_003872.1
CTACAGCCTAAACGGCAAGGACTGGGAATACATTCAGGACCCCAGGACCCAGCAGCCAAAGCTGTTCGAAGGGAAC
SEQ ID NO: 2781


 


NTN1
NM_004822.1
AGAAGGACTATGCCGTCCAGATCCACATCCTGAAGGCGGACAAGGCGGGGGACTGGTGGAAGTTCACGG
SEQ ID NO: 2782


 


NUFIP1
NM_012345.1
GCTTCCACATCGTGGTATTGGAGACAGTCTTCTGATAGGTTTCCTCGGCATCAGAAGTCCTTCAACCCTGCAGTT
SEQ ID NO: 2783


 


ODC1
NM_002539.1
AGAGATCACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTCCGTCAGACTCTGGAGTGAGAATCATAG
SEQ ID NO: 2784




CTGAGCCCG


 


OPN,
NM_000582.1
CAACCGAAGTTTTCACTCCAGTTGTCCCCACAGTAGACACATATGATGGCCGAGGTGATAGTGTGGTTTATG
SEQ ID NO: 2785


osteopontin

GACTGAGG


 


ORC1L
NM_004153.2
TCCTTGACCATACCGGAGGGTGCATGTACATCTCCGGTGTCCCTGGGACAGGGAAGACTGCCACTG
SEQ ID NO: 2786


 


OSM
NM_020530.3
GTTTCTGAAGGGGAGGTCACAGCCTGAGCTGGCCTCCTATGCCTCATCATGTCCCAAACCAGACACCT
SEQ ID NO: 2787


 


OSMR
NM_003999.1
GCTCATCATGGTCATGTGCTACTTGAAAAGTCAGTGGATCAAGGAGACCTGTTATCCTGACATCCCTGACCCTTACA
SEQ ID NO: 2788


 


P14ARF
S78535.1
CCCTCGTGCTGATGCTACTGAGGAGCCAGCGTCTAGGGCAGCAGCCGCTTCCTAGAAGACCAGGTCATGATG
SEQ ID NO: 2789


 


p16-INK4
L27211.1
GCGGAAGGTCCCTCAGACATCCCCGATTGAAAGAACCAGAGAGGCTCTGAGAAACCTCGGGAAACTTAGATCATCA
SEQ ID NO: 2790


 


p21
NM_000389.1
TGGAGACTCTCAGGGTCGAAAACGGCGGCAGACCAGCATGACAGATTTCTACCACTCCAAACGCC
SEQ ID NO: 2791


 


p27
NM_004064.1
CGGTGGACCACGAAGAGTTAACCCGGGACTTGGAGAAGCACTGCAGAGACATGGAAGAGGCGAGCC
SEQ ID NO: 2792


 


P53
NM_000546.2
CTTTGAACCCTTGCTTGCAATAGGTGTGCGTCAGAAGCACCCAGGACTTCCATTTGCTTTGTCCCGGG
SEQ ID NO: 2793


 


p53R2
AB036063.1
CCCAGCTAGTGTTCCTCAGAACAAAGATTGGAAAAAGCTGGCCGAGAACCATTTATACATAGAGGAAGGGCTTACGG
SEQ ID NO: 2794


 


PADI4
NM_012387.1
AGCAGTGGCTTGCTTTCTTCTCCTGTGATGTCCCAGTTTCCCACTCTGAAGATCCCAACATGGTCCTAGCA
SEQ ID NO: 2795


 


PAI1
NM_000602.1
CCGCAACGTGGTTTTCTCACCCTATGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGA
SEQ ID NO: 2796




GAAACCCAGCA


 


Pak1
NM_002576.3
GAGCTGTGGGTTGTTATGGAATACTTGGCTGGAGGCTCCTTGACAGATGTGGTGACAGAAACTTGCATGG
SEQ ID NO: 2797


 


PARC
NM_015089.1
GGAGCTGACCTGCTTCCTACATCGCCTGGCCTCGATGCATAAGGACTATGCTGTGGTGCTCTGCT
SEQ ID NO: 2798


 


PCAF
NM_003884.3
AGGTGGCTGTGTTACTGCAACGTGCCACAGTTCTGCGACAGTCTACCTCGGTACGAAACCACACAGGTG
SEQ ID NO: 2799


 


PCNA
NM_002592.1
GAAGGTGTTGGAGGCACTCAAGGACCTCATCAACAGGCCTGCTGGGATATTAGCTCCAGCGGTGTAAACC
SEQ ID NO: 2800


 


PDGFA
NM_002607.2
TTGTTGGTGTGCCCTGGTGCCGTGGTGGCGGTCACTCCCTCTGCTGCCAGTGTTTGGACAGAACCCA
SEQ ID NO: 2801


 


PDGFB
NM_002608.1
ACTGAAGGAGACCCTTGGAGCCTAGGGGCATCGGCAGGAGAGTGTGTGGGCAGGGTTATTTA
SEQ ID NO: 2802


 


PDGFC
NM_016205.1
AGTTACTAAAAAATACCACGAGGTCCTTCAGTTGAGACCAAAGACCGGTGTCAGGGGATTGCACAAATCACT
SEQ ID NO: 2803




CACCGAC


 


PDGFD
NM_025208.2
TATCGAGGCAGGTCATACCATGACCGGAAGTCAAAAGTTGACCTGGATAGGCTCAATGATGATGCCAAGCGTTA
SEQ ID NO: 2804


 


PDGFRa
NM_006206.2
GGGAGTTTCCAAGAGATGGACTAGTGCTTGGTCGGGTCTTGGGGTCTGGAGCGTTTGGGAAGGTGGTTGAAG
SEQ ID NO: 2805


 


PDGFRb
NM_002609.2
CCAGCTCTCCTTCCAGCTACAGATCAATGTCCCTGTCCGAGTGCTGGAGCTAAGTGAGAGCCACCC
SEQ ID NO: 2806


 


PFN1
NM_005022.2
GGAAAACGTTCGTCAACATCACGCCAGCTGAGGTGGGTGTCCTGGTTGGCAAAGACCGGTCAAGTTTT
SEQ ID NO: 2807


 


PFN2
NM_053024.1
TCTATACGTCGATGGTGACTGCACAATGGACATCCGGACAAAGAGTCAAGGTGGGGAGCCAACATACAATG
SEQ ID NO: 2808




TGGCTGTCGGC


 


PGK1
NM_000291.1
AGAGCCAGTTGCTGTAGAACTCAAATCTCTGCTGGGCAAGGATGTTCTGTTCTTGAAGGACTGTGTAGGCCCAG
SEQ ID NO: 2809


 


PI3K
NM_002646.2
TGCTACCTGGACAGCCCGTTGGTGCGCTTCCTCCTGAAACGAGCTGTGTCTGACTTGAGAGTGACTCACTA
SEQ ID NO: 2810




CTTCTTCTGGTTACTGAAGGACGGCCT


 


PI3KC2A
NM_002645.1
ATACCAATCACCGCACAAACCCAGGCTATTTGTTAAGTCCAGTCACAGCGCAAAGAAACATATGCGGAGAAA
SEQ ID NO: 2811




ATGCTAGTGTG


 


PIK3CA
NM_006218.1
GTGATTGAAGAGCATGCCAATTGGTCTGTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGAC
SEQ ID NO: 2812


 


PIM1
NM_002648.2
CTGCTCAAGGACACCGTCTACACGGACTTCGATGGGACCCGAGTGTATAGCCCTCCAGAGTGGATCC
SEQ ID NO: 2813


 


Pin1
NM_006221.1
GATCAACGGCTACATCCAGAAGATCAAGTCGGGAGAGGAGGACTTTGAGTCTCTGGCCTCACAGTTCA
SEQ ID NO: 2814


 


PKD1
NM_000296.2
CAGCACCAGCGATTACGACGTTGGCTGGGAGAGTCCTCACAATGGCTCGGGGACGTGGGCCTATTCAG
SEQ ID NO: 2815


 


PKR2
NM_002654.3
CCGCCTGGACATTGATTCACCACCCATCACAGCCCGGAACACTGGCATCATCTGTACCATTGGCCCAG
SEQ ID NO: 2816


 


PLA2G2A
NM_000300.2
GCATCCCTCACCCATCCTAGAGGCCAGGCAGGAGCCCTTCTATACCCACCCAGAATGAGACATCCAGCAGA
SEQ ID NO: 2817




TTTCCAGC


 


PLAUR
NM_002659.1
CCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTGACTGCCGAGGCCCCATGAATCAATGTCTGGTAGCCACCGG
SEQ ID NO: 2818


 


PLK
NM_005030.2
AATGAATACAGTATTCCCAAGCACATCAACCCCGTGGCCGCCTCCCTCATCCAGAAGATGCTTCAGACA
SEQ ID NO: 2819


 


PLK3
NM_004073.2
TGAAGGAGACGTACCGCTGCATCAAGCAGGTTCACTACACGCTGCCTGCCAGCCTCTCACTGCCTG
SEQ ID NO: 2820


 


PLOD2
NM_000935.2
CAGGGAGGTGGTTGCAAATTTCTAAGGTACAATTGCTCTATTGAGTCACCACGAAAAGGCTGGAGCTTCAT
SEQ ID NO: 2821




GCATCCTGGGAGA


 


PMS1
NM_000534.2
CTTACGGTTTTCGTGGAGAAGCCTTGGGGTCAATTTGTTGTATAGCTGAGGTTTTAATTACAACAAGAACGGCTGCT
SEQ ID NO: 2822


 


PMS2
NM_000535.2
GATGTGGACTGCCATTCAAACCAGGAAGATACCGGATGTAAATTTCGAGTTTTGCCTCAGCCAACTAATCTCGCA
SEQ ID NO: 2823


 


PPARG
NM_005037.3
TGACTTTATGGAGCCCAAGTTTGAGTTTGCTGTGAAGTTCAATGCACTGGAATTAGATGACAGCGACTTGGC
SEQ ID NO: 2824


 


PPID
NM_005038.1
TCCTCATTTGGATGGGAAACATGTGGTGTTTGGCCAAGTAATTAAAGGAATAGGAGTGGCAAGGATATTGG
SEQ ID NO: 2825


 


PPM1D
NM_003620.1
GCCATCCGCAAAGGCTTTCTCGCTTGTCACCTTGCCATGTGGAAGAAACTGGCGGAATGGCC
SEQ ID NO: 2826


 


PPP2R4
NM_178001.1
GGCTCAGAGCATAAGGCTTCAGGGCCCAAGTTGGGAGAAGTGACCAAAGTGTAGCCAGTTTTCTGAGTTCCCGT
SEQ ID NO: 2827


 


PR
NM_000926.2
GCATCAGGCTGTCATTATGGTGTCCTTACCTGTGGGAGCTGTAAGGTCTTCTTTAAGAGGGCAATGGAAGG
SEQ ID NO: 2828




GCAGCACAACTACT


 


PRDX2
NM_005809.4
GGTGTCCTTCGCCAGATCACTGTTAATGATTTGCCTGTGGGACGCTCCGTGGATGAGGCTCTGCGGCTG
SEQ ID NO: 2829


 


PRDX3
NM_006793.2
TGACCCCAATGGAGTCATCAAGCATTTGAGCGTCAACGATCTCCCAGTGGGCCGAAGCGTGGAAGAAACC
SEQ ID NO: 2830




CTCCGCTTGG


 


PRDX4
NM_006406.1
TTACCCATTTGGCCTGGATTAATACCCCTCGAAGACAAGGAGGACTTGGGCCAATAAGGATTCCACTTCTTTCAG
SEQ ID NO: 2831


 


PRDX6
NM_004905.2
CTGTGAGCCAGAGGATGTCAGCTGCCAATTGTGTTTTCCTGCAGCAATTCCATAAACACATCCTGGTGTCATCACA
SEQ ID NO: 2832


 


PRKCA
NM_002737.1
CAAGCAATGCGTCATCAATGTCCCCAGCCTCTGCGGAATGGATCACACTGAGAAGAGGGGGCGGATTTAC
SEQ ID NO: 2833


 


PRKCB1
NM_002738.5
GACCCAGCTCCACTCCTGCTTCCAGACCATGGACCGCCTGTACTTTGTGATGGAGTACGTGAATGGG
SEQ ID NO: 2834


 


PRKCD
NM_006254.1
CTGACACTTGCCGCAGAGAATCCCTTTCTCACCCACCTCATCTGCACCTTCCAGACCAAGGACCACCT
SEQ ID NO: 2835


 


PRKR
NM_002759.1
GCGATACATGAGCCCAGAACAGATTTCTTCGCAAGACTATGGAAAGGAAGTGGACCTCTACGCTTTGGGGC
SEQ ID NO: 2836




TAATTCTTGCTGA


 


pS2
NM_003225.1
GCCCTCCCAGTGTGCAAATAAGGGCTGCTGTTTCGACGACACCGTTCGTGGGGTCCCCTGGTGCTTCTATC
SEQ ID NO: 2837




CTAATACCATCGACG


 


PTCH
NM_000264.2
CCACGACAAAGCCGACTACATGCCTGAAACAAGGCTGAGAATCCCGGCAGCAGAGCCCATCGAGTA
SEQ ID NO: 2838


 


PTEN
NM_000314.1
TGGCTAAGTGAAGATGACAATCATGTTGCAGCAATTCACTGTAAAGCTGGAAAGGGACGAACTGGTGTAAT
SEQ ID NO: 2839




GATATGTGCA


 


PTGER3
NM_000957.2
TAACTGGGGCAACCTTTTCTTCGCCTCTGCCTTTGCCTTCCTGGGGCTCTTGGCGCTGACAGTCACCTTTTC
SEQ ID NO: 2840




CTGCAA


 


PTHLH
NM_002820.1
AGTGACTGGGAGTGGGCTAGAAGGGGACCACCTGTCTGACACCTCCACAACGTCGCTGGAGCTCGATTCA
SEQ ID NO: 2841




CGGTAACAGGCTT


 


PTHR1
NM_000316.1
CGAGGTACAAGCTGAGATCAAGAAATCTTGGAGCCGCTGGACACTGGCACTGGACTTCAAGCGAAAGGCACGC
SEQ ID NO: 2842


 


PTK2
NM_005607.3
GACCGGTCGAATGATAAGGTGTACGAGAATGTGACGGGCCTGGTGAAAGCTGTCATCGAGATGTCCAG
SEQ ID NO: 2843


 


PTK2B
NM_004103.3
CAAGCCCAGCCGACCTAAGTACAGACCCCCTCCGCAAACCAACCTCCTGGCTCCAAAGCTGCAGTTCCAGGTTC
SEQ ID NO: 2844


 


PTP4A3
NM_007079.2
AATATTTGTGCGGGGTATGGGGGTGGGTTTTTAAATCTCGTTTCTCTTGGACAAGCACAGGGATCTCGTT
SEQ ID NO: 2845


 


PTP4A3 v2
NM_032611.1
CCTGTTCTCGGCACCTTAAATTATTAGACCCCGGGGCAGTCAGGTGCTCCGGACACCCGAAGGCAATA
SEQ ID NO: 2846


 


PTPD1
NM_007039.2
CGCTTGCCTAACTCATACTTTCCCGTTGACACTTGATCCACGCAGCGTGGCACTGGGACGTAAGTGGCGCA
SEQ ID NO: 2847




GTCTGAATGG


 


PTPN1
NM_002827.2
AATGAGGAAGTTTCGGATGGGGCTGATCCAGACAGCCGACCAGCTGCGCTTCTCCTACCTGGCTGTGATCGAAG
SEQ ID NO: 2848


 


PTPRF
NM_002840.2
TGTTTTAGCTGAGGGACGTGGTGCCGACGTCCCCAAACCTAGCTAGGCTAAGTCAAGATCAACATTCCAGGGTTGGTA
SEQ ID NO: 2849


 


PTPRJ
NM_002843.2
AACTTCCGGTACCTCGTTCGTGACTACATGAAGCAGAGTCCTCCCGAATCGCCGATTCTGGTGCATTGCAGTGCT
SEQ ID NO: 2850


 


PTPRO
NM_030667.1
CATGGCCTGATCATGGTGTGCCCACAGCAAATGCTGCAGAAAGTATCCTGCAGTTTGTACACATGG
SEQ ID NO: 2851


 


PTTG1
NM_004219.2
GGCTACTCTGATCTATGTTGATAAGGAAAATGGAGAACCAGGCACCCGTGTGGTTGCTAAGGATGGGCTGAAGC
SEQ ID NO: 2852


 


RAB32
NM_006834.2
CCTGCAGCTGTGGGACATCGCGGGGCAGGAGCGATTTGGCAACATGACCCGAGTATACTACAAGGAAGCT
SEQ ID NO: 2853




GTTGGTGCT


 


RAB6C
NM_032144.1
GCGACAGCTCCTCTAGTTCCACCATGTCCGCGGGCGGAGACTTCGGGAATCCGCTGAGGAAATTCAAGCT
SEQ ID NO: 2854




GGTGTTCC


 


RAC1
NM_006908.3
TGTTGTAAATGTCTCAGCCCCTCGTTCTTGGTCCTGTCCCTTGGAACCTTTGTACGCTTTGCTCAA
SEQ ID NO: 2855


 


RAD51C
NM_058216.1
GAACTTCTTGAGCAGGAGCATACCCAGGGCTTCATAATCACCTTCTGTTCAGCACTAGATGATATTCTTGGGGGTGGA
SEQ ID NO: 2856


 


RAD54L
NM_003579.2
AGCTAGCCTCAGTGACACACATGACAGGTTGCACTGCCGACGTTGTGTCAACAGCCGTCAGATCCGG
SEQ ID NO: 2857


 


RAF1
NM_002880.1
CGTCGTATGCGAGAGTCTGTTTCCAGGATGCCTGTTAGTTCTCAGCACAGATATTCTACACCTCACGCCTTCA
SEQ ID NO: 2858


 


RALBP1
NM_006788.2
GGTGTCAGATATAAATGTGCAAATGCCTTCTTGCTGTCCTGTCGGTCTCAGTACGTTCACTTTATAGCTGCT
SEQ ID NO: 2859




GGCAATATCGAA


 


RANBP2
NM_006267.3
TCCTTCAGCTTTCACACTGGGCTCAGAAATGAAGTTGCATGACTCTTCTGGAAGTCAGGTGGGAACAGGATTT
SEQ ID NO: 2860


 


ranBP7
NM_006391.1
AACATGATTATCCAAGCCGCTGGACTGCCATTGTGGACAAAATTGGCTTTTATCTTCAGTCCGATAACAGTG
SEQ ID NO: 2861




CTTGTTGGC


 


RANBP9
NM_005493.2
CAAGTCAGTTGAGACGCCAGTTGTGTGGAGGAAGTCAGGCCGCCATAGAAAGAATGATCCACTTTGGACGA
SEQ ID NO: 2862




GAGCTGCA


 


RAP1GDS1
NM_021159.3
TGTGGATGCTGGATTGATTTCACCACTGGTGCAGCTGCTAAATAGCAAAGACCAGGAAGTGCTGCTT
SEQ ID NO: 2863


 


RARA
NM_000964.1
AGTCTGTGAGAAACGACCGAAACAAGAAGAAGAAGGAGGTGCCCAAGCCCGAGTGCTCTGAGAGCTACAC
SEQ ID NO: 2864




GCTGACGCCG


 


RARB
NM_016152.2
TGCCTGGACATCCTGATTCTTAGAATTTGCACCAGGTATACCCCAGAACAAGACACCATGACTTTCTCAGACGGCCTT
SEQ ID NO: 2865


 


RASSF1
NM_007182.3
AGTGGGAGACACCTGACCTTTCTCAAGCTGAGATTGAGCAGAAGATCAAGGAGTACAATGCCCAGATCA
SEQ ID NO: 2866


 


RBM5
NM_005778.1
CGAGAGGGAGAGCAAGACCATCATGCTGCGCGGCCTTCCCATCACCATCACAGAGAGCGATATTCGAGA
SEQ ID NO: 2867


 


RBX1
NM_014248.2
GGAACCACATTATGGATCTTTGCATAGAATGTCAAGCTAACCAGGCGTCCGCTACTTCAGAAGAGTGTACTGTCGCATG
SEQ ID NO: 2868


 


RCC1
NM_001269.2
GGGCTGGGTGAGAATGTGATGGAGAGGAAGAAGCCGGCCCTGGTATCCATTCCGGAGGATGTTGTG
SEQ ID NO: 2869


 


REG4
NM_032044.2
TGCTAACTCCTGCACAGCCCCGTCCTCTTCCTTTCTGCTAGCCTGGCTAAATCTGCTCATTATTTCAGAGGG
SEQ ID NO: 2870




GAAACCTAGCA


 


RFC
NM_003056.1
TCAAGACCATCATCACTTTCATTGTCTCGGACGTGCGGGGCCTGGGCCTCCCGGTCCGCAAGCAGTTCCA
SEQ ID NO: 2871




GTTATACTCCGTGTACTTCCTGATCC


 


RhoB
NM_004040.2
AAGCATGAACAGGACTTGACCATCTTTCCAACCCCTGGGGAAGACATTTGCAACTGACTTGGGGAGG
SEQ ID NO: 2872


 


rhoC
NM_175744.1
CCCGTTCGGTCTGAGGAAGGCCGGGACATGGCGAACCGGATCAGTGCCTTTGGCTACCTTGAGTGCTC
SEQ ID NO: 2873


 


RIZ1
NM_012231.1
CCAGACGAGCGATTAGAAGCGGCAGCTTGTGAGGTGAATGATTTGGGGGAAGAGGAGGAGGAGGAAGAGGAGGA
SEQ ID NO: 2874


 


RNF11
NM_014372.3
ACCCTGGAAGAGATGGATCAGAAAAAAAGATCCGGGAGTGTGTGATCTGTATGATGGACTTTGTTTATGGG
SEQ ID NO: 2875




GACCCAAT


 


ROCK1
NM_005406.1
TGTGCACATAGGAATGAGCTTCAGATGCAGTTGGCCAGCAAAGAGAGTGATATTGAGCAATTGCGTGCTAAAC
SEQ ID NO: 2876


 


ROCK2
NM_004850.3
GATCCGAGACCCTCGCTCCCCCATCAACGTGGAGAGCTTGCTGGATGGCTTAAATTCCTTGGTCCT
SEQ ID NO: 2877


 


RPLPO
NM_001002.2
CCATTCTATCATCAACGGGTACAAACGAGTCCTGGCCTTGTCTGTGGAGACGGATTACACCTTCCCACTTGCTGA
SEQ ID NO: 2878


 


RPS13
NM_001017.2
CAGTCGGCTTTACCCTATCGACGCAGCGTCCCCACTTGGTTGAAGTTGACATCTGACGACGTGAAGGAGCAGA
SEQ ID NO: 2879


 


RRM1
NM_001033.1
GGGCTACTGGCAGCTACATTGCTGGGACTAATGGCAATTCCAATGGCCTTGTACCGATGCTGAGAG
SEQ ID NO: 2880


 


RRM2
NM_001034.1
CAGCGGGATTAAACAGTCCTTTAACCAGCACAGCCAGTTAAAAGATGCAGCCTCACTGCTTCAACGCAGAT
SEQ ID NO: 2881


 


RTN4
NM_007008.1
GACTGGAGTGGTGTTTGGTGCCAGCCTATTCCTGCTGCTTTCATTGACAGTATTCAGCATTGTGAGCGTAACAG
SEQ ID NO: 2882


 


RUNX1
NM_001754.2
AACAGAGACATTGCCAACCATATTGGATCTGCTTGCTGTCCAAACCAGCAAACTTCCTGGGCAAATCAC
SEQ ID NO: 2883


 


RXRA
NM_002957.3
GCTCTGTTGTGTCCTGTTGCCGGCTCTGGCCTTCCTGTGACTGACTGTGAAGTGGCTTCTCCGTAC
SEQ ID NO: 2884


 


S100A1
NM_006271.1
TGGACAAGGTGATGAAGGAGCTAGACGAGAATGGAGACGGGGAGGTGGACTTCCAGGAGTATGTGGTGCT
SEQ ID NO: 2885


 


S100A2
NM_005978.2
TGGCTGTGCTGGTCACTACCTTCCACAAGTACTCCTGCCAAGAGGGCGACAAGTTCAAGCTGAGTAAGGGGGA
SEQ ID NO: 2886


 


S100A4
NM_002961.2
GACTGCTGTCATGGCGTGCCCTCTGGAGAAGGCCCTGGATGTGATGGTGTCCACCTTCCACAAGTACTCG
SEQ ID NO: 2887


 


S100A8
NM_002964.3
ACTCCCTGATAAAGGGGAATTTCCATGCCGTCTACAGGGATGACCTGAAGAAATTGCTAGAGACCGAGTGTCCTCA
SEQ ID NO: 2888


 


S100A9
NM_002965.2
CTTTGGGACAGAGTGCAAGACGATGACTTGCAAAATGTCGCAGCTGGAACGCAACATAGAGACCA
SEQ ID NO: 2889


 


S100P
NM_005980.2
AGACAAGGATGCCGTGGATAAATTGCTCAAGGACCTGGACGCCAATGGAGATGCCCAGGTGGACTTC
SEQ ID NO: 2890


 


SAT
NM_002970.1
CCTTTTACCACTGCCTGGTTGCAGAAGTGCCGAAAGAGCACTGGACTCCGGAAGGACACAGCATTGT
SEQ ID NO: 2891


 


SBA2
NM_018639.3
GGACTCAACGATGGGCAGATCAAGATCTGGGAGGTGCAGACAGGGCTCCTGCTTTTGAATCTTTCCG
SEQ ID NO: 2892


 


SDC1
NM_002997.1
GAAATTGACGAGGGGTGTCTTGGGCAGAGCTGGCTCTGAGCGCCTCCATCCAAGGCCAGGTTCTCCGTTAGCTCCT
SEQ ID NO: 2893


 


SEMA3B
NM_004636.1
GCTCCAGGATGTGTTTCTGTTGTCCTCGCGGGACCACCGGACCCCGCTGCTCTATGCCGTCTTCTCCACGT
SEQ ID NO: 2894


 


SEMA3F
NM_004186.1
CGCGAGCCCCTCATTATACACTGGGCAGCCTCCCCACAGCGCATCGAGGAATGCGTGCTCTCAGGCAAGG
SEQ ID NO: 2895




ATGTCAACGGCGAGTG


 


SEMA4B
NM_020210.1
TTCCAGCCCAACACAGTGAACACTTTGGCCTGCCCGCTCCTCTCCAACCTGGCGACCCGACTC
SEQ ID NO: 2896


 


SFRP2
NM_003013.2
CAAGCTGAACGGTGTGTCCGAAAGGGACCTGAAGAAATCGGTGCTGTGGCTCAAAGACAGCTTGCA
SEQ ID NO: 2897


 


SFRP4
NM_003014.2
TACAGGATGAGGCTGGGCATTGCCTGGGACAGCCTATGTAAGGCCATGTGCCCCTTGCCCTAACAAC
SEQ ID NO: 2898


 


SGCB
NM_000232.1
CAGTGGAGACCAGTTGGGTAGTGGTGACTGGGTACGCTACAAGCTCTGCATGTGTGCTGATGGGACGCTCTTCAAGG
SEQ ID NO: 2899


 


SHC1
NM_003029.3
CCAACACCTTCTTGGCTTCTGGGACCTGTGTTCTTGCTGAGCACCCTCTCCGGTTTGGGTTGGGATAACAG
SEQ ID NO: 2900


 


SHH
NM_000193.2
GTCCAAGGCACATATCCACTGCTCGGTGAAAGCAGAGAACTCGGTGGCGGCCAAATCGGGAGGCTGCTTC
SEQ ID NO: 2901


 


SI
NM_001041.1
AACGGACTCCCTCAATTTGTGCAAGATTTGCATGACCATGGACAGAAATATGTCATCATCTTGGACCCTGCAATTTC
SEQ ID NO: 2902


 


Siah-1
NM_003031.2
TTGGCATTGGAACTACATTCAATCCGCGGTATCCTCGGATTAGTTCTAGGACCCCCTTCTCCATACC
SEQ ID NO: 2903


 


SIAT4A
NM_003033.2
AACCACAGTTGGAGGAGGACGGCAGAGACAGTTTCCCTCCCCGCTATACCAACACCCTTCCTTCG
SEQ ID NO: 2904


 


SIAT7B
NM_006456.1
TCCAGCCCAAATCCTCCTGGTGGCACATCCTACCCCAGATGCTAAAGTGATTCAAGGACTCCAGGACACC
SEQ ID NO: 2905


 


SIM2
NM_005069.2
GATGGTAGGAAGGGATGTGCCCGCCTCTCCACGCACTCAGCTATACCTCATTCACAGCTCCTTGTG
SEQ ID NO: 2906


 


SIN3A
NM_015477.1
CCAGAGTCATGCTCATCCAGCCCCACCAGTTGCACCAGTGCAGGGACAGCAGCAATTTCAGAGGCTGAAGGTGG
SEQ ID NO: 2907


 


SIR2
NM_012238.3
AGCTGGGGTGTCTGTTTCATGTGGAATACCTGACTTCAGGTCAAGGGATGGTATTTATGCTCGCCTTGCTGT
SEQ ID NO: 2908


 


SKP1A
NM_006930.2
CCATTGCCTTTGCTTTGTTCATAATTTCAGCAGGGCAGAATAAAAACCATGGGAGGCAAAGAAAGGAAATCCGGAA
SEQ ID NO: 2909


 


SKP2
NM_005983.2
AGTTGCAGAATCTAAGCCTGGAAGGCCTGCGGCTTTCGGATCCCATTGTCAATACTCTCGCAAAAAACTCA
SEQ ID NO: 2910


 


SLC25A3
NM_213611.1
TCTGCCAGTGCTGAATTCTTTGCTGACATTGCCCTGGCTCCTATGGAAGCTGCTAAGGTTCGAA
SEQ ID NO: 2911


 


SLC2A1
NM_006516.1
GCCTGAGTCTCCTGTGCCCACATCCCAGGCTTCACCCTGAATGGTTCCATGCCTGAGGGTGGAGACT
SEQ ID NO: 2912


 


SLC31A1
NM_001859.2
CCGTTCGAAGAGTCGTGAGGGGGTGACGGGTTAAGATTCGGAGAGAGAGGTGCTAGTGGCTGGACT
SEQ ID NO: 2913


 


SLC5A8
NM_145913.2
CCTGCTTTCAACCACATTGAATTGAACTCAGATCAGAGTGGCAAGAGCAATGGGACTCGTTTGTGAAGCTGCTCT
SEQ ID NO: 2914


 


SLC7A5
NM_003486.4
GCGCAGAGGCCAGTTAAAGTAGATCACCTCCTCGAACCCACTCCGGTTCCCCGCAACCCACAGCTCAGCT
SEQ ID NO: 2915


 


SLPI
NM_003064.2
ATGGCCAATGTTTGATGCTTAACCCCCCCAATTTCTGTGAGATGGATGGCCAGTGCAAGCGTGACTTGAAGTGT
SEQ ID NO: 2916


 


SMARCA3
NM_003071.2
AGGGACTGTCCTGGCACATTATGCAGATGTCCTGGGTCTTTTGCTTAGACTGCGGCAAATTTGTTG
SEQ ID NO: 2917


 


SNAI1
NM_005985.2
CCCAATCGGAAGCCTAACTACAGCGAGCTGCAGGACTCTAATCCAGAGTTTACCTTCCAGCAGCCCTAC
SEQ ID NO: 2918


 


SNAI2
NM_003068.3
GGCTGGCCAAACATAAGCAGCTGCACTGCGATGCCCAGTCTAGAAAATCTTTCAGCTGTAAATACTGTGACAAGGA
SEQ ID NO: 2919


 


SNRPF
NM_003095.1
GGCTGGTCGGCAGAGAGTAGCCTGCAACATTCGGCCGTGGTTTACATGAGTTTACCCCTCAATCCCAAACCTTTCCTCA
SEQ ID NO: 2920


 


SOD1
NM_000454.3
TGAAGAGAGGCATGTTGGAGACTTGGGCAATGTGACTGCTGACAAAGATGGTGTGGCCGATGTGTCTATT
SEQ ID NO: 2921


 


SOD2
NM_000636.1
GCTTGTCCAAATCAGGATCCACTGCAAGGAACAACAGGCCTTATTCCACTGCTGGGGATTGATGTGTGGGAGCACGCT
SEQ ID NO: 2922


 


SOS1
NM_005633.2
TCTGCACCAAATTCTCCAAGAACACCGTTAACACCTCCGCCTGCTTCTGGTGCTTCCAGTACCAC
SEQ ID NO: 2923


 


SOX17
NM_022454.2
TCGTGTGCAAGCCTGAGATGGGCCTCCCCTACCAGGGGCATGACTCCGGTGTGAATCTCCCCGACAG
SEQ ID NO: 2924


 


SPARC
NM_003118.1
TCTTCCCTGTACACTGGCAGTTCGGCCAGCTGGACCAGCACCCCATTGACGGGTACCTCTCCCACACCGAGCT
SEQ ID NO: 2925


 


SPINT2
NM_021102.1
AGGAATGCAGCGGATTCCTCTGTCCCAAGTGCTCCCAGAAGGCAGGATTCTGAAGACCACTCCAGCGA
SEQ ID NO: 2926


 


SPRY1
AK026960.1
CAGACCAGTCCCTGGTCATAGGTCTGAAAGGGCAATCCGGACCCAGCCCAAGCAACTGATTGTGGATGACTTGAAGG
SEQ ID NO: 2927


 


SPRY2
NM_005842.1
TGTGGCAAGTGCAAATGTAAGGAGTGCACCTACCCAAGGCCTCTGCCATCAGACTGGATCTGCGAC
SEQ ID NO: 2928


 


SR-A1
NM_021228.1
AGATGGAAGAAGCCAACCTGGCGAGCCGAGCGAAGGCCCAGGAGCTGATCCAGGCCACCAACCAGATCCTCAGCCACAG
SEQ ID NO: 2929


 


ST14
NM_021978.2
TGACTGCACATGGAACATTGAGGTGCCCAACAACCAGCATGTGAAGGTGCGCTTCAAATTCTT
SEQ ID NO: 2930


 


STAT1
NM_007315.1
GGGCTCAGCTTTCAGAAGTGCTGAGTTGGCAGTTTTCTTCTGTCACCAAAAGAGGTCTCAATGTGGACCAGCTGAACATGT
SEQ ID NO: 2931


 


STAT3
NM_003150.1
TCACATGCCACTTTGGTGTTTCATAATCTCCTGGGAGAGATTGACCAGCAGTATAGCCGCTTCCTGCAAG
SEQ ID NO: 2932


 


STAT5A
NM_003152.1
GAGGCGCTCAACATGAAATTCAAGGCCGAAGTGCAGAGCAACCGGGGCCTGACCAAGGAGAACCTCGTGTTCCTGGC
SEQ ID NO: 2933


 


STAT5B
NM_012448.1
CCAGTGGTGGTGATCGTTCATGGCAGCCAGGACAACAATGCGACGGCCACTGTTCTCTGGGACAATGCTTTTGC
SEQ ID NO: 2934


 


STC1
NM_003155.1
CTCCGAGGTGAGGAGGACTCTCCCTCCCACATCAAACGCACATCCCATGAGAGTGCATAACCAGGGAGAGGT
SEQ ID NO: 2935


 


STK11
NM_000455.3
GGACTCGGAGACGCTGTGCAGGAGGGCCGTCAAGATCCTCAAGAAGAAGAAGTTGCGAAGGATCCC
SEQ ID NO: 2936


 


STK15
NM_003600.1
CATCTTCCAGGAGGACCACTCTCTGTGGCACCCTGGACTACCTGCCCCCTGAAATGATTGAAGGTCGGA
SEQ ID NO: 2937


 


STMN1
NM_005563.2
AATACCCAACGCACAAATGACCGCACGTTCTCTGCCCCGTTTCTTGCCCCAGTGTGGTTTGCATTGTCTCC
SEQ ID NO: 2938


 


STMY3
NM_005940.2
CCTGGAGGCTGCAACATACCTCAATCCTGTCCCAGGCCGGATCCTCCTGAAGCCCTTTTCGCAGCACTGCT
SEQ ID NO: 2939




ATCCTCCAAAGCCATTGTA


 


STS
NM_000351.2
GAAGATCCCTTTCCTCCTACTGTTCTTTCTGTGGGAAGCCGAGAGCCACGAAGCATCAAGGCCGAACATCATCC
SEQ ID NO: 2940


 


SURV
NM_001168.1
TGTTTTGATTCCCGGGCTTACCAGGTGAGAAGTGAGGGAGGAAGAAGGCAGTGTCCCTTTTGCTAGAGCTGACAGCTTTG
SEQ ID NO: 2941


 


TAGLN
NM_003186.2
GATGGAGCAGGTGGCTCAGTTCCTGAAGGCGGCTGAGGACTCTGGGGTCATCAAGACTGACATGTTCCAGACT
SEQ ID NO: 2942


 


TBP
NM_003194.1
GCCCGAAACGCCGAATATAATCCCAAGCGGTTTGCTGCGGTAATCATGAGGATAAGAGAGCCACG
SEQ ID NO: 2943


 


TCF-1
NM_000545.3
GAGGTCCTGAGCACTGCCAGGAGGGACAAAGGAGCCTGTGAACCCAGGACAAGCATGGTCCCACATC
SEQ ID NO: 2944


 


TCF-7
NM_003202.2
GCAGCTGCAGTCAACAGTTCAAAGAAGTCATGGCCCAAATCCAGTGTGCACCCCTCCCCATTCACAG
SEQ ID NO: 2945


 


TCF7L1
NM_031283.1
CCGGGACACTTTCCAGAAGCCGCGGGACTATTTCGCCGAAGTGAGAAGGCCTCAGGACAGCGCGTTCT
SEQ ID NO: 2946


 


TCF7L2
NM_030756.1
CCAATCACGACAGGAGGATTCAGACACCCCTACCCCACAGCTCTGACCGTCAATGCTTCCGTGTCCA
SEQ ID NO: 2947


 


TCFL4
NM_170607.2
CTGACTGCTCTGCTTAAAGGTGAAAGTAGCAGGAACAACAACAAAAGCCAACCAAAAACAAGGTAGCCAGTGCAAGACAT
SEQ ID NO: 2948


 


TEK
NM_000459.1
ACTTCGGTGCTACTTAACAACTTACATCCCAGGGAGCAGTACGTGGTCCGAGCTAGAGTCAACACCAAGGCCCAGG
SEQ ID NO: 2949


 


TERC
U86046.1
AAGAGGAACGGAGCGAGTCCCCGCGCGCGGCGCGATTCCCTGAGCTGTGGGACGTGCACCCAGGACTCG
SEQ ID NO: 2950




GCTCACACAT


 


TERT
NM_003219.1
GACATGGAGAACAAGCTGTTTGCGGGGATTCGGCGGGACGGGCTGCTCCTGCGTTTGGTGGATGATTTCT
SEQ ID NO: 2951




TGTTGGTGACACCTC


 


TFF3
NM_003226.1
AGGCACTGTTCATCTCAGTTTTTCTGTCCCTTTGCTCCCGGCAAGCTTTCTGCTGAAAGTTCATATCTGGAGCCTGATG
SEQ ID NO: 2952


 


TGFA
NM_003236.1
GGTGTGCCACAGACCTTCCTACTTGGCCTGTAATCACCTGTGCAGCCTTTTGTGGGCCTTCAAAACTCTGTC
SEQ ID NO: 2953




AAGAACTCCGT


 


TGFB2
NM_003238.1
ACCAGTCCCCCAGAAGACTATCCTGAGCCCGAGGAAGTCCCCCCGGAGGTGATTTCCATCTACAACAGCACCAGG
SEQ ID NO: 2954


 


TGFB3
NM_003239.1
GGATCGAGCTCTTCCAGATCCTTCGGCCAGATGAGCACATTGCCAAACAGCGCTATATCGGTGGC
SEQ ID NO: 2955


 


TGFBI
NM_000358.1
GCTACGAGTGCTGTCCTGGATATGAAAAGGTCCCTGGGGAGAAGGGCTGTCCAGCAGCCCTACCACT
SEQ ID NO: 2956


 


TGFBR1
NM_004612.1
GTCATCACCTGGCCTTGGTCCTGTGGAACTGGCAGCTGTCATTGCTGGACCAGTGTGCTTCGTCTGC
SEQ ID NO: 2957


 


TGFBR2
NM_003242.2
AACACCAATGGGTTCCATCTTTCTGGGCTCCTGATTGCTCAAGCACAGTTTGGCCTGATGAAGAGG
SEQ ID NO: 2958


 


THBS1
NM_003246.1
CATCCGCAAAGTGACTGAAGAGAACAAAGAGTTGGCCAATGAGCTGAGGCGGCCTCCCCTATGCTATCACA
SEQ ID NO: 2959




ACGGAGTTCAGTAC


 


THY1
NM_006288.2
GGACAAGACCCTCTCAGGCTGTCCCAAGCTCCCAAGAGCTTCCAGAGCTCTGACCCACAGCCTCCAA
SEQ ID NO: 2960


 


TIMP1
NM_003254.1
TCCCTGCGGTCCCAGATAGCCTGAATCCTGCCCGGAGTGGAACTGAAGCCTGCACAGTGTCCACCCTGTTCCCAC
SEQ ID NO: 2961


 


TIMP2
NM_003255.2
TCACCCTCTGTGACTTCATCGTGCCCTGGGACACCCTGAGCACCACCCAGAAGAAGAGCCTGAACCACA
SEQ ID NO: 2962


 


TIMP3
NM_000362.2
CTACCTGCCTTGCTTTGTGACTTCCAAGAACGAGTGTCTCTGGACCGACATGCTCTCCAATTTCGGT
SEQ ID NO: 2963


 


TJP1
NM_003257.1
ACTTTGCTGGGACAAAGGTCAACTGAAGAAGTGGGCAGGCCCGAGGCAGGAGAGATGCTGAGGAGTCCATGTG
SEQ ID NO: 2964


 


TK1
NM_003258.1
GCCGGGAAGACCGTAATTGTGGCTGCACTGGATGGGACCTTCCAGAGGAAGCCATTTGGGGCCATCCTGA
SEQ ID NO: 2965




ACCTGGTGCCGCTG


 


TLN1
NM_006289.2
AAGCAGAAGGGAGAGCGTAAGATCTTCCAGGCACACAAGAATTGTGGGCAGATGAGTGAGATTGAGGCCAAGG
SEQ ID NO: 2966


 


TMEPAI
NM_020182.3
CAGAAGGATGCCTGTGGCCCTCGGAGAGCACAGTGTCAGGCAACGGAATCCCAGAGCCGCAGGTCTAC
SEQ ID NO: 2967


 


TMSB10
NM_021103.2
GAAATCGCCAGCTTCGATAAGGCCAAGCTGAAGAAAACGGAGACGCAGGAAAAGAACACCCTGCCGAC
SEQ ID NO: 2968


 


TMSB4X
NM_021109.2
CACATCAAAGAACTACTGACAACGAAGGCCGCGCCTGCCTTTCCCATCTGTCTATCTATCTGGCTGGCAGG
SEQ ID NO: 2969


 


TNC
NM_002160.1
AGCTCGGAACCTCACCGTGCCTGGCAGCCTTCGGGCTGTGGACATACCGGGCCTCAAGGCTGCTAC
SEQ ID NO: 2970


 


TNF
NM_000594.1
GGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTTGCCGAGTCTGGGCA
SEQ ID NO: 2971


 


TNFRSF5
NM_001250.3
TCTCACCTCGCTATGGTTCGTCTGCCTCTGCAGTGCGTCCTCTGGGGCTGCTTGCTGACCGCTGTCCATC
SEQ ID NO: 2972


 


TNFRSF6B
NM_003823.2
CCTCAGCACCAGGGTACCAGGAGCTGAGGAGTGTGAGCGTGCCGTCATCGACTTTGTGGCTTTCCAGGACA
SEQ ID NO: 2973


 


TNFSF4
NM_003326.2
CTTCATCTTCCCTCTACCCAGATTGTGAAGATGGAAAGGGTCCAACCCCTGGAAGAGAATGTGGGAAATGCAGC
SEQ ID NO: 2974


 


TOP2A
NM_001067.1
AATCCAAGGGGGAGAGTGATGACTTCCATATGGACTTTGACTCAGCTGTGGCTCCTCGGGCAAAATCTGTAC
SEQ ID NO: 2975


 


TOP2B
NM_001068.1
TGTGGACATCTTCCCCTCAGACTTCCCTACTGAGCCACCTTCTCTGCCACGAACCGGTCGGGCTAG
SEQ ID NO: 2976


 


TP
NM_001953.2
CTATATGCAGCCAGAGATGTGACAGCCACCGTGGACAGCCTGCCACTCATCACAGCCTCCATTCTCAGTAA
SEQ ID NO: 2977




GAAACTCGTGG


 


TP53BP1
NM_005657.1
TGCTGTTGCTGAGTCTGTTGCCAGTCCCCAGAAGACCATGTCTGTGTTGAGCTGTATCTGTGAAGCCAGGCAAG
SEQ ID NO: 2978


 


TP53BP2
NM_005426.1
GGGCCAAATATTCAGAAGCTTTTATATCAGAGGACCACCATAGCGGCCATGGAGACCATCTCTGTCCCATC
SEQ ID NO: 2979




ATACCCATCC


 


TP53I3
NM_004881.2
GCGGACTTAATGCAGAGACAAGGCCAGTATGACCCACCTCCAGGAGCCAGCAACATTTTGGGACTTGA
SEQ ID NO: 2980


 


TRAG3
NM_004909.1
GACGCTGGTCTGGTGAAGATGTCCAGGAAACCACGAGCCTCCAGCCCATTGTCCAACAACCACCCA
SEQ ID NO: 2981


 


TRAIL
NM_003810.1
CTTCACAGTGCTCCTGCAGTCTCTCTGTGTGGCTGTAACTTACGTGTACTTTACCAACGAGCTGAAGCAGATG
SEQ ID NO: 2982


 


TS
NM_001071.1
GCCTCGGTGTGCCTTTCAACATCGCCAGCTACGCCCTGCTCACGTACATGATTGCGCACATCACG
SEQ ID NO: 2983


 


TST
NM_003312.4
GGAGCCGGATGCAGTAGGACTGGACTCGGGCCATATCCGTGGTGCCGTCAACATGCCTTTCATGGACTT
SEQ ID NO: 2984


 


TUBA1
NM_006000.1
TGTCACCCCGACTCAACGTGAGACGCACCGCCCGGACTCACCATGCGTGAATGCATCTCAGTCCACGT
SEQ ID NO: 2985


 


TUBB
NM_001069.1
CGAGGACGAGGCTTAAAAACTTCTCAGATCAATCGTGCATCCTTAGTGAACTTCTGTTGTCCTCAAGCATGGT
SEQ ID NO: 2986


 


TUFM
NM_003321.3
GTATCACCATCAATGCGGCTCATGTGGAGTATAGCACTGCCGCCCGCCACTACGCCCACACAGACTG
SEQ ID NO: 2987


 


TULP3
NM_003324.2
TGTGTATAGTCCTGCCCCTCAAGGTGTCACAGTAAGATGTCGGATAATCCGGGATAAAAGGGGAATGGATCGGG
SEQ ID NO: 2988


 


tusc4
NM_006545.4
GGAGGAGCTAAATGCCTCAGGCCGGTGCACTCTGCCCATTGATGAGTCCAACACCATCCACTTGAAGG
SEQ ID NO: 2989


 


UBB
NM_018955.1
GAGTCGACCCTGCACCTGGTCCTGCGTCTGAGAGGTGGTATGCAGATCTTCGTGAAGACCCTGACCGGCA
SEQ ID NO: 2990




AGACCATCACCCTGGAAGTGGAGCCCAGTGACACCATCGAAAATGTGAAGGCCAAGATCCAGGATAAAGAA




GGCATCCCTCCCGACCAGCAGAGGCTCATCTTTGCAGGCAAGCAGCTGGAAGATGGCCGCACTCTTTCTG




ACTACAACATCCAGAAGGAGTCGACCCTGCACCTGGTCCTGCGTCTGAGAGGTGGTATGCAGATCTTCGTG




AAGACCCTGACCGGCAAGACCATCACTCTGGAAGTGGAGCCCAGTGACACCATCGAAAATGTGAAGGCCA




AGATCCAAGATAAAGAAGGCATCCCTCCCGACCAGCAGAGGCTCATCTTTGCAGGCAAGCAGCTGGAAGAT




GGCCGCACTCTTTCTGACTACAACATCCAGAAGGAGTCGACCCTGCACCTGGTCCTGCGCCTGAGGGGTG




GCTGTTAATTCTTCAGTCATGGCATTCGC


 


UBC
NM_021009.2
ACGCACCCTGTCTGACTACAACATCCAGAAAGAGTCCACCCTGCACCTGGTGCTCCGTCTTAGAGGT
SEQ ID NO: 2991


 


UBE2C
NM_007019.2
TGTCTGGCGATAAAGGGATTTCTGCCTTCCCTGAATCAGACAACCTTTTCAAATGGGTAGGGACCAT
SEQ ID NO: 2992


 


UBE2M
NM_003969.1
CTCCATAATTTATGGCCTGCAGTATCTCTTCTTGGAGCCCAACCCCGAGGACCCACTGAACAAGGAGGCCGCA
SEQ ID NO: 2993


 


UBL1
NM_003352.3
GTGAAGCCACCGTCATCATGTCTGACCAGGAGGCAAAACCTTCAACTGAGGACTTGGGGGATAAGAAGGAAGG
SEQ ID NO: 2994


 


UCP2
NM_003355.2
ACCATGCTCCAGAAGGAGGGGCCCCGAGCCTTCTACAAAGGGTTCATGCCCTCCTTTCTCCGCTTGGGTT
SEQ ID NO: 2995


 


UGT1A1
NM_000463.2
CCATGCAGCCTGGAATTTGAGGCTACCCAGTGCCCCAACCCATTCTCCTACGTGCCCAGGCCTCTC
SEQ ID NO: 2996


 


UMPS
NM_000373.1
TGCGGAAATGAGCTCCACCGGCTCCCTGGCCACTGGGGACTACACTAGAGCAGCGGTTAGAATGGCTGAGG
SEQ ID NO: 2997


 


UNC5A
XM_030300.7
GACAGCTGATCCAGGAGCCACGGGTCCTGCACTTCAAGGACAGTTACCACAACCTGCGCCTATCCAT
SEQ ID NO: 2998


 


UNC5B
NM_170744.2
AGAACGGAGGCCGTGACTGCAGCGGGACGCTGCTCGACTCTAAGAACTGCACAGATGGGCTGTGCATG
SEQ ID NO: 2999


 


UNC5C
NM_003728.2
CTGAACACAGTGGAGCTGGTTTGCAAACTCTGTGTGCGGCAGGTGGAAGGAGAAGGGCAGATCTTCCAG
SEQ ID NO: 3000


 


upa
NM_002658.1
GTGGATGTGCCCTGAAGGACAAGCCAGGCGTCTACACGAGAGTCTCACACTTCTTACCCTGGATCCGCAG
SEQ ID NO: 3001


 


UPP1
NM_003364.2
ACGGGTCCTGCCTCAGTTGGCGGAATGGCGGCCACGGGAGCCAATGCAGAGAAAGCTGAAAGTCACAATGATTGCCCCG
SEQ ID NO: 3002


 


VCAM1
NM_001078.2
TGGCTTCAGGAGCTGAATACCCTCCCAGGCACACACAGGTGGGACACAAATAAGGGTTTTGGAACCACTAT
SEQ ID NO: 3003




TTTCTCATCACGACAGCA


 


VCL
NM_003373.2
GATACCACAACTCCCATCAAGCTGTTGGCAGTGGCAGCCACGGCGCCTCCTGATGCGCCTAACAGGGA
SEQ ID NO: 3004


 


VCP
NM_007126.2
GGCTTTGGCAGCTTCAGATTCCCTTCAGGGAACCAGGGTGGAGCTGGCCCCAGTCAGGGCAGTGGAG
SEQ ID NO: 3005


 


VDAC1
NM_003374.1
GCTGCGACATGGATTTCGACATTGCTGGGCCTTCCATCCGGGGTGCTCTGGTGCTAGGTTACGAGGGCTGG
SEQ ID NO: 3006


 


VDAC2
NM_003375.2
ACCCACGGACAGACTTGCGCGCGTCCAATGTGTATTCCTCCATCATATGCTGACCTTGGCAAAGCT
SEQ ID NO: 3007


 


VDR
NM_000376.1
GCCCTGGATTTCAGAAAGAGCCAAGTCTGGATCTGGGACCCTTTCCTTCCTTCCCTGGCTTGTAACT
SEQ ID NO: 3008


 


VEGF
NM_003376.3
CTGCTGTCTTGGGTGCATTGGAGCCTTGCCTTGCTGCTCTACCTCCACCATGCCAAGTGGTCCCAGGCTGC
SEQ ID NO: 3009


 


VEGF_altsplice1
AF486837.1
TGTGAATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAATCCCTGTGGGCCTTGCTCAGAGCGGAGAAAGC
SEQ ID NO: 3010


 


VEGF_altsplice2
AF214570.1
AGCTTCCTACAGCACAACAAATGTGAATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAAATGTGACAAGCCGAG
SEQ ID NO: 3011


 


VEGFB
NM_003377.2
TGACGATGGCCTGGAGTGTGTGCCCACTGGGCAGCACCAAGTCCGGATGCAGATCCTCATGATCCGGTACC
SEQ ID NO: 3012


 


VEGFC
NM_005429.2
CCTCAGCAAGACGTTATTTGAAATTACAGTGCCTCTCTCTCAAGGCCCCAAACCAGTAACAATCAGTTTTGC
SEQ ID NO: 3013




CAATCACACTT


 


VIM
NM_003380.1
TGCCCTTAAAGGAACCAATGAGTCCCTGGAACGCCAGATGCGTGAAATGGAAGAGAACTTTGCCGTTGAAGC
SEQ ID NO: 3014


 


WIF
NM_007191.2
TACAAGCTGAGTGCCCAGGCGGGTGCCGAAATGGAGGCTTTTGTAATGAAAGACGCATCTGCGAGTG
SEQ ID NO: 3015


 


WISP1
NM_003882.2
AGAGGCATCCATGAACTTCACACTTGCGGGCTGCATCAGCACACGCTCCTATCAACCCAAGTACTGTGGAGTTTG
SEQ ID NO: 3016


 


Wnt-3a
NM_033131.2
ACAAAGCTACCAGGGAGTCGGCCTTTGTCCACGCCATTGCCTCAGCCGGTGTGGCCTTTGCAGTGACACGCTCA
SEQ ID NO: 3017


 


Wnt-5a
NM_003392.2
GTATCAGGACCACATGCAGTACATCGGAGAAGGCGCGAAGACAGGCATCAAAGAATGCCAGTATCAATTCCGACA
SEQ ID NO: 3018


 


Wnt-5b
NM_032642.2
TGTCTTCAGGGTCTTGTCCAGAATGTAGATGGGTTCCGTAAGAGGCCTGGTGCTCTCTTACTCTTTCATCCACGTGCAC
SEQ ID NO: 3019


 


WNT2
NM_003391.1
CGGTGGAATCTGGCTCTGGCTCCCTCTGCTCTTGACCTGGCTCACCCCCGAGGTCAACTCTTCATGG
SEQ ID NO: 3020


 


WWOX
NM_016373.1
ATCGCAGCTGGTGGGTGTACACACTGCTGTTTACCTTGGCGAGGCCTTTCACCAAGTCCATGCAACAGGGAGCT
SEQ ID NO: 3021


 


XPA
NM_000380.2
GGGTAGAGGGAAAAGGGTTCAACAAAGGCTGAACTGGATTCTTAACCAAGAAACAAATAATAGCAATGGTGGTGCA
SEQ ID NO: 3022


 


XPC
NM_004628.2
GATACATCGTCTGCGAGGAATTCAAAGACGTGCTCCTGACTGCCTGGGAAAATGAGCAGGCAGTCATTGAAAG
SEQ ID NO: 3023


 


XRCC1
NM_006297.1
GGAGATGAAGCCCCCAAGCTTCCTCAGAAGCAACGCCAGACCAAAACCAAGCCCACTCAGGCAGCTGGAC
SEQ ID NO: 3024


 


YB-1
NM_004559.1
AGACTGTGGAGTTTGATGTTGTTGAAGGAGAAAAGGGTGCGGAGGCAGCAAATGTTACAGGTCCTGGTGGTGTTCC
SEQ ID NO: 3025


 


YWHAH
NM_003405.2
CATGGCCTCCGCTATGAAGGCGGTGACAGAGCTGAATGAACCTCTCTCCAATGAAGATCGAAATCTCC
SEQ ID NO: 3026


 


zbtb7
NM_015898.2
CTGCGTTCACACCCCAGTGTCACAGGGCGAGCTGTTCTGGAGAGAAAACCATCTGTCGTGGCTGAG
SEQ ID NO: 3027


 


ZG16
NM_152338.1
TGCTGAGCCTCCTCTCCTTGGCAGGGGCACTGTGATGAGGAGTAAGAACTCCCTTATCACTAACCCCCATCC
SEQ ID NO: 3028

## Claims

1. A method of predicting clinical outcome for a human subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising:
determining a normalized expression level of an RNA transcript of LAMA3, or an expression product thereof, in a biological sample comprising cancer cells obtained from said human subject, and;
predicting the likelihood of a positive clinical outcome for said human subject based on said normalized expression level of an RNA transcript of LAMA3, or an expression product thereof, wherein said normalized expression level of an RNA transcript of LAMA3, or an expression product thereof, is negatively correlated with an increased likelihood of a positive clinical outcome.

2. The method of claim 1, further comprising determining a normalized expression level of an RNA transcript, or an expression product thereof, of one or more of BGN, Ki-67, CMYC, MYBL2, FAP, INHBA, and GADD45B in the biological sample;
wherein said normalized expression level of each of BGN, FAP, INHBA, and GADD45B is negatively correlated with an increased likelihood of a positive clinical outcome; and
wherein said normalized expression level of each of Ki-67, CMYC, and MYBL2 is positively correlated with an increased likelihood of a positive clinical outcome.

3. The method of claim 1, wherein said normalized expression level of an RNA transcript of LAMA3 is determined using a PCR-based method.

4. The method of claim 1, wherein said normalized expression level of an RNA transcript of LAMA3, or an expression product thereof, is normalized relative to the expression level of an RNA transcript, or an expression product thereof, of at least one reference gene.

5. The method of claim 1, wherein said clinical outcome is expressed in terms of Recurrence-Free Interval (RFI), Overall Survival (OS), Disease-Free Survival (DFS), or Distant Recurrence-Free Interval (DRFI).

6. The method of claim 1, wherein said colorectal cancer is Dukes B (stage II) or Dukes C (stage III) colorectal cancer.

7. The method of claim 1, wherein said colorectal cancer is Dukes B (stage II) or Dukes C (stage III) colon cancer.

8. The method of claim 1, further comprising the step of creating a report summarizing said prediction.

9. A method of predicting in a human subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer a likelihood of recurrence of colorectal cancer following surgical resection of said cancer, comprising:
determining the normalized expression level of an RNA transcript of LAMA3, or an expression product thereof, in a biological sample comprising cancer cells obtained from said human subject, and;
predicting the likelihood of recurrence of colorectal cancer for the human subject based on said normalized expression level of an RNA transcript of LAMA3, or an expression product thereof, wherein said normalized expression level of an RNA transcript of LAMA3, or an expression product thereof, is positively correlated with an increased likelihood of recurrence of colorectal cancer.

10. The method of claim 9, further comprising determining a normalized expression level of an RNA transcript, or an expression product thereof, of one or more of BGN, Ki-67, CMYC, MYBL2, FAP, INHBA, and GADD45B in the biological sample;
wherein said normalized expression level of each of BGN, FAP, INHBA, and GADD45B is positively correlated with an increased likelihood of recurrence of colorectal cancer; and
wherein said normalized expression level of each of Ki-67, CMYC, and MYBL2 is negatively correlated with an increased likelihood of recurrence of colorectal cancer.

11. The method of claim 9, wherein said normalized expression level of an RNA transcript of LAMA3 is determined using a PCR-based method.

12. The method of claim 9, wherein if said likelihood of recurrence of colorectal cancer is increased, said human subject is subjected to further therapy following said surgical resection.

13. The method of claim 12, wherein said further therapy is chemotherapy and/or radiation therapy.

14. The method of claim 9, further comprising the step of creating a report summarizing said prediction.

15. The method of claim 9, wherein said normalized expression level of an RNA transcript of LAMA3, or an expression product thereof, is normalized relative to the expression level of an RNA transcript, or an expression product thereof, of at least one reference gene.

16. The method of claim 9, wherein said colorectal cancer is Dukes B (stage II) or Dukes C (stage III) colon cancer.

17. A method of predicting clinical outcome for a human subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer following surgical resection of the cancer, comprising:
extracting RNA from a fixed, paraffin-embedded biological sample comprising cancer cells obtained from the human subject;
reverse transcribing an RNA transcript of LAMA3 to produce a cDNA of LAMA3;
amplifying the cDNA of LAMA3;
producing an amplicon of the RNA transcript of LAMA3;
assaying a level of the amplicon of the RNA transcript of LAMA3;
normalizing the level of the amplicon of the RNA transcript of LAMA3 against a level of an amplicon of at least one reference RNA transcript in the biological sample to provide a normalized LAMA3 amplicon level;
comparing the normalized LAMA3 amplicon level to gene expression data obtained from at least 30 reference colorectal cancer tissue samples; and
predicting the likelihood of a positive clinical outcome for the human subject based on the normalized LAMA3 amplicon level, wherein the normalized LAMA3 amplicon level is negatively correlated with an increased likelihood of a positive clinical outcome, wherein the clinical outcome is expressed in terms of Recurrence-Free Interval (RFI), Overall Survival (OS), Disease-Free Survival (DFS), or Distant Recurrence-Free Interval (DRFI).

18. The method of claim 17, wherein the level of the amplicon of the RNA transcript of LAMA3 is a threshold cycle (Ct) value and the normalized LAMA3 amplicon level is a normalized Ct value.

19. The method of claim 1, wherein the biological sample is a fixed, paraffin-embedded biological sample.

20. The method of claim 1, wherein the biological sample is a fresh biological sample.